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Abstract 
The Gastro-Intestinal (GI) tract is a unique region in the body. Our innate immune 
system retains a fine homeostatic balance between avoiding inappropriate inflammatory 
responses against the myriad commensal microbes residing in the gut while also remaining 
active enough to prevent invasive pathogenic attack. The intestinal epithelium represents the 
frontline of this interface. It has long been known to act as a physical barrier preventing the 
lumenal bacteria of the gastro-intestinal tract from activating an inflammatory immune 
response in the immune cells of the underlying mucosa. However, in recent years, an 
appreciation has grown surrounding the role played by the intestinal epithelium in regulating 
innate immune responses, both in the prevention of infection and in maintaining a 
homeostatic environment through modulation of innate immune signalling systems. The aim 
of this thesis was to identify novel innate immune mechanisms regulating inflammation in the 
GI tract. To achieve this aim, we chose several aspects of regulatory mechanisms utilised in 
this region by the innate immune system. We identified several commensal strains of bacteria 
expressing proteins containing signalling domains used by Pattern Recognition Receptors 
(PRRs) of the innate immune system. Three such bacterial proteins were studied for their 
potentially subversive roles in host innate immune signalling as a means of regulating 
homeostasis in the GI tract. We also examined differential responses to PRR activation 
depending on their sub-cellular localisation. This was investigated based on reports that 
apical Toll-Like Receptor (TLR) 9 activation resulted in abrogation of inflammatory 
responses mediated by other TLRs in Intestinal Epithelial Cells (IECs) such as basolateral 
TLR4 activation. Using the well-studied invasive intra-cellular pathogen Listeria 
monocytogenes as a model for infection, we also used a PRR siRNA library screening 
technique to identify novel PRRs used by IECs in both inhibition and activation of 
inflammatory responses. Many of the PRRs identified in this screen were previously believed 
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not to be expressed in IECs. Furthermore, the same study has led to the identification of the 
previously uncharacterised TLR10 as a functional inflammatory receptor of IECs. Further 
analysis revealed a similar role in macrophages where it was shown to respond to 
intracellular and motile pathogens such as Gram-positive L.monocytogenes and Gram-
negative Salmonella typhimurium. TLR10 expression in IECs was predominantly 
intracellular. This is likely in order to avoid inappropriate inflammatory activation through 
the recognition of commensal microbial antigens on the apical cell surface of IECs. 
Moreover, these results have revealed a more complex network of innate immune signalling 
mechanisms involved in both activating and inhibiting inflammatory responses in IECs than 
was previously believed. This contribution to our understanding of innate immune regulation 
in this region has several direct and indirect benefits. The identification of several novel 
PRRs involved in activating and inhibiting inflammation in the GI tract may be used as novel 
therapeutic targets in the treatment of disease; both for inducing tolerance and reducing 
inflammation, or indeed, as targets for adjuvant activation in the development of oral 
vaccines against pathogenic attack. 
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Acronyms 
 
Absent In Melanoma 2 (AIM2)  
Apoptosis-associated Speck-like protein containing a CARD (ASC)  
Bovine Serum Albumin (BSA) 
Brain Heart Infusion (BHI)  
Caspase Activation and Recruitment Domain (CARD) 
c-Jun N-terminal kinase (JNK)  
Class II, major histocompatibility complex, transactivator (CIITA) 
Colony Forming Units (CFU)  
Commensal-Associated Molecular Patterns (CAMPs) 
Conexin43 (Cx43)  
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C-type Lectin Receptor (CLR) 
C-X-C motif Ligand 2 (CXCL-2) 
Danger Associated Molecular Pattern (DAMP) 
Death Domain (DD) 
Dendritic Cell (DC)  
Dendritic Cell (DC)-Specific Intercellular adhesion molecule-3 Grabbing Non-integrin (DC-
SIGN)  
Dimethyloxaloylglycine (DMOG)  
double stranded RNA (dsRNA)  
Dual Oxidase 2 (DUOX2)  
Dual specificity protein phosphatase 4 (DUSP4) 
Early Growth Response protein-1 (EGR-1) 
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Epithelial cadherin (E-cadherin)  
Extracellular signal-regulated kinases (ERK) 
Fibroblast Stimulating Ligand-1 (FSL-1) 
Forkhead box P3 (FOXP3)  
Frizzled 5 (Fzd5)  
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Heat-Killed Listeria monocytogenes (HKLM)  
Human Beta Defensin (HBD)  
Human Embryonic Kidney (HEK) 
Hypoxic Inducible Factor-1α (HIF-1α)  
Immunoglobulin A (IgA)  
Inflammatory Bowel Disease (IBD)  
Interferon (IFN) 
Interferon Response Factors (IRFs) 
Interleukin-1 receptor-associated kinase (IRAK) 
Internalin A (InlA)  
Internalin B (InlB)  
Intestinal Epithelial Cell (IEC)  
Isolated Lymphoid Follicles (ILFs) 
Listeria monocytogenes adhesion protein (LAP) 
Laboratory of Genetics and Physiology-2 (LGP2) 
Lipopolysaccharide (LPS) 
Lipoteichoic Acid (LTA) 
Listeria monocytogenes (L.monocytogenes) 
Listeriolysin O (LLO)  
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Loss-of-function (LOF)  
Melanoma differentiation-associated antigen 5 (MDA5)  
Mitochondrial antiviral signalling protein (MAVS) 
Mitogen Activated Protein Kinases (MAPK) 
Monocyte Chemotactic Protein-1 (MCP-1)  
Mramyl Di-Peptide (MDP)  
Multiplicity of infection (MOI)  
MyD88 Adaptor-Like (MAL)  
Myeloid Differentiation factor 88 (MyD88)  
Neuronal Apoptosis Inhibitor Protein (NAIP) 
NF-κB Inducing Kinase NIK (NIK) 
Nitric oxide (NO) 
Nitric Oxide Synthase 2 (NOS2)  
NLR family CARD-domain-containing (NLRC) 
NLR family pyrin-domain-containing protein (NLRP) 
NOD-Like Receptor NLR 
Nuclear Factor Kappa B (NF-B) 
Nuclear Oligomerization Domain (NOD) 
Nucleotide-binding Domain Leucine-rich Repeat containing (NLR) 
Oligodeoxynucleotide (ODN)  
Optical Density (OD)  
Pathogen Associated Molecular Pattern (PAMP) 
Pattern Recognition Receptor (PRR) 
Peptidoglycan (PGD) 
Peripheral Blood Mononuclear Cells (PBMCs) 
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Phorbol myristate acetate (PMA) 
Reactive Oxygen Species (ROS)  
Receptor-Interacting serine/threonine Kinase (RICK) 
Regulatory T cell (Treg) 
Relative centrifugal force (rcf)  
Retinoic acid-inducible gene I (RIG-I) 
Ribonuclease L (RNase L)  
RIG-I-Like Receptor RLR 
Severe combined immunodeficient (SCID) 
Single stranded RNA (ssRNA)  
Spacious L.monocytogenes-containing phagosomes (SLAPs) 
Spleen Tyrosine Kinase (Syk)  
Sterile α and HEAT-Armadillo motifs containing protein (SARM) 
Stimulator of Interferon Genes (STING) 
TIR-domain-containing adapter-inducing interferon-β (TRIF)  
TNF and inducible Nitric Oxide Synthase (iNOS) producing effector Dentritic Cells 
(TipDCs) 
TNF receptor associated factor (TRAF) 
Toll/IL-1R resistance (TIR) 
Toll-Like Protein A (TlpA)  
Toll-Like Receptor (TLR) 
Trans-Epithelial Electrical Resistance (TEER)  
Trif-Related Adaptor Molecule (TRAM) 
Tumour Necrosis Factor (TNF) 
Vascular Endothelial Growth Factor (VEGF)   
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Chapter 1 
 
 
 General Introduction 
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1.1 Innate immunity 
The innate immune system is our first line of defence against pathogenic attack on our 
body. Mammalian cells respond rapidly via the innate immune response to a diversity of 
danger signals. These include pathogen-derived molecules such as Lipopolysaccharide (LPS) 
from the outer cell membrane of Gram-negative bacteria. Such molecules are known as 
pathogen-associated molecular patterns (PAMPs). The body can even respond to self-derived 
molecular danger signals which arise from tissue damage, such as human Heat Shock 
Proteins (HSPs). These are known as Danger Associated Molecular Patterns (DAMPs) [1]. 
Recognition of these PAMPs and DAMPs is achieved by the Pattern-Recognition Receptors 
(PRRs) which constantly survey the extracellular space and cytoplasm for the presence of 
potentially harmful agents [2]. Known PRRs are divided into subfamilies including Toll-Like 
Receptors (TLRs) which sense PAMPs on the cell surface or in the endosomes, and Nuclear 
Oligodimerization Domain (NOD)-Like Receptors (Nucleotide-binding Domain Leucine-rich 
Repeat containing or NLRs) which recognize microbial molecules in the host cytosol, as well 
as playing a part in the regulation of apoptosis [2-4]. RIG-I like Receptors (RLRs) are another 
family of PRR of which there are 3 known members: retinoic acid-inducible gene I (RIG-I), 
melanoma differentiation-associated antigen 5 (MDA5) and Laboratory of Genetics and 
Physiology-2 (LGP2). These are RNA helicases which recognise viral RNA strands present 
in the host [5]. There are other forms of PRR such as C-type Lectin (CLEC) receptors 
(CLRs); these are proteins which contain a calcium dependent carbohydrate-binding domain 
and have a diverse range of functions including cell-cell adhesion and apoptosis as well as 
PRR function [6]. After stimulus recognition, each of these PRRs induces the activation of 
multiple signalling pathways, which lead to innate and adaptive immune responses [2, 4-6]. 
An important signal activated by TLRs, NLRs, and CLRs is the transcription factor NF-κB, 
which regulates the expression of many immune and inflammatory genes. They also activate 
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the Mitogen Activated Protein Kinases (MAPKs), p38 and Extracellular signal-Regulated 
Kinase 1 (ERK1) and/or ERK2, which also play a role in enhanced gene transcription (see 
Figure 1.1) [7]. 
 
 
Figure 1.1 Examples of known PRRs and their function. Shown above are each of the four 
families of PRR. Each PRR family is known to be responsible for the detection of specific PAMPs 
from various pathogens as indicated. Upon recognition of each PAMP, the PRRs initiate a 
downstream signalling cascade leading to the eventual activation of certain transcription factors which 
in turn induce expression of the appropriate immune response genes. Included among these 
transcription factors listed above are Nuclear Factor kappa B (NF-B), Mitogen Activated Protein 
Kinases (MAPKs) and Interferon Response Factors (IRFs). 
 
 
Today we know of 13 mammalian TLR paralogues, (11 of which are known to be 
expressed in humans) [8]. These can be located at both the plasma membrane and the 
endosomal membrane. Because of the cellular distribution of these TLRs, pathogen 
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recognition can be initiated from a variety of cellular locations depending on the receptor 
activated. For example, the plasma membrane associated TLRs respond to components from 
the microbial surface, whereas the endosomal TLRs recognise various nucleic acid ligands. 
Crystallographic studies on TLR1–TLR2, TLR3 and TLR4 have confirmed the dimeric 
nature of the ligand bound receptor [9]. In the case of TLR9, it has been shown that a pre-
existing dimer occurs, which presumably ―tightens‖ upon ligand binding to create a new 
conformation [10]. Specific ligands for TLRs have been elucidated through use of 
overexpression studies, ex vivo studies and knockout mice (see Table 1.1). We know, for 
example, that TLR2 responds to peptidoglycan, lipopeptides, lipoteichoic acid, 
lipoarabinomannan, GPI anchors, phenol-soluble modulin, zymosan and glycolipids [8]. 
TLR2 seems unable to mediate an immune response through recognition of PAMPs 
independently but rather dimerises with TLR1 or TLR6 to achieve this. TLR4 recognises and 
binds to LPS and lipoteichoic acid from gram-positive bacteria as well as a few viral proteins 
and self-antigens e.g. fibronectin [8]. Flagellin, found in bacterial flagella, binds to and 
activates TLR5. TLR3 recognises double stranded RNA (dsRNA) from viruses while TLR7 
and TLR8 both recognise single stranded RNA (ssRNA) from viruses. TLR9 recognises 
unmethylated CpG Oligodeoxynucleotide DNA from DNA viruses and bacteria. TLR11 
exists only in a truncated form in humans and is believed to be inactive. Furthermore, we are 
only now uncovering the exact role TLR10 has to play. This is hindered by the lack of a 
murine homologue of TLR10, although we know that it is similar in sequence and structure to 
TLRs 1, 2 and 6. All TLRs have a conserved intracellular Toll/IL-1R resistance (TIR) domain 
through which they signal via the recruitment of various TIR domain-containing adapter 
proteins in the cytosol [11].  
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Receptor Location Ligand Ligand origin 
TLR1 Cell surface multiple triacyl lipopeptides Bacteria 
TLR2 Cell surface 
multiple glycolipids 
multiple lipoproteins 
HSP70 
zymosan 
Bacteria 
Bacteria 
Host 
Fungi 
TLR3 Endosomal 
double-stranded RNA 
(dsRNA) 
Viruses 
TLR4 Cell surface 
lipopolysaccharide 
several heat shock proteins 
fibrinogen 
Gram-negative bacteria 
Bacterial and host cells 
Host 
TLR5 Cell surface Flagellin Bacteria 
TLR6 Cell surface multiple diacyl lipopeptides Mycoplasma 
TLR7 Endosomal 
Single stranded RNA 
(ssRNA) 
RNA Viruses 
TLR8 Endosomal 
Single stranded RNA 
(ssRNA) 
RNA Viruses 
TLR9 Endosomal 
unmethylated CpG 
Oligodeoxynucleotide DNA 
Bacteria, DNA Viruses 
TLR10 Cell surface ? ? 
 
Table 1.1 Intracellular location of each TLR with their known respective ligands and 
the origin of each ligand [12]. 
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The 4 main adaptor proteins which bind to TLRs and facilitate signal transduction are 
Myeloid Differentiation factor 88 (MyD88), MyD88 Adaptor-Like (MAL), TIR-domain-
containing adapter-inducing interferon-β (TRIF) and TRIF-Related Adaptor Molecule 
(TRAM), each displayed in Figure 1.2 interacting with their respective TLR. MyD88 is a 
modular protein and along with a TIR domain, it contains a Death Domain (DD) by which it 
recruits further downstream signalling components to the receptor complex via homotypic 
DD interactions [13]. These ultimately trigger the activation of immune response genes such 
as cytokines and chemokines (see Fig. 1.2). It is involved in mediating signal transduction for 
all TLRs apart from TLR3 [8]. MAL localizes to the plasma membrane where it can interact 
with TIR domains of activated TLR2 or TLR4 and recruit MyD88 [14]. Following activation 
through ligand binding, a downstream signalling cascade ensues through the cytoplasm to 
transcription factors in the nucleus of the cell which activate an enormous variety of specific 
immune response genes. The best characterised of these is probably Nuclear Factor κB (NF-
κB) [7]. The localization of TLR4 is what determines whether the MAL-MyD88 pathway or 
the TRAM-TRIF pathway is activated [15, 16]. For example, TLR4, when located on the 
plasma membrane engages with MAL, which subsequently recruits MyD88. MyD88 then 
activates another signal transducing molecule, TNF Receptor Associated Factor 6 (TRAF6) 
which mediates NF-κB activation. TLR4 will then traffic to endosomes, where TRAM is now 
engaged. TRAM subsequently recruits TRIF, which in turn recruits TRAF3. This cascade 
results in activation of TBK-1 which leads, in turn, to activation of viral immune response 
gene transcription factors, the Interferon regulatory factors (IRFs). Other TLRs using these 
adaptors signal in a similar signal cascading fashion to activate the appropriate response. 
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Figure 1.2 Signal transduction of TLRs following ligand recognition. Shown above are 
each human TLR with examples of their respective ligands. Following ligand recognition, each TLR 
initiates a downstream signalling cascade through their cytoplasmic TIR domains to their adjacent 
adaptor molecules. Every TLR is believed to signal through MyD88 with the exception of TLR3 
which requires TRIF. TLR4 may also signal through TRIF with the help of another adaptor molecule, 
TRAM. TLR2 also requires MAL to recruit MyD88 to the complex. Recruitment of MyD88 to the 
TLR receptor initiates downstream activation of TNF receptor associated factor 6 (TRAF6). This in 
turn activates transcription factor NF-kB which results in the transcription of inflammatory cytokines. 
Alternatively, if TLR4 is trafficked to the endosome upon ligand recognition, it recruits TRAM, 
which recruits TRIF. TLR3 also recruits TRIF upon ligand binding. This initiates downstream 
activation of TRAF3 and subsequently TBK1 which activates transcription factors known as IRFs. 
These IRFs then induce production of the anti-viral interferon genes. 
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NLRs, located in the cytosol, comprise more than 20 members in the mammalian 
genome, and even more in plants and some ﬁsh species [17, 18]. They are grouped into the 
following sub-families: Class II, major histocompatibility complex, Transactivator, (CIITA) 
NOD, NLR family pyrin-domain-containing proteins (NLRPs, also called NALPs), NLR 
family Caspase Activation and Recruitment Domain (CARD)-domain-containing (NLRC), 
Neuronal Apoptosis Inhibitor Proteins (NAIP) and NLRX [19]. We are still discovering the 
specific ligands for each of these receptors. We know that NOD1 senses the peptidoglycan-
derived peptide γ-D-glutamyl-meso-diaminopimelic acid, which is present mainly in Gram-
negative bacteria [20]. NOD2 detects muramyl dipeptide, which can be found in a wide range 
of both Gram-positive and Gram-negative bacteria. Obviously this would indicate that the 
recognition specificity of NOD2 is markedly broader than that of NOD1 [20]. Evidence of 
cross-talk or interplay between these PRRs is apparent. For example, in a study carried out by 
Kim et al 2008 using NOD2 deficient macrophages, they were able to show that stimulation 
with synthetic a NOD2 ligand, Muramyl Di-Peptide (MDP) led to refractoriness to both MDP 
and a synthetic NOD1 agonist [21]. In addition, this NOD1 agonist induced tolerisation, not 
only to itself, but also to MDP. The cross-tolerisation between NOD1 and NOD2 signalling 
was associated with impaired NF-κB and MAPK activation in response to pre-treatment of 
macrophages with MDP and the NOD1 agonists. This highlights the possibility that 
individuals harbouring loss-of-function (LOF) NOD2 mutations leading to reduced or loss of 
tolerisation to MDP may result in increased production of harmful cytokines in response to 
NOD1-activating bacteria [21]. In fact, several LOF NOD2 mutations have been linked to 
dysregulation of inflammation in the gut, leading to the onset of Inflammatory Bowel Disease 
(IBD) [22, 23]. 
Data are converging to indicate that NLRs can be categorized into functional 
subgroups that regulate other crucial innate immune pathways (see Figure 1.3), such as NF-
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κB, MAPK, type I interferon (IFN), cytokines, chemokines, and reactive oxygen species 
(ROS) as well as ribonuclease L (RNase L) activation [24]. Figure 1.3 depicts the concept 
that one NLR can serve multiple functions, whereas multiple NLRs can also serve similar 
functions. For example, NLR proteins signal through different multi-component 
―signallosomes‖. NLR signalling modules include the NF-κB Inducing Kinase (NIK) 
pathway as well as the CIITA transcriptosome, involved in major histocompatibility complex 
expression. The functional and physical associations of NLR proteins with the mitochondrial 
antiviral signalling protein (MAVS; also known as IPS-1, VISA, and Cardif) is referred to as 
the IFN/cytokine–inducing mito-signalosome. There is also the NF-κB/MAPK–activating 
NOD1/2 complex (referred to as the nodosome), activation of which ultimately leads to the 
regulation of caspase-1 and NF-B activation. Also included are the caspase-1–activating 
inflammasomes. 
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Figure 1.3 NLR Signallosomes, adapted from Ting et al., 2010 [24]. This figure shows 
the concept that one NLR may serve multiple functions while multiple NLRs can also serve similar 
functions. Signalling modules here include the CIITA transcriptosome, the NF-B -activating 
NOD1/2 complex (referred to here as the ‗nodosome‘), and the NIK pathway. 
 
 
The term ―inflammasome‖ is used to describe the cytoplasmic multi-protein oligomer 
which forms in response to a broad range of stimuli including DAMPs such as extracellular 
ATP, and PAMPs. It functions primarily to regulate caspase-1 activation which in turn leads 
to the proteolytic processing of the pro-cytokines pro-IL-1α and pro-IL-18 [25]. In addition to 
this, active caspase-1 can also trigger a specific type of cell death, pyroptosis [26]. Pyroptosis 
is defined by its dependence on inflammasome activation and caspase-1 activity. Activation 
of pyroptosis ultimately leads to release of cellular contents and inflammation [27]. The exact 
composition of an inflammasome depends on the activator which initiates inflammasome 
20 
 
assembly. To date, four independent inflammasomes have been characterized: NLRP1, 
NLRP3 and NLRC4 (also known as IPAF), which are all members of the NLR family, as 
well as Absent In Melanoma 2 (AIM2) which belongs to the pyrin domain and HIN200 
domain containing protein family [28] (See Figure 1.4). Each of these inflammasomes also 
appears to involve the adaptor protein Apoptosis-associated Speck-like protein containing a 
CARD (ASC) as well as pro-caspase-1 for cytokine processing. While NLRP1, NLRC4 and 
AIM2 recognise specific molecules; bacterial cell wall components such as muramyl 
dipeptide, flagellin and dsDNA respectively, the NLRP3 inflammasome responds to a much 
broader spectrum of stimuli. These range from pore forming toxins to ATP [29]. Along with 
this, it has been shown that a ―priming signal‖ such as LPS, which upregulates NLRP3 
expression, is critically required for NLRP3 activation [26], although it is yet unknown what 
the signal which activates NLRP3 itself might be.  
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Figure 1.4 Graphical depiction of known inflammasomes. (A) NLRP1 contains, in 
addition to the NLR-typical LRR and NBD domains, a PYD, a FIIND, and a CARD. NLRP1 can 
recruit pro–caspase-1 and -5 and possibly forms a complex with NOD2. Recruitment of ASC 
enhances activation of pro–caspase-1. (B) NLRC4 contains a CARD that can directly recruit pro–
caspase-1. Reports further demonstrate a role for ASC and possibly NAIP5 in NLRC4 inflammasome 
activation. (C) NLRP3 activates pro–caspase-1 via recruitment of ASC. (D) AIM2 is a bipartite 
protein consisting of a PYD and DNA-binding HIN200 domain and recognizes cytoplasmic double-
stranded DNA and assembles the DNA inflammasome with ASC and pro–caspase-1. Adapted from 
Stutz et al., 2009 [28] 
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C-type lectin receptors (CLRs) are a heterogeneous group of transmembrane proteins. 
Many are expressed in myeloid cells and signal in response to pathogen-derived or self-
ligands to initiate or regulate cell activation. Sharing structural similarities with the 
immunoglobulin superfamily [30], the C-type lectin family of proteins encompasses upwards 
of 1,000 members with diverse functions including cell adhesion, regulation of natural killer 
function, complement activation, tissue remodelling, platelet activation, endocytosis, 
phagocytosis, and innate immunity [31, 32]. PAMPs recognised by CLRs are often made up 
of carbohydrates. Examples include glucans which are prominent constituents of the cell 
walls of fungi, plants, and mycobacteria; high-mannose structures expressed by some viruses, 
fungi, and bacteria; and fucose structures found on the surface of helminths and some 
bacteria [33, 34]. C-type lectins that recognize glycans, as well as others that do not bind 
carbohydrates have been shown to bind pathogens and to play a role in host defence. Also 
included in the same group are soluble defensins such as RegIII, which is produced in the 
gut and has direct microbicidal activity [35]. 
Evidence of synergy also exists between different PRR families in activation of 
inflammatory signals. For example a member of the CLR family, Dectin-1, is essential for the 
innate response to fungal pathogens [36]. It signals via Spleen Tyrosine Kinase (Syk) and the 
protein CARD9 [37]. Clear synergies between Dectin-1 and TLR2 have been reported, 
although the fungal ligand for TLR2 awaits definition. Syk is absolutely required for this 
synergy, as is MyD88 [38]. TLRs and NOD1 or NOD2 have been shown to signal to NF-κB 
via the protein kinase Receptor-Interacting serine/threonine Kinase (RICK), which could be a 
point of synergy [39]. This is somewhat controversial, however, because there have also been 
reports that NOD2 ligands such as MDP inhibit signalling by multiple TLRs. This inhibitory 
effect was shown to involve IRF4 [40]. In addition, NOD1- and NOD2-mediated signalling 
has been shown to be enhanced in macrophages made tolerant to TLR activation [41]. TLRs 
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are also known to induce pro-IL-1β production without causing activation of caspase-1 
required for its processing to become a mature cytokine. This activation of caspase-1 in this 
scenario is mediated by inflammasome activation through NLR signalling. 
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1.2 Innate immune responses in the intestinal epithelial barrier  
The intestinal epithelial barrier is a unique site in the human body, particularly in the 
context of innate immunity. Intestinal Epithelial Cells (IECs) line the intestinal tract and 
separate the underlying vascular gut mucosal tissue from the predominantly anaerobic lumen. 
This lumenal space is packed with resident commensal microbes. In fact, there are 10 times 
more bacterial cells in the human gut than the total amount of human cells in the body [42]. 
Commensal, harmful and beneficial microbial communities co-exist with our intestine, a 
hospitable place for bacteria. They are provided with a stable microenvironment rich in 
nutrients, and these bacteria in turn provide the host with essential nutrients (such as vitamin 
K or biotin). Furthermore, these bacteria collaborate to aid in the digestion of food, prevent 
the expansion of pathogenic micro-organisms and even cooperate in intestinal development 
and in the modulation of the host immune responses [43]. Commensal bacteria, and 
specifically gut microbiota, have been given an increasing amount of attention with regard to 
their influence on our own bodily development and function at different levels. Areas 
affected include brain development and behaviour, metabolism, obesity, food digestion and 
overall resistance to stress and injury [44, 45]. Hence, the presence of these commensal 
microbes is a symbiotic relationship where both they and the host benefit from one another. 
Due to the level of contact between commensal gastro-intestinal bacteria and host 
cells in this region, maintaining homeostasis is critically important. Homeostasis is a state of 
equilibrium: maintaining enough of an immune response to control microbial growth while 
avoiding over-activation of the immune system. The gut epithelium ensures that an effective 
immune response is raised to infectious micro-organisms while itself remaining 
predominantly unresponsive to the myriad commensal bacteria it is in contact with. This is 
achieved by preventing the contact of bacteria with immune cells through the formation of a 
physical barrier and the expression of antimicrobial peptides [46-48]. Dysregulation of 
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immune responses in this region can lead to breakdown of homeostasis and onset of colonic 
inflammation or colitis and Inflammatory Bowel Diseases  such as Crohn‘s disease and 
ulcerative colitis [49]. These occur in clinically immune-competent individuals whose 
characteristic symptoms and signs arise from a robust, cytokine-driven, yet non-infectious 
inflammation of the gut [50]. Patients report gastrointestinal symptoms of abdominal pain, 
diarrhoea, and rectal bleeding as well as systemic symptoms of weight loss, fever, and 
fatigue. A better understanding of the mechanisms our body uses to maintain intestinal 
homeostasis would better allow us to treat patients with IBD when this balance has been 
dysregulated. 
Homeostasis in the intestinal tract could be maintained by unique features of IECs, 
rather than unique features of commensal bacteria. In fact, the innate immune system, to a 
great extent, controls the microbiota in the intestine [43] and in addition to their role as a 
protective barrier at this mucosal interface, IECs have also been shown themselves to play a 
very important part in our body‘s immune response [51]. IECs are structurally and 
functionally polarized, with an apical surface facing the anaerobic intestinal lumen and a 
basolateral surface facing the adjacent cells in the lamina propria.  
This polarisation gradient, leads to a differential gene expression gradient across the 
epithelium. This spatial organisation of the IECs allows for distinct functions at each surface 
utilising distinct membrane proteins [52]. The polarity and tight junctions of IECs play a 
particularly important part in this response, enabling the segregation of apical signals from 
basolateral signals in pathogen recognition. This is mediated through differentially expressed 
PRRs such as TLRs. TLRs are involved in regulation of the epithelial barrier through 
modulation of the critical mucosal antibody, Immunoglobulin A (IgA) from B cells in 
addition to the maintenance of intestinal integrity across tight junctions and expression of 
antimicrobial peptides [43]. TLR2 and TLR4, for example, have been shown to be present at 
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the apical surface of polarized, confluent IEC, in the cell line T84, which readily respond to 
acute stimulation with the corresponding bacterial ligands [53-55]. In contrast, TLR2 and 
TLR4 are mostly present in the cytoplasmic compartment in undifferentiated IEC and are 
expressed in much lower amounts than in differentiated IEC. This correlates with ligand 
tolerance as these cells are predominantly unresponsive to TLR2 and TLR4 ligands [53]. 
Furthermore, constitutively active expression of epithelial TLR4 does not induce mucosal 
inflammation in TLR4 transgenic mice [56, 57]. TLR2 expression in particular has been 
shown to play a specific role in IEC homeostasis. It controls tight-junction-associated 
intestinal epithelial barrier integrity in order to balance mucosal homeostasis against 
inflammatory-stress-induced damage. This is achieved by targeted modulation of barrier 
function proteins such as ZO-1 and Conexin43 (Cx43) following TLR2 activation [58, 59]. 
TLR2 and TLR4 have in fact been demonstrated to translocate from apical to basolateral 
surfaces upon stimulation by commensal bacterial associated molecular patterns [53]. TLR5 
has been shown to only be expressed intracellularly or basolaterally in the colon [60], thereby 
avoiding an inappropriate inflammatory response to flagellated commensal bacteria present in 
the gut lumen. Furthermore, TLR5 knockout mice develop colitis spontaneously. This 
spontaneous colitis induction is protected against by cross breeding these mice with TLR4 
knockout mice indicating that the mucosal inflammation is TLR4-dependent without TLR5 
regulation [61]. An intracellular protein in immune cells, TLR9 has been shown to be 
expressed on the cell surface of IEC, both on the apical and basolateral membranes. In vitro 
studies using IEC lines in addition to several in vivo studies using mice have revealed distinct 
signalling patterns between apical versus basolateral stimulation of TLR9 [62-64]. 
Basolateral stimulation of TLR9 initiates an inflammatory signalling cascade while apical 
stimulation induces signals which inhibit inflammatory responses from basolateral activation 
of several TLRs. This is how, in a single IEC, TLR9 is able to induce immune tolerance from 
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activation by commensal bacteria in the apical surface while still activating an inflammatory 
response when potentially pathogenic invasive microbes are detected having crossed the 
barrier on the basolateral membrane. The in vivo model of colitis has been studied using a 
substance known as dextran sodium sulphate (DSS). DSS is known to disrupt the intestinal 
barrier and alter intestinal permeability, allowing intestinal microbiota to gain access to the 
intestinal mucosa [65]. Surprisingly, stimulation of TLRs 2, 3, 5 and 9 has been shown to 
protect against DSS induced colitis, while knock-out mice for TLR2, 4 and MyD88 are more 
susceptible to DSS colitis [57]. These results are the opposite of what would be expected 
based on the direct effects of TLR activation, and therefore suggest that TLRs limit 
inflammation indirectly in the intestinal epithelium. 
With regard to the role of NLRs in IECs, much evidence exists supporting a 
protective role for these intracellular receptors in IBD. For instance, Nod1 promotes epithelial 
cell survival, reducing apoptosis and permeability [66]. Nod2 is known to promote inhibition 
of TLR signalling and inflammation in addition to enhancing regulatory T cells which curtail 
inflammatory signalling and, as discussed earlier, loss of function mutations have been 
associated with development of IBD [22, 23, 40, 67, 68]. NLRC4-deficient mice have been 
shown to have increased levels of CXCL1 in colitis and exhibit tumour formation. 
Additionally, NLRC4 is believed to be involved in differentiation between commensal and 
pathogenic bacteria [69, 70]. The role of NLRP3 has yet to be fully uncovered. One study has 
implicated DSS induced colitis in mice as being mediated by NLRP3 [71]. On the other hand, 
it can promote barrier integrity and help maintain intestinal homeostasis [72, 73]. It is also 
known to prevent colitis-associated tumourigensis [74, 75]. NLRP6 inhibits tumour formation 
during colitis and excessive epithelial proliferation [76, 77]. NLRP12 controls pro-
inflammatory cytokines and epithelial proliferation. It also represses canonical NF-κB 
signalling and tumourigenesis [78]. 
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RLRs play a role in innate immune recognition in IECs also. For example viral RNA 
sensors RIG-I and MDA-5 are known to be expressed intracellularly in IECs and are 
responsible for the detection of double stranded (ds) RNA viruses [79]. However, it is 
unlikely that they play a role in regulating homeostasis as they are specifically designed to 
prevent invasive viruses from hijacking our cellular machinery and do not recognise ligands 
from commensal microbiota. While several roles for CLRs have been implicated in immune 
cells involved in gut inflammatory regulation, there have been few studies on CLRs in IECs 
to date. We do know of a soluble CLR, RegIIIγ, which is induced by MyD88 in IECs and is 
known to have bactericidal properties against invading pathogens such as L.monocytogenes 
[80]. However, little else is known on CLR expression or function, inflammatory or 
protective, in IECs at present. 
The expression and localisation of TLRs, RIG-I receptors and NLRs in the epithelia 
of mice and humans is summarised in Table 1.1 [81]. This table draws attention to the fact 
that while some families, such as TLRs, have received a lot of attention and are quite well 
characterised, new information such as the functionality and expression of CLRs is only just 
coming to light [82-84] with much investigation yet to go. CLRs are, in fact, omitted from 
this table as they require further investigation and indeed, an update on expression/function of 
the more extensive NLR family‘s in this region would also be beneficial.  
A greater need for understanding the complete function of PRRs in IECs is called for 
in this regard. Uncovering the mechanisms underlying dysregulated inflammatory responses 
would allow us to better treat such inflammatory disorders as IBD. Learning how tolerance is 
achieved would be beneficial for several reasons. Overcoming tolerance would further the 
development of convenient orally-delivered vaccines through activation of the adaptive 
immune system. Conversely, manipulating innate immune responses in this region may also 
allow us to induce tolerance against self-antigens to treat for auto-immune disorders [85]. A 
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simpler approach is the study of how our innate immune system responds to pathogenic 
infection through the intestinal epithelial interface. All work performed in this thesis involved 
investigating the role of PRRs in the intestine. In the final two results chapters I focussed on 
detection of the pathogen L.monocytogenes by PRRs in the intestine and as such, I aim to 
introduce this topic in the next section. 
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Receptor Subcellular 
localization 
Ligand Origin of ligand 
TLR2 Cell surface Lipoteichoic acid G (+) bacteria 
    Lipoprotein/ lipopeptides Various pathogens 
    Hemoagglutinin protein Viruses (Measles Virus) 
    Glycosyl-
phosphatidylinositols 
Parasites (Toxoplasma 
gondii) 
TLR2/1 Cell surface Triacyl lipopeptides Bacteria and mycobacteria 
TLR2/6 Cell surface Diacyl lipopeptides Mycobacteria 
    Zymosan Fungi 
TLR3 Cellular 
compartment 
dsRNA Viruses 
TLR4 Cell surface Lipopolysaccharide G (−) bacteria 
    Envelope proteins Viruses (Respiratory 
Syncytial Virus) 
    Glycosyl-
phosphatidylinositols 
Parasites (Toxoplasma 
gondii) 
TLR5 Cell surface Flagellin Bacteria 
TLR7/8 Endosomal ssRNA Viruses 
TLR9 Endosomal/cell 
surface 
CpG-containing DNA Bacteria and viruses 
TLR11 Cell surface Uropathogenic bacteria 
component 
Bacteria (uropathogenic 
Escherichia coli) 
    Profilin Parasites 
NOD1 Cell cytoplasm Meso-diaminopimelic 
acid 
PGN of G (−) and some G 
(+) bacteria 
NOD2 Cell cytoplasm Muramyl dipeptide PGN of G (+) and G (−) 
bacteria 
RIG-I Cell cytoplasm 5′-triphosphate-bearing 
RNAs 
Viruses 
 
Table 1.2 The PRRs of the Intestinal Epithelium: Subcellular localization, and 
recognized ligands. Adapted from Well et al. 2011 [81]. G (+), Gram-positive; G (−), Gram-
negative; dsRNA, double-stranded RNA; ssRNA, single-stranded RNA; PGN, peptidoglycan; Meso-
DAP, γ-D-glutamyl-meso-diaminopimelic acid; MDP, muramyl dipeptide NOD1, nucleotide 
oligomerization domain-like receptor 1; NOD2 nucleotide oligomerization domain-like receptor 2. 
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1.3 Listeria monocytogenes 
Listeria monocytogenes (L.monocytogenes) is a foodborne Gram-positive bacterium 
and a facultative infectious intracellular pathogen that causes listeriosis. This may lead to life 
threatening diseases (such as septicaemia and meningitis) [86], particularly in immuno-
compromised individuals, pregnant women, and neonates [87]. Epidemics are associated with 
severe symptoms and high mortality rates. Pathogenic listeriae enter the host primarily 
through the intestine [88]. They cross the intestinal barrier by invading intestinal epithelial 
cells. This initial, subclinical step of listeriosis is actually believed to be common due to the 
frequent presence of pathogenic L.monocytogenes in food, such as meat and dairy products 
[88]. Between crossing the IECs and entry into the bloodstream, they reach their target 
organs, the liver and spleen via the lymphoid system and the blood, where they are 
internalized by splenic and hepatic macrophages. In the liver, listeriae actively multiply until 
the infection is controlled by an activated Dendritic Cell (DC) and adaptive immune cell-
mediated immune response. During severe infections, the bacteria disseminate via the blood 
and cross the blood–brain barrier resulting in infections of the meninges and the brain. 
Furthermore it can cross the foeto-placental barrier in pregnant women which leads to 
infection of the foetus.  
As with all pathogens, the ability to evade immune surveillance is critical to a 
successful infection, and L.monocytogenes employs many strategies by which it can evade 
host immune responses, thus promoting survival. L.monocytogenes infection of macrophages 
proceeds via phagocytosis followed by escape from the phagosome into the cytosol through 
the action of the pore-forming toxin Listeriolysin O (LLO) [89, 90]. Intracellular secretion of 
a pore-forming toxin appears to be unique to L.monocytogenes infection. Once it becomes 
established here, it is resistant to intracellular killing [91]. L.monocytogenes creates an 
intracellular niche dependent on its capacity to adhere to, invade and multiply within a 
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variety of normally non-phagocytic cells, such as enterocytes, hepatocytes, fibroblasts and 
endothelial cells [92]. This ability of L.monocytogenes to establish itself intracellularly 
avoiding phagocytosis aids the bacterium in evading host responses and ensures effective 
tissue dissemination and enhanced virulence. For a long time this mechanism of intracellular 
spread was thought to be the main strategy employed by L.monocytogenes to avoid immune 
detection. However, with the discovery of host recognition receptors and increased 
understanding of innate immune signalling pathways, it has been shown that the bacterium is 
also capable of avoiding detection through other mechanisms. An example of this is the 
modification of bacterial ligands to avoid detection by the PRRs of the innate immune 
system. Additionally, they are known to modulate host signalling pathways and target host 
immune effector cells, thereby evading host innate defences [93] (see Figure 1.5).  
L.monocytogenes has more recently been shown to modulate the host immune 
signalling network by a downstream approach through epigenetic manipulation. Epigenetics 
is the study of heritable changes in gene expression or cellular phenotype, caused by 
mechanisms other than changes in the underlying DNA sequence. Chromatin, the highly 
organised structure into which our DNA is packed, is made up of nucleosomes; an octamer of 
a family of proteins called histones. The structure of the chromatin may be remodelled by 
proteins which perform acetylation, phosphorylation, methylation and ubiquitination of these 
histones and the DNA [94-96]. This opens up/closes off parts of the genome for transcription 
and thus regulation of gene expression may be controlled by these histone modifying proteins 
[96]. L.monocytogenes has been shown to induce dephosphorylation of histone H3 and 
deacetylation of histone H4 by secretion of LLO prior to invasion – leading to reduced 
transcription of some key host immunity genes [95]. Among these are IRF3, C-X-C motif 
Ligand 2 (CXCL2), which encodes a proinflammatory chemotactic chemokine, and Dual 
specificity protein phosphatase 4 (DUSP4), a gene required for MAPK signalling [95]. In this 
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way, L.monocytogenes can reduce initial host inflammatory signalling by blocking TLR2 and 
NOD1 induced responses such as p38 and ERK MAPK pathways [95]. 
L.monocytogenes manipulates the endocytic and many host-cell signalling cascades in 
order to replicate and avoid detection. Some of these have been highlighted in Figure 1.5. 
However, host cells possess surveillance systems at different cellular compartments capable 
of detecting L.monocytogenes infection and activating defence pathways which in most cases 
might control infection [97]. 
 
 
  
Figure 1.5 Mechanisms by which L.monocytogenes evades innate immune recognition. 
The figure above illustrates some known mechanisms by which Listeria evades innate immune 
responses. In addition to establishing itself intracellularly avoiding phagocytosis, L.monocytogenes 
releases the toxin LLO prior to invasion. This is involved in the modification of histones H3 and H4 
which in turn leads to reduced signalling by MAPK, IRF3, p38 and ERK. Additionally, 
L.monocytogenes deacetylates its peptidoglycan (PGN) to avoid recognition by TLR2 and NOD1. It 
is also thought to induce type I IFNs in order to reduce type II IFN signalling and increase apoptosis 
of lymphocytes. 
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1.4 Systemic innate immune responses to L.monocytogenes infection. 
In humans, infection normally initiates at the intestinal epithelial interface. 
L.monocytogenes can invade epithelial cells through interactions of its virulence proteins with 
host receptors. For example, Internalin A (InlA) from L.monocytogenes interacts with 
Epithelial cadherin (E-cadherin) to mediate entry via a membrane bound vacuole [98, 99]. 
Internalin B (InlB) on the other hand, binds the host receptor tyrosine kinase, c-Met (natural 
receptor for hepatocyte growth factor HGF) thereby making use of multiple mammalian cell 
types (including murine liver cells) for invasion [100, 101]. Another important 
L.monocytogenes virulence factor known to be important in infection is the L.monocytogenes 
adhesion protein (LAP). Human Hsp60 has previously been identified as the epithelial 
receptor for LAP [37]. Following escape from the phagosome through LLO, the bacteria may 
now replicate to high numbers in the cytosol. Cytosolic L.monocytogenes express ActA 
which can induce host-cell actin polymerisation and facilitates direct cell to cell spreading; 
this again aids the bacteria to escape extracellular immune detection [102, 103]. 
Intestinal L.monocytogenes infection is not efficient in mice. This has been attributed 
to poor interactions between InlA and E-cadherin on murine intestinal epithelial cells [104]. 
Hence, due to the difficulties surrounding invasion of the bacteria when administered orally 
in mice, studies investigating immune responses to L.monocytogenes infection in vivo have 
focussed more heavily on systemic infection through intraperitoneal or intravascular 
injection, thus bypassing the intestinal epithelium. Furthermore, the ability of the pathogen to 
invade and multiply within phagocytic cells has shifted the focus of bacteria/host interactions 
away from IECs and more towards immune cells in order to further elucidate its evasion 
strategies.  
Autophagy is a cytosolic self-digestion pathway which also plays a part in innate 
immunity against intracellular pathogens. Components in the cells cytoplasm are sequestered 
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into double membrane structures known as autophagosomes and degraded [105]. 
L.monocytogenes has been reported to evade autophagy in macrophages in addition to 
escaping autophagic vacuoles and replicating cytosolically [106]. Another study using severe 
combined immunodeficient (SCID) mice reported L.monocytogenes within liver granuloma 
macrophages to be replicating within vacuoles which were termed spacious L.monocytogenes 
-containing phagosomes (SLAPs) [107]. The formation of these SLAPs is thought to result 
from an attempt to prevent bacterial escape into the cytosol by autophagy of damaged 
phagosomes. However, LLO prevents maturation of these phagosomes thereby establishing a 
more steadfast infection by allowing bacterial replication and survival within these 
compartments [107]. 
We know that when L.monocytogenes enter the bloodstream from the gut lumen, they 
move to their target organs; the liver and the spleen where they continue to multiply. 
However, there is an abundance of sentry cells in the bloodstream armed with a vast array of 
various PRRs. Within 1-2 minutes of entering the bloodstream, L.monocytogenes is taken up 
by various myeloid cells and other tissues [108]. Resident myeloid cells in the marginal zone 
of the spleen, such as dendritic cells, macrophages and neutrophils, function to filter the 
bacteria out of the blood [109, 110]. A secreted L.monocytogenes protein, p60, has been 
found to bind DCs and stimulate them to robustly activate NK cells in the absence of other 
L.monocytogenes factors in an IL-18 dependent manner [111, 112]. Production of IFN-γ 
induces bacteriocidal activity in macrophages and promotes maturation of monocytes to the 
main effector cells, the TNF and inducible Nitric Oxide Synthase (iNOS) producing effector 
Dentritic Cells (TipDCs). Some of these phagocytic cells manage to protect the host by 
killing engulfed bacteria, while others create an environment for rapid L.monocytogenes 
growth and dissemination. While patrolling neutrophils phagocytose relatively few bacteria 
initially [108, 109], their extremely effective killing has been shown to reduce 
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L.monocytogenes burdens in the liver from 10-100-fold within 12-24 hours post-infection 
[113]. However, these effects are not seen in the spleen or peritoneal cavities.  
Most reports seem to agree that initial detection occurs at the cell surface or, in the 
case of phagocytic cells, in phagosomes by TLR2 and, following internalisation, in the 
cytosol by NOD-like receptors (NOD1, NOD2) as well as NALP3 and NLRC4 (IPAF) [41, 
114, 115], which can lead to NF-κB-dependent pro-inflammatory gene expression. However, 
there remains some controversy and conflicting reports over which PRRs play the key 
effective parts in L.monocytogenes detection. For example, caspase-1 activation is known to 
be required for the clearance of L.monocytogenes in murine infection [116] and recent reports 
have suggested that L.monocytogenes activates caspase-1 through multiple NLRs. However, 
although much work has been carried out in this area, there are conflicting reports regarding 
the contributing roles of NLRP3, AIM2, and NLRC4 inflammasomes leading to caspase-1 
activation in L.monocytogenes infected macrophages [72, 74, 76-80].  
TLR2-deficient mice have been shown to have a higher susceptibility to infection 
with L monocytogenes [114]. CD14 is involved in co-recognition by TLR2 of various TLR 
ligands, such as peptidoglycan from Staphylococcus aureus and Streptococcus pneumonia 
[117], human cytomegalovirus [118] and secreted microbial products from group B 
Streptococcus [119]; lipoteichoic acid–induced cell activation also depends on CD14 [120]. 
By using neutralizing antibodies to CD14 in TLR2-transfected CHO cells, the induction of 
TNFα production by heat-killed L.monocytogenes (HKLM) was shown by one research team 
to depend, in part, on CD14 associated with TLR2 [121]. Reduced CD14 expression results 
in bacterial persistence, reduced NOS2 expression in the liver, and heightened mortality 
[122]. In addition to this, the same group discovered that mice that are both CD14 deficient 
and TLR2 deficient display susceptibility to infection that is comparable to that of mice 
deficient in either CD14 or TLR2 alone [122]. 
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While TLR2 may sense lipoteichoic acid found on the surface of L.monocytogenes, 
the bacteria is known to carry out N-deacetylation of peptidoglycan to avoid this detection by 
TLR2 and NOD-like receptors [123]. Interestingly, Edelson et al. (2002) [124] were able to 
show a redundancy for TLR2 in L.monocytogenes recognition such that in its absence, other 
molecules were sufficient for its control. In macrophage cells, killing of L.monocytogenes 
was not altered by the absence of TLR signals and was found to occur through a MyD88 and 
TLR2 independent mechanism [124]. However, MyD88 was shown to be essential for early 
L.monocytogenes resistance and full activation of the immune response in mice. This was in 
part due to its role as adaptor molecule for downstream signalling in the IL-1 and IL-18 
receptors but mainly due to its role as adaptor molecule in TLR signalling, i.e. MyD88-
independent responses to L.monocytogenes alone are insufficient for in vivo resistance [124] 
indicating that MyD88 but not TLR2 may be essential for L.monocytogenes recognition. A 
more recent finding by Jones et al. (2011) [125] using TLR2 deficient and wild type 
macrophages outlined a clear role for rapid AIM2 inflammasome  activation in 
L.monocytogenes and F.novidica infection [125]. They also explain how in similar studies 
using the same methods which found no link between TLR2 and inflammasome activation 
[126], a much higher MOI had been used which may have masked the actions of TLR2 
observed in their own model of the experiment with a smaller and perhaps more realistic 
MOI. 
Two studies involving TLR2-mediated type I IFN production in response to 
L.monocytogenes emerged quite close together. Aubry et al. used a mutant strain of 
L.monocytogenes ΔpgdA, which is unable to modify its peptidoglycan (pgdA is the gene in 
L.monocytogenes responsible for deacetylation of peptidoglycan) [127]. Using this strain, 
they were able to demonstrate an unconventional signalling pathway to IFN-β production 
requiring TLR2 and bacterial internalisation. Induction of IFN-β was independent of MAL or 
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MyD88 but required TRIF signalling to activate transcription factors IRF3 and IRF7 in 
peritoneal macrophages [127]. Dietrich et al. performed a similar study using knockdown of 
pgdA. This lead to less IFN-β production in peritoneal macrophages [128]. TLR2-dependent 
IFN-β induction was shown to be triggered intracellularly following ligand binding and while 
TLR2 or TRIF deficiency strongly reduced IFN-β synthesis, it was not enough to silence it. 
Furthermore, they managed to show that blocking TLR2 internalisation or endolysosomal 
acidification inhibited the ability of TLR2 to induce type I IFN but not pro-inflammatory 
responses. The group then investigated the potential contribution of intracellular, nucleic 
acid-dependent pathways. Intact but not DNase-treated L.monocytogenes DNA was shown to 
significantly induce IFN-β [128]. IFN-β was significantly reduced in macrophages 
transfected with DNase treated over non-DNase treated lysosome-digested L.monocytogenes 
[128], suggesting the involvement of another pathway. 
Double deficiency in MyD88 and TRIF was shown not to affect wild-type 
L.monocytogenes induced type I interferons, suggesting the mechanism to be independent of 
TLR signalling [129]. RIG-I and MAVS knock-down resulted in abolishing the IFN response 
in epithelial cells, but the IFN response in monocytic cells remained unaffected. By contrast, 
knockdown of DNA sensing Stimulator of Interferon Genes (STING) in monocytic cells 
reduced cytosolic L.monocytogenes-mediated type-I-IFN induction. These results suggest that 
detection of L.monocytogenes RNA by RIG-I represents a non-redundant cytosolic immune-
recognition pathway in non-immune cells lacking a functional STING dependent signalling 
pathway [130]. 
RNA interference and inhibitor experiments using human PBMCs as well as 
experiments in NLRP3 and RIP2 knockout bone marrow-derived macrophages were 
performed by Meixenberger et al in 2009, in order to determine the PRRs (and 
inflammasomes) which play key roles during L.monocytogenes infection. The results 
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indicated that the L.monocytogenes-induced IL-1β release was dependent on the adaptor 
protein ASC, caspase-1, and NLRP3, whereas in this case, NOD2, Rip2, NLRP1, NLRP6, 
NLRP12, NLRC4, and AIM2 appeared to be dispensable [131]. 
A study carried out in 2010 by Kim et al. showed NLRP3 and AIM2 inflammasomes 
to be critical in macrophages for control of L.monocytogenes infection [26]. LLO, used by the 
bacteria in escaping phagosomal compartments, was outlined to be critical in activating the 
apoptosis-associated speck-like protein containing a CARD (ASC) which was in turn critical 
for activation of the NLRP3 inflammasome and the AIM2 inflammasome. NLRC4 and 
NLRP1 were reported as being dispensable i.e. activation of Caspase-1 and subsequent IL-1β 
production were not critical in L.monocytogenes detection. These results would suggest that 
under conditions of predominant lysosomal damage, yet limited cytosolic replication, NLRP3 
inflammasome activation would play the major role in detection of the bacteria. This might 
happen when L.monocytogenes has infected the cell and is escaping into the cytosol. 
Following this, in the case of high cytosolic replication, AIM2 recognition of 
L.monocytogenes DNA may predominate in driving the inflammatory signal [26]. 
Similar to the above findings, another group, using RNA interference studies on 
PBMCs found no evidence that NLRC4 is critical for caspase-1 activation in 
L.monocytogenes-infected macrophages [26, 131]. Others observed a partial role for NLRC4 
in caspase-1 activation in L.monocytogenes infected macrophages [132]. NLRC4 (IPAF) 
activation is dependent on the release of cytosolic flagellin, yet flagellin expression in 
L.monocytogenes is temperature dependent with expression in some strains being switched 
off at 37°C [133]. In contrast with other results, it was reported by Wu et al. that caspase-1 
processing is almost absent in LPS-non-primed NLRC4-KO macrophages infected with WT 
and flagellin-deficient L.monocytogenes. This demonstrates a critical role for NLRC4-
mediated Caspase-1 activation in L.monocytogenes-infected macrophages in the absence of 
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LPS priming [134]. This could explain the seemingly contradictory results between these 
findings and the previous studies in which macrophages were primed with LPS prior to 
infection with L.monocytogenes. The WT L.monocytogenes strain (10403s) used in the 
experiments by Wu et al expresses flagellin at 37°C [133], which excludes the possibility that 
defective expression of flagellin under the conditions of the experiment is responsible for the 
failure to activate caspase-1 in NLRC4-KO macrophages. LPS priming was shown to 
potentiate inflammasome activation by L.monocytogenes in NLRC4-KO and NLRP3-KO 
macrophages, indicating that prior LPS priming of macrophages can bypass the requirement 
for NLRC4 and/or NLRP3 [134]. Recent studies documented that this LPS priming triggers 
de novo protein synthesis via TLR4, which is a critical prerequisite for inflammasome 
activation by various danger signals [135]. It is therefore likely that LPS priming may up-
regulate inflammasome or inflammasome-related gene expression to bypass upstream 
NLRC4 signalling. LPS priming may also obscure the roles of various inflammasomes in 
regulating caspase-1 activation in response to L.monocytogenes infection, since while 
knockout of NLRP3 is not sufficient to abrogate caspase-1 activation by either wild-type or 
flagellin-deficient L.monocytogenes, it does reduce caspase-1 activation significantly [134]. 
This suggests that NLRP3 inflammasomes contribute to caspase-1 activation in response to 
L.monocytogenes infection, which is consistent with previous reports [26, 29, 131, 132]. 
While activation of the NLRC4 inflammasome by L.monocytogenes was shown to enhance 
innate-response mediated protection, resulting in faster clearance of primary challenge, this 
gives rise to a dampened secondary response causing impaired control of secondary 
L.monocytogenes challenge [136, 137]. 
Nitric Oxide Synthase 2 (NOS2) has been reported to be dispensable for killing of 
L.monocytogenes by IFN-γ-activated macrophages while NOS2 deficient mice are only 
modestly more susceptible to systemic L.monocytogenes infection [124, 138, 139]. In a study 
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by Cole et al, TLR2, TLR3, TLR4 and TLR9-activated macrophages were shown to have 
killed cell-free L.monocytogenes before they had invaded a host cell. However, TLR 
activation was found to be enhancing the efficiency of L.monocytogenes spread from ―donor‖ 
to ―recipient‖ macrophages. This enhancement required nitric oxide (NO) production by 
NOS2 [140]. NO increased L.monocytogenes escape from secondary vacuoles in recipient 
cells and increased Listeria survival and growth in the same cells. NO also promoted 
L.monocytogenes spread during systemic in vivo infection, as shown by the fact that 
inhibition of NOS2 reduced spread dependent L.monocytogenes burdens in mouse livers 
[140]. By contrast, when IFN-γ was added with LPS to pre-stimulate the cells, it failed to 
prevent NO-dependent increases in recipient cell infection with L.monocytogenes via cell-cell 
spread. This result indicates that during cell-cell spread the effects of LPS stimulation trump 
those of IFN-γ. 
Studies on mice have shown that in the absence of type I interferon signalling in mice, 
L.monocytogenes cannot reach as high titres as wild type mice and that mice with elevated 
levels of type I interferons have greater bacterial loads [93, 141]. A study by Carrero et al. 
shows that type I interferons induce T cell apoptosis early during L.monocytogenes infection, 
resulting in greater IL-10 secretion by phagocytic cells which in turn dampens the innate 
immune response [142]. Also, it is known that IFNαβ production may down regulate IFNγR 
thus reducing vital IFNγ responsiveness in the host [143]. This suggested that 
L.monocytogenes might induce type I interferons to its benefit to either directly enhance its 
growth, or more likely, down modulate a part of the immune response that plays an important 
role in controlling bacterial growth by means of ―misdirection‖ of the immune system. 
More recently, however, it was revealed that the route of infection taken by 
L.monocytogenes plays an important role in determining the effects that type I interferons 
have on the bacteria.  Kernbauer et al. [144] examined the effects of type I IFN signalling on 
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mice following intragastric versus intraperitoneal infection with L.monocytogenes. Until this 
point, almost all studies focussed on systemic infection with the bacteria through peritoneal 
injection due to the poor uptake of the bacteria through the mouse intestine. This intragastric 
route of infection was based on work by Wollert et al. [145] whereby they used a strain of 
‗murinised‘ L.monocytognes i.e. the InlA gene was improved for interaction with mouse E-
cadherin leading to increased invasion of L.monocytogenes. Mice deficient in IFN α/β 
receptor (IFNAR) were shown to have higher lethality and higher bacterial titres when 
infection was administered intragastrically. Peritoneal or bloodstream infection, however, 
were more easily controlled in mice deficient in type I interferons. While the type I 
interferons were not found to inhibit invasion of the gut mucosa or mucosa associated 
lymphoid tissue, absence of a type I IFN response exacerbated inflammatory pathology in 
livers of mice infected via the gastrointestinal route. Type I IFNs accelerated and increased 
proinflammatory cytokine activity after intragastric Listeria monocytogenes infection [144]. 
Most importantly, increased IFNγ production in the absence of type I IFN responsiveness was 
delayed and less pronounced after intragastric compared to intraperitoneal infection. 
Therefore, the influence of the entry route on the kinetics of IFNγ regulation by IFN-I may 
function as a key determinant of innate resistance. 
An earlier study had managed to demonstrate another possible beneficial effect of 
type I IFN signalling in defence against intracellular bacterial infection [146]. It was found 
that in murine infections with L.monocytogenes, both MyD88 and type I IFN mediated 
signals provided overlapping contributions to Monocyte Chemotactic Protein-1 (MCP-1) 
production and recruitment of monocytes. In the absence of either signalling pathway, 
chemokine expression levels were only partially reduced, but residual MCP-1 production was 
sufficient to mediate monocyte emigration from bone marrow. It was only when both MyD88 
and IFNAR mediated signals were absent that MCP-1 production was significantly reduced 
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to impair monocyte recruitment and effector Tip-DC accumulation in the infected spleen 
[146]. 
A schematic of systemic infection and the vital role played by the innate immune 
system in eventual clearance of the bacteria is displayed in Figure 1.6. The bacteria escape 
through the intestinal epithelium to the bloodstream by LLO mediated escape from vacuoles. 
In the bloodstream, the bacteria quickly disseminate to the liver and spleen. They are also 
capable of invading phagocytic cells such as DCs, neutrophils and macrophages where they 
continue to multiply in the cytosol. During this stage, NALP3, AIM2 and NLRC4 are all 
known to be involved in inflammasome activation; resulting in an increase of intracellular 
killing of the bacteria. Subsequent activation of TIP DCs and lymphocytes ultimately 
mediates clearance of the bacteria from the host. 
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Figure 1.6 PRRs involved in the systemic innate immune response to L.monocytogenes 
infection. The figure above depicts the systemic clearance of L.monocytogenes through innate 
immune signalling. 1:L.monocytogenes migrate from the intestinal epithelia through to the underlying 
mucosa and into the bloodstream. 2:Type I IFNs from IEC recognition of the bacteria activates type II 
IFN responses in the bloodstream and activation of effector cells. 3:L.monocytogenes invade and 
multiply within the cytosol of phagocytic cells. Here, they are recognised by NLRs and 
inflammasome activation leads to activation of effector cells, TIP DCs, and initiation of the adaptive 
immune response. 5:Uninfected TLR-activated phagocytes produce cytokines such as type II IFNs 
which, together with the effector cells and inflammasome activation, induce ROS-mediated 
intracellular killing of L.monocytogenes. 
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1.5 Innate immune recognition of Listeria monocytogenes in the gut 
Most natural infections with L.monocytogenes are acquired following ingestion and 
the subsequent uptake of bacteria through the mucosa of the gastrointestinal tract by intestinal 
epithelial cells. However, as discussed earlier, most laboratory studies characterizing immune 
responses to this pathogen use either intravenous or intraperitoneal inoculation to initiate 
infection. Consequently, most studies of infection with L.monocytogenes focus on immune 
responses to systemic infection bypassing the gut. By contrast, mucosal immune responses to 
infection with L.monocytogenes are less well characterized but are increasingly becoming the 
focus of investigation. This interface is where the pathogen first encounters our body‘s PRRs. 
However, as discussed earlier, there is a requirement for a review of PRR expression in 
Intestinal Epithelial Cells so that we may better understand their specific function in this 
setting.  
L.monocytogenes can invade epithelial cells through interactions of its virulence 
proteins with host receptors. As discussed previously, InlA from L.monocytogenes interacts 
with E-cadherin to mediate entry via a membrane bound vacuole [98, 99]. Another important 
L.monocytogenes virulence factor, LAP, has been shown to promote adhesion to intestinal 
epithelial cells and its expression is required for full virulence in orally infected mice [36]. 
Human Hsp60 has previously been identified as the epithelial receptor for LAP [37]. In wild-
type L.monocytogenes, the interaction of InlA with the epithelial receptor E-cadherin 
promotes invasion of intestinal epithelial Caco-2 cells, while interaction of LAP with the 
epithelial receptor Hsp60 mediates para-cellular transepithelial translocation [38].  
As mentioned earlier, most studies investigating L.monocytogenes infection have 
focussed on systemic infection using mouse models by administering the bacteria through 
intravenous or intraperitoneal injection, therefore bypassing the gut epithelium. However, 
Kobayashi et al. in 2005 outlined a study whereby NOD2
-/-
 or wild type mice were infected 
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with L.monocytogenes by intravenous, intraperitoneal or intragastric administration [115]. No 
difference in bacterial numbers in the liver and spleen or IL-6 production was seen between 
the wild type mice and the NOD2
-/- 
mice challenged with intraperitoneal or intravenous 
injection. However, when L.monocytogenes was administered intragastrically, more 
accurately reflecting the infection scenario in humans, NOD2
-/- 
mice showed significantly 
greater numbers of bacteria recovered from both the liver and the spleen than did wild-type 
mice. Furthermore, Mice lacking NOD2 failed to generate adaptive responses to 
L.monocytogenes in the gut [115]. Hence, NOD2 is believed to have a crucial role in 
detecting L.monocytogenes in the gastro-intestinal tract. 
A study by Lipinski et al demonstrated using Caco-2 intestinal epithelial cells that the 
NAD(P)H oxidase family member Dual Oxidase 2 (DUOX2) is involved in NOD2-
dependent ROS production [147]. Co-immunoprecipitation and fluorescence microscopy 
were used to show that DUOX2 interacts and co-localises with NOD2 at the plasma 
membrane. Moreover, simultaneous overexpression of NOD2 and DUOX2 was found to 
result in cooperative protection against the bacterial cyto-invasion of L.monocytogenes [147]. 
RNAi-based studies revealed that DUOX2 is required for the direct bactericidal properties of 
NOD2 - highlighting ROS as effector molecules of protective cellular signalling in response 
to a defined danger signal carried out by a mammalian intracellular NLR system [147].  
Studies following the activation of a mouse intestinal epithelial cell monolayer by 
L.monocytogenes infection demonstrated that while infection is necessary for detection of 
L.monocytogenes in IECs, chemokines may be produced by adjacent non-infected cells [148]. 
Immune responses to L.monocytogenes infection of the IEC monolayer was found to be in a 
NOD2-, NLRC4-, and NALP3-dependent fashion and resulted in Reactive Oxygen Species 
(ROS) production and subsequent MAP kinase signalling. The result involved horizontal 
innate communication, independent of gap junction formation, cytokine secretion, ion fluxes, 
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or nitric oxide synthesis, although was found to be mediated through Nox4-dependent oxygen 
radical formation [148].This was found to be sufficient to induce indirect epithelial cell 
activation and subsequent CXCL2 production. Nox4 activation has previously been shown to 
be involved in TLR4-mediated NF-κB activation in human epithelial kidney cells and 
monocytes [149]. ROS have also been shown to be important intracellular signal transducing 
molecules at subtoxic doses [150]. In accordance with these results, ROS-induced activation 
of MAP kinase activity was reported [151] in addition to NF-κB activation [152], apoptosis 
[151],epidermal growth factor receptor signalling [153], regulation of cellular proliferation 
[154], and antimicrobial peptide production [155]. In addition, Nox4 can function quickly as 
it operates independently of cytosolic accessory proteins [148]. Initiation of Nox4-dependent 
ROS production upon L.monocytogenes infection was noted as early as 5–10 minutes after 
bacterial challenge. It has also been shown that inflammasome mediated release of IL-1β is 
dependent on ROS activation [156-158]. 
We know of an effective role for NOD2 in the detection and downstream effector 
signalling following L.monocytogenes infection at the intestinal epithelial interface. However, 
NOD2 has remained the only well characterised PRR involved in detection of 
L.monocytogenes in IECs to date. The role of other PRRs in the setting of the epithelia 
requires further investigation. We also know how some of the PRRs expressed in the 
epithelia, listed in Table 1.1, function to detect L.monocytogenes elsewhere in the body. This 
provides us with some starting points to examine their roles in the setting of IECs. The 
importance of small messenger molecules such as ROS in this setting is becoming apparent 
and requires further clarification. 
Following internalisation into IECs, escape to the cytosol is mediated by LLO and the 
bacteria migrate further. Infection may spread laterally across the epithelia, as well as 
disseminating through the bloodstream. The intestinal epithelium is in close proximity to a 
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large number of gut-associated lymphoid cells, such as Isolated Lymphoid Follicles (ILFs) 
and most notably perhaps, the Peyer‘s Patches [159]. Herein lie specialised PRR expressing 
antigen-sampling cells; the M-cells which take up antigens and specific binding proteins by 
endocytosis. These cells then release chemokines in response to the antigens and attract 
antigen presenting cells, quite often being the Dendritic Cells DCs, to the apical area of the 
lymphoid follicles. Lacking lysosomes, the antigens may be passed on to antigen presenting 
cells relatively intact and presented to lymphoid cells lying in close proximity to the epithelial 
basal membrane [81]. 
To summarise, we now have a schematic of infection and the vital role played by the 
innate immune system in eventual clearance of the bacteria (see Figure 1.7). We know that 
infection predominantly occurs via the intragastric route. Here, the bacteria mediate entry to 
the intestinal epithelium. At this point, TLR2, NOD2 and RIG-1 are suggested to be involved 
in ROS signalling as well as type I IFN induction. This is believed to send early alarm signals 
to the innate immune effector cells and ready a type II IFN response to the infection. The 
bacteria then escape through to the bloodstream by LLO mediated escape from vacuoles. In 
the bloodstream, the bacteria quickly migrate to the liver and spleen. They are also capable of 
invading phagocytic cells such as DCs, neutrophils and macrophages where they continue to 
multiply in the cytosol. During this stage, NALP3, AIM2 and NLRC4 are all known to be 
involved in inflammasome activation; resulting in an increase of intracellular killing of the 
bacteria. Subsequent activation of TIP DCs and lymphocytes ultimately mediates clearance of 
the bacteria from the host. 
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Figure 1.7 Mechanisms of innate immune mediated detection and clearance of 
L.monocytogenes. 1: Bacteria mediate entry to the intestinal epithelium. 2: Escape from vacuoles 
mediated by LLO. TLR2, NOD2 and RIG I are believed to be involved in ROS signalling to adjacent 
cells and activating a type I IFN response. 3: Bacteria escape through the sub-mucosa to the 
bloodstream to reach the liver and the spleen. 4: Here they invade and multiply within phgocytic cells 
cells such as DCs, neutrophils and macrophages. 5: While in the cytosol, NALP3, AIM2 and NLRC4 
are all known to be involved in inflammasome activation; resulting in an increase of intracellular 
killing of the bacteria. 6: TIP DCs and lymphocytes are ultimately involved in clearance of the 
bacteria from the host.   
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Through discussing the route of infection and clearance of pathogenic 
L.monocytogenes, I hope to have highlighted the differential responses that take place 
throughout the body from various innate immune genes. How PRRs function elsewhere in the 
body is certainly not a definite indicator of how we expect them to operate in the intestinal 
epithelia for example. Yet, an understanding of both is necessary for us to get an overall 
picture of how the innate immune system functions so that we may better treat inflammatory 
disorders through manipulation of the immune system. Additionally, it will help us treat 
infectious diseases where we have identified the methods by which pathogens have evaded 
our host defence systems; this would allow us to specifically target pathogens by preventing 
such evasion. Overall, any further understanding of PRR function in this mucosal area is vital 
for the progression of oral vaccine development.  
The following thesis presents several studies in which I have aimed to investigate 
novel innate immune mechanisms regulating inflammation in the gastro-intestinal tract. Gut 
homeostasis is known to be maintained through complex interactions between the commensal 
microbes and host cells in addition to the polarisation of IECs and highly regulated 
expression of PRRs across this gradient and within the cells. Furthermore, in some cases PRR 
activation has been directly linked to maintaining homeostasis. With this knowledge, I chose 
three main strategies through which aimed to achieve uncovering novel innate immune 
mechanisms regulating inflammation in the gastro-intestinal tract. Firstly, I investigated the 
expression of TIR-domain containing proteins in commensal bacteria strains with the aim to 
subsequently study their potential innate immune subversion tactics through biomimicry. 
Secondly, I examined the hypothesis that direct stimulation of apical TLR9 on IECs has the 
ability to abrogate inflammatory signalling from further TLR activation. Thirdly, I identified 
several novel PRRs involved in detection of pathogenic L.monocytogenes in IECs, both those 
involved in activating and regulating an inflammatory response. The same study has led to 
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the identification of the previously uncharacterised TLR10 as a functional inflammatory 
receptor of IEC and macrophages responding to intracellular pathogens such as 
L.monocytogenes and S.typhimurium. 
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2.1 The following buffers were utilised in the laboratory: 
 
TBE buffer 
90mM Tris 
90 mM Boric Acid 
2mM EDTA 
 
RIPA lysis buffer 
50mM Tris-HCL pH 8.0  
150mM NaCl 
0.1% SDS 
0.5% Sodium deoxycholate 
1% Triton X-100 
1mM phenylmethylsulfonyl  
 
PBS (pH adjusted to 7.4) 
137mM NaCl 
2.7mM of KCl 
10mM of Na2HPO4.2H2O 
2mM KH2PO4 
 
SDS sample buffer (50ml) 
5ml glycerol 
10ml 10% SDS 
10mg bromophenol blue 
6.25 ml 1M Tris pH 6.25 
28.75 ml H2O 
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Stacking gel for Western blot (6ml) 
1ml 30% bisacrylamide mix 
0.75 ml 1 M Tris pH 6.8 
60μl 10% ammonium persulphate 
6μl TEMED made up to 6ml with H2O 
 
Resolving polyacrylamide gel for Western blot (15ml) 
30% bisacrylamide mix 
3.75ml 1.5 M Tris pH 8.8 
150μl 10% (w/v) ammonium persulphate 
6μl TEMED made up to 15 ml with H2O 
 
 
Unless stated otherwise, all reagents were obtained from Sigma-Aldrich, Dorset, UK. 
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2.2 Cell culture 
Caco-2 (ATCC number HTB-37), C2Bbe1 (ATCC number CRL-2102), HCA-7 
(Sigma-Aldrich), HEK 293 cells (ATCC number CRL-1573) and RAW 264.7 murine 
macrophages (a gift from Dr. R. J. Carmody, UCC) were maintained in DMEM (Thermo 
Scientific, Leicestershire, UK), HT-29 (ATCC number HTB-38D) in McCoys 5A (Thermo 
Scientific), T84 cells (ATCC number CCL-248) were grown in DMEM F12 (Sigma-Aldrich, 
Dorset, UK) and THP-1 cells (ATCC number TIB-202) in RPMI (Thermo Scientific), 
supplemented with 10% FCS (Thermo Scientific) and 10 g/ml of penicillin and 
streptomycin (Sigma-Aldrich) and cultured in a humidified incubator at 37ºC with 5% CO2. 
C2Bbe1 cell media was also supplemented with 10µg/ml transferrin (Sigma-Aldrich). For 
continuing cell culture, cells were seeded at ~1 x 10
5
 /ml and subcultured every 3-4 days up 
until passage number 24. In all cases cell viability was determined using the dye Trypan blue 
(Invitrogen, Paisley, UK) which is excluded from healthy cells but taken up by non-viable 
cells. Cells were counted using the Countess cell counter (Invitrogen). THP-1 cells were 
differentiated into adherent, well-spread macrophages by the addition of phorbol myristate 
acetate (PMA) (Sigma) (5 nM) and maintained for 3 days at 37°C, 5% CO2. Differentiated 
THP-1 cells were allowed to adhere over 48 hours prior to utilization in experiments. 
To obtain polarized epithelial-cell monolayers, T84 or Caco-2 IECs were grown on 
microporous filter inserts (0.4 μm pore size, Transwell; Costar, Washington D.C, USA) for 
21 days to obtain a differentiated monolayer. This was after transepithelial electrical 
resistance (TEER) reached at least 600 Ω cm2 as measured with WPI's EVOM Epithelial 
Voltohmmeter. 
The ligands Pam3Cys (50μg/ml); PGN (10μg/ml); LTA (10μg/ml); FSL-1 (5μg/ml); 
LPS (10ng/ml); Poly(I:C) (20μg/ml); TNFα (10ng/ml) (All Invitrogen) were used for cell 
stimulation assays as were bacteria (below).  
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Additionally, TLR9 stimulation involved the use of a range of concentrations of ODN 
2006 from Invitrogen or obtaining constructs of ODN 2006 CpG from MWG (Eurofins, 
Germany). Constructs were as follows where upper-case indicates phosphordiester bases and 
lower case indicates phosphorothioate bases: 
Invivogen construct: 5'-TcgTcgTTTTGTcgTTTTGTcgTT-3' –  
Indicated in text as ―Invivogen.‖ 
CpG as used in Lee et al. [1, 2]: 5'-TCGTcgTTTTGTcgTTTTGTcgTT-3' -  
Indicated in text as ―Lee.‖ 
 
2.3 Hypoxia simulation 
The HIF-1α gene was stabilised by adding Dimethyloxaloylglycine (DMOG) (a gift 
from the lab of Prof. Cormac Taylor, UCD, Dublin, Ireland) to a concentration of 500μM in 
the THP-1 or HT-29 cell culture medium 24 hours prior to analysis/further treatment in 
studies investigating effects of hypoxic conditions. 
 
2.4 Generation of competent bacterial cells for plasmid transformation 
The bacterial strain DH5α (a gift from Dr. S. Joyce, UCC) was grown in 10mls of LB 
broth (Sigma) and cultured overnight shaking at 37°C. 150μl of this culture was then 
transferred to fresh 10ml of LB broth and cultured for ~2 hours until an absorbance of 0.6 at 
600nm was reached. The cells were then centrifuged at 10,000 rcf for 10 minutes at 4°C and 
resuspended in 5 ml of ice cold 50 mM CaCl2. The cells were then incubated on ice for ~90 
minutes, aliquoted, frozen in liquid N2 and stored at -80°C. 
 
2.5 Bioinformatics 
All BLAST searches and sequence alignments were performed using UniProt 
(http://www.uniprot.org/) unless stated otherwise. 
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2.6 Subcloning of bacterial TIR proteins into plasmid vectors 
TIR gene sequences from bacteria were subcloned into the vectors pcDNA3.1 A 
Myc/His and pEF4/Myc-His A (both gifts from the lab of Dr. R. J. Carmody, UCC) the 
sequence of the constructs were confirmed by sequence analysis. A map of pcDNA3.1 A and 
its restriction site may be seen in the Appendix Figure 8.1. The cloning of BifTIR, EschTIR 
and POTTIR into the expression vector pcDNA3.1 myc-His A was performed using the 
restriction enzymes Hind III and Xho I (New England Biolabs, Hitchin, Herts, UK) and the 
primers used to amplify each TIR gene before insertion are as follows: 
 
BifTIR 
Forward primer: 5‘-GGG AAG CTT AG GTC ATG GCA CAC AAG ACT TTC ATC TCA- 3‘ 
Reverse primer: 5‘-CCC CTC GAG AAG CAG TTT TGT GAG GTC GTA- 3‘ 
 
EschTIR 
Forward primer: 5‘ -GCG AAG AAG CTT GG GTC ATG TAT AAT ATC CTT TTC TTC ATC- 3‘ 
Reverse primer: 5‘ -GC CTC GAG TCT TCT CCT GTA TGA TAT TTC- 3‘ 
 
POTTIR 
Forward primer: 5‘-CGCG AAG CTT GG GTC ATG GAA AAT ACT GTA TTT TTT- 3‘ 
Reverse primer: 5‘-GC CTC GAG CAT ATC ATC AGA GAA ATT ACA- 3‘ 
 
Each primer is shown with an underlined Hind III restriction site in the forward primer and an 
Xho I restriction site in the reverse primer. PCR was performed to amplify each of the TIR 
inserts using the Expand High Fidelity PCR system (Roche, West Sussex, UK). Inserts were 
then run on a 1% Agarose TBE gel and viewed using Ethidium Bromide under UV light. 
Using the PCR and Agarose gel Cleanup Kit (Roche), samples were then purified and ~1µg 
of DNA was cut with 1 unit of each restriction enzyme in the buffer at 37°C for 1 hour. The 
plasmid was purified following this ligation reaction using the High Pure PCR Clean Up 
Micro Kit (Roche). Following this, a ligation reaction was performed at room temperature 
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overnight with the insert and the vector using 1 unit of T4 ligase (New England Biolabs) at a 
ratio of 4:1 insert:vector. 
 
2.7 Transformation of ligation reactions 
Ligation reactions were incubated with 100μl of competent bacteria on ice for 10 
minutes. Bacteria were then subjected to 30 seconds heat shock at 42°C before being placed 
back on ice for a further 5 minutes. The mixture was then plated out on pre-warmed LB-agar 
plates, allowed to air-dry, inverted, and incubated at 37°C overnight. The resulting colonies 
from the transformation were streaked onto an agar plate and grown overnight at 37°C and 
thereafter stored at 4°C. 
 
2.8 Mini-preparations of plasmid DNA 
DNA from bacterial colonies was isolated using Wizard
©
 Plus SV Minipreps DNA 
purification system (Promega, Madison WI, USA). Briefly, bacterial cultures were grown in a 
5ml LB medium before being centrifuged and resuspended in 250μl Cell Resuspension 
Solution. Cells were incubated for 5 minutes with the addition of 250μl Cell Lysis Solution 
before addition of 350 μl Neutralization Solution. The mixture was centrifuged at 13,000 rcf 
for 10 mins at room temperature. The cleared lysate was transferred to a spin column inserted 
into a 2ml collection tube and the supernatant was centrifuged for 1 minute at room 
temperature and then washed with 750μl, then 250μl of Column Wash solution. The DNA 
was finally eluted by addition of 100μl Nuclease Free water. Insertion of the PCR product 
into the vector was then confirmed by restriction digest and running on a gel. 
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2.9 Maxi-preparations of plasmid DNA 
Plasmids were purified following the protocol for using the GenElute™ HP Plasmid 
Maxiprep Kit (Sigma). Transfected bacterial cultures were inoculated into LB media 
containing selection antibiotic e.g. 100 µg/ml of ampicillin. Bacterial cultures were grown, 
shaking at 275 rpm overnight at 37 °C. Each sample was prepared by harvesting 150 ml of 
bacterial culture by centrifugation at 5,000 rcf for 10 minutes. The pellets were thoroughly 
resuspended in 12 ml of Resuspension Solution and then subjected to a modified alkaline-
SDS lysis by the addition of 12 ml of Lysis Solution. The lysates were neutralized with the 
addition of 12 ml of Neutralization Solution. The lysates were transferred to individual filters 
and incubated at room temperature for 5 minutes. The lysates were drawn through the filters 
by vacuum resulting in a clarified lysate. The clarified lysates were prepared for loading onto 
the binding columns by the addition of 9 ml of Binding Solution. Binding columns were 
prepared by attaching them to a standard laboratory vacuum manifold followed by the 
addition of 12 ml of Column Preparation Solution, which was drawn through by vacuum. The 
lysate mixtures from above were loaded onto the binding columns and drawn through by 
vacuum. Contaminants were removed from the columns by washing with 12 ml of Wash 
Solution 1, followed by 12 ml of Wash Solution 2. The columns were allowed to dry for 10 
minutes while still under vacuum and then transferred to individual collection tubes. Finally, 
the plasmid DNA was eluted by the addition of 3 ml of endotoxin-free water and 
centrifugation at 3,000 rcf for 5 minutes. The plasmid concentrations of recovered eluates 
were then determined by taking absorbance readings at 260 nm. Total yield (ng/μl) was 
calculated by multiplying the concentration by the volume of recovered eluate. The purity of 
the plasmid DNA was determined by calculating the ratio of absorbance at 260 nm/280 nm. 
Samples were run on a 1% TBE agarose gel at 100 volts with a DNA ladder to reference size 
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and visually inspected to confirm their yield and purity. All sequencing was performed by 
Eurofins, MWG, Germany. 
 
2.10 Luciferase Assays 
HEK 293 or RAW cells were seeded at 2.5 x 10
4
/well in a 96 well plate 24h prior to 
transfection. Cells were transfected using Turbofect (Fermentas, Thermo Fisher Scientific, 
Waltham, MA, United States of America) according to the manufacturer‘s protocol using  
50ng of ISRE or NF-κB luciferase plasmid  and 5ng of Thymidine kinase Renilla luciferase 
along with varing amounts of either MyD88, Mal, TLR1, TLR2, TLR4, TLR6 or TLR10 (gift 
from Prof. L. O‘Neill, Trinity College Dublin, Ireland). 24 hours post transfection cells were 
infected with L.monocytogenes for 8 hours. Extracts were prepared by lysing the cells for 15 
minutes in 50μL Passive Lysis Buffer (Promega) and measured for Firefly luciferase and 
Renilla luciferase activity. Firefly luminescence readings were corrected for Renilla activity 
and expressed as fold stimulation over unstimulated empty vector (EV) control. 
 
2.11 Bacterial culture 
L. monocytogenes (wild-type, strain EGD-e serotype 1/2a) was a gift from Prof. 
Cormac Gahan, (UCC, Cork, Ireland). Bacteria were grown to the logarithmic growth phase 
in brain heart infusion (BHI) broth (Merck, NJ, USA) at 37˚C shaking at 200 rpm. The Heat-
Killed Listeria monocytogenes (HKLM) used for stimulation were prepared by heating the 
bacteria to 70°C for 1 hour prior to washing in PBS. The Salmonella typhimurium strain 
SJW1103 (wild type) was a kind gift from Prof. P. O‘Toole (UCC, Cork, Ireland). Bacteria 
were grown to the logarithmic growth phase in LB broth (Sigma) at 37˚C shaking at 200 rpm. 
Bacteria were subsequently washed with PBS by two steps of centrifugation (4000 rcf for 5 
min) and diluted in PBS for infection at multiplicity of infection (MOI) of 10:1. 
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2.12 Determining the growth curve of L.monocytogenes 
Bacteria were streaked on a Brain Heart Infusion (BHI) agar plate and incubated at 
37°C inverted overnight. The following day, a single colony was selected from the plate to 
inoculate 10ml of BHI broth. This was grown with shaking at 37°C overnight. Serial dilution 
was performed on the culture in sterile PBS and spotted in triplicate on an agar plate. The 
plate was then incubated overnight at 37°C and was labelled T=0. This was repeated taking 
an aliquot every hour until T=8. Colonies were counted and Colony Forming Units (CFU) per 
ml was calculated as follows: CFU per ml = no. of colonies X 100 X dilution factor. The 
growth curve generated with this data was graphed against Optical Density (OD) at 
Absorbance 595 and used as validation when determining precise CFU at a given OD. 
 
2.13 Live/Dead staining of bacteria 
L. monocytogenes was seeded overnight and cultured (2%) under the time and culture 
conditions specified (either 1 hour treatment with Gentamicin, no treatment or 1 hour 
treatment with Formalin); aerobically at 37°C in BHI broth (Merck). Following culture 
bacteria were washed twice in sterile PBS solution analysed for viability using Live/Dead 
BacLight viability and counting system (Invitrogen) in 0.85% sterile NaCl solution on an 
Accuri C6 Flow Cytometer (Becton Dickinson Biosciences, NJ, USA). Each strain was 
evaluated and specific gates were set for each strain; based on the viability profile bacteria 
were then provided at the required CFU in a blinded fashion to the researcher. Plate counts 
were also performed for each strain with the respective agar plates.  
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2.14 Infection of THP-1 and HT-29 cell lines 
L. monocytogenes was grown overnight (1 colony from a plate was grown in 10ml 
BHI broth, 37°C, shaking). The following morning, 200μl was taken and diluted in 10ml BHI 
broth (1/50) and incubated for further growth. From the CFU/OD validation curve, an 
accurate CFU count could be calculated at Early (3 hour culture), Mid (4 hours culture) and 
Late (6 hours culture) log phases. In each case, an appropriate amount of culture was 
removed (e.g. OD600, 1 ml = ~2x10
9
 CFU) and spun at 1000 rcf for 5 minutes. Following 
this, the bacteria were washed 3 times in sterile PBS. Subsequently, a serial dilution of the 
bacteria was made up and spotted on an agar plate in order to record CFU the following day 
to ensure accuracy of bacterial counts. The remainder of the culture was then subject to serial 
dilution such that 5μl of bacteria suspended in PBS would contain the appropriate MOI when 
added to a 96 well plate e.g. 4x10
4
 cells on a plate at MOI 10 = 4x10
5
 bacteria in 5uL from a 
stock of 8x10
7
 CFU./ml. For Heat Killed Listeria monocytogenes (HKLM), the bacteria were 
incubated at 70°C for 1 hour prior to washing in PBS. Following the addition of the bacteria, 
the tissue culture plate was spun at 250 rcf for 3 minutes. This was found to increase contact 
between the bacteria and the cells for efficient, reproducible infection. The cells were washed 
at 1 hour post-infection with antibiotic free cell culture medium and supplemented with cell 
culture medium containing Gentamicin (Invitrogen) (50g/ml). Cells were then incubated for 
the times indicated in the results section prior to analysis.  
 
2.15 Bacterial survival assays in HT-29 and THP-1 cells 
For bacterial survival assays, the HT-29 or THP-1 cells were washed at 8 hours post-
infection and treated with 0.2% Triton X-100 PBS. The lysates were then subjected to serial 
dilution and spotted on a BHI agar plate. CFU/lysate of internalised bacteria was then 
determined. Following infection, cells were washed and treated with 0.2% Triton X-100 PBS 
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in order to lyse the cells. The lysates were then subject to serial dilution and spotted on an 
agar plate to achieve CFU counts of internalised bacteria. In this way, bacterial internalisation 
efficiency was measured under different MOIs (10, 50 and 100), different bacterial growth 
phases (early log, mid log and late log) and for different infection times (1 hour infection + 1 
hour Gentamicin treatment or 2 hours infection and 1 hour gentamicin treatment). 
 
2.16 Confocal Microscopy on THP-1/HT-29 infected with L. monocytogenes to examine 
Internalisation 
Bacteria were labelled with CellTrace CFSE (Invitrogen) as per standard protocol (i.e. 
2μl CFSE added to 1x109 bacteria and incubated at room temperature in the dark for 15 min 
and bacteria were then washed three times in PBS). After final wash step, bacteria were 
resuspended in PBS pH 8.0. To biotinylate the bacteria, one microtube of No-Weigh™ Sulfo-
NHS-Biotin (Pierce, Rockford, IL, USA) per ml of bacterial suspension was incubated at 
room temperature for 30 min. The bacteria were washed three times with PBS + 100mM 
glycine (0.75g in 100ml PBS) to quench and remove excess biotin reagent and by-products. 
After final wash step, bacteria were resuspended in 100μl PBS and 4μl (1:25 dilution) 
Streptavidin-Allophycocyanin (Pierce) was added for 30 min on ice. For co-incubation, 
human cells were seeded in 6-well plates containing a poly-L-Lysine coated glass coverslip 
with 3ml at 1x10
6
 cells/ml/well (THP-1) or 3ml at 0.5x10
6
 cells/ml/well (HT-29). CFSE-
biotin-labelled bacteria were added to each well to give a 10:1 or 100:1 bacteria to cell ratio 
appropriately. Cells and bacteria were co-incubated for 2 hours at 37°C following a spin at 
300 rcf for 3 minutes. Unbound cells were then aspirated with the media and the coverslips 
were washed once with PBS. The bound cells were fixed with formalin (~200μl/coverslip) 
for 20 min. Coverslips were washed three times with PBS. For each coverslip, 100μl of 
streptavidin-APC in 1% BSA was added (0.1g Bovine Serum Albumin (Sigma) in 10ml PBS) 
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and incubated for 30 min at 4°C. Cells were washed once with PBS and 0.2% Triton X-100 
(20μl in 10ml PBS) was added to each coverslip for 5 min to permeabilise the cells. 
Coverslips were washed once with PBS. F-actin (Pierce) was stained red with fluorescent 
phallotoxins. Vial contents were dissolved in 1.5ml methanol to give a stock concentration of 
6.6μM. For each coverslip to be stained, 5μl of 6.6μM stock solution was diluted in 200μl of 
PBS containing 1% BSA. Coverslips were incubated with the staining solution for 20 min at 
room temperature in the dark and were then washed with PBS and mounted on a slide with 
fluorescent mounting medium, DakoCytomation (S3023, Dako, Glostrup, Denmark). Slides 
were viewed using the FITC settings for the CFSE-labelled bacteria, the Rhodamine-
Phalloidin settings for the phalloidin-labelled actin in the HT-29 or THP-1 cells, and the 
AlexaFluor 647 settings for the streptavidin-allophycocyanin. 
 
2.17 siRNA transfection 
All siRNA transfections were performed with SMARTpool siRNAs (Thermo 
Scientific). Sequences are contained in Appendix Table 1. For the TLR siRNA screen, cells 
were seeded at 1x10
4
/well in a 96 well plate the day before transfection. DharmaFECT 4 
(Thermo Scientific) was then used to transfect the cells with siRNA (100nM) according to the 
manufacturer‘s instructions 48 hours prior to infection. THP-1 siRNA transfections were 
performed using the Amaxa (Lonza, Basel, Switzerland) system according to the 
manufacturer‘s protocol. Cells were cultured for a further 48 hours prior to infection. 
 
2.18 Lentiviral transfection and clonal selection 
HT-29 cells were grown to 50% confluency on a 12 well plate. The following day, 
5μg of Polybrene (Santa Cruz biotechnology, Heidelberg, Germany) were added to the cells 
with 100,000 transfection units of lentiviral particles. The TLR10 shRNA and copGFP 
lentiviral particles were also obtained from Santa Cruz. The control lentiviral particles 
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contained sequences encoding for expression of the GFP protein as an added control to 
ensure transfection had taken place. 16 hours after transfection, fresh media was added to the 
cells due to the toxic nature of the polybrebne. 24 hours later, the cells were split 1:3 and 
4μg/ml Puromycin (Invivogen, Toulouse, France) was supplemented into the medium of 
transfected cells. ―Parental‖ HT-29 cells were grown in parallel without puromycin as an 
untreated control. Following 2 further passages, positive selection on the lentiviral particle 
transfected cells using puromycin had occurred and cells were split 1:100 in order to achieve 
single cell colonies. Following another week of growth, colonies were selected using a 
pipette tip and cultured for further analysis.  
 
2.19 Western blot analysis  
Preparation of cell extracts by radioimmune precipitation (RIPA) method 
Prior to Western blot analysis, cells were washed with ice-cold PBS followed by 
centrifugation at 1500 rcf for 5 minutes. Pellets were resuspended in 1 ml PBS and 
transferred to eppendorfs. The samples were centrifuged at 12,000 rcf for 5 minutes at 4°C 
and the pellets were resuspended in 100μl of RIPA buffer with 10% Protease Inhibitor 
Cocktail (Sigma). The cells were then disrupted by sonication before incubation on ice for a 
further 30 minutes. The samples were then centrifuged at 14,000 rcf for 20 minutes at 4°C. 
The supernatants (total cell lysates) were then assayed for protein concentration using the 
BCA Protein Assay Kit (ThermoScientific) according to the manufacturer‘s instructions. 
Aliquots containing equal amounts of protein were mixed with 5μl SDS sample buffer. 250μl 
β-mercaptoethanol was added per ml of sample loading buffer immediately prior to use. 
Samples were then incubated at 95°C for 5 minutes prior to resolving them on Sodium 
Dodecylsulphate (SDS) polyacrylamide gel using a constant current of 30 mA per gel. 
Samples were first run through a stacking gel and then resolved according to size using a 
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10% polyacrylamide resolving gel. A prestained molecular weight marker (New England 
Biolabs) was also used to confirm the size of the protein being examined. The following 
antibodies were used: anti-TLR10 (H-165) (sc-30198, Santa Cruz) and β-actin antibody (AC-
15) (Sigma). Proteins were detected using the Fujifilm LAS-3000 Imager (R&D Sytems, 
Abingdon, UK).  
 
2.20 Gene expression analysis using qRT-PCR 
Following treatment, cells cultured in 96 well plates were washed in PBS. 25μl of 
Sidestep Lysis Buffer (Agilent Technologies, Geneva, Switzerland) was then added to each 
sample of and mixed well by pipetting. The SideStep technology achieves cell lysis and 
nucleic acid stabilization in the same buffer, eliminating the need for RNA purification. 5μl 
of a 1/5 dilution of this lysate was then prepared in DEPC treated H2O prior to reverse 
transcriptase. For all other plate types used (12, 24 and 6-well plates), total RNA was isolated 
using the RNeasy Kit (Qiagen, West Sussex, UK) and 1g of total RNA was used for reverse 
transcriptase. The reverse transcription for first strand cDNA synthesis from the mRNA 
present in the cell lysate was performed using the following protocol per reaction (all 
reagents from Roche): 4μl of 5x Transcriptor Buffer was added to 5μl DEPC treated water 
with 3μl of Random Primer, 2μl dNTP (ATGC) mix (10mM) and finally, 5μl of the lysate 
dilution. This reaction was run using a Veriti 96 well Thermal Cycler (Applied Biosystems) 
for 10 mins at 25°C, 30 minutes at 55°C, 5 mins at 85°C before cDNA being cooled to 4°C.  
Individual PCR primer pairs and probes were designed using the Roche Universal 
Probe Library Assay Design Centre (https://www.roche-applied-
science.com/sis/rtpcr/upl/adc.jsp). PCR reactions were performed using Sensi Mix II (Bio 
Line, London, UK), 900 nM of each primer and 250 nM of probe mix in the LightCycler480 
System (Roche). Thermal cycling conditions were as recommended by the manufacturer 
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(Roche). 95°C for 5 min followed by 40 amplification cycles consisting of 95°C for 15 s, 
60°C for 30 s, and 72°C for 1 min. Linear amplification ranges were determined for all 
primer sets. Data analysis was carried out using the LightCycler® 480 Real-Time PCR 
System (Roche) software. β-actin was used as a housekeeping gene, the 2-ΔΔCt method [3] was 
used to calculate relative changes in gene expression. Relative expression in each figure 
refers to induction levels of the gene of interest relative to the housekeeeper control, beta 
actin, and then compared to an untreated control calibrator sample. Table 1 contains the 
primer sequences used (all designed for human genes).  
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Table 1: Sequences of primers used in qRT-PCR analysis 
 Left Primer Right Primer UPL # 
β-actin 5‘ attggcaatgagcggttc 3‘ 5‘ tgaaggtagtttcgtggatgc 3‘ 11 
GAPDH 5‘ agccacatcgctcagacac 3‘ 5‘ gcccaatacgaccaaatcc  3‘ 64 
Fzd5a 5‘ accccaggggagagaaact  3‘ 5‘ tgcaaattgggggaagtaag  3‘ 83 
Wnt5a 5‘ actcgcccaccacacaag  3‘ 5‘ cattgcgcacgcagtagt  3 23 
Cx43 5‘ gcctgaacttgccttttcat  3‘ 5‘ ctccagtcacccatgttgc  3‘ 88 
TNFα 5‘ cagcctcttctccttcctgat  3‘ 5‘ gccagagggctgattagaga  3‘ 40 
EGR-1 5‘ ggatggacatttgcaggagt 3‘ 5‘ ctccactttcacgctgctc 3‘ 22 
IL-1β 5‘ tacctgtcctgcgtgttgaa 3‘ 5‘ tctttgggtaatttttgggatct 3‘ 78 
IL-8 5‘ agacagcagagcacacaagc 3‘ 5‘ atggttccttccggtggt 3‘ 72 
IL-23 5‘ tgttccccatatccagtgtg 3‘ 5‘ ggatcctttgcaagcagaac 3‘ 76 
CCL-1 5‘ ttgctgctagctgggatgt 3‘ 5‘ ctggagaagggtacctgcat 3‘ 56 
CCL-20 5‘ gctgctttgatgtcagtgct 3‘ 5‘ gaagaatacggtctgtgtatccaa 3‘ 39 
MAPK1 5‘ ccgtgacctcaagccttc 3‘ 5‘ gccaggccaaagtcacag 3‘ 62 
TLR10 5‘ cttttgccaccaacctgaa 3‘ 5‘ ccctctctcacatctccttttg 3‘ 34 
TLR1 5‘ aggggacaatccattccaa 3‘ 5‘ ttggtctatatttttgacaaattctcc 3‘ 100 
TLR2 5‘ tgtcattctttcttcctgctaaga 3‘ 5‘ ctaggtaggacagagaatgccttt 3‘ 82 
TLR6 5‘ tgaaacagtctcttttgagtaaatgc 3‘ 5‘ tccatttgggaaagcagagt 3‘ 17 
MyD88 5‘ tgctcgagctgcttaccaa 3‘ 5‘ cctgctgctgcttcaagata 3‘ 33 
Caspase-1 5‘ agggacgctgggactctc 3‘ 5‘ aagcttgacattcccttctgag 3‘ 17 
VEGF 5‘ ttaaacgaacgtacttgcagatg 3‘ 5‘ gagagatctggttcccgaaa 3‘ 12 
 
Primers were generated by Eurofins MWG. 
 
2.21 Flow Cytometry  
Antibodies against TLR1, TLR2 and TLR6 (IMG-5012, IMG-6720A, IMG-304A) were from 
Imgenex (San Diego, CA, USA) and the TLR10 antibody was from Santa Cruz 
Biotechnology (TLR10 H-165). The secondary antibodies used were Alexa Fluor-488 goat 
anti-mouse IgG (Invitrogen) and PE-conjugated goat anti-rabbit IgG H+L (Imgenex). The 
respective isotype controls for each antibody were also from Imgenex. On the day of analysis, 
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1x10
6 
cells were harvested using 0.2% EDTA PBS and washed twice in running buffer (PBS 
0.5% BSA, 1% FBS 0.1% Sodium Azide). For intracellular staining, cells were fixed in BD 
Cytofix Cytoperm (Becton Dickinson) for 30 minutes on ice. For extracellular staining, cells 
were not fixed. Each primary antibody was used at 0.5g/ml for 30 minutes on ice. Each 
wash step for intracellular staining was performed using BD Perm/Wash buffer (Becton 
Dickinson) while the running buffer was used for extracellular staining washes. The 
secondary antibodies were used at a 1:1000 dilution for 20 minutes in the dark on ice and 
cells were analysed using the Accuri C6 flow cytometer (Becton Dickinson). The gating 
method employed was designed to include the live cell population only. Population gates 
were set using negative controls and IgG isotype controls. The results were expressed as the 
percentage or median fluorescence intensity (MFI) of the total live cell population after 
subtracting the MFI of control cells stained with the appropriate isotype control antibodies.  
 
2.22 ELISA analysis of supernatants for cytokine production  
CCL-20 levels were quantified using the anti-CCL20 kit (Meso Scale Discovery (MSD), 
Maryland, USA) according to the manufacturer's instructions. Concentrations were 
determined using the MSD Sector Imager 2400. IL-8 levels were quantified using the Ready-
Set-Go!® Human IL-8 ELISA kit (eBiosciences, San Diego, USA) according to the 
manufacturer‘s instructions.  
 
2.23 NF-κB Activity   
SEAP reporter HEK-Blue-MD2-CD-14 cells (Invivogen) were used according to the 
manufacturer‘s instructions. Briefly, cells were maintained in selective antibiotics and seeded 
at 2x10
4
 cells/well on a 96 well plate the day before transfection. Cells were then transfected 
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and infected with L.monocytogenes. Supernatants were collected 8 hours later and NF-κB 
activity was measured using QUANTI-Blue
TM
.  
 
2.24 Statistics  
qRT-PCR results from the PRR siRNA screen in 5.12 - 5.15 were analysed using the Mann 
Whitney U test. This test is relatively stringent and was useful for analysing significant 
changes in gene induction across a large group of treatments with a relatively large number of 
samples/treatment. All other results were statistically evaluated using the relatively less 
stringent Student‘s t test with Welch‘s correction which is useful for discerning significant 
effects on gene induction following cell treatments. Values of p < 0.001 are indicated by 
three asterisks (***). Values of p < 0.01 are indicated by two asterisks (**). Values of p < 
0.05 are indicated by one asterisk (*).  
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Chapter 3 
 
 
Identification of TIR domain-containing 
Proteins from Commensal Bacteria and 
analysis of their potential 
immunomodulatory properties 
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3.1 Introduction 
 
The innate immune system‘s sentinels in the first line of defence against infection by 
invading microorganisms are its Pattern Recognition Receptors (PRRs). Of these, the Toll-
Like Receptor (TLR) family was one of the first to be identified and as such is now well 
characterised. TLR signalling elicits a pro-inflammatory response which is characterized by 
the secretion of cytokines such as tumour necrosis factor (TNF), type I and II interferons 
(IFNs), and chemokines. In turn, these control the recruitment of inflammatory cells to 
infected tissues and also function to cross-talk with the adaptive immune system [1].  
TLRs are part of a larger superfamily of receptors which include the IL-1 Receptor 
family members. All members of this family are characterised by a 200-residue intracellular 
domain termed the Toll-IL-1-Receptor (TIR) domain. This TIR domain has been shown to be 
critical in the activation of signalling pathways from these receptors, such as MAP kinases 
and the transcription factor NF-κB, which is known to be involved in the activation of 
approximately a thousand immune and inflammatory genes. This conserved TIR domain is 
also contained in the IL-1R/TLR adaptor proteins MyD88, MAL, TRIF and TRAM. These 
adaptor molecules directly interact with the activated TLR in order to relay downstream 
signalling for appropriate immune response/transcription factor activation. Sequence 
conservation of this TIR domain is primarily confined to three short motifs; (Boxes 1, 2, and 
3) located at amino acid residue positions 10 (Box 1), 60 (Box 2), and 170 (Box 3) and with 
consensus sequences: Box 1 – FDAFISY; Box 2 - GYKLC—RD—PG; and Box 3 - a 
conserved W surrounded by basic residues [2] (see Figure 3.1). These 3 regions map to the 
hydrophobic core of the domain structure as well as a long ―BB‖ loop which had been 
proposed as the primary protein-protein interaction site [2]. While mutations in all three lead 
to a loss of surface expression, only mutations in Box 1 and Box 2 cause a direct loss of 
signalling activity [3]. No clear differences were found between the effects of Box 1 and Box 
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2 mutations in various signalling assays, although Box 2 mutations appeared to have stronger 
effects on signalling [3]. 
 
 
Figure 3.1 TIR domain consensus Box motifs. Shown above are the three highly conserved 
regions among the different members of the TIR family. These motifs are located at amino acid 
residue positions 10 (Box 1), 60 (Box 2), and 170 (Box 3). While Box 1 and Box 2 are believed to be 
more crucial for TIR:TIR signalling, the conserved W surrounded by basic residues in Box 3 is 
believed in directing localisation of the TIR protein [3]. 
 
 
Initial indications that the TIR domain was critical for TLR signalling were realised 
when a proline to histidine point mutation within the domain at position 712 of the 
polypeptide chain was shown to confer lipopolysaccharide (LPS) unresponsiveness to 
C3H/HeJ mice [4]. Further molecular analysis of signalling from the TIR domain has 
revealed that it requires the homo- or heterodimerisation of their extracellular leucine-rich 
repeats region, to be mediated by the microbial pathogen-associated molecular patterns 
(PAMPS). Following this, dimerization of the receptor cytoplasmic TIR domain occurs [5]. 
Only in this active conformation are the receptor TIR domains capable of a functionally 
productive interaction with TIR domains of adaptor molecules; MyD88, MAL, TRIF and 
TRAM. Competition at the level of the TIR domain has been suggested as an efficient 
mechanism to control TLR signalling [3]. In fact, a truncated splice variant of MyD88 has 
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been identified named MyD88s. MyD88s has been shown to compete with wild-type MyD88 
for TLR:TIR domain interactions and inhibits an inflammatory response as MyD88s is unable 
to mediate any further downstream signalling [6]. More specifically, another TIR adaptor, 
SARM, has been identified as the only known TIR inhibitor molecule and functions as a 
negative regulator of TRIF signalling [7]. 
Several pathogens have recently been found to evade our immune system by using 
genes which mimic components of immune signalling pathways. Pathogens have been 
identified which produce TIR domain containing proteins which, in some cases, have been 
shown to interfere with TLR signalling, thereby limiting the immune response. The first 
example of this was the protein A46R, found in vaccinia virus which suppresses signalling 
from multiple TLRs and the type 1 IL-1 receptor [8]. A46R also blocked IRF3 activation by 
TRIF mediated signalling and thus prevented the secretion of IFN-β, which functions to 
suppress viral replication [8]. Using an intranasal infection model, the authors showed that 
A46R-deficient virus had diminished virulence, consistent with the above observations. 
A46R was shown to be able to form protein complexes with host TIR domain containing 
adaptor proteins; MyD88, MAL, TRIF, or TRAM. This suggests that A46R specifically 
targets IL-1R/TLR signalling through interaction with adaptor proteins [8]. An example of 
how this mechanism may occur is displayed in Fig. 3.2. 
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Figure 3.2 Possible Mechanism for bacterial/viral TIR domain containing protein-
mediated inhibition of TLR signalling. TLR1 and TLR2 hetero-dimerise at the plasma 
membrane. These are prevented from initiating signal transduction through their TIR domains due to 
the TIR:TIR interaction between the TIR domain of the TIR containing bacterial/viral protein and the 
TLR‘s. 
 
More recently similar targeting of the TIR domain has been identified as an immune 
evasion mechanism in bacteria. The Salmonella enterica protein, Toll-Like Protein A (TlpA) 
was shown to be required for suppression of NF-κB activation and IL-1β production during 
Salmonella infection. Mice infected with wild-type bacteria had a significantly higher 
mortality than those infected with a TlpA-deficient strain [9]. There are detectable sequence 
similarities between TlpA and TIR domains from human and other bacterial proteins, 
particularly at the Box 1 and Box 2 regions. However, direct interaction with any of the 
human TIR domain signalling proteins has not been demonstrated [9].  
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Two TIR-containing proteins have also been identified in Brucella bacteria. TcpB and 
Btp1 are identical proteins except for a single mutation within the predicted α-helix of their 
TIR domains [10, 11]. Both proteins have been shown to abrogate TNFα production by 
macrophages [10] and dendritic cells [11]. Infection with Btp1-deficient bacteria did not, 
however, alleviate symptoms of murine brucellosis [11], suggesting other mechanisms of 
immune evasion are used by this bacteria. Because of the delayed maturation of dendritic 
cells upon Brucella infection, it was proposed that Brucella might play a role in immune 
tolerance induction and chronic infection [11], although the exact role of Btp1 or other 
Brucella proteins in this process is not yet well understood. Recent studies suggest that TcpB 
targets signalling by MAL (the TLR2 and TLR4 specific adaptor protein) in at least two 
ways. Firstly, Radhakrishnan et al. demonstrated that TcpB associated with phosphoinisitides 
(PtdIns) at the plasma membrane [12]. MAL is known to be recruited to the plasma 
membrane through the binding of its N-terminus to phosphatidylinositol-4,5-bisphosphate 
(PtdIns(4,5)P2). This membrane localization is necessary for MAL to act as a bridging 
adapter between MyD88 and TLR2 or TLR4 [13]. Nevertheless, the implicit mimicry of 
MAL by TcpB has not been substantiated by direct binding of TcpB with MAL partner 
proteins such as MyD88 or TLR4, either through their TIR domains or otherwise. A new 
study by Sengupta et al. showed that TcpB promoted polyubiquitination and subsequent 
degradation of MAL, and this degradation process seemed more efficient for phosphorylated 
MAL [14]. This raises the question as to whether TcpB is an adapter for other proteases, is a 
protease itself, or contains E3 ligase activity. The two mechanisms outlined above for TcpB 
mediated MAL inhibition are not necessarily independent of each other either – for example, 
localization of TcpB to the plasma membrane can facilitate the binding, ubiquitination, or 
degradation of MAL by TcpB or other associated ubiquitination enzymes or proteases. 
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TcpC from uropathogenic E. coli strain CFT073 was identified in a bacterial genomic 
sequence search [10]. Despite minimal sequence similarity to the human TIR domain 
proteins, the typical Box 1, 2, and 3 sequences are all present within the C-terminal of TcpC. 
Following various pull down assays, TcpC was found to interact directly with full length 
MyD88, presumably through their TIR domains [10]. It was also shown to directly impair 
TLR2 and TLR4 signalling, reduce pro-inflammatory cytokine secretion, and increase 
virulence as well as bacterial burden in murine urinary tract and renal tissue infection models. 
The significance of TcpC as a virulence factor was highlighted also by the fact that most 
uropathogenic E. coli strains seemed to express TcpC, based on clinical samples [10]. Despite 
TcpC not containing a typical secretion signal, it was shown to be secreted by bacteria and 
taken up by macrophages - leading to abrogated cytokine production [10]. Since the 
mammalian TIR domain proteins are only known to be present in the cytosol, this finding 
suggests a novel shuttling ability of TIR domain proteins through the lipid membrane, 
possibly aided by undiscovered localization signalling and/or other chaperone transport 
proteins. 
Further application of genomic sequence mining led to a TIR domain containing 
protein PdTLP being identified in P. denitrificans [15]. Similar to the previous studies 
highlighted above, GST pull-down and co-immunoprecipitation studies demonstrated direct 
binding of the PdTLP TIR domain (PdTIR) with the human and mouse MyD88 TIR domain 
[15, 16]. The crystal structure of PdTIR was the first among microbial TIR domains to be 
determined [16]. It adopts a typical TIR domain fold, with an exposed BB loop that was 
proposed to be the site of heterotypic interaction with partner TIR domains, such as that from 
MyD88 [16]. The function of PdTLP as a virulence factor has not been characterized, as it is 
unclear whether its ability to interact with MyD88 dampens signalling from TLRs, or offers 
any advantage for bacterial infection, replication, or dissemination. Finally, another bacterial 
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TIR-domain protein (Tdp) was identified from Yersinia pestis (highly pathogenic bacteria 
responsible for the plague) and named YpTdp [17]. Although its removal from the bacteria 
had no obvious effect on virulence, when over-expressed in vitro, YpTdp has been shown to 
disrupt immune signalling pathways [17].  
In a 2009 review by Spear et al, the distribution of TIR domain proteins among 
bacteria, fungi, archaea and viruses was discussed and evaluated [18]. These authors 
proposed that due to the wide distribution of TIR domains across species, it is likely that they 
act simply as protein-protein interaction domains put to diverse uses and are not specific for 
immune evasion. However, another paper released in 2010 by Zhang et al. addresses this 
controversy in a study relating the TIR domain containing negative regulator of TLR 
signalling, SARM, to bacterial TIR domains. By use of close phylogenetic analysis, SARM 
was shown to be closely related to bacterial proteins with TIR domains suggesting that 
perhaps this family has a different evolutionary history from animal TIR-containing adaptors, 
possibly emerging via lateral gene transfer from bacteria to animals [19]. An ancient origin of 
the TIR protein is suggested by the generally separate animal, plant, fungi, archaea, and 
bacterial branches of TIR domain found in nature. Interestingly, the study also shows that 
68% of the bacterial genomes analysed that do contain TIR proteins only have one such 
protein. Since its role is presumably to form complexes with other TIR domains, such 
proteins have no obvious partners to form complexes with [19]. They highlight the previously 
addressed paper by Spear et al [18] and agree that the broad distribution of TIR-domain 
containing proteins in bacteria challenges the view of their primary function as virulence 
factors, but go on to hypothesize that bacterial TIR-domain containing proteins may play 
important roles in commensal or mutualistic interactions between bacteria and eukaryotes 
[19].  
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The aim of the following study was to investigate the hypothesis that some 
commensal microbes may use TIR domain-containing proteins in order to avoid host immune 
detection, preventing the hosts‘ inflammatory response. Use of the immuno-modulatory 
properties of the TIR domain might, in this instance, help maintain homeostasis in the gut and 
contribute to the intestinal epitheliums‘ general tolerance to the presence of commensal 
bacteria. To date, such immune evasion has only been shown in pathogenic microbes, but we 
wished to study commensal bacteria for the presence of these proteins in order to identify 
possible mechanisms by which they maintain inflammatory homeostasis in the unique 
environment of the microbe-filled human gastro-intestinal tract. In order to test this 
hypothesis TIR domain containing proteins in commensal bacteria were identified and their 
potential role as immuno-evasive agents examined. In particular, we focussed on potential 
interaction between these candidates and TIR containing proteins involved in human innate 
immune signalling such as TLRs and their adaptor proteins such as MyD88 and MAL. 
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3.2 Results  
 
3.2.1 Identification of bacterial TIR proteins  
 
A bioinformatics search was performed by a colleague in the Alimentary 
Pharmabiotic Centre (APC) Core 4 lab (Dr. Marcus Claesson). This search examined the 
presence of TIR domains as well as other conserved domains known to be important in PRR 
signalling (DEATH/CARD/NACHT domains) in bacterial proteins. PFAM and Interpro 
databases were searched using the conserved regions of these domains. The results of this 
search may be seen in Table 3.1. Of the 591 bacterial proteins found to contain TIR domains, 
17 were found to also have signal-peptide domains – a feature which could potentially allow 
the protein to be translocated from the bacteria to the cytoplasm of a host where it could 
possibly interact with host TIR proteins. 
 
 
Domain 
No. of Bacterial 
Strains 
No. of PRR signalling domain-
containing proteins 
TIR 319 591 
DEATH 21 21 
CARD 4 12 
NACHT 35 35 
 
Table 3.1 Results of signalling domains found in proteins of bacteria. Shown above are the 
results of the bioinformatics search to identify proteins in bacteria containing a 
TIR/DEATH/CARD/NACHT signalling domain. The results were obtained using the Interpro 
database. The numbers of proteins containing the corresponding domain are shown in the rows above 
along with the number of bacterial strains found to contain that domain. 
 
These results were followed by an extensive analysis of both bacterial strains and the 
proteins themselves in an effort to identify the most likely target proteins. Many of the strains 
from the list generated were not known to interact with humans. We focussed our search to 
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examine only the known commensal strains of bacteria. Furthermore, we focussed on strains 
which carried only one TIR domain-containing protein to minimise the likelihood of these 
proteins interacting with other TIR proteins from the same strain - since the bacteria contains 
no other TIR protein for it to interact with. From the remaining candidates, we examined 
sequence alignments with known human TIR proteins, such as TLRs and their adaptor 
molecules. Following these analyses, two proteins were selected, containing TIR domains 
from commensal bacterial strains Bifidobacterium longum subsp. infantis CCUG 52486 and 
Escherichia sp. 3_2_53 FAA. The TIR domain containing proteins from these strains were 
named BifTIR and EschTIR respectively (A full list of all TIR domain containing strains 
identified is shown in Appendix Table 2).  
Bifidobacterium longum subsp. infantis is a Gram-positive anaerobic rod-shaped 
bacterium found in the intestines of infant humans. Escherichia is a genus of Gram-negative, 
facultatively anaerobic, rod-shaped bacteria. A number of the species of Escherichia are 
pathogenic, however, in those species which are inhabitants of the gastrointestinal tract of 
warm-blooded animals, such as the strain we had selected, may benefit their host in a number 
of ways [20]. Each strain also contained only one TIR protein, therefore decreasing the 
likelihood for involvement in internal signalling interactions within the bacteria. One of these 
proteins, (EschTIR) contains a signal peptide domain which, as mentioned earlier, could be 
used to allow the protein to be translocated from the bacteria into the cytoplasm of a host. 
Both have been identified as commensal bacteria and there was prior in-house experience of 
working with Bifidobacterial strains. Another reason for the selection of these proteins from 
the list generated was their relatively strong sequence homology (22 – 28%) to host PRRs 
TLR1, TLR2, TLR6 and TLR10. Figure 3.3 displays alignment of these bacterial proteins to 
TLR1 and TLR6 - to which both bacterial proteins showed 27-28% sequence alignment. This 
was better than the slightly lower homology seen between TLR2 and TLR10 with 26% and 
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28% for EschTIR and 22% and 28% for BifTIR respectfully. While both BifTIR and 
EschTIR can be seen to have quite strong homology in the Box 1 region of the TIR domain, 
very little or no homology exists in the Box 2 and Box 3 regions.  
 
Fig. 3.3 A 
 
 
  
TLR1 and BifTIR 
 
TLR1   LQFHAFISYSGHDSFWVKNELLPNLEKEGMQICLHERN-----FVPGKSIVENIITCIEK 689  
C5ECT5 MAHKTFISYKYSESRFYRDQILDALGDDAVFYKGETSDSPNLTDTTTENIKNHLKQMIYD 60 
       : .::****.  :* : ::::*  * .:.:    .  :      .. :.* :::   * . 
 
TLR1   SYKSIFVLSPNFVQSEWCHYELYFAHHNLFHEGSNSLILILLEPIPQYSIPSSYHKLKS- 114 
C5ECT5 TTVTIIVLSPNMLQSNWIDWEISYSLKNISRDGRTSHTDGLLGVIPPFYGNYSWFISEIN 120 
       :  :*:*****::**:* .:*: :: :*: ::* .*    **  ** :    *:.  :   
 
TLR1   ------LMARRTYLEWPKEKSKRG----------------------LFWANLRAAIN--I 778 
C5ECT5 HPDGHVTVSYNEELTFPIMKANRGNQKPKVYACPDCQSIDKLSGSYLSYVKMEDFVNNPS 180 
              :: .  * :*  *::**                      * :.::.  :*    
 
TLR1   KLTEQAKK--------------- 786 
C5ECT5 RYIDNAYDKSLNADNNYDLTKLL 203 
       :  ::* .                
 
 
TLR6 and BifTIR 
 
 
TLR6   NLQFHAFISYSEHDSAWVKSELVPYLEKEDIQICLHERNFVP------GKSIVENIINCI 692  
BifTIR -MAHKTFISYKYSESRFYRDQILDALG-DDAVFYKGETSDSPNLTDTTTENIKNHLKQMI 58 
        : .::****.  :* : :.:::  *  :*  :   * .  *       :.* ::: : * 
 
TLR6   EKSYKSIFVLSPNFVQSEWCHYELYFAHHNLFHEGSNNLILILLEPIPQNS-------IP 745  
BifTIR YDTTVTIIVLSPNMLQSNWIDWEISYSLKNISRDGRTSHTDGLLGVIPPFYGNYSWFISE 118 
        .:  :*:*****::**:* .:*: :: :*: ::* ..    **  **             
 
TLR6   NKYHKLKALMTQRTYLQWPKEKSKRG----------------------LFWANIRAAFN- 782  
BifTIR INHPDGHVTVSYNEELTFPIMKANRGNQKPKVYACPDCQSIDKLSGSYLSYVKMEDFVNN 178 
        :: . :. :: .  * :*  *::**                      * :.::.  .*  
 
TLR6   --------MKLTLVTENNDVKS--- 796  
BifTIR PSRYIDNAYDKSLNADNNYDLTKLL 203 
                . :* ::**   :    
 
 
---- = Box 1 
 
---- = Box 2 
 
---- = Box 3 
 
TLR1 and EschTIR 
 
TLR1    CSYLDLPWYLRMVCQWTQTRRRARNIPLEELQRNLQFHAFISYSGHDSFWVKNELLPNLE 660 
EschTIR ---- ----------------------------NTHYDFFISHAKEDKDTFVRPLVDELN 174 
                                      * ::. ***:: .*.  . . *: :*: 
 
TLR1    KEGMQICLHERNFVPGKSIVENIITCIEKSYKSIFVLSPNFVQSEWCHYELYFAHHNLFH 720 
EschTIR RLGVIIWYDEQTLEVGDSLRRNIDLGLRKANYGIVILSHNFLNKKWTQYELDSLINRAVY 234 
       : *: *  .*:.:  *.*: .**   :.*:  .*.:** **::.:* :***    :. .: 
 
TLR1    EGSNSLILILLEPIPQYSIPSSYHKLKSLMARRTYLEWPKEKSKRGLFWANLRAAINIKL 780 
EschTIR D-DNKIILPIWHNINAQEVSKYSHYLADKMALQTSLYSVKEIARELAEIAYRRR------ 287 
       : .*.:** : . *   .:..  * * . ** :* *   ** ::.    *  *        
 
 
TLR6 and EschTIR 
 
TLR6    TVTSLCIYLDLPWYLRMVCQWTQTRRRARNIPLEELQRNLQFHAFISYSEHDSAWVKSEL 660 
EschT R --------------------------------------NTHYDFFISHAKEDKDTFVRPL 169 
                                        * ::. ***:::.*.  .   * 
 
TLR6    VPYLEKEDIQICLHERNFVPGKSIVENIINCIEKSYKSIFVLSPNFVQSEWCHYELYFAH 720 
EschTIR VDELNRLGVIIWYDEQTLEVGDSLRRNIDLGLRKANYGIVILSHNFLNKKWTQYELDSLI 229 
       *  *:: .: *  .*:.:  *.*: .**   :.*:  .*.:** **::.:* :***     
 
TLR6    HNLFHEGSNNLILILLEPIPQNSIPNKYHKLKALMTQRTYLQWPKEKSKRGLFWANIRAA 780 
EschTIR NRAVYD-DNKIILPIWHNINAQEVSKYSHYLADKMALQTSLYSVKEIARELAEIAYRRR- 287 
       :. .:: .*::** : . *  :.:.:  * *   *: :* *   ** ::.    *  *   
 
 
---- = Box 1 
 
---- = Box 2 
 
---- = Box 3 
BifTIR 
BifTIR 
BifTIR 
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Fig. 3.3 B 
 
 
 
 
 
 
 
 
 
Figure 3.3: Sequence alignment of BifTIR and EschTIR with human TLR1 and TLR6. 
Using the Interpro website, a BLAST search was run on each of the bacterial TIR proteins. A strong 
sequence homology was found between TLR1 and TLR6 for both proteins with 27% and 28% identity 
for BifTIR respectively and 28% and 27% for EschTIR respectfully. Shown above are the alignments 
for each of these TLRs with BifTIR (A) and EschTIR (B). Also shown are the regions for the Box 1, 
Box 2 and Box 3 domains from the TIR consensus sequence. While very strong homology exists for 
Box 1 in each bacterial TIR protein when compared to the TLRs, there does not seem to be much 
homology in the Box 2 or Box 3 regions. 
TLR1 and EschTIR 
 
TLR1    CSYLDLPWYLRMVCQWTQTRRRARNIPLEELQRNLQFHAFISYSGHDSFWVKNELLPNLE 660 
EschTIR ---------------------------------NTHYDFFISHAKEDKDTFVRPLVDELN 174 
                                        * ::. ***:: .*.  . . *: :*: 
 
TLR1    KEGMQICLHERNFVPGKSIVENIITCIEKSYKSIFVLSPNFVQSEWCHYELYFAHHNLFH 720 
EschTIR RLGVIIWYDEQTLEVGDSLRRNIDLGLRKANYGIVILSHNFLNKKWTQYELDSLINRAVY 234 
       : *: *  .*:.:  *.*: .**   :.*:  .*.:** **::.:* :***    :. .: 
 
TLR1    EGSNSLILILLEPIPQYSIPSSYHKLKSLMARRTYLEWPKEKSKRGLFWANLRAAINIKL 780 
EschTIR D-DNKIILPIWHNINAQEVSKYSHYLADKMALQTSLYSVKEIARELAEIAYRRR------ 287 
       : .*.:** : . *   .:..  * * . ** :* *   ** ::.    *  *        
 
 
TLR6 and EschTIR 
 
TLR6    TVTSLCIYLDLPWYLRMVCQWTQTRRRARNIPLEELQRNLQFHAFISYSEHDSAWVKSEL 660 
EschTIR --------------------------------------NTHYDFFISHAKEDKDTFVRPL 169 
                                             * ::. ***:::.*.  .   * 
 
TLR6    VPYLEKEDIQICLHERNFVPGKSIVENIINCIEKSYKSIFVLSPNFVQSEWCHYELYFAH 720 
EschTIR VDELNRLGVIIWYDEQTLEVGDSLRRNIDLGLRKANYGIVILSHNFLNKKWTQYELDSLI 229 
       *  *:: .: *  .*:.:  *.*: .**   :.*:  .*.:** **::.:* :***     
 
TLR6    HNLFHEGSNNLILILLEPIPQNSIPNKYHKLKALMTQRTYLQWPKEKSKRGLFWANIRAA 780 
EschTIR NRAVYD-DNKIILPIWHNINAQEVSKYSHYLADKMALQTSLYSVKEIARELAEIAYRRR- 287 
       :. .:: .*::** : . *  :.:.:  * *   *: :* *   ** ::.    *  *   
 
 
---- = Box 1 
 
---- = Box 2 
 
---- = Box 3 
TLR1 and EschTIR 
 
TLR1    CSYLDLPWYLRMVCQWTQTRRRARNIPLEELQRNLQFHAFISYSGHDSFWVKNELLPNLE 660 
EschTIR ---------------------------------NTHYDFFISHAKEDKDTFVRPLVDELN 174 
                                        * ::. ***:: .*.  . . *: :*: 
 
TLR1    KEGMQICLHERNFVPGKSIVENIITCIEKSYKSIFVLSPNFVQSEWCHYELYFAHHNLFH 720 
EschTIR RLGVIIWYDEQTLEVGDSLRRNIDLGLRKANYGIVILSHNFLNKKWTQYELDSLINRAVY 234 
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TLR6 and EschTIR 
 
TLR6    TVTSLCIYLDLPWYLRMVCQWTQTRRRARNIPLEELQRNLQFHAFISYSEHDSAWVKSEL 660 
EschTIR --------------------------------------NTHYDFFISHAKEDKDTFVRPL 169 
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TLR6    HNLFHEGSNNLILILLEPIPQNSIPNKYHKLKALMTQRTYLQWPKEKSKRGLFWANIRAA 780 
EschT R N AVYD-DNKIILPIWHNINAQEVSKYSHYLADKMALQTSLYSVKEIARELAEIAYRRR- 287 
   :. .:: .*::** : . *  :.:.:  * *   *: :* *   ** ::.    *  *   
 
 
---- = Box 1 
 
---- = Box 2 
 
---- = Box 3 
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A third bacterial TIR protein from a strain of Lactobacillus salivarius was identified 
by an APC colleague. Their research on this bacterium had suggested that it was using some 
form of innate immune subversion and a bioinformatics search revealed it to have a 
significant TIR domain containing protein (O‘Toole et al. unpublished). For the purposes of 
this report this protein is termed LacTIR and was included with BifTIR and EschTIR in 
subsequent experiments to investigate possible interference of host innate immune signalling 
by the TIR domains of these proteins.  
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3.2.2 Subcloning of selected bacterial TIR proteins 
 
TIR sequences were amplified by PCR from genomic bacterial DNA and inserted into 
the pcDNA 3.1 myc-HisA vector as described in the methods section 2.6. The corresponding 
restriction enzyme nucleases used for cloning were also used to digest the plasmids following 
insertion. The samples were run on a 1% Agarose gel to confirm insertion of the bacterial 
TIR sequences (Fig. 3.4). The sequence of the construct was confirmed by sequence analysis.  
 
 Figure 3.4 Confirmation of insertion of TIR sequence into pcDNA3.1 myc-His A vector. 
Shown above is a photo of an agarose gel containing the plasmids for each of the three TIR 
proteins listed. Lane 1 contains the undigested BifTIR plasmid. Lane 2 contains the BifTIR 
plasmid digested with Xho I and HindIII. Lane 3 contains the undigested EschTIR plasmid. 
Lane 4 contains the EschTIR plasmid digested with Xho I and HindIII. Lane 5 contains the 
undigested LacTIR plasmid. Lane 6 contains the LacTIR plasmid digested with Xho I and 
HindIII. Circled on the photo and indicated with arrows are the TIR domain-containing 
bacterial protein inserts having been cut out of the vectors by the restriction digest. 
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3.2.3 Attempts at detection of protein expression by western blot and PCR 
 
The bacterial TIR protein sequences, now ligated into the pcDNA3.1 vector, should 
also contain a Myc tag attached to the C terminus, resulting in a total protein size of between 
25 and 35 kDa. Expression of the TIR proteins in transfected host cells should have been 
detectable by use of Western Blot. However, following several transfections using increasing 
amounts of each bacterial TIR protein plasmid into the Human Embryonic Kidney (HEK) 
293 cells; this was found not to be the case (Fig. 3.5). This was despite clear detection of a 
positive control plasmid used (Myc-tagged p53). Transfecting into different cell lines, U373 
and HT-29 cells, also resulted in no detection of the bacterial TIR proteins (data not shown). 
 
  
Figure 3.5 Western Blot for Myc tagged bacterial TIR proteins in HEK cells transfected 
with LacTIR, EschTIR, BifTIR or p53 pcDNA3.1 Myc plasmids. HEK cells were seeded on 
a 12 well plate and transfected with 2μg of each of the plasmids indicated as above (with E.V. 
standing for empty pcDNA3.1 Vector) as described in the methods section. Following 48 hours, cells 
were lysed and treated for Western blot analysis. 
96 
 
This procedure was repeated by a colleague from the O‘Toole lab using the LacTIR-
Myc plasmid. This group also failed to show expression of the construct with the PcDNA3.1 
myc-his plasmid. To avoid concerns over the plasmid used, they cloned the LacTIR sequence 
into a new vector, pEF4/Myc-His A. This was sequenced several times to ensure the insert 
had been ligated into the correct region of the vector with the tag attached and with a good 
Kozak sequence, required for efficient expression. This was similarly not detectable by 
Western Blot following transfection into the cell line HEK293 (Fig. 3.6).  
 
 
Figure 3.6 Western Blot for Myc tag in HEK 293 cells transfected with LacTIR pEF4 
plasmids with p53 pEF4 plasmid as a positive control. HEK 293 cells were seeded on a 12 
well plate and transfected with varying amounts of the LacTIR plasmid indicated as above. 
Following 48 hours, cells were lysed and treated for Western Blot analysis as described in the 
methods section. 
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Finally, HEK cells were transfected with empty vector, BifTIR, EschTIR or LacTIR 
plasmids and mRNA was prepared from the cell lysates the next day. cDNA was generated 
using reverse transcription and PCR was performed to detect the presence of mRNA for the 
BifTIR or EschTIR proteins. Primers were unavailable for LacTIR detection as this protein 
was the intellectual property of the Paul O‘Toole laboratory. Figure 3.7 displays an agarose 
gel with PCR products from these reactions. An mRNA sample which had not been treated 
with reverse transcriptase was used as a negative control (lane 1). The presence of similar 
mRNA levels of housekeeper gene, β-actin, was confirmed for each of the lysates (Fig. 
3.7A). However, the presence of the BifTIR mRNA was not detected in lane 3, where the 
BifTIR plasmid had been transfected, nor was it detected in any other sample. Similarly, 
EschTIR was not detected in lane 4, containing cDNA from a lysate transfected with 
EschTIR plasmid, nor was EschTIR mRNA detected in any other sample. 
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Figure 3.7 Agarose gel analysis of PCR products of cDNA from HEK cells transfected 
with TIR plasmids. HEK cells were transfected with an empty vector, BifTIR plasmid, EschTIR 
plasmid or LacTIR plasmid as described in the methods section. The next day, mRNA was isolated 
from the HEK lysates and cDNA was generated using reverse transcription. PCR was then performed 
on the cDNA using primers for housekeeper gene β-actin (A), BifTIR (B) and EschTIR (C) to 
investigate the presence of these genes in the cDNA. The products of these PCR reactions were then 
ran on an agarose gel as indicated.   
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3.2.4 Effects of bacterial TIR proteins on TLR mediated NF-κB activation by luciferase 
assay 
Despite the failure to detect the protein by Western Blot or PCR, the extensive 
sequence analysis of the plasmids revealed that the insert had been ligated in the correct 
position of each corresponding vector. We hypothesised that the protein might be expressed 
at low levels and as such we proceeded with some functional analyses of the constructs, 
specifically investigation of the effect of the bacterial TIR domains on TLR induced NF-B 
activation. The murine macrophage RAW264 cell line was selected due to their 
responsiveness to ligand stimulation. These cells were transfected with each of the bacterial 
TIR proteins and stimulated with LPS. Effects on NF-B activity were monitored using an 
NF-κB luciferase reporter assay with a plasmid for the NF-κB subunit p65 as a positive 
control for NF-κB activation. Figure 3.8 shows that although no statistically significant 
change was recorded in NF-κB activity between the LPS stimulated RAW264 cells, there is a 
trend towards lower NF-κB activity in the TIR protein transfected samples. 
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Figure 3.8 NF-κB luciferase reporter assay in RAW cells. RAW264 cells were transfected 
with TK Renilla and NF-κB luciferase reporter plasmids. Some samples were transfected with 100ng 
of the TIR plasmids or p65 plasmid as indicated on the graph. All transfections were normalised to a 
total of 200ng DNA with empty vector. 24 hours later, LPS was added as indicated at 100ng/ml for 8 
hours. Cells were then lysed and luciferase activity was measured relative to the untreated control as 
described in the methods section. Values are shown as Mean ± SEM relative to the unstimulated 
empty vector control from three separate experiments, each carried out in triplicate. Statistics were 
carried out using t test with Welch‘s correction. 
 
 
A level of variation in NF-κB was seen between experiments and as such we performed 
subsequent experiments in the HEK 293 cell line. Although these cells do not respond to 
most TLR ligands, they are highly transfectable so NF-κB may be activated by over-
expressing plasmid constructs expressing TLRs or their adaptor proteins. In Figures 3.9, 3.10 
and 3.11 NF-κB activation was driven by over-expression of TLR4, MyD88 or MAL 
respectively in HEK 293 cells. The HEK 293 cells were then transfected with increasing 
amounts of the bacterial TIR proteins in order to measure any abrogation of the NF-κB 
activity, driven by the TLR4, Mal or MyD88 constructs, from cross-talk between the TIR 
domains of these constructs and the bacterial TIR proteins.  
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In Figure 3.9A, TLR4 increased NF-κB activity 4-fold over untransfected and this 
was reduced to 50% by BifTIR in a dose-dependent manner. Despite a visible decrease in 
TLR4-induced NF-κB activity due to the transfection of the EschTIR protein at lower doses 
and an increase at higher doses, these differences were not found to be statistically significant 
(Fig. 3.9B). Similar to the effect seen by BifTIR in Fig. 3.9A, transfection of the LacTIR 
plasmid results in a highly significant decrease in TLR4-driven NF-κB activity. However, 
this decrease is also less than 50% and there was no significant effect when the plasmid was 
transfected at the highest dose (50ng). 
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Figure 3.9 NF-κB luciferase reporter assay in HEK 293 cells following over-expression 
of TLR4. All cells were transfected with NF-κB reporter plasmid as described in the methods. 
Varying amounts of the TIR plasmids BifTIR (A), EschTIR (B) or LacTIR (C) were also transfected 
as indicated. NF-κB was activated by overexpressing TLR4. All transfections were normalised to 
200ng DNA using the empty vector. * P<0.05, ** P<0.01 and *** P<0.001, Statistics were carried out 
using t test with Welch‘s correction.. Values are shown as Mean ± SEM relative to the unstimulated 
Empty Vector reporter control. n=3.  
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Figure 3.10 displays a consistent 3-fold increase in NF-κB activity following over-
expression of MAL. While this activation is significantly decreased when 5ng of the BifTIR 
plasmid is transfected, this effect is not observed at higher doses. No changes were observed 
in MAL-driven NF-κB activation at all concentrations of EschTIR plasmid transfection and 
the minimal decrease visible from LacTIR transfection was not found to be significant. 
 
104 
 
  
Figure 3.10 NF-κB luciferase reporter assay in HEK 293 cells following over-expression 
of Mal. All cells were transfected with NF-κB reporter plasmid as described in the methods. Varying 
amounts of the TIR plasmids BifTIR (A), EschTIR (B) or LacTIR (C) were also transfected as 
indicated. NF-κB was activated by overexpressing MAL. All transfections were normalised to 200ng 
DNA using the empty vector. * P<0.05, ** P<0.01 and *** P<0.001, Statistics were carried out using 
t test with Welch‘s correction. Values are shown as Mean ± SEM relative to the unstimulated Empty 
Vector reporter control. n=3. 
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Over-expression of MyD88 was used to drive NF-κB activation in Fig. 3.11. Fig. 3.11 
A and C display a 7-fold increase in NF-κB activation relative to the reporter control. A 5-
fold increase is seen in Fig. 3.11B. However, despite slight increases in NF-κB activity 
observed when MyD88 is transfected with all 3 of the bacterial TIR protein plasmids, 
particularly LacTIR and BifTIR, these increases were not statistically significant. 
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Figure 3.11 NF-κB luciferase reporter assay in HEK 293 cells following over-expression 
of MyD88. All cells were transfected with NF-κB reporter plasmid as described in the methods. 
Varying amounts of the TIR plasmids BifTIR (A), EschTIR (B) or LacTIR (C) were also transfected 
as indicated. NF-κB was activated by overexpressing MyD88. All transfections were normalised to 
200ng DNA using the empty vector. * P<0.05, ** P<0.01 and *** P<0.001, Statistics were carried out 
using t test with Welch‘s correction. Values are shown as Mean ± SEM relative to the unstimulated 
Empty Vector reporter control. n=3. 
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3.3 Discussion 
 
Interest has grown in the use of mimicry by microbes to evade immune responses 
through modulation of host TIR:TIR signalling by use of their own TIR domain containing 
proteins. The advances that arise from studying such interactions not only include a better 
understanding of how microbes evade our immune system, but offer such additional benefits 
as potential cancer and auto-immune treatments [21]. Highly potent TLR signalling inhibitors 
have already been generated based on the A46R protein from vaccinia virus [22]. Many more 
such immune evading proteins have been discovered in pathogenic bacteria since the 
discovery of A46R which use host signal domain bio-mimicry [21] offering the potential for 
further exploitation at a clinical level. To date, however, no extensive study has been 
performed on the existence or use of such proteins in commensal bacteria of the human 
gastro-intestinal tract. The human intestine itself is known to differentially express its 
receptors on the surface of cells facing into the gut lumen to avoid an over-active immune 
response [23]. It has even been shown to respond directly to specific Commensal-Associated 
Molecular Patterns (CAMPs) from commensal microbes to further drive this expression 
differentiation [24]. We wished to investigate if some organisms might utilise bacterial:host 
TIR:TIR signalling with their own proteins in order to create a habitable niche for themselves 
in this environment through direct subversion of innate immune signalling. Furthermore, we 
wished to investigate the possibility that these interactions may facilitate the general state of 
immune unresponsiveness that the intestinal epithelial layer maintains to the presence of 
commensal bacteria. Inflammatory Bowel Diseases (IBD) leads to dysregulation of 
inflammation in the gut. Targeting any specific part of the immune system can be quite 
difficult without having undesired side-effects. However, if commensal bacteria used 
microbe:host TIR:TIR interactions in order to reduce immune signalling in the gut, it would 
likely be in a very site-directed and specific manner. This opens the door for potentially using 
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either the microbes or their TIR proteins themselves as anti-inflammatory treatment in 
diseases such as IBD. 
Bifidobacterium infantis is a Gram-positive commensal bacteria. It inhibits the growth 
of Gram-negative bacteria by producing lactic acid, and helps digest complex sugars in 
human breast milk [25]. It has been proven to help in cases of digestive disorders [26-29] and 
is believed to work in enhancing healthy homeostatic properties in the gastro-intestinal 
environment by influencing both the microbial and host physiology [30, 31]. We wished to 
investigate if the selected strain of Bifidobacterium used its TIR domain-containing protein to 
reduce TLR signalling in the gut as a potential mechanism for immuno-regulation in this 
region. While Escherichia bacterial strains are perhaps better known for their pathogenic 
ability, however, species which are inhabitants of the gastrointestinal tract of warm-blooded 
animals, such as the strain we had selected, have been known to offer protective attributes to 
the intestinal epithelia also [32]. Escherichia species provide a portion of the microbially 
derived vitamin K for their host [20]. Furthermore, speciﬁc commensal strains of Escherichia 
coli have been shown to reduce intestinal epithelial inﬂammatory signalling, in vitro, through 
repression of NF-κB signalling [33]. This is achieved through inhibiting the ubiquitination of 
the NF-κB subunit Iκα. Similarly, we wished to investigate if the selected commensal strain 
of Escherichia used its TIR domain-containing protein to reduce inflammatory TLR 
signalling in this region also, in order to maintain a homeostatic environment in the gut. 
Furthermore, a signal peptide was identified on the EschTIR protein which may allow for the 
protein to be translocated to a specific region to act upon host signalling if the protein were 
secreted by the bacteria. 
Similar to the previously characterised bacterial TcpB and TlpA proteins, known to 
modulate TLR and adaptor molecule signalling, the two proteins we had selected, EschTIR 
and BifTIR, were found to have strong Box 1 homology while lacking Box 2 and Box 3 
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regions [14]. Similarly also, they shared higher sequence similarities with the gene cluster of 
TLRs 1, 2, 6 and 10, in particular with TLR1 and TLR6. Additionally, the sequence of the 
EschTIR protein was quite similar to the subversive immune evading TcpC protein identified 
in uropathogenic E.coli [10]. However, an important point to note here is that when TIR 
domains with marginal sequence similarity are identified, such as between microbes and 
humans, some of the proteins with certain TIR domain signature sequences may turn out to 
differ in their tertiary structure folding, which may affect their interactions [34]. 
Although sequence analysis of the plasmids into which we had cloned these two 
bacterial TIR proteins confirmed that insertion had taken place correctly, we were unable to 
detect expression of the proteins through western blotting when these plasmids were 
transfected into human cell lines. Positive controls were used in such analyses in order to 
confirm the functionality of the transfection and blotting procedures. Similarly, PCR 
reactions were performed to detect the presence of bacterial TIR protein mRNA in HEK cells 
transfected with TIR plasmids although none was detected. It was hypothesised that the small 
proteins from these plasmids may not be detectable by Western Blot or PCR. This could be 
due to very low expression efficiency of the proteins in the plasmid. Furthermore, smaller 
proteins are more difficult to detect than larger proteins by Western blotting and the milk 
solution used in the blocking stage of the Western blot technique may have resulted in non-
specific binding to the bacterial proteins – resulting in a lack of detection. It would be worth 
using other known Western blotting blocking agents such as BSA or casein to investigate if 
this is the case. 
Despite the difficulties in protein detection, NF-κB activation luciferase assays were 
performed in order to investigate if expression of these proteins resulted in abrogation of TLR 
induced NF-κB activation. This was achieved through TLR4 activation using LPS 
stimulation as well as over-expression of TLR4 and adaptor molecules MyD88 and MAL. 
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The BifTIR protein, in addition to the LacTIR protein appeared to have the most potential for 
inhibiting TIR-mediated, NF-κB activation. Both exhibited a trend for reduced NF-κB 
activity in response to a challenge with endotoxic LPS in RAW macrophage cells. These cells 
were used due to their high transfectability and endogenous expression of TLRs. However, 
they are a murine cell line and it is likely that any potential modulation of TIR signalling by 
the bacterial TIR proteins studied here would be specific to TIR signalling in the human host. 
With the use of the human HEK cell line, both BifTIR and LacTIR proteins were also able to 
significantly reduce NF-κB activity caused by overexpression of TLR4. These results were 
similar to effects were seen following expression of bacterial proteins TcpB and TcpC [34]. 
Unlike these two proteins, however, neither of the two proteins in this study was able to 
abrogate NF-κB activation driven by TLR4 adaptor proteins MyD88 and MAL indicating that 
they may exert their potential immuno-modulatory effects by inhibiting directly at the level 
of the receptor.  
The EschTIR protein however, did not appear to have any consistent or significant 
effect on the inflammation processes investigated. This protein was found to contain a signal 
peptide, which may be used to deliver the protein to a specific part of the host for signalling. 
Additionally, it is possible that its function may not be uncovered by over-expression within 
the cell; it may need to be isolated and added to the cell to fully reveal its function. Since we 
did not explore every method of TIR signalling interfaces upon which these proteins might 
act, it is possible that this protein evades innate immune surveillance through TIR interactions 
we have not explored. In addition to NF-κB, other known downstream effectors in the TLR 
signalling cascade could also be affected from interactions between these bacterial TIR 
proteins and our innate immune signalling systems; such as Extracellular signal-Regulated 
Kinase (ERK), p38 MAPK and c-Jun N-terminal kinase (JNK) [35]. The same may, of 
course, be said of the LacTIR and BifTIR proteins. Furthermore, these proteins might behave 
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differently in the setting of IEC or gut macrophages known to have distinct signalling 
mechanisms. An in vivo study using isolated forms of each protein might prove to yield more 
information on this. However, using a mouse model, one should be conscious of the fact that 
these TIR proteins have been isolated from human commensal bacteria. Investigation of 
effects on TLR2 signalling would also be a worthwhile area in which to study these proteins 
further. Through BLAST analysis, the BifTIR and EschTIR proteins were found to share the 
best homology with TLR1 and TLR6 which both require TLR2 for signalling. It could be that 
the proteins bind to TLR2 – preventing it from forming a dimer with TLR1 or TLR6 through 
which it can mediate an inflammatory signal. Based on the results from this study, it is likely 
that TLR4-driven NF-κB activation is limited somewhat by the BifTIR and LacTIR proteins 
due to their binding to the receptor itself; both proteins had little or no effect on NF-κB 
activation driven by over-expressing either MAL or MyD88, two adaptor molecules required 
for TLR4 signalling, indicating that any interference in TIR:TIR interactions likely to be 
happening upstream of the adaptors at the level of the receptor itself. If this effect was 
observed with TLR4, it is quite possible that the same could be true for the closely related 
TLR2 or that EschTIR may play a role in modulating signalling here.  
Many obstacles were encountered surrounding plasmid cloning and detection of 
expression throughout the study. Furthermore, inconsistencies were associated with studies 
using the RAW murine macrophage cell line and the non-quantitative luciferase assays. Due 
to time constraints, it was impractical to progress this work any further because of these 
obstacles and difficulties. A definitive result regarding the expression of the TIR proteins 
following transfection of the plasmids is crucial before any direct result can be taken from 
this work. Furthermore, there remains the possibility that any decreases seen in NF-κB 
activity following transfection may be due to transfection artefact when measured using the 
luciferase reporter assay. A purification of the TIR proteins may be performed and added to 
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cells in culture to observe such effects and avoid the possibility of ambiguous data due to 
transfection artefact. 
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Chapter 4 
 
 
 An investigation into colonic 
homeostasis induced by TLR9 signalling  
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4.1 Introduction 
 
The gut epithelium has an important function in the maintenance of intestinal immune 
homeostasis. It ensures that an effective immune response is raised to infectious micro-
organisms while itself remaining predominantly unresponsive to the myriad of commensal 
bacteria it is in contact with. This is achieved by preventing the contact of bacteria with 
immune cells through the formation of a physical barrier and the expression of antimicrobial 
peptides [1-3]. At the frontline of this interface, the Intestinal Epithelial Cells (IECs) line the 
gut epithelium. It is possible that homeostasis in the intestinal tract could in fact be 
maintained by unique features of IECs, rather than unique bacterial features. They are 
structurally and functionally polarized, with an apical surface facing the intestinal lumen and 
a basolateral surface facing the adjacent cells in the lamina propria. This spatial organisation 
of the IECs allows for distinct functions at each surface utilising distinct membrane proteins 
[4]. In addition to their role as a protective barrier at this mucosal interface, IECs have also 
been shown themselves to play a very important part in our body‘s immune response [5]. The 
polarity and tight junctions of IECs play a particularly important part in this response, 
enabling the segregation of apical signals from basolateral signals in pathogen recognition. 
This is mediated through differentially expressed Pattern Recognition Receptors (PRRs) such 
as Toll-Like Receptors (TLRs).  
IECs are known to express mRNA for all known TLRs, TLR1-10 [6], and have also 
been shown to express TLR1-9 protein [7-12]. The expression and function of TLR2 [13], 
TLR4 [14], TLR5 [15], and TLR9 [6, 16, 17] has been best characterised in IECs. Certain 
TLRs are expressed on the apical vs. the basolateral membranes. For example, TLR5 is 
expressed intracellularly or basolaterally in the colon [15], thereby avoiding an inappropriate 
inflammatory response to flagellated commensal bacteria present in the gut lumen, (apical 
side of the epithelia). TLR2 and TLR4 have been shown to be present at the apical surface of 
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polarized, confluent IEC, in the cell line T84, which readily respond to acute stimulation with 
the corresponding bacterial ligands [6, 9, 13]. In contrast, TLR2 and TLR4 are mostly present 
in the cytoplasmic compartment in undifferentiated IEC and are expressed in much lower 
amounts than in differentiated IEC. This correlates with ligand tolerance as IECs are 
predominantly unresponsive to TLR2 and TLR4 ligands [13]. TLR2 expression in particular 
has been shown to play a specific role in IEC homeostasis. It controls tight-junction-
associated intestinal epithelial barrier integrity in order to balance mucosal homeostasis 
against inflammatory-stress-induced damage. This is achieved by targeted modulation of 
barrier function proteins such as ZO-1 and Conexin43 (Cx43) following TLR2 activation [18, 
19]. TLR9 is also involved in maintenance of intestinal homeostasis. Several groups have 
shown that TLR9 knockout mice have increased severity in cases of artificially induced 
colitis [20, 21]. Furthermore, feeding mice with CpG Oligodeoxynucleotides (ODNs), the 
ligand for TLR9, resulted in inhibition of induced colonic proinflammatory cytokines and 
chemokines such as IL-8 in addition to colitis symptoms [22, 23].  
In addition to differential expression, differential regulation of TLRs between the 
apical and the basolateral surfaces of these cells may allow activation of signalling pathways 
necessary for TLR mediated homeostasis but not TLR-mediated pro-inflammatory effects. A 
study performed by Lee et al. further highlighted a role for TLR9 in intestinal homeostasis 
through differential regulation of TLR signalling. HCA-7 cells, an IEC line, when grown to a 
polarised monolayer, produced IL-8 in response to basolateral, but not apical, stimulation of 
TLR3, TLR5 and TLR9 while only responding to apical and not basolateral stimulation of 
TLR2 [12]. Apical TLR9 stimulation was, however, found to confer intracellular tolerance to 
subsequent TLR challenges [12]. Moreover, apical TLR9 stimulation was also shown to 
inhibit IL-8 production in response to apical TLR2 and basolateral TLR3 or TLR5 
stimulation [12]. Taken together, these data suggest that this ―polarising-tolerising‖ ability of 
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IECs represents a unique mechanism, which helps restrain inflammatory responses in a 
bacteria rich environment. 
The mechanism by which TLR9 signalling maintains this homeostasis and in addition, 
how apical TLR9 signalling may inhibit inflammatory responses from other TLRs was 
investigated further by Lee et al. [12]. Microarray analysis revealed that the most prominent 
apical TLR9-specific target gene was Frizzled5 (Fzd5) [12]. Fzd5, a major gut receptor for 
Wnt, a signalling glycoprotein, is involved in the maturation of Paneth cells in the small 
intestine, which produce anti-microbial peptides such as cryptdins and defensins [24]. In 
concordance with this in vitro data, Fzd5 mRNA levels, together with its target genes, 
cryptdins and defensins, were downregulated in the small intestines of TLR9
–/– 
mice 
compared with wild-type mice [21]. β-catenin, an intracellular signalling intermediate located 
on the Wnt signalling pathway, can physically complex with NF-κB, resulting in a reduction 
of NF-κB DNA binding, transactivation activity, and target gene expression [25]. Activated 
β-catenin has been found to inhibit the expression of NF-κB target genes. Since Wnt 
signalling activates β-catenin, and Fzd5 is involved in this pathway, these authors proposed 
that, by using this pathway, apical TLR9 signalling may mediate an inhibitory effect on NF-
B. This is in clear contrast with data showing that TLR2 and 4 induce expression of Wnt5a 
and Fzd5 in macrophages, T cells and B cells in an NF-kB dependant manner and that this 
induction of Wnt5/Fzd5 subsequently enhanced IL-12 and IFNγ production by M. 
tuberculosis, also in an NF-kB dependant fashion [26]. Given the conflicting evidence 
between these reports and the data of Lee et al showing that TLR9 strongly upregulates Fzd5 
in a non-NF-kB dependant manner, it is clear that further studies are needed to clarify the 
cross-talk between Wnt and TLR signalling. In addition, there has been no study performed 
identifying the direct effects of TLR signalling on the Wnt/β−catenin pathway in IECs. 
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In the following study, I aimed to identify novel mechanisms behind the maintenance 
of tolerance in the gastro-intestinal tract through TLR9 regulation and signalling.  
Specifically, I aimed to characterise apical TLR9 signalling in IECs and determine the 
involvement of known signalling intermediates in apical TLR9 signalling to elucidate what 
signalling pathways were used to activate Fzd5 while inhibiting IL-8 production. In addition, 
I aimed to examine the role of TLR inhibitory proteins in the control of both proinflammatory 
and homeostatic signalling in IECs in addition to identifying novel TLR interacting proteins 
in IECs. To do this, I used different intestinal epithelial cell lines grown in the polarising 
transwell system to allow differentiation of both apical and basolateral surfaces to initially 
confirm the results of Lee et al. This involved an attempt to induce tolerance to TLR-induced 
inflammatory signalling through apical TLR9 stimulation with its ligand, CpG, in a 
monolayer of IEC using the transwell system. I then investigated pro-inflammatory gene 
activation and also induction of Fzd5 . I further aimed to elucidate the mechanism through 
which this occurs by investigating the Fzd5/Wnt/β-catenin signalling cascade through TLR9 
stimulation.
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4.2 Results  
 
4.2.1 Validation of monolayer formation in a Caco-2 cell clone  
Initially, we wished to define the optimal time-frame required for an effective 
polarized monolayer of intestinal epithelial cells to be generated. This was to ensure efficient 
polarisation of the cells with the aim of producing differential TLR expression and signalling 
mechanisms, on the apical and basolateral surfaces of the cells. C2Bbe1 (C2B) cells, a clone 
of the Caco-2 cell line, were used as they have been reported to form monolayers more 
efficiently than other IEC lines. Trans-Epithelial Electrical Resistance (TEER) measures the 
resistance between the apical and basolateral chambers through the transwell membrane and 
hence correlates to the formation of a monolayer of cells, as described in the methods section 
2.2. The tighter and more complete the monolayer formed, the higher the TEER value. The 
graph in Figure 4.1 was constructed by measuring the TEER over time of several transwells 
(graph shown representative of 12 wells in 2 different plates). 
The graph demonstrates that a resistance of 1,000Ω is reached after 12 days from 
which time it remains relatively constant – confirming that the formation of a monolayer of 
cells is achieved after 12 days. This information was utilised in ensuring complete formation 
of a monolayer in future experiments in order to achieve an efficiently polarised epithelial 
monolayer.  
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Figure 4.1 Trans-Epithelial Electrical Resistance measured over C2Bbe1 cells in a 
transwell system. C2Bbe1 cells were grown in a transwell system while trans-epithelial electrical 
resistance was measured over a duration of 3 weeks. Values are shown as Mean ± SEM, n=3 
 
 
4.2.2 Response to TLR ligands using C2Bbe1 Intestinal Epithelial Cell lines 
The aim of our initial experiments was to reproduce the observations of Lee et al., 
whereby a twofold induction of Fzd5 was observed following apical stimulation with TLR9 
ligand (CpG) in IECs while IL-8 production was only induced following basolateral CpG 
stimulation [12]. Prior to attempting to reproduce this effect in C2Bbe1 cells, their ability to 
produce IL-8, Fzd5α and TNFα in response to TLR9 stimulation was initially examined. 
Figure 4.2 displays qRT-PCR data from C2Bbe1 lysates which had been grown to a 
monolayer on transwells prior to stimulation with TLR9 ligand. This stimulation, however, 
failed to induce any significant changes in IL-8, Fzd5α or TNFα expression, as seen in Figure 
4.2 A, B and C respectively, with a surprising 2-fold decrease in TNFα induction from 
basolateral stimulation seen in Figure 4.2C. 
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Figure 4.2 Response to apical or basolateral TLR9 stimulation in a C2Bbe1 monolayer. 
Polarized C2BBe1 cells were stimulated with CpG (ISS ODN; 5μg/ml; TLR9); apically or 
basolaterally (basally) as indicated for 8 hours. mRNA levels were measured by qRT-PCR for relative 
expression of IL-8 (A), TNFα (B) or Fzd5α (C). Values are shown as Mean ± SEM, n=3 Statistics 
were carried out using t test with Welch‘s correction. 
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4.2.3 Response to TLR ligands in vitro using T84 and Caco-2 Intestinal Epithelial Cell 
lines 
Having failed to observe a measurable response in the C2Bbe1 cells when subjected 
to TLR9 ligand stimulation, we sought to use other Intestinal Epithelial cell lines. Caco-2 
(Figure 4.1) and T84 (Figure 4.2) Intestinal Epithelial Cells (IECs) were grown to a confluent 
monolayer over 21 days with the aim of achieving polarisation on a transwell system. The 
cells were then stimulated with a range of TLR ligands; LPS (TLR4), Flagellin (TLR5) and 
CpG DNA (TLR9). qRT-PCR was used to measure induction of IL-8 and TLR9 response 
gene, Fzd5, in response to these ligands. We also attempted to reproduce the findings of Lee 
et al. showing that apical stimulation of IECs with CpG was able to abrogate subsequent TLR 
stimulation [12]. This result was of particular interest to us as the aim of this project was to 
identify the mechanistic basis underlying the homeostatic role of TLR9 in IECs. For this 
investigation, some of the cells were stimulated apically with TLR9 ligand prior to 
basolateral stimulation with TLR4, TLR5 and TLR9 ligands. LPS was selected as a negative 
control for IL-8 induction as polarised IECs are broadly unresponsive to extracellular LPS 
following apical stimulation [13]. Flagellin was selected as a positive inflammatory control as 
IECs have been shown to produce pro-inflammatory cytokines following basolateral but not 
apical stimulation [12].  
In Figure 4.3A, IL-8 expression was increased 2.5-fold over untreated control 
following apical CpG stimulation, although apical TLR4 and TLR5 stimulation with LPS and 
flagellin respectively resulted in no increased IL-8 expression. This was in contrast to 
previously published results [12, 13]. 3-fold induction of IL-8 was observed following 
basolateral LPS stimulation, however. In addition, basal stimulation of TLR5 resulted in a 
1.5-fold level of IL-8 induction, similar to previous findings [15]. A 50% reduction in IL-8 
induction was observed over the untreated cells in cells subjected to basolateral LPS and CpG 
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stimulation following pre-treatment with apical TLR9 stimulation. However, this was not on 
a similar level to the total abrogation observed by Lee et al [12]. Figure 4.3B shows a 3-fold 
induction of Fzd5α following apical TLR9 stimulation but also 5-fold from basolateral TLR4 
stimulation. Furthermore, none of these changes in expression were found to be statistically 
significant. 
 
 
 
Figure 4.3 Apical/Basolateral stimulation of polarised Caco-2 cells with TLR ligands. 
Polarized Caco-2 cells were stimulated with the indicated TLR ligands: LPS (100 ng/ml; TLR4); 
Flagellin (10 ng/ml; TLR5); CpG (ISS ODN; 5μg/ml; TLR9); apically or basolaterally as indicated 
for 16hrs. Apical pre-stimulation involved stimulating the cells apically with CpG (ISS ODN; 5 
μg/ml; TLR9) for 8 hours before stimulating basolaterally with the indicated TLR ligands for a further 
16 hours. mRNA levels were measured by qRT-PCR for relative expression of IL-8 (A) or Fzd5α (B). 
Statistics were carried out using t test with Welch‘s correction. 
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This experiment was subsequently repeated in the other selected IEC line, T84. Figure 
4.4A displays no measurable IL-8 induction in T84 cells through stimulation with the 
negative control LPS, possibly due to lack of surface TLR4 expression [27]. Basal 
stimulation with flagellin and CpG DNA did, however, induce IL-8 expression, 3-fold over 
untreated cells. Although in contrast with previous reports, induction of 7-fold and 4-fold 
respectively was also seen over untreated controls following apical stimulation with these 
ligands. This result indicates that the IEC monolayer may not have been polarised correctly 
since it implies apical surface expression of TLR5, previously published to only be expressed 
basolaterally [12, 28], although these studies did not use the T84 IEC line. Apical pre-
stimulation of TLR9 did seem to abrogate IL-8 induction by subsequent basolateral 
stimulation of TLR9, in keeping with results seen by Lee et al. [12]. This apical pre-
stimulation, however, had no effect on basolateral LPS or flagellin-induced IL-8 induction, 
measured at 3-fold and 7-fold over untreated cells respectively. Furthermore, IL-8 expression 
levels from apical CpG stimulation alone were higher than those seen by basolateral 
stimulation. Similarly, 7-fold induction of Fzd5α was observed not only through TLR9 
stimulation as expected (Figure 4.4B) but also through TLR5 stimulation following both 
apical and basolateral stimulation. Furthermore, none of these changes in expression were 
found to be statistically significant. 
While a more differential response had been observed between apical and basolateral 
stimulation of the Caco-2 cells, some of the data obtained was not in line with several 
previous published findings and all the data obtained showed a general lack of consistent 
level of activation between experiments. Experiments performed to generate the data in 
Figures 4.3 and 4.4 displayed a high level of discrepancy in terms of the level of response to 
TLR ligands and the high levels of variation between apical and basolateral stimulation. This 
indicates that there may have been issues associated with the ligands used; model chosen or 
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cell lines selected in reproducing the data of Lee et al. As a result, subsequent experiments 
were performed on the HCA-7 cell line, which was used by Lee et al. in the studies 
examining the differential effect of TLR9 signalling in IECs [12, 21]. 
 
 
 
 
 
 
Figure 4.4 Apical/basolateral stimulation of polarised T84 cells with TLR ligands. 
Polarized T84 cells were stimulated with the indicated TLR ligands: LPS (100 ng/ml; TLR4); 
Flagellin (10 ng/ml; TLR5); CpG (ISS ODN; 5 μg/ml; TLR9); apically or basolaterally as indicated 
for 16hrs.Apical pre-stimulation involved stimulating the cells apically with CpG (ISS ODN; 5 μg/ml; 
TLR9) for 8 hours before stimulating basolaterally with the indicated TLR ligands for a further 16 
hours.  mRNA levels were measured by qRT-PCR for relative expression of IL-8 (A) or Fzd5α (B). 
Statistics were carried out using t test with Welch‘s correction. 
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4.2.4 Response to TLR ligands using HCA-7 Intestinal Epithelial Cell lines 
The ability of HCA-7 cells to produce IL-8, Fzd5α and TNFα in response to TLR9 
stimulation was subsequently examined. Figure 4.5 displays IL-8 induction from HCA-7 cells 
which had been grown to a monolayer on transwells prior to apical or basolateral stimulation 
with TLR9 ligand. The positive control of a dual stimulation with TNFα and IFNγ was also 
used in order to verify a measurable IL-8 response could be generated and also to confirm the 
formation of an efficient monolayer. CpG treatment failed to induce any IL-8 expression, 
following either apical or basolateral stimulation. Basolateral but not apical stimulation with 
TNFα and IFNγ however, resulted in a 3.5-fold increase in IL-8 induction over untreated 
cells; similar results had been reported in other studies [29]. However, this change in 
expression was not found to be statistically significant. 
 
 
Figure 4.5 IL-8 expression in response to apical or basolateral TLR9 stimulation in a 
HCA-7 monolayer. Polarised HCA-7 cells were stimulated with CpG (ISS ODN; 5μg/ml; TLR9); 
apically or basolaterally as indicated for 8 hours. mRNA levels were then measured by qRT-PCR for 
relative expression of IL-8.TNFα and IFNγ were used apically or basolaterally as positive 
inflammatory controls and added at 10ng/ml each together as indicated for 8 hours. Statistics were 
carried out using t test with Welch‘s correction. 
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A possible explanation for the results obtained so far was that the mRNA induction 
was being measured 8 hours post-stimulation. This timepoint might be too late to measure 
effective mRNA responses to TLR ligand stimulation. To assess this, we measured protein 
production by MSD ELISA. No measureable IL-8 mRNA induction was observed in 
response to CpG stimulation in Figure 4.5. As this was in direct contrast to data shown by 
Lee et al. we subsequently quantified the pro-inflammatory cytokines IL-6, TNFα and IL-8 
from the supernatants of the cells used in Figure 4.5. The mRNA for these cytokines may not 
have been present 8 hours post-stimulation although the cytokines themselves may have 
accumulated and remained in the supernatant. Figure 4.6 displays the production levels of 
these cytokines accumulated over the 8-hour stimulation from the supernatants of apical and 
basolateral chambers from each of these transwells.  
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No significant increase in IL-6 or IL-8 production was observed from each of the 
graphs in Figure 4.6 (A to D) in response to apical or basolateral stimulation with 5μg/ml 
CpG. However an increase was observed in the level of IL-8 production from the apical and 
basolateral supernatants of Figure 4.6 (A and B) following stimulation with positive controls 
TNFα and IFNγ. Moreover, Figure 4.6C displays a 2-fold increase in IL-6 in response to 
apical TNFα and IFNγ stimulation in the apical chamber. A significant increase in IL-6 
production was also observed in response to basolateral TNFα and IFNγ stimulation in the 
basolateral chamber (Figure 4.6D).  
Taken together, Figure 4.5 and Figure 4.6 indicate no activation of pro-inflammatory 
cytokines in response to TLR9 stimulation. However, stimulation with TNFα and IFNγ 
resulted in high inflammatory responses as can be seen in TNFα production levels of >5000 
pg/ml (Figure 4.6E and F). This suggests that inflammatory stimulation is occurring in the 
cells although it is not apparent in response to TLR9 stimulation. Furthermore, these data 
confirm that polarisation had occurred and formation of a monolayer had taken place; this is 
seen through lack of inflammatory cytokines detected in the apical compartment of cells 
stimulated basolaterally with TNFα and IFNγ and vice versa. Ultimately, these data implied 
that the cells were forming a monolayer and were responsive to other ligands but not the 
TLR9 ligand used.  
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Figure 4.6 Cytokine production in response to apical or basolateral TLR9 stimulation in 
a HCA-7 monolayer. Supernatants from transwell samples in Figure 4.5 were measured for 
inflammatory cytokine production by use of an MSD plate. IL-8 and IL-6 levels were measured from 
both the apical and basolateral chambers as indicated. Statistics were performed using student‘s t-test. 
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4.2.5 Treatment of HCA-7 with different CpG ODN constructs 
A possible explanation for the results obtained so far and the divergent results 
displayed by Lee et al. was in the nature of the oligodeoxynucleotide (ODN) TLR9 ligands 
used. To address this potential issue, the identical ODN construct as used by Lee et al. was 
obtained. A dose response was performed using this construct (indicated as Lee in Figure 
4.7A), and the construct which had been used up until now (indicated as Invivogen in Figure 
4.7A), on un-polarised HCA-7 cells and IL-8 expression levels were measured by qRT-PCR 
(Figure 4.7). Neither construct showed an increase IL-8 mRNA induction whilst the positive 
control (TNFα and IFNγ) showed a low but consistent increase in IL-8 expression (Figure 
4.7A and B). These results demonstrated that the lack of responsiveness observed in HCA-7 
cells when challenged with TLR9 stimulation, contradictory to the result reported by Lee et 
al. [12] was not due to the CpG ODN constructs used. 
In addition to measuring IL-8 induction to monitor an inflammatory response, Fzd5α 
levels were also measured since this gene should be induced following TLR9 activation in 
HCA-7 cells, as described by Lee et al. [12]. Over timepoints of 0, 1, 3 or 6 hours, 
stimulation with the TLR9 ligand (Lee) did not strongly induce IL-8 expression (<1.5-fold 
over untreated) as seen in Figure 4.7C. Induction of TLR9 target gene, Fzd5α, mRNA levels 
following TLR9 stimulation was seen to rise between 1 and 6 hours with a peak of ~4-fold 
induction over unstimulated at 3 hours. This suggests that TLR9 stimulation may have been 
occurring, although but a measurable pro-inflammatory response was not observable 
following TLR9 stimulation. However, the pro-inflammatory response was reported to be 
from basolateral TLR9 stimulation and these cells had not been polarised 
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Figure 4.7 IL-8 induction in unpolarised HCA-7 cells following stimulation by 
increasing concentrations of TLR9 ligand. Unpolarised HCA-7 cells were treated with varying 
concentrations of the different ODN constructs as indicated on the graph for 8 hours (A and B) or 
with CpG (ISS ODN, Lee; 5 μM) for the times indicated (C) and IL-8 mRNA levels were quantified 
by qRT-PCR (see methods section). These data are representative of 3 such experiments. Statistics 
were carried out using t test with Welch‘s correction. 
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Despite the lack of responsiveness observed in Figure 4.7, a final experiment was 
performed. In Figure 4.8, polarised HCA-7 cells were stimulated with TLR9 ligand in order 
to observe any differential activation in IL-8 expression using exactly the same cells, ligand 
constructs and parameters as used by Lee et al. Figure 4.8A and B display no significant 
levels of IL-8 or TNFα expression induced following 1, 3 or 6 hour stimulation with 5 μM of 
the CpG construct. The 2-3 fold increase in expression of IL-8 and TNFα seen following 
stimulation with TNFα and IFNγ confirms that induction of these genes was measurable but 
not in response to TLR9 stimulation. Figure 4.8C displays no increase, and indeed a decrease, 
in what Lee et al. outlined as a TLR9 target gene Fzd5α over the 6 hour time period. These 
data suggest that TLR9 stimulation was not likely to be occurring in this instance. 
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Figure 4.8 Response of polarised HCA-7 cells to TLR9 stimulation. HCA-7 cells which had 
been grown to a confluent monolayer on transwells as described in methods were stimulated either 
apically or basolaterlly with TLR9 ligand CpG (ISS ODN, Lee; 5 μM) in a, b and c or TNFα with 
IFNγ at 10ng/ml each as a positive inflammatory control (a, b), for the time indicated. mRNA levels 
of the indicated genes were then measured by qRT-PCR.  Statistics were carried out using t test with 
Welch‘s correction. 
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4.3 Discussion 
TLR9 has been reported to be located on both apical and basolateral surfaces of the 
IECs [12, 30]. Recent work by Lee et al shows that the ability of the TLR9 ligand CpG DNA 
to activate NF-κB depends on which surface of the IEC is stimulated [12]. The study by Lee 
et al describes differential effects of TLR9 ligation on polarized vs. unpolarised HCA-7 IECs. 
Pre-stimulation of apical TLR9 on HCA-7 cells induced tolerance to subsequent basolateral 
stimulation with TLR9. However, these tolerised cells did not reduce NF-κB activation 
through ubiquitination and subsequent degradation of regulatory IκBα but instead induced 
inhibitory molecules towards NF-κB such as IRAK-M and Tollip. Furthermore, apical TLR9 
stimulation was found to confer intracellular tolerance to subsequent TLR challenges. Apical 
TLR9 stimulation was also shown to inhibit IL-8 production in response to apical TLR2 and 
basolateral TLR3 or TLR5 stimulation. In contrast, apical stimulation with TLR3 or TLR5 
ligand failed to induce tolerance to subsequent basolateral TLR signalling. IECs in TLR9-
deficient mice, when compared with wild-type and TLR2-deficient mice, displayed a lower 
NF-κB activation threshold and these mice were highly susceptible to experimental colitis. 
Microarray analysis performed by this group showed that apical stimulation of TLR9 resulted 
in activation of a different subset of genes when compared to basolateral stimulation, with 
only a 40% overlap in genes activated between the two surfaces. This indicates that there is 
likely to be activation of alternative signalling pathways in IECs by TLRs depending on 
which surface is stimulated by the TLR ligand. 
 In order to explore this theory, we wished to examine activation of novel TLR 
regulated genes which appear to have a role in TLR induced IEC homeostasis rather than a 
TLR induced pro-inflammatory role. Hence, we aimed to further characterise TLR induction 
of proteins such as Fzd5, identifying precisely which TLRs can induce these proteins, 
whether they can be induced through apical and/or basolateral stimulation and what TLR 
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signalling intermediates are necessary for induction of these proteins. We wished to 
characterise the regulatory and signalling mechanisms by which TLRs achieve their dual 
roles in IECs with the intention to further elucidate potential mechanisms that may be 
dysregulated in disease states such as IBD. We also hypothesised that different TLR 
signalling molecules and co-receptors may be utilised in intestinal epithelial cells compared 
with leukocytes in order to activate specific signalling pathways and achieve the divergent 
pro-inflammatory or homeostatic roles played by TLRs in these cells. As inappropriate 
activation of TLRs on IECs has been implicated in the development of several 
gastrointestinal disorders including colon cancer [31], colitis [32] and celiac disease [33], a 
greater understanding of the mechanism of action of TLRs in IECs under normal conditions 
and how these mechanisms are disrupted during inflammation is essential for the 
development of effective therapies against these diseases. 
As the initial aim of this study was to identify a differential signalling pathway existed 
between apical and basolateral activation of TLR9, we initially wished to replicate data by 
Lee et al. This was attempted by use of the transwell system to achieve a polarised monolayer 
of IECs and stimulation of TLRs by synthetic ligands. We examined TLR9 stimulation in 
several IEC lines. Using C2Bbe1 and also Caco-2 cells, a general lack of response to the 
TLR9 ligand was observed by both apical and basolateral stimulation. This is similar to 
reports from de Kivit et al [34]. These authors also investigated IEC responsiveness to TLR9 
stimulation. Using Caco-2 and C2Bbe1 cells, however, they reported that apical exposure to 
TLR ligands had no observable effect on an immune response when activated PBMC were 
co-cultured with Caco-2 cells. They highlight in this study that in comparison to HT-29 cells, 
Caco-2 cells show markedly less TLR expression, especially TLR9 [17, 35]. This can also 
perhaps explain the results seen in the data presented here where Caco2 and their subclone, 
C2Bbe1 cells, were used. While this study used unpolarised HT-29 cells and polarised T84 
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IECs in co-culture with activated PBMC, they reported that apical stimulation of T84 cells 
with TLR9 ligand resulted in enhanced IFN-γ and immune-regulatory IL-10 secretion by 
activated PBMC in co-culture. A similar effect was observed using unpolarised HT-29 cells, 
where a significant decrease win IL-13 was also observed. IL-6, IL-12 and TNFα were also 
measured using both HT-29 and T84 but no significant change was observed following 
stimulation with TLR9 ligand. Conversely, despite the absence of polarisation in the HT-29 
co-cultures, apical and basolateral exposure to TLR9 ligand elicited differential responses in 
their study. Ultimately, their results showed that only apical exposure resulted in a Th1 
response that coincided with regulatory IL-10 secretion. This was lost upon basolateral TLR9 
ligand exposure, which resulted in enhanced secretion of pro-inﬂammatory cytokines 
including TNFα [34]. We did not investigate responses in HT-29 as these cells do not 
polarise in the transwell system. 
Similarly, a study by Pederson et al also found that CpG ODN stimulation completely 
failed to induce a signiﬁcant increase in IL-8 protein secretion in normal primary colonic 
epithelial cells [17]. They stated that fully differentiated human colonic epithelial cells, unlike 
HT-29, are completely unresponsive to TLR9 ligand stimulation in vitro despite spontaneous 
TLR9 gene expression. They also measured expression levels of TLR9 in Caco-2 compared 
to HT-29 cell lines in addition to the primary intestinal epithelial cell line, DLD-1. The 
results displayed a comparable level of expression in the HT-29 and DLD-1 cells but with 
relatively very low expression in the Caco-2 cell line. Furthermore, at least ﬁve isoforms of 
TLR9 protein exist and the same study reported that two of these isoforms were present in 
freshly isolated colonic epithelial cells, while only one isoform was seen in HT-29 cells. As 
the functional role of these different isoforms is unknown, further investigations are required 
to elucidate whether CpG ODN responsiveness is correlated to the presence of distinct 
isoforms of TLR9. While the expression levels of TLR9 or its different isoforms were not 
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investigated in my own study, it is another possible reason why I did not observe the same 
results as Lee et al., when repeating their work using the Caco-2 or C2Bbe1 cell lines.  
Finally we used HCA-7 cells as the model cell line for our study, in keeping with the 
exact procedure used by Lee et al [12]. While these cells responded to stimulation by TNFα 
and IFNγ, there were few significant or consistent responses to stimulation of TLR9. This 
lack of sensitivity to TLR9 ligand was investigated further. It was found, however, that while 
no inflammatory response was seen, the TLR9 target gene Fzd5a was responding to TLR9 
stimulation. Further to the difficulties which arise when comparing different cell lines of the 
same cell type [34], phenotypes of cell lines are also known to differ between laboratories. 
Cell culture conditions in different labs can affect the responsiveness of cells. In addition, the 
aforementioned studies of Pederson et al highlighted the significance of different isoforms of 
TLR9 and possible different signalling pathways. It could well be that isoforms are expressed 
or not in cell lines between different laboratories over time.  
In contrast to my data and also that of de Kivit et al., however, oral administration of 
TLR9 agonists has been shown to provide protective effects in an IL-10-dependent manner 
[36] in animal models of colitis [22, 23]. In one study, Rachmilewitz et al found that in all 
models of experimental and spontaneous colitis examined, TLR9 ligand ISS-ODN 
administration ameliorated clinical, biochemical, and histologic scores of colonic 
inflammation in addition to inhibiting the induction of colonic pro-inflammatory cytokines 
and chemokines [22]. A couple of years later, the same group reported that the intragastric 
administration of probiotic and E. coli DNA ameliorated the severity of DSS-induced colitis 
in mice [23]. Methylated probiotic DNA, calf thymus DNA, and DNase-treated probiotics on 
the other hand had no effect. This reduction in severity of colitis was also observed to the 
same extent through intragastric administration of nonviable γ-irradiated or viable probiotics. 
Administering these γ-irradiated probiotics was also shown to significantly decrease the 
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severity of DSS-induced colitis in TLR2 and TLR4 deﬁcient mice, whereas, in TLR9-
deﬁcient mice, γ-irradiated had no effect. However, while these protective anti-inflammatory 
effects may be seen through TLR9 stimulation in vitro, caution should be exercised when 
dealing with in vitro studies using cell lines. It has been demonstrated several times that 
transformed intestinal cell lines are not fully representative for the differentiated human 
colonic epithelium with regard to phenotypic markers of differentiation [37-39]. While 
similar results to those observed by Lee et al. [12, 21] have been reported in other cell lines 
such as T84 and HT-29 [12, 34], our study also highlights the importance of variations within 
different cell lines and their phenotypes, even among different laboratories.  
To summarise, throughout the course of my experiments I was unable to reproduce 
results reported by Lee et al regarding differential TLR9 signalling in polarised IECs. As 
outlined above, this may be due to differential expression and signalling mechanisms of 
TLR9 between different cell lines in different laboratories. Comparable to what was 
encountered by de Kivit et al, I found that results from Lee et al could not be reproduced 
using IEC lines [12, 34]. My inability to reproduce the data published by Lee et al prevented 
me from further pursuing the project. 
140 
 
4.4 References 
 
1. Abreu, M.T., M. Fukata, and M. Arditi, TLR signaling in the gut in health and 
disease. J Immunol, 2005. 174(8): p. 4453-60. 
2. Macdonald, T.T. and G. Monteleone, Immunity, inflammation, and allergy in the gut. 
Science, 2005. 307(5717): p. 1920-5. 
3. Wehkamp, J., et al., Mechanisms of disease: defensins in gastrointestinal diseases. 
Nat Clin Pract Gastroenterol Hepatol, 2005. 2(9): p. 406-15. 
4. Kazmierczak, B.I., K. Mostov, and J.N. Engel, Interaction of bacterial pathogens with 
polarized epithelium. Annu Rev Microbiol, 2001. 55: p. 407-35. 
5. Cario, E. and D.K. Podolsky, Intestinal epithelial TOLLerance versus inTOLLerance 
of commensals. Mol Immunol, 2005. 42(8): p. 887-93. 
6. Otte, J.M., E. Cario, and D.K. Podolsky, Mechanisms of cross hyporesponsiveness to 
Toll-like receptor bacterial ligands in intestinal epithelial cells. Gastroenterology, 
2004. 126(4): p. 1054-70. 
7. Liu, Y., et al., Changes in intestinal Toll-like receptors and cytokines precede 
histological injury in a rat model of necrotizing enterocolitis. Am J Physiol 
Gastrointest Liver Physiol, 2009. 297(3): p. G442-50. 
8. Bogunovic, M., et al., Enteroendocrine cells express functional Toll-like receptors. 
Am J Physiol Gastrointest Liver Physiol, 2007. 292(6): p. G1770-83. 
9. Cario, E. and D.K. Podolsky, Differential alteration in intestinal epithelial cell 
expression of toll-like receptor 3 (TLR3) and TLR4 in inflammatory bowel disease. 
Infect Immun, 2000. 68(12): p. 7010-7. 
10. Stroinigg, N. and M.D. Srivastava, Modulation of toll-like receptor 7 and LL-37 
expression in colon and breast epithelial cells by human beta-defensin-2. Allergy 
Asthma Proc, 2005. 26(4): p. 299-309. 
11. Steenholdt, C., et al., Expression and function of toll-like receptor 8 and Tollip in 
colonic epithelial cells from patients with inflammatory bowel disease. Scand J 
Gastroenterol, 2009. 44(2): p. 195-204. 
12. Lee, J., et al., Maintenance of colonic homeostasis by distinctive apical TLR9 
signalling in intestinal epithelial cells. Nat Cell Biol, 2006. 8(12): p. 1327-36. 
13. Cario, E., et al., Commensal-associated molecular patterns induce selective toll-like 
receptor-trafficking from apical membrane to cytoplasmic compartments in polarized 
intestinal epithelium. Am J Pathol, 2002. 160(1): p. 165-73. 
14. Ortega-Cava, C.F., et al., Strategic compartmentalization of Toll-like receptor 4 in the 
mouse gut. J Immunol, 2003. 170(8): p. 3977-85. 
15. Gewirtz, A.T., et al., Cutting edge: bacterial flagellin activates basolaterally 
expressed TLR5 to induce epithelial proinflammatory gene expression. J Immunol, 
2001. 167(4): p. 1882-5. 
16. Akhtar, M., et al., Bacterial DNA evokes epithelial IL-8 production by a MAPK-
dependent, NF-kappaB-independent pathway. FASEB J, 2003. 17(10): p. 1319-21. 
17. Pedersen, G., et al., Expression of Toll-like receptor 9 and response to bacterial CpG 
oligodeoxynucleotides in human intestinal epithelium. Clin Exp Immunol, 2005. 
141(2): p. 298-306. 
18. Cario, E., G. Gerken, and D.K. Podolsky, Toll-like receptor 2 controls mucosal 
inflammation by regulating epithelial barrier function. Gastroenterology, 2007. 
132(4): p. 1359-74. 
141 
 
19. Ey, B., et al., TLR2 mediates gap junctional intercellular communication through 
connexin-43 in intestinal epithelial barrier injury. J Biol Chem, 2009. 284(33): p. 
22332-43. 
20. Obermeier, F., et al., In vivo CpG DNA/toll-like receptor 9 interaction induces 
regulatory properties in CD4+CD62L+ T cells which prevent intestinal inflammation 
in the SCID transfer model of colitis. Gut, 2005. 54(10): p. 1428-36. 
21. Lee, J., J.M. Gonzales-Navajas, and E. Raz, The "polarizing-tolerizing" mechanism of 
intestinal epithelium: its relevance to colonic homeostasis. Semin Immunopathol, 
2008. 30(1): p. 3-9. 
22. Rachmilewitz, D., et al., Immunostimulatory DNA ameliorates experimental and 
spontaneous murine colitis. Gastroenterology, 2002. 122(5): p. 1428-41. 
23. Rachmilewitz, D., et al., Toll-like receptor 9 signaling mediates the anti-inflammatory 
effects of probiotics in murine experimental colitis. Gastroenterology, 2004. 126(2): p. 
520-8. 
24. Schmausser, B., et al., Expression and subcellular distribution of toll-like receptors 
TLR4, TLR5 and TLR9 on the gastric epithelium in Helicobacter pylori infection. Clin 
Exp Immunol, 2004. 136(3): p. 521-6. 
25. Deng, J., et al., beta-catenin interacts with and inhibits NF-kappa B in human colon 
and breast cancer. Cancer Cell, 2002. 2(4): p. 323-34. 
26. Blumenthal, A., et al., The Wingless homolog WNT5A and its receptor Frizzled-5 
regulate inflammatory responses of human mononuclear cells induced by microbial 
stimulation. Blood, 2006. 108(3): p. 965-73. 
27. Abreu, M.T., et al., Decreased expression of Toll-like receptor-4 and MD-2 correlates 
with intestinal epithelial cell protection against dysregulated proinflammatory gene 
expression in response to bacterial lipopolysaccharide. J Immunol, 2001. 167(3): p. 
1609-16. 
28. Bambou, J.C., et al., In vitro and ex vivo activation of the TLR5 signaling pathway in 
intestinal epithelial cells by a commensal Escherichia coli strain. J Biol Chem, 2004. 
279(41): p. 42984-92. 
29. Ou, G., et al., Contribution of intestinal epithelial cells to innate immunity of the 
human gut--studies on polarized monolayers of colon carcinoma cells. Scand J 
Immunol, 2009. 69(2): p. 150-61. 
30. Ewaschuk, J.B., et al., Surface expression of Toll-like receptor 9 is upregulated on 
intestinal epithelial cells in response to pathogenic bacterial DNA. Infect Immun, 
2007. 75(5): p. 2572-9. 
31. Abreu, M.T., Toll-like receptor signalling in the intestinal epithelium: how bacterial 
recognition shapes intestinal function. Nat Rev Immunol, 2010. 10(2): p. 131-44. 
32. Sanchez-Munoz, F., et al., Transcript levels of Toll-Like Receptors 5, 8 and 9 
correlate with inflammatory activity in Ulcerative Colitis. BMC Gastroenterol, 2011. 
11: p. 138. 
33. Szebeni, B., et al., Increased mucosal expression of Toll-like receptor (TLR)2 and 
TLR4 in coeliac disease. J Pediatr Gastroenterol Nutr, 2007. 45(2): p. 187-93. 
34. de Kivit, S., et al., Apical TLR ligation of intestinal epithelial cells drives a Th1-
polarized regulatory or inflammatory type effector response in vitro. Immunobiology, 
2011. 216(4): p. 518-27. 
35. Uehara, A., et al., Various human epithelial cells express functional Toll-like 
receptors, NOD1 and NOD2 to produce anti-microbial peptides, but not 
proinflammatory cytokines. Mol Immunol, 2007. 44(12): p. 3100-11. 
142 
 
36. Bleich, A., et al., CpG motifs of bacterial DNA exert protective effects in mouse 
models of IBD by antigen-independent tolerance induction. Gastroenterology, 2009. 
136(1): p. 278-87. 
37. Pedersen, G., et al., Cultures of human colonic epithelial cells isolated from 
endoscopical biopsies from patients with inflammatory bowel disease. Effect of 
IFNgamma, TNFalpha and IL-1beta on viability, butyrate oxidation and IL-8 
secretion. Autoimmunity, 2000. 32(4): p. 255-63. 
38. Gibson, P.R., et al., Contrasting effects of butyrate on the expression of phenotypic 
markers of differentiation in neoplastic and non-neoplastic colonic epithelial cells in 
vitro. J Gastroenterol Hepatol, 1992. 7(2): p. 165-72. 
39. Mariadason, J.M., et al., Resistance to butyrate-induced cell differentiation and 
apoptosis during spontaneous Caco-2 cell differentiation. Gastroenterology, 2001. 
120(4): p. 889-99. 
 
 
 
  
143 
 
Chapter 5 
 
 
 Identification of novel Pattern 
Recognition Receptors involved in 
detection of L.monocytogenes in 
intestinal epithelial cells by use of siRNA 
screening   
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5.1. Introduction 
 
Listeria monocytogenes (L. monocytogenes), a Gram-positive bacterium and a 
facultative intracellular pathogen, has the potential to cause life-threatening diseases such as 
septicaemia and meningitis [1], particularly in immuno-compromised individuals, pregnant 
women, and neonates [2]. Pathogenic listeriae, being a foodborne pathogen, enter the host 
primarily through the intestine [3]. They cross the intestinal barrier by invading intestinal 
epithelial cells (IECs). From here, they enter the bloodstream, to reach their target organs, the 
liver and spleen, where they are internalized by hepatic and splenic macrophages. They then 
multiply until infection is finally controlled by the TNFα and iNOS producing effector 
Dendritic Cells (TipDCs). These effector cells require infected cells to signal to activate them 
but are not themselves infected [4].  
L.monocytogenes is known to evade host immune responses by several means in order 
to promote its survival. It is able to invade non-phagocytic cells and is resistant to 
intracellular killing by macrophages after phagocytosis [5]. L.monocytogenes invades and 
multiplies within non-phagocytic cells, such as enterocytes, hepatocytes, fibroblasts and 
endothelial cells [6]. This ability of L.monocytogenes to establish itself intracellularly 
avoiding phagocytosis aids the bacterium to avoid host responses and ensures effective tissue 
dissemination and enhanced virulence. For a long time this mechanism of intracellular spread 
was thought to be the main strategy employed by L.monocytogenes to avoid immune 
detection. With the discovery of host pattern recognition receptors (PRRs) and increased 
understanding of innate immune signalling pathways, however, it has been shown that the 
bacterium is also capable of avoiding detection through other mechanisms. L. monocytogenes 
can de-acetylate its peptidoglycan to avoid detection by TLR2 [7]. Effective immune 
responses to L.monocytogenes infection relies on co-ordinated innate and adaptive immune 
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responses, with the first line of innate defence being mediated by detection of the invading 
bacterium by these PRRs. Several families of these receptors have been identified including 
the transmembrane Toll-Like Receptors (TLRs), the cytosolic NOD-Like Receptors (NLRs) 
and RIG-I like Receptors (RLRs) and in more recent years C-type Lectin Receptors (CLRs) 
[8] (see Introduction Section 1.1).  
The activation of innate immunity by PRRs in response to L.monocytogenes infection 
is still not fully understood. RNA interference and inhibitor experiments using human 
Peripheral Blood Mononuclear Cells (PBMCs) were performed by Meixenberger et al in 
2010 in order to determine which PRRs and inflammasomes play key roles during infection. 
The results indicated that the Listeria-induced IL-1β release was dependent on the adaptor 
protein ASC, caspase-1, and NLRP3, whereas in this case, NOD2, RIP2, NLRP1, NLRP6, 
NLRP12, NLRC4, and AIM2 appeared to be dispensable [9]. However, mice lacking NOD2 
fail to generate adaptive responses to L. monocytogenes in the gut [10]. RNAi-based studies 
revealed that a producer of Reactive Oxygen Species (ROS), called Dual Oxidase 2 
(DUOX2), is required for the direct bactericidal properties of NOD2. This highlights ROS as 
effector molecules of protective cellular signalling in response to a defined danger signal by 
the intracellular NLRs of IECs [11]. L.monocytogenes has also been shown to be recognised 
by TLR2 [12, 13] and NOD1 [14, 15] in macrophage and endothelial cells, resulting in NF-
B activation and pro-inflammatory gene expression. The role of TLR5 in detection of 
L.monocytogenes remains unclear; although flagellin from L.monocytogenes activates TLR5, 
bacterial mutants deficient in flagellin display an unaltered virulence [16, 17]. More recent 
studies have identified several inflammasome components responsible for recognition of the 
bacterium such as NLRC4 and AIM2 in macrophages. Recognition of L.monocytogenes 
through these receptors results in activation of caspase-1 and cleavage of IL-1 [18]. 
L.monocytogenes infection has also been shown to induce a type I interferon response, 
146 
 
potentially mediated by TLR2 and the adaptor protein TRIF in peritoneal macrophages [19]. 
Most recently the IFN- response has been shown to be triggered by nucleic acids released 
from L.monocytogenes acting through the intracellular sensor RIG-I in macrophage cells 
[20]. Much of these studies contradict the Meixenberger study in 2009, which used PBMCs 
and suggested many of these PRRs were dispensable or redundant during infection [9]. It is 
important to note here, however, that functionality of PRRs may differ from cell type to cell 
type. 
Epithelial cells line the enteric mucosal surface providing barrier function against 
microbial invasion. Similar to immune cells, IECs express many of these receptors of the 
innate immune system and are the first site of bacterial recognition in the intestine. 
Characterisation of the innate immune responses to L.monocytogenes infection has been 
studied in several cells types, including endothelial cells, PBMCs, and macrophages [7]. 
However, no extensive screen has been performed on innate and PRR mediated mechanisms 
of detection of L.monocytogenes in the intestinal epithelia. To date, NOD2 is the only PRR 
directly shown to play a role in detecting L.monocytogenes in the intestinal epithelium [10]. 
Recently in fact, a study by Kernbauer et al. using an in vitro mouse model of oral 
L.monocytogenes infection revealed that the type I IFN response increased bacterial clearance 
when infection occurred intra-gastrically [21]. Previous studies worked with intraperitoneal 
infection models for in vitro mouse studies and type I IFN responses were believed to be 
detrimental to bacterial clearance; however, this detrimental effect of type I IFNs is only the 
case when infection occurs through a route other than intra-gastric, highlighting the need for 
further study of intestinal epithelial innate immunity.  
In addition to the lack of understanding surrounding the immune response in the 
context of IECs, the importance of further investigating the role of the main effector PRRs 
involved in early detection of L.monocytogenes along with identifying PRRs which the 
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bacteria may use to subvert the immune system requires further clarification. The aim of this 
study was to identify novel PRRs involved in the early detection of L.monocytogenes in IECs 
by use of siRNA screening. This involved optimisation of infection parameters and siRNA 
transfection in addition to inflammatory outputs. I have identified several novel PRRs which 
appear to negatively regulate the inflammatory response upon detection of the bacteria in 
addition to discovering that TLR10 plays a role in activating an inflammatory response to the 
bacteria in IECs.  
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5.2 Results  
 
5.2.1 Identification of L. monocytogenes growth phases and CFU/ml to be 
used in invasion assays 
There exists some discrepancy in the literature regarding the methodology used in 
performing in vitro infection assays using L. monocytogenes; therefore optimisation of 
infection assays was required for THP-1 (monocyte) and HT-29 (epithelial) cells. Several 
variables such as; multiplicity of infection (MOI), growth rate prior to infection and 
incubation time of the bacteria with the host cells were examined. A reference growth curve 
of the bacteria over time, by counts of the colony forming units (CFU)/ml of culture, made 
relative to Optical Density (OD) was required (Figure 5.1). This ensured accuracy in counting 
for MOI when using L. monocytogenes for all invasion assays and also in the reproducibility 
of each experiment. Furthermore, it also allowed for the identification of the time points and 
OD values for the Early, Middle and Late log growth phases, indicated on the graph.  
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Figure 5.1 Optimisation of growth curve and log phases for L. monocytogenes vs. 
Optical Density (OD) at A595 A single colony of L. monocytogenes was selected and cultured 
overnight at 37°C. The next day, a 1/50 dilution of the culture was prepared. An aliquot was taken 
from this new culture every hour (including time-point zero) for 8 hours. With each aliquot, an OD 
measurement was made as well as serial dilutions of the culture. These dilutions were then spotted on 
an agar plate to determine CFU/ml for each aliquot as described in the methods section 2.12. The 
graph above is representative of 3 such experiments carried out on separate days. 
 
 
We also wished to identify which growth phase resulted in the most efficient invasion 
during infection. HT-29 cells were chosen for this investigation over the monocytic THP-1 
cells as the epithelial HT-29 cells should be less efficient at internalisation. This allowed the 
most efficient growth phase to use for infection to be more distinguishable. The results of this 
may be seen in Table 5.1. 
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Table 5.1 Optimisation of growth phase of L. monocytogenes to be used in invasion 
assays with HT-29 cells. L. monocytogenes was grown to the growth phases indicated, based on 
the graph from Figure 5.1. A known number of bacteria could then be used for infection of HT-29 
cells at an MOI of 100. Infection was performed as described in 2.15 of the methods section and 
lysate of host HT-29 cells were used to spot on agar plates to count CFU post-infection. This total 
CFU count recovered/lysate was calculated as a percentage of the total number of bacteria used to 
infect the cells. Using this method, an internalisation or invasion efficiency of the bacteria was 
calculated. The table above represents the mean values with the standard error of the mean for 4 such 
assays. 
 
 
Following the addition of the bacteria to the host cells, gentamicin, which is not 
believed to enter host cells, was added to prevent further bacterial replication without killing 
intracellular bacteria. Verification that the gentamicin was not killing the intracellular 
bacteria but was preventing their growth was required since controversy on this issue, 
regarding the uptake of gentamicin by host cells, is also found throughout the literature [22, 
23]. Figure 5.2 displays a live/dead staining of bacteria treated with Gentamicin or formalin 
for 1 hour using flow cytometry. This demonstrates that the gentamicin did not kill all of the 
bacteria, as the formalin treatment did. The gentamicin treatment did, however, prevent 
further bacterial replication or growth; since no colonies were recovered from the agar plates 
spotted with the gentamicin-treated culture despite more than half of the bacteria remaining 
viable following the gentamicin treatment. 
 
Log Phase Early Mid Late 
Invasion Efficiency 
(CFU recovered from 
lysate post-infection) 
0.25 ± 0.06% 0.08 ± 0.05% 0.1 ± 0.06% 
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Figure 5.2 Verification of Gentamicin induced inhibition of bacterial replication 
without resulting in bacterial cell death. A culture of L. monocytogenes was grown 
overnight. The following day, half of the cells were washed and treated with 50μg/ml of Gentamicin 
in BHI broth for 1 hour, while the rest were treated with 4% formalin for 1 hour. A live/dead screen 
was then performed as described in the methods section 2.13 in order to determine what percentage of 
the bacteria had survived following the gentamicin or formalin treatment.  Binding of SYTO9 to DNA 
is dependent on active transport, so SYTO9 diffuses through the intact cell membrane and binds 
cellular DNA of viable cells only, while PI binds DNA of damaged cells only. Thus, the X axis 
represents SYTO9 bound DNA, or live bacterial staining, and the Y axis represents PI-bound DNA or 
non-viable cells. In addition to the live/dead screen, bacteria were spotted on an agar plate to 
determine how much growth of L. monocytogenes took place following gentamicin treatment. 
 
The results in Figure 5.2 above show that only half of the bacteria treated with 
gentamicin were dead/unviable. An overnight culture of bacteria such as this contains a 
number of dead bacteria already, as the cells enter death phase following stationary phase of 
growth naturally. The killing effect of the gentamicin was relatively mild compared to the 
formalin treated cells where all of the bacteria are dead. However, no colonies from either of 
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these cultures were observed  confirming that the gentamicin treatment had prevented further 
bacterial growth. 
The optimal incubation time of the bacteria with the host cells, and the MOI used was 
next determined. Figure 5.3 displays internalisation efficiency of L. monocytogenes at various 
MOI using either an incubation period of 1 or 2 hours for the bacteria with the host cells 
before the addition of gentamicin. It was concluded from these results that 2 hours 
incubation prior to addition of antibiotic was the optimal incubation time.  
 
 
Figure 5.3 Optimisation of MOI and incubation time of L. monocytogenes with the 
host cells. L.monocytogenes was grown to Early Log Phase growth. HT-29 (a), THP-1 (b), or THP-
1 cells pre-treated with PMA (c) were then subject to infection at various MOI. Following either 1 or 
2 hours incubation with the bacteria, media was supplemented with 50μg/ml gentamicin for a further 
hours. Subsequently, cells were lysed and the number of internalised bacteria was calculated by 
counting the CFU from the lysates as described in the methods section 2.15. 
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Confocal microscopy was used to verify internalisation of L. monocytogenes and to 
exclude the possibility of external adherence of the bacteria to the cell. Internalisation of the 
bacteria is vital in order to measure the potential response of any cytoplasmic PRRs, such as 
NLRs. As is evident in Figure 5.4, after 2 hours incubation with the host cells, Listeria are 
internalised by the cells and also appear to adhere externally. 
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Figure 5.4 (a) HT-29 cells infected for 2 hours at MOI 100 
  
Orange = External  
bacteria 
Green = Internalised 
bacteria 
Blue = F-actin 
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Figure 5.4 (b) THP-1 cells infected for 2 hours at MOI 100 
 
Figure 5.4 Confirmation of cellular internalisation of L. monocytogenes. Host cells 
were prepared for confocal microscopy as described in the methods section 2.16. Bacteria were CFSE 
(green) labelled and biotinylated. Infection was then carried out as described previously at the MOI of 
100 for 2 hours. Cells were fixed and host F-actin was stained with fluorescent phallotoxins (blue). 
Streptavidin-allophycocyanin was used to bind to the biotinylated bacteria such that all bacteria were 
CFSE labelled but only extracellular bacteria had also taken up the streptavidin-allophycocyanin dye 
(red). Figure 5.4 (a) shows HT-29 cells while (b) contains THP-1 cells, each stained blue with 
internalised bacteria shown as green and external bacteria as orange (green + red).  
 
 
Based on this optimisation data, the parameters chosen were for L. monocytogenes to 
be in early log phase at the time of infection, MOI of 50, and incubated with host cells for 2 
hours, prior to gentamicin treatment for 1 hour. The next step was to characterise the host cell 
immune response to infection.  
Orange = External bacteria 
Green = Internalised bacteria 
Blue = F-actin 
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5.2.2 Measuring the host inflammatory response to internalised L. 
monocytogenes in THP-1 and HT-29 cells 
 
As the overall aim of the assay was to measure the innate immune response mediated 
by PRRs in response to L. monocytogenes, an early time-point of infection was selected at 3 
hours based on the data above. qRT-PCR was used to measure mRNA of select cytokines 
expressed following infection at this timepoint. A range of cytokines and chemokines from 
the literature believed to be involved in epithelial inflammatory signalling were measured for 
induction in HT-29 cells following the 3 hour infection. The cytokines measured were CCL-
1, CCL-2, CCL-5, CCL-17, CCL-19, CCL-20, IL-1β, IL-6, IL-8, IL-12, IL-17, IL-18, IL-23, 
Caspase-1 and EGR-1. Of these, CCL-2, CCL-5, CCL-17, CCL-19, IL-6, IL-12 and IL-17 
were undetectable by qRT-PCR. However, IL-8, CCL-1, CCL-20 and EGR-1 were induced 
10, 17, 75 and 30-fold respectively over uninfected controls (Figure 5.5). Based on this, we 
used the early transcription factor, EGR-1 and the chemotactic agents CCL-20 and IL-8 in the 
measurement of an inflammatory response to infection with L.monocytogenes in HT-29 cells. 
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Figure 5.5 Cytokine and chemokine induction in HT-29 cells following L. 
monocytogenes infection. Levels of CCL-1, CCL-2, CCL-5, CCL-17, CCL-19, CCL-20, IL-1β, 
IL-6, IL-8, IL-12, IL-17, IL-18, IL-23, Caspase-1 and EGR-1 induction were measured in HT-29 cells 
following a 3 hour infection with L. monocytogenes. Results from all detectable genes measured are 
displayed above with each induction made relative to the uninfected control. . * P<0.05, ** P<0.01 
and *** P<0.001, Values are shown as Mean ± SEM, n=3. Statistics were carried out using t test with 
Welch‘s correction. 
 
These genes were examined further to ensure that they provided a consistently robust 
output in response to infection (Fig. 5.6). Each gene was significantly induced in response to 
infection (p<0.05). Induction of Early Growth Response protein-1 (EGR-1), Chemokine (C-C 
motif) Ligand 20 (CCL-20) and IL-8 over untreated controls was measured at 40, 20, 60-fold 
induction respectively. THP-1 cells were also examined for induction of each of these genes 
with the addition of IL-1β (Figure 5.7). EGR-1 and IL-1β were significantly induced with 10 
and 6–fold induction measured respectively over the untreated cells. There was no significant 
increase in CCL-20 or IL-8 induction in THP-1s despite induction levels seen at 8 and 6-fold 
over untreated cells respectively. PMA treatment for differentiation of the THP-1 cells was 
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not performed at this stage due to inflammatory activation by PMA which made an L. 
monocytogenes-mediated response more difficult to differentiate.  
 
Figure 5.6 Measurement of HT-29 Response to L. monocytogenes infection by qRT-
PCR. Shown above is the qRT-PCR data for EGR-1 (a), CCL-20 (b), and IL-8 (c) in HT-29 cells 
following infection with L. monocytogenes at MOI of 50 for 3 hours. Each infection was carried out 
as described in the methods section 2.14. Cells were then lysed and RNA was extracted for qRT-PCR 
analysis. * P<0.05, ** P<0.01 and *** P<0.001, Values are shown as Mean ± SEM, n=3. Statistics 
were carried out using t test with Welch‘s correction. 
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Figure 5.7 Measurement of THP-1 Response to L. monocytogenes infection by qRT-
PCR. Shown above is the qRT-PCR data for EGR-1 (a), CCL-20 (b), IL-8 (c) and IL-1β (d) in THP-
1 monocyte cells following infection with L. monocytogenes at MOI of 50 for 3 hours. Each infection 
was carried out as described in the methods section 2.14. Cells were then lysed and RNA was 
extracted for qRT-PCR analysis. * P<0.05, ** P<0.01 and *** P<0.001, Values are shown as Mean ± 
SEM, n=3. Statistics were carried out using t test with Welch‘s correction. 
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5.2.3 Optimisation of siRNA treatment for THP-1 and HT-29 cells 
 
In addition to having defined the genes measured for induction by qRT-PCR 
following infection with L. monocytogenes as an output for the siRNA library screen, siRNA 
treatment also required optimisation for each cell type. In addition to confirmation of a 
successful knockdown, it was also necessary to show that infection with L. monocytogenes 
did not affect siRNA treatment. MAPK1 siRNA, which was readily available in the lab, was 
used as a negative control. This gene is not believed to be involved in an immune response to 
the bacteria, so knocking down MAPK1 should not lower the response of any of the 
cytokines selected as an output following L. monocytogenes infection. CCL-20 was used as a 
measurement of inflammatory response for the epithelial cells since they strongly induce this 
chemokine in response to L. monocytogenes; similarly IL-1β induction was measured for the 
monocytic THP-1 cells (see Fig. 5.6, 5.7). IL-8 was measured for each as it is induced in both 
cell types. Figure 5.8(a) confirms the silencing of MAPK1 in HT-29 cells with at least 50% 
reduction in MAPK1 expression following siRNA treatment. No significant change in the 
expression of IL-8 (b) or CCL-20 (c) was recorded between MAPK-1 and control siRNA 
treated samples following infection.  
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Figure 5.8 Verification of siRNA technique in HT-29 cells using MAPK-1 siRNA. 
Cells were seeded in a 96 well plate. siRNA treatment was performed as described in the methods 
2.17 using either a non-targeting siRNA control or MAPK-1 siRNA. Cells were then subject to 
infection with L. monocytogenes as described in the methods section 2.14. Lysates of the cells were 
then prepared for analysis by qRT-PCR of MAPK1 expression (a), IL-8 expression (b) or CCL-20 
expression (c) made relative to the untreated control. * P<0.05, ** P<0.01 and *** P<0.001. Statistics 
were carried out using t test with Welch‘s correction. 
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Similarly in THP-1s, a silencing of 50% was seen in MAPK1 induction following 
MAPK1 siRNA treatment (Fig. 5.9 (a). Again, there was no change in the induction of IL-8 
(Figure 5.9 (b)) or in IL-1β induction (c) between the control or MAPK1 siRNA treated 
samples following L. monocytogenes infection. Importantly, neither cell type underwent any 
changes in knockdown efficiency following infection, nor were there any significant 
differences in the inflammatory outputs used for infection following siRNA treatment. 
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Figure 5.9 Verification of siRNA technique in THP-1 cells using MAPK-1 siRNA. 
Cells were seeded in a 96 well plate. siRNA treatment was performed as described in the methods 
section 2.17 using either a non-targeting siRNA control or MAPK-1 siRNA. Cells were then subject 
to infection with L. monocytogenes as described in the methods section 2.14. Lysates of the cells were 
then prepared for analysis by qRT-PCR of MAPK1 expression (a), IL-8 expression (b) or IL-1β 
expression (c) made relative to the untreated control. * P<0.05, ** P<0.01 and *** P<0.001. Statistics 
were carried out using t test with Welch‘s correction. 
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Subsequently, 2 positive controls were used for siRNA treatment; RelA, a subunit of 
the inflammatory gene regulator, NF-κB, and the TLR adaptor protein, MyD88. Silencing of 
either of these genes should lead to reduced induction of the inflammatory genes selected as 
an output following infection since both RelA and MyD88 are reported to be vital for 
detection and clearance of L. monocytogenes in the human system [24]. Figure 5.10 displays 
the successful silencing of each of these genes in HT-29 cells with 60 to 80% silencing of 
RelA induction (5.10a) and at least 75% reduction in MyD88 induction (5.10b) as measured 
by qRT-PCR. The corresponding inflammatory response following infection also revealed a 
decrease from 5-fold induction of CCL-20 over uninfected cells in the control siRNA treated 
samples, to 2-fold in the RelA siRNA treated samples and 4-fold in the MyD88 siRNA 
treated samples (5.10c). A similar result was obtained when IL-8 expression was examined 
with the same levels of induction and decreased induction across the control, RelA and 
MyD88 siRNA treated samples following L. monocytogenes infection (5.10d). It is 
interesting to note that RelA appears to be involved in epithelial responses but not MyD88. 
This implies that NF-κB activation is necessary for induction of IL-8 and CCL-20 in response 
to L. monocytogenes but suggests that either MyD88 is dispensable or perhaps the level of 
knockdown achieved was not sufficient to affect the epithelial response to the bacteria as 
measured by CCL-20 and IL-8 induction.  
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Figure 5.10 Verification of siRNA technique in HT-29 cells using MyD88 and RelA 
siRNA. Cells were seeded in a 96 well plate. siRNA treatment was performed as described in the 
methods section 2.17 using either a non-targeting siRNA control , RelA or MyD88 siRNA. Cells were 
then subject to infection with L. monocytogenes as described in the methods section 2.14. Lysates of 
the cells were then prepared for analysis by qRT-PCR of RelA expression (a), MyD88 expression (b), 
CCL-20 expression (c) or IL-8 (d) made relative to the untreated control. * P<0.05, ** P<0.01 and 
*** P<0.001. Statistics were carried out using t test with Welch‘s correction. 
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In THP-1 cells, there was a 60% reduction in both RelA expression (Fig. 5.11 a) and MyD88 
expression (Fig. 5.11 b) following siRNA treatment compared to the control siRNA treated 
samples. Neither RelA nor MyD88 siRNA had an effect on IL-8 induction (Fig. 5.11 c) over 
uninfected samples following infection with L. monocytogenes. There was, however, a 
significant reduction of IL-1β expression in the uninfected cells which had been treated with 
RelA or MyD88 siRNA (Fig. 5.11 d). This was reflected in the significant decrease of IL-1β 
levels induced in response to infection; control siRNA samples responded with 3-fold 
induction over uninfected while RelA and MyD88 siRNA treated samples displayed similar 
levels of induction to the uninfected scrambled siRNA treated control. This would seem to 
imply that unlike the epithelial cells, THP-1 did not require RelA or MyD88 for IL-8 
induction following infection, or again, that the knockdown was not sufficient to affect the 
response to the bacteria. IL-1β induction, however, was greatly reduced upon silencing RelA 
and MyD88, implying a more critical function for each of these genes in IL-1β induction. 
This was seen both in uninfected and infected samples.  
 
Taken together these experiments show that we were able to perform efficient 
knockdown in both HT-29 and THP-1 cells and also that we could affect innate immune 
response outputs following knockdown of known immune genes. 
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Figure 5.11 Verification of siRNA technique in THP-1 cells using MyD88 and RelA 
siRNA Cells were seeded in a 96 well plate. siRNA treatment was performed as described in the 
methods section 2.17 using either a non-targeting siRNA control, RelA or MyD88 siRNA. Cells were 
then subject to infection with L. monocytogenes as described in the methods section 2.14. Lysates of 
the cells were then prepared for analysis by qRT-PCR of RelA expression (a), MyD88 expression (b), 
CCL-20 expression (c) or IL-1β (d) made relative to the untreated control. * P<0.05, ** P<0.01 and 
*** P<0.001. Statistics were carried out using t test with Welch‘s correction. 
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5.2.4 PRR siRNA library screen used to measure changes in inflammatory 
response following infection with L. monocytogenes  
 
Following the optimisation of the infection parameters for L. monocytogenes and the 
inflammatory response output and siRNA treatment in both THP-1 monocytes and HT-29 
epithelial cells, the next phase of the study involved using the PRR siRNA library. A list of 
the genes involved in this screen is shown in Table 5.2 below.  
 
 
Toll-Like 
Receptors 
 
NOD-like receptors 
 
C-type Lectin 
Receptors 
 
TLR1 
 
CIITA NLRP5 
 
CD209 CLEC12B 
 
TLR2 
 
NAIP NLRP6 
 
CD207 CLEC6A 
 
TLR3 
 
NOD1 NLRP7 
 
CLEC10A CLEC4C 
 
TLR4 
 
NOD2 NLRP8 
 
CLEC5A CLEC4E 
 
TLR5 
 
NLRC3 NLRP9 
 
CLEC7A CLEC4A 
 
TLR6 
 
NLRC4 NLRP10 
 
CLEC12A MRC1 
 
TLR7 
 
NLRC5 NLRP11 
 
CLEC1B LY75 
 
TLR8 
 
NLRP1 NLRP12 
 
CLEC9A 
 
 
TLR9 
 
NLRP2 NLRP13 
   
 
TLR10 
 
NLRP3 NLRP14 
   
   
NLRP4 NLRX1 
   
        Adaptors: MYD88 
 
CASP1 RIPK2 
    
Table 5.2 The PRRs and adaptor proteins included in the siRNA library screen 
 
We decided to focus on using the HT-29 cell line with the silencing library as most 
previous studies have focussed on L. monocytogenes interaction with macrophage cells rather 
than epithelia. It is thought that L. monocytogenes initially invades epithelia; therefore, this 
may be the first site where PRR activation occurs. Figures 5.12, 5.13 and 5.14 below display 
the qRT-PCR results from EGR-1, IL-8 and CCL-20 expression levels respectively in 
response to L. monocytogenes infection following siRNA treatment for the genes indicated in 
the graphs.   
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Figure 5.12 Relative mRNA expression of EGR-1 in HT-29 cells treated with PRR 
siRNA compared with non-targeting siRNA treated control following L. monocytogenes 
infection. Cells were treated with the PRR siRNA library as described in the methods section 2.17. 
Following infection with L.monocytogenes, lysates were analysed by qRT-PCR for EGR-1 induction. 
Each bar represents the expression of EGR-1 relative to the non-targeting siRNA treated infected 
control. For clarity, the results have been divided into samples treated with siRNA targeting TLR 
genes (a), NLR genes (b) and CLR genes (c). * P<0.05, ** P<0.01 and *** P<0.001. Values are 
shown as Mean ± SEM, n=3. Statistics were carried out using the Mann Whitney U test. 
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Figure 5.13 Relative mRNA expression of IL-8 in HT-29 cells treated with PRR siRNA 
compared with non-targeting siRNA treated control following L. monocytogenes 
infection. Cells were treated with the PRR siRNA library as described in the methods section 2.17. 
Following infection with L.monocytogenes, lysates were analysed by qRT-PCR for EGR-1 induction. 
Each bar represents the expression of IL-8 relative to the non-targeting siRNA treated infected 
control. For clarity, the results have been divided into samples treated with siRNA targeting TLR 
genes (a), NLR genes (b) and CLR genes (c). * P<0.05, ** P<0.01 and *** P<0.001. Values are 
shown as Mean ± SEM, n=3. Statistics were carried out using the Mann Whitney U test.
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Figure 5.14 Relative mRNA expression of CCL-20 in HT-29 cells treated with PRR 
siRNA compared with non-targeting siRNA treated control following L. monocytogenes 
infection. Cells were treated with the PRR siRNA library as described in the methods section. 
Following infection with L.monocytogenes, lysates were analysed by qRT-PCR for EGR-1 induction. 
Each bar represents the expression of CCL-20 relative to the non-targeting siRNA treated infected 
control. For clarity, the results have been divided into samples treated with siRNA targeting TLR 
genes (a), NLR genes (b) and CLR genes (c). * P<0.05, ** P<0.01 and *** P<0.001. Values are 
shown as Mean ± SEM, n=3. Statistics were carried out using the Mann Whitney U test. 
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EGR-1 expression, displayed in Figure 5.12, was increased 7-fold upon infection with 
L. monocytogenes in the control siRNA treated cells. However, it was not significantly 
affected by siRNA treatment with any of the 50 PRR targets in the library following 
infection. Figure 5.13 displays IL-8 expression, which increased 6-fold following infection 
with L. monocytogenes in the control siRNA treated cells. CCL-20 was induced 10-fold in the 
control siRNA treated samples following infection (Fig. 5.14). Several significant changes in 
IL-8 and CCL-20 induction were measured following PRR siRNA treatment. Therefore, due 
to the large volume of data generated from Figures 5.13 and 5.14, each of the statistically 
significant changes in expression are displayed on a separate figure (Figure 5.15). 
Figure 5.15 displays expression levels of CCL-20 (a) and IL-8 (b) made relative to the 
control siRNA treated sample following infection. The samples with lowered expression of 
each of these genes indicate PRRs involved in early L. monocytogenes detection in intestinal 
epithelial cells have been silenced by siRNA. The samples with higher expression could 
reveal some regulatory PRRs involved in controlling an otherwise detrimental inflammatory 
response. Alternatively, they could reveal PRRs utilised by L. monocytogenes to evade 
detection by our innate immune surveillance system.  
CCL-20 expression increased almost 2-fold following siRNA treatment for regulatory 
genes NLRP7 and NLRP10 over samples treated with non-targeting siRNA. We have 
observed a decrease of 50% in CCL-20 expression following treatment with NLRP2 siRNA 
in infected cells. The same trend was conserved in IL-8 expression levels with a 50% 
decrease observed following siRNA treatment for NLRP2 and a 2-fold increase after NLRP1, 
NLRP7 and NLRP10 were silenced. In addition, siRNA treatment for several other NLRs 
resulted in increased IL-8 expression in response to the bacteria. siRNA targeting NLRC3, 
NLRC4, NLRC5, NLRP4, NLRP6, NLRP8, NLRP9 and NLRP11 resulted in a 3-fold 
increase in IL-8 expression following infection. NOD1 and NOD2 are known to be involved 
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in detection of L. monocytogenes and eliciting an inflammatory response [15, 25, 26]. 
Although no significant change in any inflammatory genes we measured were observed in 
response to infection following treatment with siRNA for NOD1, NOD2 or their adaptor 
molecule RIPK2, there was a trend in decreased IL-8 and CCL-20 expression (Figure 5.13 b 
and 5.14 b). 
 
 
Figure 5.15 Relative expression of CCL-20 and IL-8 in HT-29 cells in response to 
L.monocytogenes infection following treatment with PRR siRNA. Due to the volume of data 
generated from the screen, Figure 5.15 displays only the data from Figures 5.12, 5.13 and 5.14 in 
which a statistically significant change in expression of the gene measured was observed following 
treatment with the PRR siRNA indicated. Changes in CCL-20 induction (a) in addition to IL-8 
induction (b) are displayed while no significant changes were observed in EGR-1 expression 
following siRNA treatment. * P<0.05, ** P<0.01 and *** P<0.001. Values are shown as Mean ± 
SEM, n=3. Statistics were carried out using the Mann Whitney U test. 
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Among the lesser studied CLR family, silencing of DC-SIGN, CLEC-9A and CLEC-
12B resulted in a 2-fold increase in CCL-20 induction following infection. The same can be 
said of the increased IL-8 induction following silencing of each of these CLRs with the 
addition of CLEC1B. Silencing of LY75 resulted in a notably significant decrease in CCL-20 
induction following infection with L. monocytogenes, although no effect was observed on IL-
8 induction.  
Few significant changes in IL-8 or CCL-20 induction were recorded in response to 
infection following treatment with TLR siRNA. Similar to the result in Figure 5.10, silencing 
of MyD88 had no effect on the cells ability to respond to L. monocytogenes infection through 
IL-8 and CCL-20 production, despite all TLRs with the exception of double-stranded RNA 
sensing TLR3 signalling via MyD88. This is reflected in the screen results (Figures 5.9, 5.10 
and 5.11). It is somewhat surprising in this regard to observe significant decreases in CCL-20 
and IL-8 expression upon silencing of TLR1 and TLR10, both believed to require MyD88 for 
signalling [27]. Since TLR10 has not yet been fully characterized, this is particularly novel. 
Additionally, the TLR1 siRNA treated samples showing reduced early inflammatory 
activation has not been reported previously. There is relatively little reduction in CCL20 and 
IL-8 induction due to TLR2 siRNA treatment compared to that observed when siRNA for 
TLR1 and TLR10 were used. 
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5.3. Discussion 
 
In this study, I aimed to identify novel PRRs involved in early detection of 
L.monocytogenes through means of siRNA screening. This involved the optimisation of such 
parameters as bacterial growth phase, multiplicity of infection, incubation time with bacteria, 
use of antibiotics during infection, output of inflammatory response, and successful 
transfection of siRNA and achieving knockdown of the target genes. In doing so, novel 
information regarding the roles played by various PRRs of intestinal epithelial cells involved 
in activation or suppression of the immune response to Listeria was generated. 
EGR-1 has been implicated in the regulation of a number of genes involved in 
inflammation, differentiation, growth, tissue repair and regeneration and development [28, 
29]. Its expression has been shown to be induced by a range of pro-inflammatory stimuli, 
including many known to induce NF-κB expression [30, 31]. Additionally, both transcription 
factors are known to synergistically be involved in TNFα-mediated gene transcription [32]. 
While strongly induced in response to the bacteria, EGR-1 was not affected by any of the 
siRNA from the PRR screen. Although the reason for this is unclear, it suggests that perhaps 
it is being driven by mechanisms other than PRR-mediated inflammatory responses; for 
example modulation of the host cell membrane from invading bacteria. It might also suggest 
that NF-κB activation was not silenced sufficiently by any PRR siRNA treatment to block 
induction of the EGR-1 transcription factor. Since this is a very early transcription factor, it is 
possible that the 3 hour time-point may have been too long to measure any observable 
changes induced by the PRR siRNAs in response to the bacteria.  
The PRRs identified in mediating the response to infection are TLR1, TLR2, TLR10, 
NALP2 and LY75. The PRRs identified in abrogating IL-8 and CCL-20 expression in 
response to infection, however, is more expansive: NLRC3, NLRC4, NLRC5, NLRP1, 
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NLRP4, NLRP6, NLRP7, NLRP8, NLRP9, NLRP10 NLRP11, DC-SIGN, CLEC1B, 
CLEC9A and CLEC12B (See Figure 5.16).  
Similar to data generated here, it has been previously reported that NLRP7 and 
NLRP10 repress NF-κB activation and IL-1β production induced by other NLRs of the same 
family [33]. The same group also reported that NLRP2 plays a similar role in repressing NF-
κB induction from these NLRs in monocytic cells. This is similar to other reports studying 
this effect of NLRP2, again performed on THP-1 monocytes [34]. In contrast, however, we 
have observed a decrease of 50% in CCL-20 expression following treatment with NLRP2 
siRNA in infected cells indicating that, NLRP2 may be essential, not inhibitory for immune 
activation. Our work, however, was performed in epithelial cells and this result most closely 
reflects other work by Ji et al. [35]. Their studies were performed using an invasive bacteria 
on gingival epithelial cells and an important inflammatory role was highlighted for NLRP2 
and TLR2 in mediating an inflammatory response to the bacteria through human beta 
defensin production [35]. NLRP1 is known for its role in inflammasome activation [36] 
however there has not been any other findings to date which report an NLRP1 mediated 
reduction in inflammatory response to intracellular pathogenic attack, such as in our findings 
presented here. It is of note that most studies involving inflammasome activation have been 
performed on cells such as macrophages and dendritic cells and epithelial cells are not 
regarded to be involved in inflammasome activation so it is likely that these NLRs may have 
different roles here. The same trend was conserved in IL-8 expression levels decreasing 
following siRNA treatment for NLRP2 and increasing after NLRP1, NLRP7 and NLRP10 
were silenced.  
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Figure 5.16 PRRs involved in regulating an inflammatory response to L.monocytogenes 
in intestinal epithelial cells identified by siRNA screening. Illustrated above is an intestinal 
epithelial cell (IEC) in the monolayer of cells which make up the intestinal epithelial barrier. Depicted 
are the tight junctions between cells in this monolayer and the apical brush border of the cell facing 
the microbe rich lumenal space. Listeria gains entry to the cells from this lumenal space where upon it 
is recognised by various intracellular and plasma membrane located PRRs before it makes its way into 
the sub-mucosa and eventually, the bloodstream. On the left-hand side are PRRs identified in our PRR 
siRNA screen believed to be directly involved in the production of pro-inflammatory CCL-20 and IL-
8 production. On the right-hand side are PRRs believed to be involved in curtailing or regulating these 
responses. 
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Additionally, siRNA treatment for several other NLRs resulted in increased IL-8 
expression in response to the bacteria. siRNA targeting NLRC3, NLRC4, NLRC5, NLRP4, 
NLRP6, NLRP8, NLRP9 and NLRP11 resulted in an increase in IL-8 expression following 
infection. While NLRP3 is known for its ability to inhibit TLR-mediated inflammatory 
responses in macrophages [37], it is the first time that a similar result has been reported in 
intestinal epithelial cell lines. NLRC4 is known for its role in inflammasome activation in 
response to bacterial flagellin [38, 39], however to date, its inhibitory role for Listeria 
mediated IL-8 induction has not been reported. NLRC5 has also been shown to be involved 
in attenuating NF-κB activation and repressing type I IFN responses [40, 41]. However, the 
mechanism has not been clearly defined, and indeed in some cell population it was found to 
positively regulate type I IFN signalling [42]. The fact that NLRC5 siRNA attenuated IL-8 
induction in response to L. monocytogenes may indicate an inhibitory role for NLRC5 in 
epithelial signalling. NLRP4 is also known for its ability to inhibit type I IFN signalling. It 
achieves this through targeting kinase TBK1, which is involved in NF-κB activation, for 
degradation [43]. NLRP6 has already been shown to inhibit immune responses to L. 
monocytogenes in vivo [44]. Much less is known about NLRP8, NLRP9 and NLRP11 with no 
studies yet published on their immune function. The results from this screen however would 
indicate that, similar to their familial counterparts, NLRP4, NLRP6, NLRP7 and NLRP10, 
they too play a part in regulating immune activation in the intestinal epithelia. 
Dendritic Cell (DC)-Specific Intercellular adhesion molecule-3 Grabbing Non-
integrin (DC-SIGN) is known for its role in recognising a broad range of pathogen-derived 
ligands and self-glycoproteins, particularly, as the name suggests in dendritic cells, and 
presenting them to T-cells [45]. The role for DC-SIGN in epithelial cells or in negatively 
regulating the inflammatory response has not yet been investigated thoroughly. However, 
intracellular Mycobacteria and the Human Immuno-deficiency Virus (HIV) have previously 
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been shown to target DC-SIGN, both to infect DCs and to down-regulate DC-mediated 
immune responses [46, 47]. Furthermore, DC-SIGN activation is believed to modulate TLR-
mediated inflammatory responses [48]. Silencing DC-SIGN also resulted in a significant 
increase in CCL-20 induction in response to the infection in IECs, suggesting a broader 
expression pattern and functionality than had originally been suggested – potentiating new 
targets for gut-associated microbial attack. Little is known of CLEC9A, in the setting of IECs 
or elsewhere. CLEC12B, however, is known to have the ability to counteract Natural Killer 
cell signalling by unconventional means and is believed to be involved in limiting the activity 
of monocyte-derived immune cells [49]. Due to both of these receptors being of the same 
family, there might be a similar novel role for them in regulating inflammatory responses in 
epithelial cells. The same can be said of the increased IL-8 induction following silencing of 
each of these CLRs with the addition of CLEC1B, of which there is very little known in the 
context of IECs. It is known, however, that CLEC1B is believed to function as an activation 
receptor in neutrophils [50], suggesting an alternate role in the context of IECs due to the 
increased IL-8 production measured upon silencing CLEC1B. LY75, also known as DEC-
205, has been primarily investigated in dendritic cells where it is involved in binding to and 
increasing the uptake of the synthetic bacterial and viral DNA homologue, CpG ODNs. It is 
then believed to deliver the antigen to TLR9 [51], which sends inflammatory signals in 
response to CpG DNA. It is also thought to play roles not only in endocytosis/phagocytosis 
but also in cell adhesion and migration [52]. Silencing of LY75 resulted in a notably 
significant decrease in CCL-20 induction following infection with L. monocytogenes, 
although no effect was observed on IL-8 induction. This suggests a specific response for 
LY75, perhaps in recruiting phagocytic cells to the site of infection in IECs. NOD1 and 
NOD2 are known to be involved in detection of L. monocytogenes and eliciting an 
inflammatory response [15, 25, 26]. Although no significant change in any inflammatory 
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genes measured were observed in response to infection when cells were treated with siRNA 
for NOD1, NOD2 or their adaptor molecule RIPK2, there was, however, a trend in decreased 
IL-8 and CCL-20 expression. 
The most significant reductions in inflammatory cytokine induction were seen 
following siRNA treatment against TLR1, TLR2, TLR10 and NALP2. TLR2 has previously 
been shown to be involved in L. monocytogenes detection and clearance [13, 53-55] although 
not in the specific context of IECs. NALP2 has also been demonstrated to be involved in 
detection of L.monocytogenes in gingival epithelial cells [35] although this is the first time it 
has been implicated in IECs also. Ligands for TLR1 such as peptidoglycan are known to be 
expressed by L.monocytogenes so it was not surprising to see a significant decrease in 
inflammatory gene induction in response to the bacteria following siRNA treatment for this 
gene. TLR10, however, having never been assigned a specific ligand or function, has never 
before been documented to play a role in detection of any pathogens or indeed to mediate an 
inflammatory response against any ligands tested. It is also of note that silencing of TLR10 
resulted in the most statistically significant reduction in inflammatory cytokine induction in 
response to the bacteria.  
Despite an observable reduction in IL-8 and CCL-20 induction following siRNA 
treatment for these TLR genes, no significant effect was measured following MyD88 siRNA 
transfection. This is surprising since each of TLR1, TLR2 and TLR10 are believed to require 
MyD88 for signal transduction [56]. Furthermore, the siRNA optimisation experiments 
revealed that RelA appeared to be involved in epithelial responses but not MyD88. This 
demonstrated that NF-κB activation is necessary for induction of IL-8 and CCL-20 in 
response to L. monocytogenes but suggested that MyD88 is dispensable. It is important also, 
however, to consider the possibility that although 80% knockdown of MyD88 was observed 
following siRNA transfection, perhaps the level of knockdown achieved was not sufficient 
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enough to affect the epithelial response to the bacteria as measured by CCL-20 and IL-8 
induction. It may be that these cells require relatively minimal amounts of MyD88 for 
efficient signal transduction. Moreover, it could also be possible that in addition to the well 
documented roles MyD88 plays in mediating inflammatory responses against pathogenic 
attack in IECs [57, 58], there might exist a role for MyD88 in mediating more homeostatic 
and less pro-inflammatory responses in IECs. This could be through the immuno-suppressive 
effects associated with TLR activation in IECs, for example [59]. 
Shortcomings in this data set include the lack of consistency and effectiveness of 
siRNA mediated gene silencing. As this was a large screen, it was not practical to measure 
each sample for quantifying the level of knockdown for each gene. Therefore, it is impossible 
to know how successful each siRNA transfection was. Nevertheless, much optimisation was 
performed in this regard prior to using the screen and the use of Smart Pool siRNA increased 
the chances of successful silencing. It should also be pointed out that TLR expression levels 
have recently been linked to circadian rhythm [60], a factor which we did not appreciate and 
would require future studies. Ultimately however, almost all of the data generated and almost 
every ―hit‖ from the siRNA screen has been a novel find, particularly in the context of 
intestinal epithelial cells which have not classically been associated with PRR expression or 
innate immune functioning. A large amount of novel data in particular was produced 
involving several of the lesser known PRRs particularly with regard to regulating/abrogating 
the immune response to L.monocytogenes: in particular, members of the CLR and NLR 
families. While little else is known about many of these, it is important too to remember that 
this was only performed in one cell type and further studies involving any in vitro analysis 
should offer more interesting clues to their functionality. Fewer PRRs from the total number 
involved in this siRNA screen were implicated in mounting an inflammatory response to the 
bacteria in this study compared to the number of PRRs implicated in curtailing any 
183 
 
inflammatory responses. This again illustrates the importance of homeostatic regulation by 
PRRs in IECs. The two most novel PRRs involved in mounting an inflammatory response 
were LY75 and TLR10. Since silencing of TLR10, the only TLR to which a ligand has not 
previously been assigned resulted in the most significantly different expression levels of 
CCL-20 and IL-8 across all PRRs tested, I chose to focus on this candidate for the final 
chapter of my thesis.  
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Chapter 6 
 
 
Validation and further characterisation 
of the role of TLR10 in the immune 
response to L.monocytogenes 
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6.1 Introduction 
 
Toll-like receptors (TLRs), a major family of the innate immune system‘s cohort of 
Pattern Recognition Receptors (PRRs), play a crucially important role in the early stages of 
infection. In addition to the induction of innate immunity, they are also pivotal in subsequent 
recruitment of adaptive immune response cells. In humans, 10 functional TLRs have been 
discovered and their ligands for each have been identified; except for in the case of TLR10 
[1]. In mammals, TLR1, 6, and 10 genes are arranged closely together on the genome and 
seem to have arisen from a duplication event [2, 3]. TLR10 shares the highest homology with 
TLR1 and TLR6, both of which mediate immune responses to a variety of microbial and 
fungal components in cooperation with TLR2 [4]. In addition to the ability of TLR10 to 
homodimerise [5], it can also form a heterodimer with TLR1 or TLR2 and like other TLRs, it 
is believed to transmit an intracellular signal via the adaptor protein MyD88 [6]. However, 
multiple gaps and retroviral insertions have rendered the TLR10 receptor a pseudogene in 
mice; hence the useful tool of a TLR10 deficient mouse strain has not been available to help 
us elucidate its function and discover its ligand [6]. 
The structure of TLR10 has been well characterised in an attempt to fully understand 
its signalling potential. Similar to the rest of its family, TLR10 has multiple Leucine-Rich 
Repeats (LRRs) for recognising and binding to Pattern Associated Molecular Patterns 
(PAMPs) and a Toll/interleukin-1 receptor (TIR) domain for downstream signalling. The 
crystal structure of the cytoplasmic TLR10 TIR domain has been used as a structural model 
for TIR domain signalling [5]. In fact, it was this study which revealed the dimeric nature of 
the ligand-bound TLR TIR domains which are required for further downstream signalling. 
Recent crystallographic studies of the TLR dimers TLR1/2, TLR2/6 in addition to TLR4, and 
TLR3 homodimers have provided an explanation for in vivo, in vitro, and clinical 
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observations [7]. While crystallographic analysis of TLR10 has not offered as much 
information, it has been used to predict TLR10 signalling and ligand binding. A study by 
Govindaraj et al. used computer modelling of these crystal structures in order to identify the 
potential sites of interaction between the homo (TLR10/10) and heterodimers of TLR10 
(TLR10/2 and TLR10/1) in addition to attempting to determine a specific ligand for each of 
these complexes [8]. Figure 6.1 displays an alignment of the LRRs contained in TLR1, TLR2 
and TLR10 which was generated in this study for helping determine TLR10 ligand 
recognition. Their computer modelling data revealed that the binding orientations of the 
TLR10 heterodimer were found to be similar to other TLR2 family members. The binding 
orientation of the TLR10 homodimer, however, was shown to be different from the 
heterodimer due to the presence of negatively charged surfaces at the LRR11-14 (Fig. 6.1), 
providing a specific cavity for ligand binding [8]. They went on to show that the TLR1/2 
ligand, Pam3Cysk4, might be the ligand for the TLR10/2 complex. They also suggested that 
PamCysPamSK4 a di-acylated peptide, might activate the TLR10/1 hetero and TLR10 
homodimers [8].  
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Figure 6.1 Structure based sequence alignments of TLR1, TLR2 and TLR10. The TLR10, 
2 and 1 sequences are aligned based on their structures. Conserved leucines and asparagine ladder are 
written in red and green, respectively. The positions of β-strands are shown above the consensus 
patterns . 
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An in vitro study attempting to identify the specific ligand sensed by TLR10, and the 
consequent immune response it may activate, was performed using chimeric receptors of 
TLR1 and TLR10. TLR1 was chosen based on the strong homology shared by TLRs 1 and 
TLR10, and the fact that TLR1 was already well characterised. These chimeras were 
produced by fusing the extracellular recognition domain of TLR10 and the intracellular 
signalling domain of TLR1 (TLR10x1) and were compared with a receptor which had the 
extracellular recognition domain of TLR1 and the intracellular signalling domain of TLR10 
(TLR1x10) [9]. Thus, by stimulating the TLR10x1 receptor with a variety of ligands, one 
could measure typical TLR1 responses to test for ligand responsiveness. Similarly, by 
stimulating TLR1x10 with known TLR1 ligands, typical TLR activation responses such as 
NF-B activity could be measured, giving an indication as to what downstream signalling 
TLR10 activation leads to. Investigations using TLR10x1 revealed that TLR10 is likely to 
sense triacylated lipopeptides and a wide variety of other microbial-derived agonists shared 
by TLR1, but not TLR6 [9]. TLR10 was revealed in this study to colocalise with TLR2 in the 
phagosome and physically interact in an agonist-dependent fashion. Although prior to our 
studies, TLR10, alone or in cooperation with TLR2, had not been shown to activate typical 
TLR-induced signalling, including NF-κB–, IL-8–, or IFN-β–driven reporters [9].  
Polymorphisms in TLR10 have been linked to several disease states. It has been 
reported that a haplotype of TLR10 is associated with an increase in the risk of 
nasopharyngeal carcinoma in a Cantonese population [10]. Mutations in the TLR10 gene 
have also been linked to asthma [11] and Crohn‘s disease [12, 13], independent of the well-
recognised NOD2 mutation associated with this disease [14]. Studies on single nucleotide 
polymorphisms in the TLR1-6-10 gene cluster have suggested that mutations within this 
cluster may also be associated with a risk of asthma [15], prostate cancer [16-18], sarcoidosis 
[19] or non-Hodgkin lymphoma [20]. These reports are for the most part based on sequence 
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mutation analysis without investigating the altered function of TLR10 in each case. Further 
understanding of the natural function of TLR10 would allow us to better predict phenotypes 
associated with each mutation for these illnesses and determine its altered function. This, of 
course, could potentially provide invaluable information towards creating better treatment 
strategies for each of these diseases. 
In this chapter, we initially verified the effect of reduced inflammatory response to 
L.monocytogenes in HT-29 IECs upon TLR10 silencing using PRR siRNA screening, 
outlined in Chapter 4. We explored this effect in other IEC lines and in THP-1 macrophage 
cells and further attempted to elucidate the function and signalling mechanism of TLR10 in 
these cell types. We also explored the effects of simulated hypoxia on TLR10 expression and 
microbial sensing in HT-29 and THP-1 cells through stabilisation of HIF-1α, achieved 
through stimulation with a substance known as Dimethyloxaloylglycine (DMOG).  
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6.2 Results 
6.2.1 Validation of the specificity of TLR1, TLR2 and TLR10 siRNAs 
Following our observations of a reduced inflammatory response in HT-29 cells upon 
treatment with siRNA targeting TLR1, TLR2 and TLR10, we wished to further investigate 
the effects of TLR1, TLR2 and TLR10 siRNA on HT-29 responsiveness to L.monocytogenes. 
However, prior to any further analysis using siRNA mediated knockdown, we wished to 
verify the specificity and efficiency of the siRNAs used. These genes, along with TLR6, are 
very closely related, each located together in a gene cluster on chromosome 4, as well as 
being structurally similar. Since problems of ―off-target effects‖ have been reported using 
siRNAs in the past, the specificity of the TLR siRNA used were investigated. qRT-PCR 
measurements were made to quantify relative expression levels of each of these genes 
following siRNA treatment against TLR1, TLR2 and TLR10 (Fig. 6.2). THP-1 macrophage 
cells were used to determine this due to the higher expression levels of TLRs found in these 
cells compared to cell lines of the intestinal epithelium. TLR1 induction was significantly 
affected (~70% reduction) by TLR1 siRNA alone (Fig. 6.2A). Similarly, TLR2 siRNA 
treatment alone had an effect on TLR2 expression with a reduction of 80% measured in 
TLR2 expression levels (Fig. 6.2B). The same was true of TLR10 expression; only reduced 
by TLR10 siRNA (Fig. 6.2D). Importantly, TLR6 induction was unaffected by any of the 
siRNA for TLR1, 2 or 10. Additionally no ―off-target‖ effects were measured on any of these 
closely related genes following siRNA treatment. This confirmed the specificity and efficacy 
of the TLR siRNA used. 
194 
 
 
Figure 6.2 Specificity of TLR1, TLR2 and TLR10 siRNA analysis by qRT-PCR. THP-1 
cells were treated with the either scrambled siRNA or siRNA against TLR1, TLR2 or TLR10 with 
5ng/ml PMA for 48 hours. qRT-PCR was used to monitor expression levels of TLR1 (A), TLR2 (B), 
TLR6 (C) and TLR10 (D). Statistics were carried out using t test with Welch‘s correction. 
 
Given the importance of ensuring efficient knockdown of TLR10 was being observed, 
Western blotting was also employed using HT-29 cells in order to demonstrate endogenous 
expression of TLR10 and a reduction in TLR10 expression following siRNA treatment. 
TLR10 expression is displayed in Fig. 6.3(a). The ~75 kDa isoform is visible in the empty 
vector transfected sample (lane B) and the specificity of the antibody was confirmed through 
transfection with TLR10 in lanes C-F. Silencing of TLR10 protein levels was also confirmed 
through TLR10 siRNA treatment in lanes I and K. TLR1 expression was seen also at ~75 
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kDa (Fig. 6.3(b)) in lane A. Silencing was confirmed following TLR1 siRNA treatment (lane 
B) with no change seen following TLR10 siRNA treatment (lane C). 
 
 
Figure 6.3 Validation of TLR1 and TLR10 siRNA efficiency by Western blot in HT-29 
cells. Lysates of HT-29 cells were prepared for western blotting analysis 48 hours after transfection 
as described in the methods section 2.19. Each lane on the left blot against TLR10 represents the 
following transfection: Untreated (A), Empty Vector (B), TLR10 (1μg) (C), TLR10 (1μg) (D), TLR10 
(2μg) (E), TLR10 (4μg) (F), Untreated (G) Control siRNA (H) TLR10 siRNA (I), Control siRNA (J) 
TLR10 siRNA (K). In addition to TLR10 expression, β-actin expression was also examined to ensure 
equal levels of protein were loaded on the gel. Similarly, TLR1 expression was measured on the right 
in HT-29 cells. Each lane represents the following siRNA treatment: Scrambled control (A), TLR1 
(B) and TLR10 (C). β-actin expression was also examined to ensure equal levels of protein were 
loaded. 
  
(a) 
 
 
(b) 
 
196 
 
In addition to measurement by qRT-PCR and western blot analysis, flow cytometry 
was also used to verify the specificity of each siRNA at a protein level (Fig. 6.4). While an 
efficient antibody for TLR6 was unavailable, expression levels of TLR1, TLR2 and TLR10 
protein were quantified following siRNA treatment for each. Gating strategies were 
employed (see methods section 2.21) in order to quantify the expression levels of each TLR 
detected over the isotype control in the control siRNA or TLR siRNA treated samples. THP-1 
macrophage-like cells were used once again due to the higher levels of expression of each of 
the TLRs measured. Fig. 6.4A compares expression levels of TLR1, TLR2 and TLR10 
following siRNA treatment with TLR1. A reduction from 3.4% to 0.5% was observed in 
TLR1 expression following siRNA treatment with no sizable changes in TLR2 or TLR10 
expression. Fig. 6.4B displays a slight decrease in TLR1 expression following TLR2 siRNA 
treatment at 14.7% compared to 17.6% in control samples. TLR2 expression however, was 
reduced from 57.5% to 38.7% and a negligible change was observed in TLR10 expression. 
TLR10 siRNA treatment in Fig. 6.4C resulted in no changes for TLR1 or TLR2 expression 
but a 50% decrease in TLR10 expression from 2.7% to 1.3% compared to control siRNA 
treated samples. This confirmed that the effects seen in inflammatory gene responses to 
L.monocytogenes following TLR10 siRNA treatment were not likely to be due to ―off-target‖ 
effects.  
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Figure 6.4 Specificity of silencing of siRNA used against TLR1, TLR2 and TLR10. THP-
1 cells were treated with control (scrambled) siRNA and TLR1 siRNA (A), TLR2 siRNA (B) or 
TLR10 siRNA (C) with 5ng/ml PMA for 48 hours. Flow cytometry was used to monitor expression 
levels of TLR1, TLR2 and TLR10. Gating was performed against the isotype control and all control 
siRNA samples were measured against the corresponding TLR siRNA at the time of analysis to avoid 
intra-assay variation in staining efficiency. Representative scatter plots of flow data are shown with 
relative knockdown (KD) of target TLR. 
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6.2.2 Confirmation of reduced chemokine production following TLR10 silencing 
Having confirmed the specificity and efficacy of these siRNA, we could now examine 
with confidence the effects of TLR1, TLR2 and TLR10 siRNA on HT-29 responsiveness to 
L.monocytogenes. We subsequently wished to examine the relative involvement of TLR10 as 
compared to TLR1 and TLR2 in mediating the immune response to L.monocytogenes (Fig. 
6.5). Similar to the results seen in the screen data, TLR10 siRNA had the most significant 
effect on IL-8 and CCL-20 induction in response to the bacteria compared with TLR1 and 2 
siRNA. CCL-20 was induced 12-fold in the control siRNA treated samples (Fig. 6.5A). This 
was reduced to 10-fold when TLR1 was silenced and 9-fold when TLR2 siRNA was 
employed. The TLR10 siRNA treatment however, reduced induction to 6-fold over the 
uninfected control. Similarly, in Fig. 6.5B, IL-8 was induced 8-fold over uninfected controls 
in control siRNA treated samples, 6-fold following TLR1 siRNA treatment, 7-fold with 
TLR2 siRNA and reduced to 4-fold with TLR10 siRNA.  
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Figure 6.5 Contrast between the effects of TLR1, TLR2 or TLR10 siRNA on gene 
induction in HT-29 cells following infection with L.monocytogenes. HT-29 cells were treated 
with siRNA against TLR1, TLR2 or TLR10 and infected with L.monocytogenes for 3 hours. qRT-
PCR was then used to analyse expression levels of CCL-20 (A) or IL-8 (B).  
* P<0.05, ** P<0.01 and *** P<0.001, Values are shown as Mean ± SEM, n=3. Statistics were carried 
out using t test with Welch‘s correction. 
 
Since the level of silencing for each of three TLRs 1, 2 and 10 was not quantified for 
Fig. 6.5, one cannot definitively claim any of the TLRs to be more involved than the other 
despite the result due to the inconsistency of efficacy of siRNA on their targets. Nevertheless, 
our studies shown in Fig. 6.2 and Fig. 6.4 validating the siRNAs used had shown roughly 
comparable levels of KD of all TLRs, indicating that TLR10 may be a key mediator of the 
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immune response o L.monocytogenes. Furthermore, as no direct mediation of an immune 
response against a specific pathogen had been identified before with TLR10, the result 
warranted further investigation. In addition to verifying the reduction caused by TLR10 
siRNA treatment in IL-8 and CCL-20 induction following L.monocytogenes infection, CCL-1 
induction was also measured and silencing of TLR10 mRNA expression by qRT-PCR was 
performed (Fig. 6.6). CCL-20 was induced 12-fold over uninfected cells in the control siRNA 
treated samples, compared to 6-fold in the TLR10 siRNA treated cells. IL-8 induction was 
also decreased significantly, from 8-fold induction in the control siRNA treated samples to 4-
fold induction in the TLR10 siRNA treatment after infection with L.monocytogenes. This 
50% reduction is comparable with the siRNA screen data also. Although a highly significant 
50% reduction was observed in CCL-20 and IL-8 induction following infection in TLR10 
siRNA treated samples, CCL-1 induction was less affected, only being reduced by 40% (Fig. 
6.6C). As much as 60% silencing of TLR10 induction is observed in Fig. 6.6D. This effect 
was unchanged following infection with L.monocytogenes.  
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Figure 6.6 Effects of TLR10 siRNA on gene induction in HT-29 cells following infection 
with L.monocytogenes HT-29 cells were treated with TLR10 siRNA and infected with 
L.monocytogenes for 3 hours. qRT-PCR was then used to analyse expression levels of TLR10 (A), 
CCL-20 (B), CCL-1 (C) and IL-8 (D). * P<0.05, ** P<0.01 and *** P<0.001, Values are shown as 
Mean ± SEM, n=3. Statistics were carried out using t test with Welch‘s correction. 
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6.2.3 Effect of TLR10 silencing seen in both other IEC lines and Macrophages 
It had initially been reported that TLR10 was exclusively expressed in B cells and 
lymphoid tissue [6]. However, the results from our experiments investigating the effect of 
TLR10 siRNA had led to detection of TLR10 mRNA in HT-29 IECs. In order to confirm that 
the same effect was reproducible using other IEC lines, HCA-7 cells were treated with 
TLR10 siRNA similar to HT-29 cell treatments and were subject to infection with 
L.monocytogenes (Fig. 6.7). Endogenous expression and silencing of TLR10 was confirmed 
in the HCA-7 cells by qRT-PCR (Fig. 6.7A). Levels of CCL-20, CCL-1 and IL-8 induction 
were similar to those results seen in HT-29 cells. TLR10 siRNA treatment reduced CCL-20 
induction to a 60-fold induction over uninfected samples. CCL-1 was unaffected by TLR10 
siRNA treatment, however (Fig. 6.7C), and relatively little IL-8 induction (3-fold) was 
recorded in response to the bacteria (Fig. 6.7D). This was, however, reduced almost 50% by 
TLR10 siRNA treatment. Higher levels of TLR10 mRNA were measured in HCA-7 cells 
compared to HT-29 cells. This may account for the higher levels of CCL-20 induction 
following infection; 120-fold over uninfected (Fig. 6.7B).  
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 Figure 6.7 Effect of silencing TLR10 on inflammatory gene induction in HCA-7 cells. 
HCA-7 cells were treated with TLR10 siRNA and infected with L.monocytogenes for 3 hours. qRT-
PCR was then used to analyse expression levels of TLR10 (A), CCL-20 (B), CCL-1 (C) and IL-8 (D). 
* P<0.05, ** P<0.01 and *** P<0.001, Values are shown as Mean ± SEM, n=3. Statistics were carried 
out using t test with Welch‘s correction. 
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All studies on the effects of TLR10 siRNA mediated silencing had until now been 
generated measuring mRNA levels by qRT-PCR. In order to observe this effect at a protein 
level, HT-29 cells were subject to TLR10 siRNA transfection and CCL-20 protein production 
was measured by ELISA following L.monocytogenes infection over a 48 hour period (Fig. 
6.8A). The same was performed in the IEC line, HCT-116 cells (Fig. 6.8B). A comparable 
result was observed between the two cell lines, each showing a significant decrease in CCL-
20 production in the TLR10 siRNA treated samples following infection. 
 
Figure 6.8 Effect of silencing TLR10 on CCL-20 production in HT-29 and HCT-116 
cells. HT-29 (A) or HCT-116 (B) were treated with TLR10 siRNA and infected with 
L.monocytogenes for up to 48 hours. Supernatants were analysed for CCL-20 production by ELISA at 
the times indicated post-infection. * P<0.05, ** P<0.01 and *** P<0.001, Values are shown as Mean 
± SEM, n=3. Statistics were carried out using t test with Welch‘s correction. 
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 Finally, in order to investigate if this effect was seen in cells other than IECs, THP-1 
macrophage-like cells were treated with TLR10 siRNA and infected with L.monocytogenes. 
A dramatic decrease in CCL-20 production was observed in these cells over a 48 hour period 
also (Fig. 6.9).  
 
 
Figure 6.9 Effect of silencing TLR10 on CCL-20 production in THP-1 macrophage-like 
cells. THP-1 cells were treated with PMA TLR10 siRNA and infected with L.monocytogenes for up 
to 48 hours. Supernatants were analysed for CCL-20 production by ELISA at the times indicated post-
infection. * P<0.05, ** P<0.01 and *** P<0.001, Values are shown as Mean ± SEM, n=3. Statistics 
were carried out using t test with Welch‘s correction. 
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6.2.4 TLR10 effects L.monocytogenes survival in IECs and macrophages 
Altering expression of the PRRs NALP3 and Aim2 has been previously shown to 
reduce the ability of L.monocytogenes to survive and replicate within cells [21]. We wished 
to identify whether altering expression of TLR10 would have a similar effect. Survival of 
L.monocytogenes was analysed by calculating the intracellular bacterial burden in both HT-
29 and THP-1 following TLR10 silencing over an 8 hour period. Increased survival of the 
bacteria is seen in both cell lines indicating a critical role for the receptor in antagonizing 
bacterial intracellular viability (Fig. 6.10A and B respectively). 
 
 
Figure 6.10 TLR10 silencing increases intracellular L.monocytogenes survival in HT-29 
epithelial cells. HT-29 and THP1 macrophage like cells were transfected with control or TLR10 
siRNA and then infected with L.monocytogenes,(MOI 50:1),  for 8 hours before intracellular bacterial 
survival was then determined by plate counting (A and B). * P<0.05, Values are shown as Mean ± 
SEM, n=3. Statistics were carried out using t test with Welch‘s correction. 
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6.2.5 TLR10 requires TLR2 to mediate optimal NF-B activation in response to 
L.monocytogenes. 
Recognition of L.monocytogenes by different PRRs has been shown to lead to NF-
B-dependent pro-inflammatory gene expression, inflammasome activation and caspase-1 
cleavage and IFN-β responses [22]. As both NF-B and IFN-β are major downstream 
signalling outputs of TLRs we investigated activation of these in response to overexpression 
of TLR constructs with or without stimulation by L.monocytogenes. A TLR10 construct was 
used for overexpression studies in either an NF-B reporter cell line or in conjunction with an 
ISRE (Interferon Stimulated Response Element) -luciferase reporter construct. As TLR10 has 
been shown to dimerise with TLR2 [9] a variety of combinations of TLRs1/2/10 were 
overexpressed in conjunction with the reporter constructs. In Fig. 6.11A it can be seen that 
overexpression of either TLR 1, 2 or 10 alone did not activate NF-B significantly above 
control level. Stimulation of the overexpressed constructs with L.monocytogenes, however, 
results in a twofold level of activation above control with TLR2 and significantly higher NF-
κB activation following co-transfection of TLR2 and TLR10 (5 fold above control), which 
was comparable to co-transfection of TLR1 and 2. This data indicates that TLR10 alone is 
not able to respond to L.monocytogenes but that together with TLR2, it facilitates optimal 
NF-B activation. ISRE activation was also measured by luciferase assay in response to 
L.monocytogenes following overexpression of combinations of TLR constructs (Fig. 6.11B). 
Unlike NF-B, no increase in the ability of any of the TLR combinations to drive an ISRE-
luciferase construct was seen following L.monocytogenes stimulation. 
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Figure 6.11 TLR10 requires TLR2 for NF-κB activation in response to 
L.monocytogenes. (A), The NF-κB SEAP reporter HEK293 cell line was transfected with the 
plasmid combinations indicated, and were then infected with or without L.monocytogenes for 8 hours. 
The cell free supernatants were then collected and used to quantify NF-κB activation by colorimetric 
QUANTI-blue™ determination (B). HEK293 cells were transfected with an ISRE-luciferase reporter, 
plasmid combinations indicated, and were then infected with or without L.monocytogenes for 8 hours. 
Cell extracts were then lysed and luciferase activity and corresponding luminescence was determined 
for ISRE activity ** P<0.01, Values are shown as Mean ± SEM, n=3. Statistics were carried out using 
t test with Welch‘s correction. 
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Despite the NF-κB reporter cell line used having stably transfected CD14 and MD2, 
this alone was not enough to fully explain the NF-κB activation observed in response to the 
bacteria when TLR2 was expressed on its own. While endogenous levels of TLR10 have 
been reported in data sheets pertaining to the cell line, this had never been demonstrated in a 
publication. Using the TLR10 plasmid construct for verification, Fig. 6.12 displays 
endogenous TLR10 expression in the HEK cells used (lanes A-C) with its presence 
confirmed by overexpression of TLR10 (lanes D-F).  
 
Figure 6.12 Presence of endogenous TLR10 expression in HEK 293 T cells. Lysates of 
HEK 293 cells were prepared for analysis by western blotting 48 hours following transfection as 
described in the methods section 2.19. Each lane represents the following treatment: Untreated (A), 
Transfection reagent only (B), Empty Vector (C), TLR10 plasmid (0.5μg) (D), TLR10 plasmid (2μg) 
(E), TLR10 plasmid (3μg) (F). In addition to TLR10 expression, β-actin expression was also 
examined to ensure equal levels of protein were loaded on the gel.  
 
  
TLR10 
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6.2.6 Intracellular expression of TLR10 protein in IECs  
Literature concerning the subcellular location of TLR10 reported it to be 
predominantly based on the plasma membrane. However, it had also been reported that 
TLR10 expression was not present in IECs and due to the fact that we had discovered TLR10 
to be present in IECs, we wished to also investigate its location in HT-29 cells. By use of 
intracellular and extracellular flow cytometry staining, it would appear that intracellular 
TLR10 expression is much higher than its expression on the plasma membrane. This is 
demonstrated in Fig. 6.13 with a difference of 0.3% staining by extracellular staining (Fig. 
6.13A) compared to 14.7% staining observed by intracellular staining (Fig. 6.13B). Using 
heat-killed L.monocytogenes (HKLM), and live Listeria, HT-29 cells were subject to TLR10 
siRNA treatment and stimulated with the bacteria. qRT-PCR analysis revealed that CCL-20 
induction was reduced by 75% by TLR10 siRNA treatment from 100- to 25-fold over 
uninfected cells (Fig. 6.13C) in response to L.monocytogenes infection. HKLM, however, 
which is unable to invade the HT-29 cells, failed to induce any major increase in CCL-20 
induction over uninfected cells. A similar result was observed in IL-8 induction (Fig. 6.13D). 
A reduction of over 50% in IL-8 induction was observed in response to live bacteria 
following TLR10 siRNA treatment but the HKLM once again failed to induce IL-8. Taken 
together these data imply that intracellular TLR10 might be responsible for detecting the 
invasive L.monocytogenes. 
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Figure 6.13 TLR10 is expressed intracellularly in HT-29 cells. Flow cytometry was used to 
analyse expression levels of TLR10 in HT-29 cells extracellularly (A) or intracellularly (B). 
Following transfection with TLR10 siRNA, HT-29 cells were subject to 3 hour stimulation with either 
live or heat-killed L.monocytogenes (HKLM). qRT-PCR was used to analyse cells for expression 
levels of CCL-20 (C) or IL-8 (D). * P<0.05, ** P<0.01 and *** P<0.001, Values are shown as Mean 
± SEM, n=3. Statistics were carried out using t test with Welch‘s correction. 
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6.2.7 TLR10 is not involved in recognition of other known TLR2 ligands but is involved 
in detection of another motile intracellular pathogen, Salmonella typhimurium. 
We had observed a comparable result between the TLR1/TLR2 dimer and the 
TLR2/TLR10 dimer in NF-κB activity following Listeria infection when these TLRs were 
transfected in together. Since TLR10 is most closely related to the more extensively 
researched TLR1 [9], we wished to compare the TLR1 versus TLR10 mediated response to 
some known TLR-ligands. Using THP-1 macrophages, IL-8 production was measured in 
response to a range of TLR2 ligands following siRNA treatment against TLR1 or TLR10 
(Fig. 6.14). We also investigated the response to another intracellular pathogen, Salmonella 
typhimurium, in addition to L.monocytogenes, based on the intracellular location of TLR10 
expression outlined in Fig. 6.13. While a significant reduction in IL-8 production was 
measured following TLR1 siRNA treatment in response to L.monocytogenes infection, this 
reduction was not as significant as that seen in TLR10 siRNA treated cells. Silencing of 
TLR1 and TLR10, however, resulted in a similarly significant reduction in IL-8 production in 
response to Salmonella infection. Besides the significant reduction of IL-8 production seen in 
response to Pam3Cys following TLR1 siRNA treatment, no further statistically significant 
changes in IL-8 were observed in response to the other TLR2 ligands; Peptidoglycan (PGN), 
Lipoteichoic Acid (LTA) or fibroblast stimulating ligand-1 (FSL-1), nor by the positive 
control, LPS.  
 
 
  
213 
 
Figure 6.14 Effects of TLR1 versus TLR10 siRNA treatment on IL-8 production in 
THP-1-macrophages following 24 hour stimulation with TLR2 ligands. THP-1 cells were 
treated with either non-targeting control, TLR1 or TLR10 siRNA with 5ng/ml PMA for 48 hours. The 
cells were then subject to stimulation with the ligands indicated. Bacterial infections were performed 
as described in the methods section 2.14. 24 hours after stimulation, supernatants were analysed by 
ELISA for IL-8 production.  * P<0.05, ** P<0.01 and *** P<0.001, Values are shown as Mean ± 
SEM, n=3. Statistics were carried out using t test with Welch‘s correction. 
 
 
 
6.2.8 Hypoxic Inducible Factor-1α (HIF-1α) stabilisation increases TLR10 expression 
and function in intestinal epithelia and macrophages 
Hypoxia has been shown to increase bactericidal activity in phagocytes in addition to 
increasing TLR10 expression levels in THP-1 monocytes [23, 24]. Additionally, the hypoxic 
gene, HIF-1α, has been shown to play a role in increasing the barrier function of intestinal 
epithelial cells, protecting them from an over-active inflammatory response [25]. We wished 
to investigate the effects on TLR10 expression and function in HT-29 IECs and THP-1 
macrophage-like cells when treated with a substance known as Dimethyloxaloylglycine 
(DMOG). DMOG simulates hypoxic conditions by stabilising HIF-1α expression in cells 
which were not in a hypoxic environment – simulating the effects of hypoxia within the cell. 
While TLR10 expression was shown to increase during hypoxia in phagocytic cells such as 
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THP-1 cells, we hypothesised that a hypoxic environment may induce regulatory features in 
IECs, such as decreased expression of TLR10 or decreased inflammatory responses following 
its activation. Thus, the effect of stabilising HIF-1α on TLR10 induction through the use of 
DMOG was investigated in HT-29 IECs (Fig. 6.15) and also in THP-1 macrophage-like cells 
as a positive control (Fig. 6.16). Additionally, the TLR10-mediated inflammatory response 
was measured in untreated and DMOG treated cells following a 3 hour infection with the 
TLR10 activating pathogens L.monocytogenes or S.typhimurium.  
The induction of a target gene of HIF-1α known as Vascular Endothelial Growth 
Factor (VEGF) was used to confirm the stabilisation of HIF-1α in DMOG treated cells. In 
Fig. 6.54A, VEGF expression was increased by 4.5-fold in the DMOG treated cells over the 
untreated controls. DMOG treatment also increased TLR1 induction levels 1.5-fold (Fig. 6.15 
B) and TLR10 was induced 45-fold over untreated controls by DMOG treatment (Fig. 6.15 
C). Although TLR2 induction was measured, it was not detectable by qRT-PCR in these 
cells. CCL-20 induction was decreased from 800-fold in the untreated samples to 50-fold 
induction in the DMOG-treated samples over uninfected controls in response to 
L.monocytogenes (Fig. 6.15D). Similarly, infection with S.typhimurium resulted in a 1,100-
fold in the untreated cells compared to a 600-fold induction in the DMOG treated samples. 
Conversely however, IL-8 induction was found to be increased from 7-fold to 11-fold 
induction in response to L.monocytogenes following DMOG treatment, although this increase 
was not statistically significant (Fig. 6.15E). Infection with S.typhimurium resulted in a 
statistically significant increase from 6-fold to 11-fold induction in the DMOG treated 
samples over the uninfected control. Taken together, these data suggested a differential effect 
of HIF-1α on the inflammatory response in IEC. 
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Figure 6.15 Effects of HIF-1α induction on TLR expression and inflammatory response 
in HT-29 cells. HT-29 cells were subject to 500µM DMOG treatment for 24 hours prior to infection 
with L.monocytogenes MOI 50 or S.typhimurium MOI 10 for 3 hours. qRT-PCR was used to analyse 
cells for expression levels of VEGF (A), TLR1 (B), TLR10 (C), CCL-20 (D) or IL-8 (E). * P<0.05, 
** P<0.01 and *** P<0.001, Values are shown as Mean ± SEM, n=3. Statistics were carried out using 
t test with Welch‘s correction. 
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We subsequently investigated the effects of DMOG on THP-1 macrophage-like cells. 
Fig. 6.16A displays a 10-fold increase in VEGF induction in DMOG treated samples. DMOG 
treatment increased the expression of TLR1 3 –fold (Fig. 6.16B), TLR2 4–fold (Fig. 6.16C) 
and resulted in a12 –fold increase in TLR10 induction (Fig. 6.16D). In correlation with this, 
IL-1β induction was induced 3000-fold compared to the uninfected controls in untreated cells 
following infection with L.monocytogenes compared to a 9000-fold induction in DMOG 
treated cells in response to the bacteria (Fig. 6.16E). Similarly following infection with 
S.typhimurium, IL-1β induction increased from 2000-fold in the untreated cells to 13000-fold 
induction in the DMOG treated samples over the uninfected controls. IL-8 followed a similar 
pattern with a 1000-fold induction over uninfected cells observed following infection with 
L.monocytogenes compared to a 13000-fold induction in DMOG treated samples (Fig. 
6.16F). Infection with Salmonella resulted in a 500-fold increase in IL-8 induction in the 
untreated samples and an 8000-fold induction over uninfected controls seen in DMOG treated 
samples. 
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Figure 6.16 Effects of HIF-1α induction on TLR expression and inflammatory response 
in THP-1 macrophage-like cells. THP-1 cells were differentiated into macrophage-like cells as 
described in the methods section 2.1 by PMA treatment. Following this, they were subject to 500µM 
DMOG treatment for 24 hours prior to infection with L.monocytogenes MOI 50 or S.typhimurium 
MOI 10 for 3 hours. qRT-PCR was used to analyse cells for expression levels of VEGF (A), TLR1 
(B), TLR2 (C), TLR10 (D), IL-1β (E) or IL-8 (F). * P<0.05, ** P<0.01 and *** P<0.001, Values are 
shown as Mean ± SEM, n=3. Statistics were carried out using t test with Welch‘s correction. 
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6.2.9 Attempt to generate a stable TLR10 knockdown HT-29 cell line by use of shRNA 
lentiviral particle transfection 
 
For reasons of practicality while studying TLR10 function in IECs, I attempted to 
create a stable knockdown of TLR10 in HT-29 cells. In addition to reduced cost and 
resources, this would also avoid the inconsistencies of siRNA transfection and the level of 
silencing achieved from each assay. Benefits of creating such a cell line would allow the 
effects of TLR10‘s absence to be more easily distinguished in comparative studies between 
this cell subset, the untreated parental HT-29 cells and over-expression studies using a 
TLR10 plasmid construct. 
Following transfection with either scrambled control, or TLR10 shRNA lentiviral 
particles as described in the methods section 2.18, HT-29 cells were treated with a selective 
antibiotic pressure using puromycin. The lentiviral particles carried resistance to this 
antibiotic, thus ensuring the removal of any non-transfected cells. After three more passages, 
cells were seeded at a very low density. This allowed for individual cell colonies to develop. 
A week after allowing these clones to develop, 24 individual colonies were selected. Initially 
the cells‘ responsiveness to L.monocytogenes infection was measured – given that based on 
my earlier work, a phenotype of silencing TLR10 in HT-29 cells should be a significantly 
reduced responsiveness to L.monocytogenes infection. 17 of the healthiest looking TLR10 
shRNA treated clones were selected together with a scrambled shRNA treated control clone 
and 2 clones of the parental HT-29 cells. Cells were then seeded and subjected to a 24 hour 
incubation with L.monocytogenes as described in the methods 2.14. Supernatants were 
analysed for CCL-20 production in response to the bacteria (Fig. 6.17). None of the 
uninfected samples from any clone produced more than 100 pg/ml of CCL-20 (not shown). In 
contrast, the parental cells produced an average of 600 pg/ml CCL-20 following infection. 
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Several of the TLR10 shRNA treated clones produced CCL-20 levels in response to 
L.monocytogenes comparable with CCL-20 production seen in the uninfected samples. 
Clones S2, L1, L5 and L7 produced less than 100 pg/ml CCL-20 in response to the bacteria; 
hence these clones were selected for further analysis. 
 
Figure 6.17 CCL-20 production by HT-29 lentiviral clones in response to 
L.monocytogenes infection. Following lentiviral transfection and clonal selection, HT-29 clones 
were seeded on a 96 well plate and subject to a 24 hour L.monocytogenes infection. Supernatants were 
then analysed for CCL-20 production.  Statistics were carried out using t test with Welch‘s correction. 
 
 
To further analyse the phenotypes of TLR10 silencing in the selected clones from Fig. 
6.17, qRT-PCR analysis was performed following infection with L.monocytognes. Figure 
6.18A displays CCL-20 induction in response to infection with L.monocytogenes from the 
TLR10 shRNA clones S2, L1, L5 and L7 in conjunction with the parental and control clones. 
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The most visible reduction in CCL-20 production when compared to the parental or control 
lentiviral clones was observed in TLR10 shRNA clones L5 and L7. These clones were further 
analysed once again for CCL-20 production in response to L.monocytogenes infection (Fig. 
6.18B). The most significant reduction in CCL-20 induction when compared to the parental 
and control shRNA clones was observed in the L5 clone. The L5 clone was selected for 
further study and this cell line was now referred to as TLR10 Knock Down (KD). 
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Figure 6.18 CCL-20 induced by lentiviral clones in response to L.monocytogenes 
infection. HT-29 lentiviral clones indicated were seeded in a 12-well plate and were subject to 
infection with L.monocytogenes for 3 hours. Relative CCL-20 induction was then measured by qRT-
PCR (B). Selected HT-29 clones were seeded on a 96-well plate and infected with L.monocytogenes 
for 24 hours. Supernatants were then analysed for CCL-20 production (C). * P<0.05, ** P<0.01 and 
*** P<0.001, Values are shown as Mean ± SEM, n=3. Statistics were carried out using t test with 
Welch‘s correction. 
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In order to confirm silencing of TLR10 protein expression in the selected TLR10 KD 
clone, L5 and lentiviral clone L7, further analysis by Western blotting was performed. The 
left hand panel of Figure 6.19 displays a TLR10 Western blot analysis of parental and control 
clones in addition to the TLR10 shRNA clones and L7, indicated in lanes A-D. -actin 
expression on the right hand panel verified equal loading of the lysates. The Western blot 
revealed that the TLR10 KD L5 clone expressed almost no detectable TLR10. The L7 clone, 
however, expressed TLR10 levels more similar to that of the parental.  
 
 
 
Figure 6.19 TLR10 protein expression in HT-29 TLR10 KD lentiviral clones. Lysates of 
Parental, Control shRNA and TLR10 shRNA HT-29 lentiviral clones (L5 and L7) were prepared and 
analysed by Western blot for TLR10 expression (left-hand panel). Housekeeper gene, β-actin, levels 
were also measured to ensure equal amounts of protein were loaded in each lane (right-hand panel). 
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The TLR10 KD (L5), Parental and Control lentiviral clones were further analysed for 
CCL-20 and IL-8 mRNA induction in response to L.monocytogenes infection in Fig. 6.20. 
The control and parental clones yielded a robust response to the bacteria; 130- and 170-fold 
induction of CCL-20 and Il-8 was increased to 40 and 55-fold over uninfected cells in the 
parental and control samples respectively. Both CCL-20 (A) and IL-8 levels (B) were 
significantly reduced by over 50% in the TLR10 KD clone relative to levels induced by the 
control and parental HT-29 clones in response to infection with L.monocytogenes. 
 
Figure 6.20 Inflammatory response to L.monocytogenes infection in HT-29 lentiviral 
clones. Selected HT-29 lentiviral clones were seeded overnight and subject to infection with 
L.monocytogenes the following day for 3 hours. qRT-PCR was used to analyse relative mRNA 
expression levels of CCL-20 (A) and IL-8 (B). * P<0.05, ** P<0.01 and *** P<0.001, Values are 
shown as Mean ± SEM, n=3. Statistics were carried out using t test with Welch‘s correction. 
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Frozen stocks were made of the TLR10 KD (L5 clone). Upon thawing these stocks to 
grow more cells, an inflammatory response to L.monocytogenes infection was examined (Fig. 
6.21). The control and parental clones responded to the infection similarly to the response 
seen in Fig. 6.19 with a 120-fold increase in CCL-20 and 40-fold increase in IL-8 mRNA 
induction over uninfected controls. The TLR10KD clones, however, responded with similar 
levels of induction, with no statistical difference between any of the 3 clone types. 
 
Figure 6.21 Inflammatory response to L.monocytogenes infection in HT-29 lentiviral 
clones. Selected HT-29 lentiviral clones were seeded overnight and subject to infection with 
L.monocytogenes the following day for 3 hours. qRT-PCR was used to analyse relative mRNA 
expression levels of CCL-20 (A) and IL-8 (B). * P<0.05, ** P<0.01 and *** P<0.001, Values are 
shown as Mean ± SEM, n=3. Statistics were carried out using t test with Welch‘s correction. 
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This was a surprising result, since reduced TLR10 expression should have resulted in 
a reduced inflammatory response from HT-29 cells to Listeria infection. I next investigated 
by Western blot the TLR10 expression levels in each of the 3 clone types; parental, control 
and TLR10 KD (Fig. 6.22). The parental and control clones display similar levels of TLR10 
protein in each lysate (Fig. 6.22 lanes A, B). The TLR10 KD (L5) clones displayed slightly 
lower levels of TLR10 expression (lane C) than either of the other 2 clones. However, this 
difference in expression levels is not comparable to that seen in Fig. 6.19. Taken with the 
results from Fig. 6.21, we concluded that the TLR10 KD (L5) clone had regained TLR10 
expression levels upon growing them back from frozen stocks.  
 
 
Figure 6.22 TLR10 expression in HT-29 lentiviral clones. Lysates of Parental, Control 
shRNA and TLR10 shRNA HT-29 lentiviral clones were prepared and analysed by Western blot for 
TLR10 expression (left-hand panel). Housekeeper gene, β-actin, levels were also measured to ensure 
equal amounts of protein were loaded in each lane (right-hand panel). 
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6.3 Discussion 
 
Here, for the first time, we have shown recognition of a pathogen by TLR10. 
Additionally, we have demonstrated that in addition to macrophages, TLR10 plays a 
functional role in intestinal epithelial cells. In humans, TLR10 expression has been reported 
to be somewhat restricted. It was initially characterised to be primarily expressed on immune 
cell subtypes with a predominance found in spleen, lymph nodes, thymus and tonsils [4]. It is 
worth noting that in this study by Chuang et al, expression of TLR10 in colon tissue was not 
investigated. However, a study by Otte et al. in 2004 reported no detectable expression of 
TLR10 in intestinal epithelia [26]. Problems with detection have been encountered in the 
past, for example, its mRNA had been detected in gingival epithelial cell cultures by qRT-
PCR, but the same group and others failed to detect its presence in tissue samples immuno-
histochemically [27, 28]. Furthermore, unlike TLR1 and TLR6, TLR10 is expressed in a 
highly restricted fashion as a highly N-glycosylated protein [6]. This heavy glycosylation 
may account for some of the difficulty encountered in detecting its presence in the past. The 
development of better detection methods in recent years has allowed us to more accurately 
explore the extent of its expression in human cells. More recently, two separate groups have 
reported its expression in human monocytes and the monocytic THP-1 cell line [4, 23]. Its 
presence has also been detected in human PBMCs, trophoblasts, airway epithelium, renal 
cells in addition to the SW480 colonic adeno-carcinoma cell line [26, 29-32]. Human 
regulatory T cells (Treg cells) have also been shown to express TLR10, and this expression is 
believed to be regulated through a cooperative complex of immune-regulating transcription 
factors Forkhead box P3 (FOXP3) [33]. Following results from our study, the list of cell 
types that express TLR10 can now be extended to include colonic adeno-carcinoma HT-29 
and HCA-7 intestinal epithelial cell lines.  
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To date, no specific ligands for TLR10 have been shown, nor has TLR10 activation 
been shown outside of this study to elicit an inflammatory immune response. Recently, 
TLR10 has been indicated to be involved in Peptidoglycan (PGN) mediated TLR signalling 
[30]. This study demonstrated using a dominant negative TLR10 that trophoblast TLR10 
plays a role in promoting apoptosis triggered by gram-positive bacterial components and 
suggests that TLR10 may play a role in determining trophoblast survival and cell death, but 
not in any inflammatory response [30]. A possible involvement of TLR10 has been 
implicated in response to specific pathogens, such as malaria Plasmodium falciparum [34] 
and a study on TLR10 polymorphism with asthmatic patients suggested that TLR10 may be 
involved in the recognition of airborne pathogens or airborne allergens [15]. Until my own 
studies however, TLR10 had not been linked with inducing any innate immune activation in 
response to purified ligands or pathogens. In fact, several groups have suggested an immune-
regulatory role for TLR10 in preventing an over-active inflammatory response [9, 30, 33]. 
We have since demonstrated TLR10 to be involved in eliciting an immune response to at 
least two different intracellular pathogens. 
Previous studies suggested that similar to TLR1 and TLR6, TLR10 signals with TLR2 
but does not activate NF-κB following stimulation [9]. Since we had reported an 
inflammatory immune response from NF-κB activated genes such as IL-8 and CCL-20, we 
wished to test this hypothesis regarding the requirement for TLR2 to mediate TLR10 
signalling using an NF-κB reporter cell line. These HEK reporter cells also stably expressed 
the adaptor molecules CD14 and MD-2, both believed to be involved in TLR signalling [35, 
36]. Although NF-κB activation was not recorded when TLR10 was transfected alone or with 
TLR1 or TLR6, we confirmed NF-κB activation in response to L.monocytogenes after 
transfecting TLR10 with TLR2. This level of activation appeared to be similar to that which 
was observed when the TLR1 and TLR2 receptors were transfected together. This data 
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suggested that TLR10 could mediate an NF-κB response following infection with 
L.monocytogenes but, similar to TLR1 and TLR6, required TLR2 for this activation. 
Interestingly, NF-κB activation was observed following infection with L.monocytogenes 
when TLR2 was transfected alone. Further analysis on the HEK cells through western 
blotting revealed an endogenous expression of TLR10. While this data was previously 
unpublished, it was reported in the data sheets from several companies pertaining to the HEK 
cells they provide. HEK 293 cells are not reported to express endogenous levels of any other 
TLRs besides small levels of TLR3 and TLR5 [37] so this endogenous TLR10 expression 
may account for the NF-κB activation observed in response to L.monocytogenes when TLR2 
is transfected alone. The results from this study also highlight the advantages of using siRNA 
techniques instead of over-expression studies using plasmids; while one may over-express a 
protein of interest in cells such as HEKs, it is impossible to know every adaptor molecule 
which this protein may require interaction with in order to fully mediate signalling, and these 
adaptor molecules might be absent in HEKs. In this manner, observing the effects in a cell 
type when a particular gene is switched off rules out this potential problem. In our case, it 
may be that the CD14 receptor is required to fully mediate NF-κB activation by the 
TLR2/TLR10 signalling dimer since previous studies reported that this signalling dimer was 
unable to activate NF-κB in response to ligand activation [9]. 
In addition to sharing strong homology with one another, TLR1 and TLR10 have also 
been hypothesised to detect similar ligands [8, 9]. In our own studies, we observed similar 
levels of NF-κB activation observed in response to L.monocytogenes infection between the 
TLR1/2 and TLR2/10 signalling dimers. The direct effects of TLR1 versus TLR10 mediated 
signalling were investigated in this study using various TLR2 ligands. Using Pam3Cysk4, the 
well characterised TLR1/TLR2 ligand, also suggested as a potential ligand for TLR10 [8] we 
indeed observed a decrease in IL-8 production following TLR10 siRNA treatment, although 
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this decrease was not statistically significant, as it was in the case of TLR1 siRNA treated 
cells. This suggests that, contrary to predictions [8], TLR10 does not sense Pam3Cysk4 but 
may be involved in sensing structurally similar ligands. Additionally, IL-8 production in 
response to the TLR2 ligand PGN was higher in the TLR10 siRNA treated samples although 
TLR1 siRNA treatment yielded no significant effects. While this increase was also not found 
to be statistically significant, it is worth noting since the only instance in which TLR10 was 
directly linked to PGN mediated-signalling, mentioned earlier, implicated an immuno-
regulatory role for TLR10 in trophoblasts [30]. While a similarly significant decrease in IL-8 
production was reported in response to infection with the intracellular gram negative 
pathogen S.typhimurium following siRNA treatment against TLR1 and TLR10, TLR10 
siRNA treatment resulted in a more significant decrease in IL-8 production in response to 
L.monocytogenes infection. Taken together, these data imply a differential role for TLR1 and 
TLR10 in innate immune signal activation and ligand binding, contrary to the reports of Guan 
et al. and Govindaraj et al. [8, 9]. While their ligand binding may be similar, it certainly 
appears to be distinct from one another also. Moreover, this study provided the first evidence 
that TLR10 may be involved in the detection of other intracellular pathogens. It should also 
be noted that while both L.monocytogenes and S.typhimurium are intracellular bacteria, the 
former is Gram-positive and the latter is Gram-negative. Furthermore, both bacteria are 
motile. Therefore, it may be worthwhile investigating potential ligands from the flagellae or 
pili of these bacteria also in determining the specific ligand for TLR10.  
Investigation into the sub-cellular localisation of TLR10 by intracellular and surface 
flow cytometry staining revealed a predominantly intracellular expression of TLR10 in HT-
29 intestinal epithelial cells. It should be pointed out, however, that the antibody may 
preferentially bind the intracellular region of surface bound TLR10. Confocal microscopy 
may yield a clearer answer concerning TLR10 subcellular localisation although few efficient 
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antibodies for this gene exist. The lack of inflammatory gene induction from these cells 
following stimulation with non-viable HKLM in comparison to the strong induction of 
inflammatory genes in response to live L.monocytogenes suggested that the intracellular 
expression of TLR10 in the intestinal epithelium may help regulate the innate inflammatory 
signalling against microbial antigens, highly abundant in the gastro-intestinal tract. However, 
it should be noted that heat-treatment of the bacteria may denature the ligand for TLR10. 
That is, the ligand may be heat labile. For this reason, a strain of Listeria inoccua or 
L.monocytogenes mutants with inactive InlA and InlB virulence factors may give a clearer 
indication as to whether TLR10 may recognise the bacteria extracellularly as these do not 
invade host cells. Such subcellular compartmentalisation of TLRs has been well documented 
to regulate homeostasis in IECs. For example, TLR2 and TLR4, which detect bacterial 
lipoproteins and lipopolysaccharides respectively, are known to translocate from apical to 
basolateral surfaces upon stimulation by commensal bacterial associated molecular patterns 
[38]. TLR5 has been shown to only be expressed intracellularly or basolaterally in the colon 
[39], thereby avoiding an inappropriate inflammatory response to flagellated commensal 
bacteria present in the gut lumen. Our data showing TLR10 as the dominant TLR involved in 
mediating the immune response to L.monocytogenes in the intestine open up intriguing 
possibilities concerning the balance of pro-inflammatory versus homeostatic TLR responses 
to infection in epithelial cells. It is possible that a TLR2/10 dimer may be pro-inflammatory 
in epithelial responses whilst TLR2 on its own or in combination with 1 and 6 may mediate a 
more homeostatic effect. Additionally, it could be that TLR10, reported elsewhere to be 
present on the cell surface [6, 23] might localise to the cytoplasm of IEC in order to avoid 
inappropriate inflammatory activation. Indeed as several polymorphisms in TLR10 are 
associated with Crohn‘s disease [12-14], a possible line of investigation would be to 
determine if these polymorphisms affect the subcellular localisation of TLR10 in the 
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intestinal epithelium. Inappropriate subcellular expression forms may then lead to 
inappropriate inflammatory activation from, for example, increased lumenal expression. 
Subcellular location of TLR2 is known to change upon stimulation with certain 
ligands [40] and the type of signal induced by TLR2 activation is sometimes dependent on 
the location of TLR2 at the time of stimulation. As predicted in published studies and, indeed, 
demonstrated in my own data, TLR10 is believed to require TLR2 for signalling, similar to 
TLR1 and TLR6 [6, 8, 9]. L.monocytogenes appears to activate an inflammatory innate 
immune response via TLR10. Therefore, if TLR10 utilises TLR2 for signal transduction, 
subcellular location of TLR2 may be different in the absence of TLR10 following infection 
with L.monocytogenes. For this reason, confocal microscopy would be an interesting tool to 
investigate subcellular localisation of TLR2 in parental or a stable TLR10 silenced HT-29 
IEC line upon stimulation with various TLR2 ligands or intracellular microbes such as 
L.monocytogenes. Additionally, measuring the inflammatory response after stimulating the 
TLR10 silenced or parental HT-29 cells using L.monocytogenes with lipoprotein mutations 
might also help determine the specific ligand for TLR10. In order to follow this line of 
investigation, I attempted to create a stable TLR10 Knock Down (KD) cell line in HT-29 
cells by lentiviral transfection. However, upon thawing frozen stocks of the TLR10 KD cell 
line I had generated, the associated phenotype (unresponsiveness to L.monocytogenes 
infection) had been lost. Furthermore, Western blotting analysis revealed that the selected 
TLR10 KD clone had regained TLR10 expression to a level comparable with the control and 
parental HT-29 clones. The control scrambled lentiviral particle shRNA clones all carried a 
GFP protein as an additional marker. None of the TLR10 shRNA clones displayed any 
presence of GFP, even after the TLR10 KD clone was grown back from frozen stocks. This 
ruled out the possibility of contamination of the TLR10 KD clone with the control cells. 
Furthermore, since the selective antibiotic, puromycin, was used on the control and TLR10 
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KD cells, a contamination from the parental HT-29 cells was also ruled out. It is possible, 
however, that during initial clonal selection, the single colony selected may have originated 
from more than one single cell. As colonies grew from these cells, they may have merged and 
appeared as a colony from one cell. The result of this would be that different integration of 
the TLR10 shRNA particles may have occurred throughout this mixed population. The cells 
exhibiting the TLR10 silenced phenotype may have initially predominated. Upon freezing the 
cells to make stocks and re-growing them, much stress would have been placed on the cells. 
This stress may have allowed any remaining cells from the other population present, which 
may not have had correct integration of the TLR10 shRNA particles, to out-compete the cells 
which had achieved TLR10 silencing. 
In addition to THP-1 macrophage-like cells, we have also shown that depletion of 
TLR10 increases Listeria survival in HT-29 epithelial cells. Whilst the mechanism by which 
TLR10 might act to reduce bacterial survivability in intestinal epithelial cells such as HT-29s 
is unclear although our observation that TLR10 may regulate expression of chemokines such 
as CCL-20 may be a key factor. Indeed observations by Yang et al. [41] and Starner et al. 
[42] have demonstrated the antimicrobial effect of chemokines and cytokines such as CCL-
20. These studies demonstrate that some chemokines, in addition to their role as a signalling 
messenger molecules, may also function similar to Human Beta Defensins (HBDs) which 
have been well characterised for their antimicrobial properties [43]. CCL20 was shown to 
rapidly permeabilise bacterial membranes over a time course comparable to HBDs [42]. 
Structural analysis of CCL20 revealed that most of its positively charged residues are 
concentrated to one area of its topological surface, a characteristic considered to be important 
for the antimicrobial activity of defensins [41]. Yang et al. also discovered that 17 out of a 
total of 30 chemokines which they had investigated exhibited antimicrobial properties in 
vitro. We have shown that TLR10 activation leads to chemokine production in response to 
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L.monocytogenes infection. Thus, in this manner, TLR10 activation may result in increased 
bacterial killing through antimicrobial chemokine production. Specific mutagenesis studies of 
both TLR10 and bacterial strains may also further elaborate this question.  
We have shown that simulating hypoxic conditions through stabilisation of HIF-1α 
using DMOG not only had the effect of greatly increasing TLR10 expression in THP-1 
macrophage-like cells but in HT-29 IECs also. Hypoxia had already been shown to increase 
TLR10 expression in THP-1 monocytes [23] and is also believed to increase bactericidal 
activity in these cells [44, 45]. Areas of inflamed, infected, and diseased tissues are often 
hypoxic due to multiple factors: metabolically active inflamed tissue results in elevated 
oxygen demand; local blood supply is occluded; local vessel growth cannot keep pace with 
growth and/or infiltration of cells in affected tissue [45]. Reactive Oxygen Species (ROS), 
primarily superoxide and hydrogen peroxide (O2
−
 and H2O2), are used by phagocytic cells in 
bacterial killing, with their ability to damage biomolecules and the integrity of DNA [46]. In 
hypoxic conditions, macrophages not only increase intracellular levels of bactericidal ROS 
but also up-regulate the expression of genes required for macrophage survival, angiogenesis, 
and recruitment and activation of macrophages and/or other inflammatory cells increasing 
bacterial killing [47]. The intestinal epithelium, on the other hand, exists in a unique 
environment with a hypoxic gradient across the cell from the oxygen rich vascular mucosa 
across to the apical surface facing the low oxygen environment of the lumen. Levels of 
hypoxia are known to increase for these cells during IBDs such as Crohn‘s disease when the 
intestinal epithelial barrier is disrupted. This increase in hypoxia leads to increased levels of 
HIF-1α which is believed to mediate a protective effect for the intestinal barrier [25]. We 
wished to investigate if this protective effect had any role to play in the modulation of TLR10 
expression levels or in the IEC response to TLR10 activating microbes, L.monocytogenes and 
S.typhimurium. Our results revealed that an increase was observed in TLR1 and TLR10 
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induction following HIF-1α induction. This increase in TLR mRNA correlated with an 
increase in IL-8 induction in response to infection with both bacterial species. However, a 
significant decrease in CCL-20 was observed in response to the bacteria when cells were 
treated with HIF-1α inducing DMOG. Interestingly, while HCA-7 cells were found to 
express more TLR10 mRNA than HT-29 cells, IL-8 induction was lower in HCA-7 cells than 
in HT-29 cells following infection with L.monocytogenes. Conversely, there was increased 
CCL-20 induction in HCA-7 following infection compared HT-29 cells. Silencing TLR10 in 
both cell types resulted in a decrease in both CCL-20 and IL-8 induction in response to 
L.monocytogenes. Although, despite HCA-7 cells and DMOG treated HT-29 cells both 
displaying greater expression of TLR10 than untreated HT-29 cells, their differences in IL-8 
and CCL-20 induction levels do not align. Not only does this result highlight the caveats 
associated with different phenotypes across different cell lines in culture, but it also 
demonstrates that despite increased TLR expression during hypoxia, much further complex 
regulation must be taking place to curtail the inflammatory response from intestinal epithelia. 
This is likely to be a specific protection mechanism against over-responsiveness to the vast 
array of microbial ligands the intestinal lumen is exposed to, especially during IBD when the 
intestinal epithelial barrier‘s integrity is decreased. It is also possible therefore that the 
polymorphisms in TLR10 associated with Crohn‘s disease mentioned earlier may lead to 
over-activation in response to gastro-intestinal antigens when TLR10 induction is increased 
in the hypoxic environment of the gut mucosa during IBD. This may be due to the mutations 
in TLR10 preventing appropriate transduction of the regulatory features deployed during 
hypoxia.  
Evidence supports the claim that the increase in TLR10 expression during hypoxic 
conditions in THP-1 cells is directly due to the subsequent increase in ROS [23]. This is 
reflected in our own studies with DMOG treated THP-1 macrophage-like cells; these 
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displayed much higher expression of TLR1, TLR2 but especially TLR10. Following this, we 
observed a significant increase in IL-1β and IL-8 induction following infection with 
L.monocytogenes and S.typhimurium. Both of these pathogens have been shown to mediate 
an inflammatory response via TLR10 in our studies. As discussed earlier, we revealed that 
decreased TLR10 expression in THP-1 macrophage-like cells resulted in increased survival 
of L.monocytogenes. Taken together, these data suggest that TLR10 may play a role in ROS 
mediated clearance of bacteria in a positive feedback loop i.e. TLR10 activation from 
detection of intracellular microbes causes inflammation; this inflammation may increase 
hypoxic conditions in the area, due to increased oxygen consumption by the proliferation of 
bacteria, the accumulation of phagocytes at the infected site, and/or the vasoconstriction of 
vessels in the area that could impede delivery of oxygen to the site of inflammation. This is 
followed by an increase in ROS which in turn may up-regulate TLR10 expression resulting in 
further inflammatory activation (see Fig. 6.23). It should also be noted that in the absence of 
hypoxia, mouse and rat macrophage cell lines have been shown to rapidly up-regulate HIF-1α 
levels when exposed to Gram-positive or Gram-negative bacteria [47] or even in response to 
the presence of LPS alone [48]. 
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 Figure 6.23 L.monocytogenes mediated TLR10 activation in macrophages 
1. L.monocytogenes invades the cytoplasm of the cell. 2. Bacterial particles are detected in the 
phagosome by TLR10 sensing. 3. TLR10 mediates an inflammatory signal through its TIR domain. 4. 
Chemokines induced by TLR10 activation increase inflammation and attract more macrophages to the 
site of inflammation. 5. This increase in inflammation and oxygen consumption leads to hypoxia 
which increases in ROS within the cell. 6. ROS production increases bacterial killing within the 
phagosome. 7. ROS also increases TLR10 expression, believed to be mediated through NF-κB 
activation. 
Despite recent advances in gene detection, I encountered several difficulties in my 
own efforts over the duration of this study with regard to TLR detection, TLR10 in particular. 
We initially wished to confirm the effect of TLR10 silencing seen in the PRR siRNA screen; 
this involved verifying the specificity of the siRNA constructs used and excluding the 
possibility of off-target effects. As TLRs 1, 2, 6 and 10 are all closely related [6] and siRNA 
against TLR1, TLR2 and TLR10 were used in our studies, the specific targeted silencing of 
each gene was verified by qRT-PCR and flow cytometry. Although the screen was performed 
on HT-29 cells, it was not possible to detect TLR10 by qRT-PCR in these cells using the 
primers we had initially obtained. The consistent effect of reduced immune response 
following infection seen in the TLR10 siRNA treated cells prompted the acquisition of more 
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suitable primers in order to detect its presence in HT-29 cells. Having accomplished this, 
mRNA levels detected were still relatively low compared to the THP-1 cell line. Hence, we 
confirmed the siRNA specificity using THP-1 macrophage-like cells which express high 
levels of TLRs allowing more accurate results. Detection of TLR10 through Western blot 
proved difficult also, with a high degree of variation in blot quality encountered relative to 
detection of other proteins. Detection of TLR protein using flow cytometry produced the 
most consistent results. However, intra-assay discrepancies in TLR quantification were 
encountered using this method also. Inconsistencies in levels of detection were also met 
between cell types using different assays. An example of this may be seen in the flow 
cytometry data versus qRT-PCR data displaying TLR10 expression in THP-1 macrophage-
like cells compared to HT-29 cells. The HT-29 cells were shown to have 14.7% staining 
compared to 1.3% in the THP-1 macrophage-like cells despite THP-1 cells having more 
detectable TLR10 mRNA than HT-29 cells. Indeed a recent study has found that the 
circadian rhythm of intestinal epithelial cells governs the signalling of TLR mediated 
homeostasis [49] which may in part explain the intra-assay variation associated with TLR10 
detection over the course of this study. The difficulties I encountered in detection and 
quantification of TLR10 during the course of my work might also explain why previous 
studies have reported a lack of TLR10 expression in certain cell types [26]. 
 
Much previously unknown information regarding TLR10 functionality, expression 
and signalling has been uncovered in this study. It is clear, however, that we are only just 
beginning to understand its role and much further analysis is required to fully reveal its 
physiological functions. A particularly useful tool would be clear visualisation of the protein 
at an endogenous level within the cell. Over-expression studies are useful for visualising the 
protein if it has a fluorescent tag although over-expression may prove to obstruct a clear view 
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of the natural role TLR10 is playing within the cell. Trafficking of TLR10 upon ligand 
recognition in addition to differences in sub-cellular localisation throughout different cell 
types have yet to be investigated thoroughly. With particular regard to the recent information 
surrounding the expression of TLR10 throughout the body [4, 23, 26, 29-32] in addition to 
the information revealed here regarding TLR10 expression, it is clear that advancements in 
antibody specificity and detection formats will aid in this endeavour. It should also be 
mentioned here that throughout all western blotting analysis, it was the ~75 kDa isoform of 
TLR10 that was detected rather than the more commonly referred to 94 kDa isoform. I have 
found this to be a common phenomenon through discussions with other researches 
investigating TLR10. More study in this area could reveal functionally distinct isoforms of 
TLR10, similar to those of TLR7 and TLR9 where cleavage of the full-length protein is 
required for efficient signal transduction [50]. 
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Chapter 7 
 
 
General Discussion 
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7.1 The intestinal epithelium is increasingly recognised as an important site for innate 
immune regulation. 
Throughout the course of this thesis, several novel aspects of innate immune 
regulation of inflammation and signalling have been uncovered within the setting of the 
intestinal epithelium. As discussed throughout each chapter, the intestinal epithelial interface 
is a unique area for inflammatory regulation in the maintenance of homeostasis. Furthermore, 
in addition to their role in maintaining homeostasis, it is only recently that intestinal epithelial 
cells have also been identified as important mediators of the inflammatory response. Many 
PRRs, previously believed not to be expressed in the epithelium are now known to function 
as innate immune activators in these cells, involved either in initiating an inflammatory 
response or in the maintenance of homeostasis. In this thesis, several PRRs have been 
revealed to be involved in the detection of L.monocytogenes in IECs. These novel data not 
only suggested a role for PRRs believed not to be expressed in IECs, but also revealed 
several PRRs to function as regulators of the inflammatory response in IECs.  
In recent years, we have begun to understand the true function of our immune system 
is not to eliminate every non-self organism in our body; rather it is to maintain a homeostatic 
balance between our own bodily functions and those of the various microbes in our 
environment, including our resident commensal bacteria. The intestinal epithelium is a key 
region in regulating this balance. The last decade has revealed several mechanisms for 
regulating PRR activation in IECs. For instance, Single Immunoglobulin (Ig) Interleukin-1R-
Related molecule (SIGIRR) is an Ig-like membrane protein found in IECs [1]. It acts as a 
critical negative regulator of TLR4-mediated signalling. Furthermore, as discussed 
throughout this thesis, the expression patterns of PRRs in IECs are known to modulate to 
avoid inappropriate activation [2-6]. Several mutations in such genes are known to lead to 
autoimmune disorders such as IBD [7-12]. Novel data presented in this thesis have revealed 
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new information pertaining to PRRs involved in curtailing an inflammatory response to the 
invasive pathogen L.monocytogenes in IECs. For instance, NLRC3-5, several NLRP 
receptors and four members of the CLR family were all found to be involved in mediating 
this abrogation of inflammatory gene induction. It is quite possible that several of these PRRs 
may be involved in the maintenance of homeostasis in the unique environment of the gastro-
intestinal tract through the detection of microbial antigens from the bacteria filled lumen. 
Moreover, the involvement of PRRs previously not known to be expressed in IECs requires 
further attention, in particular the CLR family of PRRs, about which we know relatively little 
compared to other PRR families such as the much studied TLRs. Studies have demonstrated 
induction of the bactericidal C-type lectin RegIIIγ in response to MyD88 and TLR signalling 
during L.monocytogenes infection in IECs [13]. However, research has not yet focussed on 
potential regulatory roles for CLRs in maintaining homeostasis in the gastro-intestinal tract. 
Given the function and setting of IECs, we should begin to speculate further about the 
function of these PRRs in the context of maintaining homeostasis and, indeed, their roles in 
autoimmune disorders such as IBD. It is clear that previous detection methods are lacking in 
efficiency and further data are required for a better understanding of innate immune 
signalling in the context of IECs.  
 
7.2 A more comprehensive knowledge of innate immune signalling mechanisms in the 
gut could deliver safe and efficient treatments against autoimmune and pathogenic 
diseases. 
Therapeutic targets in treating IBD require specifically directed treatments to avoid 
undesired side-effects affecting the immune system which may lead to infection or an 
inappropriately increased inflammatory response. Through direct targeting of novel PRRs 
involved in regulating inflammatory responses in IECs, we open possibilities to more 
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precisely treat IBD, thus reducing over-active inflammation in this region. Furthermore, the 
gut is a unique region through which our body may become tolerised to certain antigens [14]. 
In addition to the treatment of over-active inflammatory disorders in the gut, a greater 
knowledge of the innate immune mechanisms through which this mucosal region is regulated 
could also lead us to discover novel mechanisms of inducing systemic tolerance to self-
antigens. Using a broader understanding of innate immune functioning in IECs, for example, 
we may induce tolerance to self-antigens which the body may be inappropriately recognising, 
as in the case of other autoimmune disorders. This may be due to mutations in innate immune 
detection systems which respond inappropriately to self or commensal antigens. If a systemic 
response may be achieved through correct and specific targeting of the innate immune system 
through the gut in this manner, it opens up the possibility of generating vaccines for a whole 
range of auto-immune disorders, such as rheumatoid arthritis or lupus erythematosus. 
Naturally, the ease of vaccine delivery through oral ingestion is an enormous advantage.  
Further to the use of oral vaccines to induce tolerance, there is also an obvious 
advantage to the convenience of cost and administration of oral immune vaccines over the 
currently more commonly used intradermal application. In addition to regulating homeostasis 
and avoiding inappropriate inflammatory responses, we are also becoming increasingly more 
aware of innate immune mechanisms by which a response is initiated in IECs against 
pathogens. These cells, forming a monolayer as an integral part of the intestinal barrier, have 
now also been established to express several intracellular PRRs that detect bacteria and 
mediate an inflammatory immune response [15, 16]. The importance of this physical barrier 
has been highlighted throughout the thesis but cannot be overlooked. While retaining 
homeostasis is crucial in this region with the presence of so many transient and resident 
antigens in the lumenal space, this barrier is also a frontline defence against any potentially 
harmful pathogens that may try to break through. Therefore, when confronted with an 
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invasive pathogen, it is important that the IECs offer the earliest response in order to ready 
the leukocytes of the underlying mucosa and prime a systemic immune response if required. 
A complete understanding of the unique innate signalling mechanisms in the intestinal 
epithelia will offer invaluable assistance in generating efficient adjuvants for vaccine delivery 
through this route [17]. The importance of basic science in this regard is crucial for the 
generation of vaccines directed at initiating an overall systemic cellular response to offer 
protection against pathogenic attack while retaining a balanced response. 
If we are to gain insight into new therapeutic deliveries for existing inflammatory 
disorders, or indeed the development of oral vaccines, further basic scientific research is 
required if we wish to unravel the intricacies of innate immune signalling. In particular, there 
is a clear requirement for an update on expression patterns of PRRs. For example, TLR10 
was previously believed not be expressed in IECs [18]. Several groups have since reported a 
more widespread expression pattern for TLR10 than was originally suggested [18-24]. 
However, this highlights that despite advances in technology, there exist many shortcomings 
in conventional methods of determining expression patterns, such as the use of antibodies, 
which may not always be specific or sensitive enough, for example. This again emphasises 
the importance of other PRRs in these cells, the presence or function of which may have been 
overlooked until now. Moreover, it also illustrates the advantage of siRNA screening 
techniques, such as that used in this thesis, in the contribution of knowledge towards the 
function of genes not known to be expressed in various cell types. The potential issue of 
adequately efficient detection formats not providing us with complete knowledge of 
expression patterns may be avoided by measuring the effects of silencing particular genes in 
cells when challenged with pathogenic attack for example. Novel information on PRR 
expression and function will be fundamental in the advancement of available therapy and 
preventative medicine. 
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Attention has been growing towards the direct targeting of PRRs in treating 
autoimmune disorders [25]. Recent success has been reported having used an IgG antibody 
against TLR2 for the prevention of reperfusion injury following transplantation. Thus far, it 
has proved effective in treatment against myocardial ischemia/reperfusion injury [26] and 
clinical trials have shown positive results in the prevention of reperfusion injury following 
renal transplantation [27]. Targeting TLR2 has also shown promise in reducing inappropriate 
cytokine signalling in rheumatoid arthritis [28]. Genetic analysis studies have shown a 
correlation between certain mutations in TLR10, or in the TLR1-6-10 gene cluster, such as 
nasopharyngeal carcinoma, prostate cancer, non-Hodgkin's lymphoma, asthma, sarcoidosis 
and Crohn's disease [29-37]. It may be possible that specifically targeting TLR10 may result 
in a more directed response against these diseases such as the autoimmune disorder, Crohn‘s 
disease, in the gut. Furthermore, we and other groups have shown that TLR10 is likely to use 
TLR2 in signal transduction. This leaves open the possibility that a more specifically targeted 
therapy directed at blocking TLR2 may be achieved through blocking TLR10 in other 
disorders also. The identification of the specific ligand for TLR10 and each of its signalling 
dimers is essential for these potential treatments.  
 
7.3 It is evident that there exists a high level of complexity involving multi-functional 
PRRs and innate immune cross-talk.  
The evidence of interplay between different PRRs has been growing in recent years. 
Furthermore, it is not acceptable to distinguish PRR functions according to their separate 
families, but rather to examine their role in the broader sense of innate immunology with a 
more open mind. As previously mentioned, TLR activation during L.monocytogenes infection 
in IECs is believed to be responsible for the induction of the bactericidal C-type lectin 
RegIIIγ [13]. Furthermore, as discussed in the Introduction section of this thesis, clear 
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synergy exists between CLR member Dectin-1 and TLR2 [38]. In addition to activation 
synergy, there also exists a level of regulation between PRR families, such as between TLR 
and NLR families. NOD2 activation has been demonstrated to inhibit TLR mediated 
signalling [8] while TLR signalling has also been suggested to reduce NOD1 and NOD2 
responses [39]. Clear examples of how TLR functions may vary between different cell types 
have also been given throughout this thesis [4-7, 40]. Thus, it is also important to recognise 
the setting in which the PRRs are expressed in order to fully understand the context of their 
function. Our finding that TLR10 performs a pro-inflammatory role may not be true for all 
cell types. Our finding that CLEC1B somehow acts to reduce inflammatory responses against 
L.monocytogenes infection in IECs, while it is known to have a pro-inflammatory role in 
phagocytic cells [41], is a specific example of such inter-cellular multi-functionality. It could 
also be possible that TLR10 acts to regulate the activation of an inflammatory response or to 
regulate signalling from other TLRs when various regions of the body are confronted with 
different challenges. 
The multi-faceted role of several PRRs has also by now been well established. 
Particularly in IECs, a regulatory role has been described for several PRRs often associated 
with an inflammatory response. For example, TLR2, TLR9 and NOD2 have all been well 
defined in maintaining a homoeostatic environment in IECs through direct regulation of 
inflammatory responses [4-6, 8-12, 42, 43]. Additionally, MyD88 did not appear to be 
required for mediating an immune response against L.monocytogenes infection in Chapter 5. 
Whilst TLR1, TLR2 and TLR10 were all believed be involved in mediating an inflammatory 
response during this infection, all are believed to require MyD88 for signal transduction [44]. 
This suggests that in this setting MyD88 may be mediating more homeostatic and less pro-
inflammatory responses through the immuno-suppressive effects associated with TLR 
activation in IECs, for example [7]. It could also be the case that TLR10 somehow bypasses 
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the requirement for MyD88-mediated signal transduction for an inflammatory response upon 
ligand recognition, a possibility which charges us with the question of what alternative signal 
transduction pathways TLR10 may be utilising. TLR4 is known to use the TRIF pathway for 
intracellular signalling and the MyD88 pathway for signalling from the plasma membrane 
[45, 46]. TRIF has also recently been implicated in TLR2 signalling [47]. It may be 
interesting to examine more closely potential involvement of TRIF in TLR10-mediated 
signalling. Several NLR proteins other than NOD2, such as NLRP3 and NLRP6, have been 
associated with maintaining a homeostatic environment in this region through maintaining an 
efficient barrier and controlling epithelial cell proliferation [48-53]. The CLR, LY75, has 
previously been implicated in cell adhesion and migration in microvilli in addition to 
phagocytosis in macrophage cells [54] but has been outlined in Chapter 5 to have a potential 
role in mediating an inflammatory response against L.monocytogenes in IECs. Conversely, 
CLRs DC-SIGN and CLEC1B have been associated with the activation of phagocytosis in 
macrophages and PBMCs [41, 55] but have been demonstrated in our data to reduce 
inflammatory responses towards L.monocytogenes in IECs. The novel discovery of the 
TLR10 mediated inflammatory response to intracellular pathogens in IECs should be 
regarded as a potentially important jig-saw piece we have yet to find a place for in the grand 
puzzle of understanding innate immune regulation in this unique environment. TLR10 has 
also recently been identified as mediating PGN-induced apoptosis of trophoblasts [22]. 
Results from research presented in Chapter 6 would suggest that the inflammatory response 
from L.monocytogenes mediated TLR10 activation occurs through the TLR2/TLR10 receptor 
pair, with the possible requirement of CD14. However, future studies need to address the 
function of the TLR1/TLR10 heterodimer in addition to the TLR10/TLR10 homodimer of 
which we are also aware. It is likely that these dimers may be responsible for the detection of 
different specific ligands and, indeed also possible, that these dimers may be involved in the 
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initiation of differential responses, such as apoptosis in the case of trophoblasts [22] or 
potentially initiating a regulatory rather than inflammatory immune response. Such 
potentially differential signalling outcomes are also likely to operate using alternate 
signalling intermediates, another facet of investigation required to elucidate the full extent of 
TLR10 functionality. Furthermore, the potential requirement of CD14 requires further 
examination and draws attention to the importance of these co-receptors in mediating 
efficient and potentially alternate responses from PRR activation. However, elucidation of 
these potential complex differential interplays requires an open mind and careful 
observations. Perhaps a starting point for such studies might involve siRNA screening 
techniques such as the PRR siRNA screen used in Chapter 5. Moreover, several diseases are 
associated with PRR mutations. Examining the functional consequences of these mutations 
and how they lead to disease symptoms and characteristics might reveal novel interplays or 
functionalities of these PRRs. 
 
7.4 Summary and future directions. 
Together with the novel discoveries made throughout the course of this thesis, it has 
been illustrated that there exists a level of inflammatory regulation in the intestinal 
epithelium, perhaps far more complex than we might have previously imagined, which we 
know very little about. We have known for some time now that IECs protect us from invasive 
attack by providing a valuable barrier function and anti-microbial defensin production. We 
have also known that IECs are crucial in the maintenance of homeostasis in the environment 
of the commensal microbe-filled gastro-intestinal tract. However, as more data in this field is 
generated we are learning more and more the concept that, in addition to their barrier 
function, they are also involved in initiating an innate inflammatory immune response against 
pathogenic attack. We are not only discovering that the repertoire of PRRs extends beyond 
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that which we previously believed, but that PRRs also display multi-faceted functioning [40]. 
In other words, the same PRRs involved in pathogen recognition may be involved in 
activation or abrogation of an inflammatory response depending on the context in which they 
themselves are activated. Additionally, factors such as hypoxic gradient may alter the 
expression patterns and functionality of some of these PRRs, but this is an area that has only 
recently been investigated in the context of the intestinal barrier [56]. Moreover, aside from 
internal regulation of innate immune inflammatory responses in the gut, it is clear that we 
also have much to learn concerning potential mechanisms of biomimicry utilised by microbes 
in the subversion of our immune surveillance system. This has been seen in the recent 
discoveries of TIR domain containing proteins in bacteria being involved in hi-jacking our 
TLR signalling mechanisms to aid their own survival. While this has been demonstrated in 
several pathogenic strains of bacteria [57] it has yet to be investigated in the context of 
commensal microbes. Some of these themes concerning IEC interactions in this broader 
context of the gastro-intestinal tract at a molecular level are illustrated in Figure 7.1 below. It 
outlines the differential functionality of PRRs such as CLEC1B when expressed in different 
cell types. Additionally, it displays an example of differential functionality of PRRs such as 
TLR9 depending on their subcellular localisation. A greater understanding of these signalling 
mechanisms will undoubtedly yield a more directed and systemic control over our bodies‘ 
immune functionality. 
252 
 
 
Figure 7.1 Molecular mechanisms of regulating innate immune inflammatory responses 
in the gastro-intestinal tract. Depicted above are commensal bacteria potentially utilising TIR 
domain containing proteins to modulate inflammatory TLR signalling in IECs. PRRs involved in the 
activation and abrogation of an inflammatory response when met with L.monocytogenes in IECs 
infection are also illustrated. This also offers an example of the differential response of PRRs such as 
NLRC4 and CLEC-1B depending on which cell they are expressed in. This is also true of the 
subcellular localisation of PRRs; apical TLR9 sensing of microbial ligands inhibits inflammatory 
signalling induced by basolateral TLRs. This apical/basolateral polarity is strengthened by the steep 
hypoxic gradient between the lumen and the vascular rich mucosa. It is known to promote barrier 
integrity and may regulate PRR expression and function.  
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Table 1 PRR siRNA library sequences 
Gene 
Symbol 
GENE 
ID 
Gene 
Accession 
GI 
Number 
Sequence 
TLR1 7096 NM_003263 41350336 GGCAAUAUGUCUCAACUAA 
TLR1 7096 NM_003263 41350336 CCGCAGUACUCCAUUCCUA 
TLR1 7096 NM_003263 41350336 CCAAUUGCUCAUUUGAAUA 
TLR1 7096 NM_003263 41350336 GUUGAGCACCACACACUUA 
TLR2 7097 NM_003264 68160956 AAAUCUGAGAGCUGCGAUA 
TLR2 7097 NM_003264 68160956 AGGUAAAGUGGAAACGUUA 
TLR2 7097 NM_003264 68160956 UGUUUGGAACUGCGAGAUA 
TLR2 7097 NM_003264 68160956 AGUAGGAAUGCAAUAACUA 
TLR3 7098 NM_003265 19718735 GAACUAAAGAUCAUCGAUU 
TLR3 7098 NM_003265 19718735 CAGCAUCUGUCUUUAAUAA 
TLR3 7098 NM_003265 19718735 AGACCAAUCUCUCAAAUUU 
TLR3 7098 NM_003265 19718735 UCACGCAAUUGGAAGAUUA 
TLR4 7099 NM_138554 88758616 UGGUGGAAGUUGAACGAAU 
TLR4 7099 NM_138554 88758616 GUUUAGAAGUCCAUCGUUU 
TLR4 7099 NM_138554 88758616 CAUUGAAGAAUUCCGAUUA 
TLR4 7099 NM_138554 88758616 GGAAAAUGGUGUAGCCGUU 
TLR5 7100 NM_003268 19718736 AGACAUAUAUUGUGUGUAC 
TLR5 7100 NM_003268 19718736 CACGGAAGGUUGUGAUGAA 
TLR5 7100 NM_003268 19718736 CUUCUUGAGUGGCAAUAAA 
TLR5 7100 NM_003268 19718736 CACAGAACCUGAUAUGUAC 
TLR6 10333 NM_006068 20143970 GGUGAAAAGUGAAUUGGUA 
TLR6 10333 NM_006068 20143970 CAACUAGUUUAUUCGCUAU 
TLR6 10333 NM_006068 20143970 GCACCAAGCACAUUCAAGU 
TLR6 10333 NM_006068 20143970 CCUGUGGAAUAUCUCAAUA 
TLR7 51284 NM_016562 67944638 CAACAACCGGCUUGAUUUA 
TLR7 51284 NM_016562 67944638 GGAAAUUGCCCUCGUUGUU 
TLR7 51284 NM_016562 67944638 GAAUCUAUCACAAGCAUUU 
TLR7 51284 NM_016562 67944638 GGAAUUACUCAUAUGCUAA 
TLR8 51311 NM_016610 20302165 GAACGGAAAUCCCGGUAUA 
TLR8 51311 NM_016610 20302165 CAGAAUAGCAGGCGUAACA 
TLR8 51311 NM_016610 20302165 GUGCAGCAAUCGUCGACUA 
TLR8 51311 NM_016610 20302165 CUUCCAAACUUAUCGACUA 
TLR9 54106 NM_138688 20302170 CAGACUGGGUGUACAACGA 
TLR9 54106 NM_138688 20302170 GCAAUGCACUGGGCCAUAU 
TLR9 54106 NM_138688 20302170 CGGCAACUGUUAUUACAAG 
TLR9 54106 NM_138688 20302170 ACAAUAAGCUGGACCUCUA 
TLR10 81793 NM_001017388 62865620 GCAACGAAAUCUUAGUUUA 
TLR10 81793 NM_001017388 62865620 CGAAUUAUCUUGCAACACA 
TLR10 81793 NM_001017388 62865620 CAACAAGGAGUUAAGAUAU 
TLR10 81793 NM_001017388 62865620 CAUCGGUUCUAUUGCUUAA 
MYD88 4615 NM_002468 19923143 CGACUGAAGUUGUGUGUGU 
MYD88 4615 NM_002468 19923143 GCUAGUGAGCUCAUCGAAA 
MYD88 4615 NM_002468 19923143 GCAUAUGCCUGAGCGUUUC 
MYD88 4615 NM_002468 19923143 GCACCUGUGUCUGGUCUAU 
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Gene 
Symbol 
GENE 
ID 
Gene 
Accession 
GI 
Number 
Sequence 
MHC2TA 4261 NM_000246 73747680 GGCUAAGCUUGUACAAUAA 
MHC2TA 4261 NM_000246 73747680 GAAGUGAUCGGUGAGAGUA 
MHC2TA 4261 NM_000246 73747680 CAAGGCCGACGCCCUAUUU 
BIRC1 4671 NM_004536 4758751 GCAUCGAACUCCAUUUAAA 
BIRC1 4671 NM_004536 4758751 GAACAUUAUCCAGCAGUUA 
BIRC1 4671 NM_004536 4758751 GAGCGAAAUUUAGCUGAAA 
BIRC1 4671 NM_004536 4758751 GUACAAGAUUCCCUGUCUA 
CARD4 10392 NM_006092 5174616 CAAAUCAAUCUCUGAGGUU 
CARD4 10392 NM_006092 5174616 AGAAGCGGAUUAUCUGUUU 
CARD4 10392 NM_006092 5174616 GCAAAGGCCUCACGCAUCU 
CARD4 10392 NM_006092 5174616 GGGUAAAGGUGCUAAGCGA 
CARD15 64127 NM_022162 11545911 GGAAUUACCAGUCCCAUUG 
CARD15 64127 NM_022162 11545911 GCUCUGUAUUUGCGCGAUA 
CARD15 64127 NM_022162 11545911 GGGAAUAACUACAUCACUG 
CARD15 64127 NM_022162 11545911 GUAUGAAUGUGAUGAAAUC 
NOD3 197358 NM_178844 30524927 GCGGAGAACCAGAUCAGUA 
NOD3 197358 NM_178844 30524927 GCUUAGAUUUACAGGAGAA 
NOD3 197358 NM_178844 30524927 GAGCUCAUGUUCUCCAGUA 
NOD3 197358 NM_178844 30524927 GCAACACCGUUAGGGAUGA 
CARD12 58484 NM_021209 40788014 GACAUUACAUCCACUUAUA 
CARD12 58484 NM_021209 40788014 UUAAAGGACUUGUACCAUA 
CARD12 58484 NM_021209 40788014 GCACAUCACAUCUGUAACA 
CARD12 58484 NM_021209 40788014 GUACACAGCAGGACGAAGA 
NLRC5 84166 NM_032206 28951070 GAGAUCAGCUUGGCGGAAA 
NLRC5 84166 NM_032206 28951070 GAGCAGAGCUUCCGGAUUC 
NLRC5 84166 NM_032206 28951070 AGCAGAAGCUUGACGCUCA 
NLRC5 84166 NM_032206 28951070 GGGGUUAGCAGGAAGUAAA 
NALP1 22861 NM_001033053 74271813 GCUAGAAGCAUAUGGAAUA 
NALP1 22861 NM_001033053 74271813 CCAAAUGGCCCACUUUAAA 
NALP1 22861 NM_001033053 74271813 GAUGAAAGGCAAGCAAUUA 
NALP1 22861 NM_001033053 74271813 GAGCUGGACCUAAGUGGAA 
NALP2 55655 NM_017852 8923472 GAAUGUAACCUGCGAUAUC 
NALP2 55655 NM_017852 8923472 GCAAAGAGGUCCAGGUUAU 
NALP2 55655 NM_017852 8923472 GCACUUAAAUGCAGUAGAC 
NALP2 55655 NM_017852 8923472 GCGUAAACCUCUCCGACAA 
CIAS1 114548 NM_183395 34878689 GGAUCAAACUACUCUGUGA 
CIAS1 114548 NM_183395 34878689 UGCAAGAUCUCUCAGCAAA 
CIAS1 114548 NM_183395 34878689 GAAGUGGGGUUCAGAUAAU 
CIAS1 114548 NM_183395 34878689 GCAAGACCAAGACGUGUGA 
NALP4 147945 NM_134444 54792746 GCUCUGACGCAUACGGAUU 
NALP4 147945 NM_134444 54792746 CUGAAAUGCUUCUGCGUAA 
NALP4 147945 NM_134444 54792746 ACAACAAGAAGCUGACGUA 
NALP4 147945 NM_134444 54792746 CCUAUCAAGCUCACGCAAA 
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Gene 
Symbol 
GENE 
ID 
Gene 
Accession 
GI 
Number 
Sequence 
NALP5 126206 NM_153447 32481210 ACACAAGGGUUGCGUGCGA 
NALP5 126206 NM_153447 32481210 AAGUGUGGCUUCCGAUUAA 
NALP5 126206 NM_153447 32481210 GCGUGAAGCUUCUGUGCGA 
NALP5 126206 NM_153447 32481210 CGGUGGUUCUGCACGGAAA 
NALP6 171389 NM_138329 21264319 GCGCCUACCGCUUCGUGAA 
NALP6 171389 NM_138329 21264319 GGGCGCAGUUUGCCGAGAA 
NALP6 171389 NM_138329 21264319 UCUCCGUGUCCGAGUACAA 
NALP6 171389 NM_138329 21264319 GUGCAGACGGUCAGGGUAC 
NALP7 199713 NM_206828 75709195 UGGGAUCGCUCUACGAAUU 
NALP7 199713 NM_206828 75709195 CGACCUGAUUCAAGUAGGA 
NALP7 199713 NM_206828 75709195 CUGUCGAGAGGUAGGAUUU 
NALP7 199713 NM_206828 75709195 GAGAAACAGUCUUUGGUCU 
NALP8 126205 NM_176811 33667039 UGGAGAGGCUGUCGAUAGA 
NALP8 126205 NM_176811 33667039 GCAAGGUGUCUUUCGGUAA 
NALP8 126205 NM_176811 33667039 GGAAAUGGGUGUUAGGUAA 
NALP8 126205 NM_176811 33667039 UCUAAAGACUCUCAUACUA 
NALP9 338321 NM_176820 33519449 GAACAGAGCCCGACUAAAA 
NALP9 338321 NM_176820 33519449 GAACAUUUGGUAAUAGCUU 
NALP9 338321 NM_176820 33519449 UCACAUGGACCUUGGAUUG 
NALP9 338321 NM_176820 33519449 GAAGUCGUAUUUCUCCUAC 
NALP10 338322 NM_176821 78191799 CGCAGGAUCUGAAGCAUUU 
NALP10 338322 NM_176821 78191799 GCUCCUAUUUCACGGAUGA 
NALP10 338322 NM_176821 78191799 GAGAGGCAAAGUUGUCUUA 
NALP10 338322 NM_176821 78191799 GGAGGGCAAAGAUAAUAUA 
NALP11 204801 NM_145007 21450724 AGAAGUAUCUGGCACGCAA 
NALP11 204801 NM_145007 21450724 CGGAAAAGUUGACGCACCA 
NALP11 204801 NM_145007 21450724 GAUCAUUGGCAGACGAAAC 
NALP11 204801 NM_145007 21450724 CAACAUAAGAUUCGAGUUA 
NALP12 91662 NM_033297 15193291 CCAAUAAGAAUUUGACAAG 
NALP12 91662 NM_033297 15193291 GGAUGGACCUGAAUAAAAU 
NALP12 91662 NM_033297 15193291 CUACGGACUUUGUGGCUGA 
NALP12 91662 NM_033297 15193291 GGAUUUGGGCCUGAGGUUA 
NALP13 126204 NM_176810 28827788 CCACGUAUAUAUCCGUAAU 
NALP13 126204 NM_176810 28827788 GAAGGGCUGUGGUCUAUGA 
NALP13 126204 NM_176810 28827788 GAUGUUGGGUCGUAUCUUU 
NALP13 126204 NM_176810 28827788 CUACGUUGGUCACAAAUGA 
NALP14 338323 NM_176822 31543282 GAAUAUGGACUAUGACUUA 
NALP14 338323 NM_176822 31543282 GAUAAGAGGUGGGCCAUGA 
NALP14 338323 NM_176822 31543282 GAAUGAAGAUCGAGUAAAA 
NALP14 338323 NM_176822 31543282 GAAUUGGACCUGUACCAUA 
NOD9 79671 NM_170722 25777609 GCACAUCUUCCGUCGGGAU 
NOD9 79671 NM_170722 25777609 UCGUCAACCUGCUGCGCAA 
NOD9 79671 NM_170722 25777609 CCACACCAGCUCAGCGUGA 
NOD9 79671 NM_170722 25777609 GUGCUGGGUUUGCGCAAGA 
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Gene 
Symbol 
GENE 
ID 
Gene 
Accession 
GI 
Number 
Sequence 
RIPK2 8767 NM_003821 40255024 GAAAUUGCCCUUGGUGUAA 
RIPK2 8767 NM_003821 40255024 GGGAAGACAUUGUGAACCA 
RIPK2 8767 NM_003821 40255024 GGGAAGUGUUAUCCAGAAA 
RIPK2 8767 NM_003821 40255024 GGACAUCGACCUGUUAUUA 
CASP1 834 NM_033295 73622117 GGAAGACUCAUUGAACAUA 
CASP1 834 NM_033295 73622117 GAUGGUAGAGCGCAGAUGC 
CASP1 834 NM_033295 73622117 CCGCAAGGUUCGAUUUUCA 
CASP1 834 NM_033295 73622117 GAGUGACUUUGACAAGAUG 
CD209 30835 NM_021155 22095359 CCAGGCAAGACGCGAUCUA 
CD209 30835 NM_021155 22095359 AGGAAGACUGCGCGGAAUU 
CD209 30835 NM_021155 22095359 GAGGAGAGCCCAACAACGU 
CD209 30835 NM_021155 22095359 GUAAUAAAAUGGCGAGUUG 
CD207 50489 NM_015717 90991711 GGGUGGAUGACACGCCAUU 
CD207 50489 NM_015717 90991711 AGGAUGACUUUGCACGUUA 
CD207 50489 NM_015717 90991711 UCUUUGAGCUCCAACGCUU 
CD207 50489 NM_015717 90991711 GGUAUAGUGCCGAGCAGUU 
CLEC10A 10462 NM_006344 53832015 GGACUGUGCUCACUUCCAU 
CLEC10A 10462 NM_006344 53832015 CUGAAAUGCUCCUGCGAGU 
CLEC10A 10462 NM_006344 53832015 CCUCAAACACUGUGGCGGA 
CLEC10A 10462 NM_006344 53832015 CAGCUUGGAAGAAACGAUA 
CLEC5A 23601 NM_013252 31747574 AGGAUCAGUUUUACGGAAA 
CLEC5A 23601 NM_013252 31747574 GAGAAAAGGUGGCGUUGGA 
CLEC5A 23601 NM_013252 31747574 UGGAUAGUCUCUUAGGCAA 
CLEC5A 23601 NM_013252 31747574 GAGCCAAACACACUAGAUU 
CLEC7A 64581 NM_197954 88999595 CAGGAUAGCUGUUGUUUCA 
CLEC7A 64581 NM_197954 88999595 GGAUGAAGAUGGAUAUACU 
CLEC7A 64581 NM_197954 88999595 GAAGAUGGAUAUACUCAAU 
CLEC7A 64581 NM_197954 88999595 CUUCGACUCUCAAAGCAAU 
MICL 160364 NM_201623 189181661 GAAUAGACUGUGAAUGUUA 
MICL 160364 NM_201623 189181661 CUCUACAACUGAUGAGUAA 
MICL 160364 NM_201623 189181661 GGUAUGAGAGUGGAUAAUA 
MICL 160364 NM_201623 189181661 CCACCAAAUUAUGUCGUGA 
CLEC2 51266 NM_016509 56711305 UAGCAAAGCGCUUCUGUCA 
CLEC2 51266 NM_016509 56711305 GGGAGGAUGGCUCGGUUAU 
CLEC2 51266 NM_016509 56711305 AGCCAGGACUCAUUUAAUU 
CLEC2 51266 NM_016509 56711305 CGGAUUAUCUCGCCAGAAG 
UNQ9341 283420 NM_207345 141803213 GAGUUAAGAACAAACGCAA 
UNQ9341 283420 NM_207345 141803213 AGAAGUAUGCGUUGAGAUC 
UNQ9341 283420 NM_207345 141803213 AGUCUGUGGAUACGUGAAA 
UNQ9341 283420 NM_207345 141803213 CGGAAUGACUGUAACUUUC 
UNQ5782 387837 NM_001129998 194018500 UGUCCAUGGAGGAGGAAUU 
UNQ5782 387837 NM_001129998 194018500 UGACAUUAACUCAGAUUCA 
UNQ5782 387837 NM_001129998 194018500 GCAAGGAAUAACCGAGAUG 
UNQ5782 387837 NM_001129998 194018500 CUAAGAUGUGGCAAUGGUA 
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GENE 
ID 
Gene 
Accession 
GI 
Number 
Sequence 
CLEC6A 93978 NM_001007033 55742773 GAGAAGAAUUACUGACGUA 
CLEC6A 93978 NM_001007033 55742773 GAAGAGAAGGUUUGGUCUA 
CLEC6A 93978 NM_001007033 55742773 GCAAGCAGGGUGUUCGAUA 
CLEC6A 93978 NM_001007033 55742773 GUUAAGAUCUCUCGCUGAU 
CLEC4C 170482 NM_203503 45580691 UGAUGAGCGUUGUGCGAUA 
CLEC4C 170482 NM_203503 45580691 CCAAGUUACGAGAGUAUCA 
CLEC4C 170482 NM_203503 45580691 GGGAUGCAAUCUUGGACUA 
CLEC4C 170482 NM_203503 45580691 CCUGCGUCAUGGAAGGAAA 
CLEC4E 26253 NM_014358 90577173 ACGAGAAAUUUGUGCGCUG 
CLEC4E 26253 NM_014358 90577173 CCUCAAUUAUUUUCGGAUU 
CLEC4E 26253 NM_014358 90577173 CACCAUUUCCUGGGCGUUA 
CLEC4E 26253 NM_014358 90577173 CAAUUUAUUCUAAGCGAAC 
CLECSF6 50856 NM_194448 37577116 AUCCAGAAGGUCAGCGACA 
CLECSF6 50856 NM_194448 37577116 CGGAAAUCACUUAUGCUGA 
CLECSF6 50856 NM_194448 37577116 UGAAUCAGCAUCUUGGCAA 
CLECSF6 50856 NM_194448 37577116 GAAUUUAGGUGGUCUGUCA 
MRC1 4360 NM_002438 4505244 GGAUCGCCCUGAACAGUAA 
MRC1 4360 NM_002438 4505244 GGACAAUGCGCGAGCGUUU 
MRC1 4360 NM_002438 4505244 GCUAUUCACUCAUGAGACA 
MRC1 4360 NM_002438 4505244 GAAGCAAAGUGGAUUACGU 
LY75 4065 NM_002349 4505052 GGGAUAAGGCACAUGCGAA 
LY75 4065 NM_002349 4505052 GGGAAGAAGCUGAACGAUU 
LY75 4065 NM_002349 4505052 UUUCAUAGGCCAUGGCGAA 
LY75 4065 NM_002349 4505052 CGGUAAAUGAGCUGAGAAU 
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Figure 8.1 (a) Plasmid Map for pcDNA 3.1 A Myc/His (adapted from Invitrogen) 
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Figure 8.1 (b) Multiple Cloning Site (MCS) for pcDNA 3.1 A Myc/His (adapted from 
Invitrogen) 
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Table 8.2 TIR domain containing bacterial proteins 
1 Abiotrophia defectiva ATCC 49176 C4G0E7_ABIDE 
2 Acaryochloris marina (strain MBIC 11017) A8ZQA4_ACAM1 
3 Acaryochloris marina (strain MBIC 11017) A8ZQX8_ACAM1 
4 Acaryochloris marina (strain MBIC 11017) B0BZW8_ACAM1 
5 Acaryochloris marina (strain MBIC 11017) B0C5D8_ACAM1 
6 Acaryochloris marina (strain MBIC 11017) B0C8G4_ACAM1 
7 Acaryochloris marina (strain MBIC 11017) B0C978_ACAM1 
8 Acaryochloris marina (strain MBIC 11017) B0CEC7_ACAM1 
9 Acaryochloris marina (strain MBIC 11017) B0CFH1_ACAM1 
10 Acidithiobacillus ferrooxidans (strain ATCC 53993) B5EKQ0_ACIF5 
11 Acidobacteria bacterium (strain Ellin345) Q1IIP0_ACIBL 
12 Acidobacteria bacterium (strain Ellin345) Q1IKX5_ACIBL 
13 Acidovorax sp. (strain JS42) A1W808_ACISJ 
14 Acidovorax sp. (strain JS42) A1W966_ACISJ 
15 Actinosynnema mirum DSM 43827 C0T5V7_9PSEU 
16 Actinosynnema mirum DSM 43827 C0TBX5_9PSEU 
17 Agrobacterium tumefaciens O52292_9RHIZ 
18 Algoriphagus sp. PR1 A3I187_9SPHI 
19 Algoriphagus sp. PR1 A3I1A7_9SPHI 
20 Algoriphagus sp. PR1 A3I2H7_9SPHI 
21 Alteromonadales bacterium TW-7 A0Y5N5_9GAMM 
22 Alteromonadales bacterium TW-7 A0Y5W7_9GAMM 
23 Anabaena sp. (strain PCC 7120) Q8YWN0_ANASP 
24 Anabaena variabilis (strain ATCC 29413 / PCC 7937) Q3M5F3_ANAVT 
25 Anabaena variabilis (strain ATCC 29413 / PCC 7937) Q3M6G5_ANAVT 
26 Anabaena variabilis (strain ATCC 29413 / PCC 7937) Q3M6G6_ANAVT 
27 Anaeromyxobacter sp. (strain Fw109-5) A7HHI0_ANADF 
28 Anaeromyxobacter sp. (strain Fw109-5) A7HHI1_ANADF 
29 Arthrobacter chlorophenolicus (strain A6 / ATCC 700700 / DSM 12829 / JCM 12360) B8HJ58_ARTCA 
30 Arthrobacter nitroguajacolicus A4V8K8_9MICC 
31 Azoarcus sp. (strain BH72) A1K4X6_AZOSB 
32 Azoarcus sp. (strain BH72) A1K8M8_AZOSB 
33 Azoarcus sp. (strain BH72) A1K8Q9_AZOSB 
34 Bacillus anthracis Q81R77_BACAN 
35 Bacillus anthracis (strain CDC 684 / NRRL 3495) C3LKC8_BACAC 
36 Bacillus cereus 172560W C2P7Y4_BACCE 
37 Bacillus cereus 95/8201 C2TFW9_BACCE 
38 Bacillus cereus A1BYI4_BACCE 
39 Bacillus cereus A1BZT6_BACCE 
40 Bacillus cereus AH621 C2PY00_BACCE 
41 Bacillus cereus AH676 C2YJM0_BACCE 
42 Bacillus cereus ATCC 10876 C2N145_BACCE 
43 Bacillus cereus BDRD-Cer4 C2T6L0_BACCE 
44 Bacillus cereus BDRD-ST26 C2SCP6_BACCE 
45 Bacillus cereus F65185 C2XMK4_BACCE 
46 Bacillus cereus H3081.97 B5Z5J6_BACCE 
47 Bacillus cereus NVH0597-99 B3Z968_BACCE 
48 Bacillus cereus R309803 C2QHL7_BACCE 
49 Bacillus cereus Rock3-42 C2VT33_BACCE 
50 Bacillus cereus (strain AH187) B7I119_BACC7 
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51 Bacillus cereus (strain AH820) B7JLM7_BACC0 
52 Bacillus cereus (strain AH820) B7JU61_BACC0 
53 Bacillus cereus (strain ATCC 14579 / DSM 31) Q817S7_BACCR 
54 Bacillus cereus (strain G9842) B7ITS9_BACC2 
55 Bacillus cereus (strain ZK / E33L) Q63BZ9_BACCZ 
56 Bacillus cereus W B3YTA2_BACCE 
57 Bacillus mycoides Rock3-17 C3B0W1_BACMY 
58 Bacillus subtilis YDDK_BACSU 
59 Bacillus thuringiensis serovar andalousiensis BGSC 4AW1 C3G2D4_BACTU 
60 Bacillus thuringiensis serovar andalousiensis BGSC 4AW1 C3GCI3_BACTU 
61 Bacillus thuringiensis serovar monterrey BGSC 4AJ1 C3F103_BACTU 
62 Bacillus thuringiensis serovar pondicheriensis BGSC 4BA1 C3GI95_BACTU 
63 Bacillus thuringiensis serovar pulsiensis BGSC 4CC1 C3HH54_BACTU 
64 bacterium Ellin514 B9XJV3_9BACT 
65 bacterium Ellin514 B9XT12_9BACT 
66 Bacteroides dorei DSM 17855 B6VVW8_9BACE 
67 Bacteroides ovatus ATCC 8483 A7LTE8_BACOV 
68 Bacteroides ovatus ATCC 8483 A7M4L8_BACOV 
69 Bacteroides ovatus ATCC 8483 A7M4L9_BACOV 
70 Bacteroides sp. 2_2_4 C3QSH1_9BACE 
71 Bacteroides sp. 2_2_4 C3R0H4_9BACE 
72 Bacteroides sp. D1 C3QAR9_9BACE 
73 Bacteroides sp. D4 C3RB07_9BACE 
74 Bacteroides thetaiotaomicron Q8A3F1_BACTN 
75 Bacteroides uniformis ATCC 8492 A7UZK0_BACUN 
76 Bacteroides vulgatus (strain ATCC 8482 / DSM 1447 / NCTC 11154) A6L6F9_BACV8 
77 Beggiatoa sp. PS A7BQY8_9GAMM 
78 Beggiatoa sp. PS A7BWJ5_9GAMM 
79 Beijerinckia indica subsp. indica (strain ATCC 9039 / DSM 1715 / NCIB 8712) B2ILB7_BEII9 
80 Bifidobacterium longum subsp. infantis CCUG 52486 C5ECT5_BIFLO 
81 Blautia hansenii DSM 20583 B7XY17_RUMHA 
82 Bordetella bronchiseptica Q7WQ48_BORBR 
83 Bradyrhizobium sp. (strain BTAi1 / ATCC BAA-1182) A5EGM8_BRASB 
84 Bradyrhizobium sp. (strain BTAi1 / ATCC BAA-1182) A5EU74_BRASB 
85 Bradyrhizobium sp. (strain ORS278) A4YL05_BRASO 
86 Bradyrhizobium sp. (strain ORS278) A4YQ51_BRASO 
87 Brevibacillus brevis (strain 47 / JCM 6285 / NBRC 100599) C0ZIP1_BREBN 
88 Brucella abortus Q57E10_BRUAB 
89 Brucella abortus Q57FA5_BRUAB 
90 Brucella abortus str. 2308 A C4IP75_BRUAB 
91 Brucella abortus str. 2308 A C4IQ27_BRUAB 
92 Brucella abortus (strain 2308) Q2YN91_BRUA2 
93 Brucella abortus (strain 2308) Q2YPC4_BRUA2 
94 Brucella abortus (strain S19) B2S4Y7_BRUA1 
95 Brucella abortus (strain S19) B2S8Z8_BRUA1 
96 Brucella canis (strain ATCC 23365 / NCTC 10854) A9MAB8_BRUC2 
97 Brucella ceti str. Cudo C0G5K2_9RHIZ 
98 Brucella melitensis biotype 2 (strain ATCC 23457) C0RGW8_BRUMB 
99 Brucella melitensis Q8YF53_BRUME 
100 Brucella ovis (strain ATCC 25840 / 63/290 / NCTC 10512) A5VNJ7_BRUO2 
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101 Brucella ovis (strain ATCC 25840 / 63/290 / NCTC 10512) A5VPS1_BRUO2 
102 Brucella suis Q8G1I0_BRUSU 
103 Brucella suis (strain ATCC 23445 / NCTC 10510) B0CJM4_BRUSI 
104 Brucella suis (strain ATCC 23445 / NCTC 10510) B0CL60_BRUSI 
105 Burkholderia ambifaria (strain MC40-6) B1YX30_BURA4 
106 Burkholderia glumae BGR1 C5ADB1_BURGL 
107 Burkholderia multivorans (strain ATCC 17616 / 249) A9AIH1_BURM1 
108 Burkholderia thailandensis (strain E264 / ATCC 700388 / DSM 13276 / CIP 106301) Q2STL3_BURTA 
109 Burkholderia xenovorans (strain LB400) Q13FM1_BURXL 
110 Campylobacter coli RM2228 Q4HDI4_CAMCO 
111 Capnocytophaga ochracea DSM 7271 C1QKW6_CAPOC 
112 Catenulispora acidiphila DSM 44928 C1QPT7_9ACTO 
113 Catenulispora acidiphila DSM 44928 C1QPT9_9ACTO 
114 Catenulispora acidiphila DSM 44928 C1QVU3_9ACTO 
115 Caulobacter crescentus Q9A8E1_CAUCR 
116 Caulobacter crescentus (strain NA1000 / CB15N) B8H592_CAUCN 
117 Caulobacter sp. (strain K31) B0SV40_CAUSK 
118 Chlorobaculum parvum (strain NCIB 8327) B3QMC2_CHLP8 
119 Chlorobaculum parvum (strain NCIB 8327) B3QNJ9_CHLP8 
120 Chlorobaculum parvum (strain NCIB 8327) B3QPF1_CHLP8 
121 Chlorobium ferrooxidans DSM 13031 Q0YTA6_9CHLB 
122 Chlorobium limicola (strain DSM 245 / NBRC 103803) B3EDA8_CHLL2 
123 Chlorobium phaeobacteroides (strain BS1) B3EQ75_CHLPB 
124 Chlorobium phaeobacteroides (strain DSM 266) A1BCV0_CHLPD 
125 Chlorobium phaeobacteroides (strain DSM 266) A1BD62_CHLPD 
126 Chlorobium phaeobacteroides (strain DSM 266) A1BER4_CHLPD 
127 Chlorobium phaeobacteroides (strain DSM 266) A1BEW4_CHLPD 
128 Chlorobium phaeobacteroides (strain DSM 266) A1BEX3_CHLPD 
129 Chlorobium phaeobacteroides (strain DSM 266) A1BG03_CHLPD 
130 Chlorobium tepidum Q8KCF6_CHLTE 
131 Chlorobium tepidum Q8KDK2_CHLTE 
132 Chloroflexus aurantiacus (strain ATCC 29364 / DSM 637 / Y-400-fl) B9LJZ6_CHLSY 
133 Chloroflexus aurantiacus (strain ATCC 29366 / DSM 635 / J-10-fl) A9WHX9_CHLAA 
134 Chloroherpeton thalassium (strain ATCC 35110 / GB-78) B3QW13_CHLT3 
135 Chloroherpeton thalassium (strain ATCC 35110 / GB-78) B3QZ81_CHLT3 
136 Chthoniobacter flavus Ellin428 B4CWT1_9BACT 
137 Chthoniobacter flavus Ellin428 B4CYW5_9BACT 
138 Clostridium beijerinckii (strain ATCC 51743 / NCIMB 8052) A6LX75_CLOB8 
139 Clostridium beijerinckii (strain ATCC 51743 / NCIMB 8052) A6LX76_CLOB8 
140 Clostridium bolteae ATCC BAA-613 A8RK35_9CLOT 
141 Clostridium bolteae ATCC BAA-613 A8RZZ9_9CLOT 
142 Clostridium botulinum (strain Eklund 17B / Type B) B2TJC8_CLOBB 
143 Clostridium butyricum 5521 B1QWU9_CLOBU 
144 Clostridium butyricum 5521 B1QWV1_CLOBU 
145 Clostridium butyricum E4 str. BoNT E BL5262 C4IHA9_CLOBU 
146 Clostridium butyricum E4 str. BoNT E BL5262 C4IHB1_CLOBU 
147 Clostridium hylemonae DSM 15053 C0BZ05_9CLOT 
148 Clostridium perfringens B str. ATCC 3626 B1R789_CLOPE 
149 Clostridium sp. M62/1 C0FML8_9CLOT 
150 Clostridium thermocellum DSM 4150 B4BDH0_CLOTM 
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151 Clostridium thermocellum (strain ATCC 27405 / DSM 1237) A3DEI8_CLOTH 
152 Clostridium thermocellum (strain ATCC 27405 / DSM 1237) A3DFE7_CLOTH 
153 Colwellia psychrerythraea (strain 34H / ATCC BAA-681) Q484I8_COLP3 
154 Colwellia psychrerythraea (strain 34H / ATCC BAA-681) Q488J9_COLP3 
155 Congregibacter litoralis KT71 A4ACG4_9GAMM 
156 Coprococcus eutactus ATCC 27759 A8SY38_9FIRM 
157 Coprococcus eutactus ATCC 27759 A8SY52_9FIRM 
158 Cyanothece sp. PCC 7822 B4B2I6_9CHRO 
159 Cyanothece sp. PCC 8802 B4BUR4_9CHRO 
160 Cyanothece sp. PCC 8802 B4BVU7_9CHRO 
161 Cyanothece sp. PCC 8802 B4BYU0_9CHRO 
162 Cyanothece sp. PCC 8802 B4BZP7_9CHRO 
163 Cyanothece sp. PCC 8802 B4C3A5_9CHRO 
164 Cyanothece sp. PCC 8802 B4C520_9CHRO 
165 Cyanothece sp. (strain ATCC 51142) B1WZ79_CYAA5 
166 Cyanothece sp. (strain PCC 7424) B7K6V7_CYAP7 
167 Cyanothece sp. (strain PCC 7424) B7K6V8_CYAP7 
168 Cyanothece sp. (strain PCC 7424) B7K751_CYAP7 
169 Cyanothece sp. (strain PCC 7424) B7K9I0_CYAP7 
170 Cyanothece sp. (strain PCC 7424) B7K9I1_CYAP7 
171 Cyanothece sp. (strain PCC 7424) B7K9N6_CYAP7 
172 Cyanothece sp. (strain PCC 7424) B7K9Q8_CYAP7 
173 Cyanothece sp. (strain PCC 7424) B7KBC3_CYAP7 
174 Cyanothece sp. (strain PCC 7424) B7KBK1_CYAP7 
175 Cyanothece sp. (strain PCC 7424) B7KCU4_CYAP7 
176 Cyanothece sp. (strain PCC 7424) B7KD29_CYAP7 
177 Cyanothece sp. (strain PCC 7424) B7KEE8_CYAP7 
178 Cyanothece sp. (strain PCC 7424) B7KFY0_CYAP7 
179 Cyanothece sp. (strain PCC 7424) B7KJH4_CYAP7 
180 Cyanothece sp. (strain PCC 7424) B7KJY5_CYAP7 
181 Cyanothece sp. (strain PCC 7424) B7KMW7_CYAP7 
182 Cyanothece sp. (strain PCC 7424) B7KMW9_CYAP7 
183 Cyanothece sp. (strain PCC 7425 / ATCC 29141) B8HMW8_CYAP4 
184 Cyanothece sp. (strain PCC 7425 / ATCC 29141) B8HPE5_CYAP4 
185 Cyanothece sp. (strain PCC 7425 / ATCC 29141) B8HVB7_CYAP4 
186 Cyanothece sp. (strain PCC 8801) B7JVD1_CYAP8 
187 Cyanothece sp. (strain PCC 8801) B7JVT5_CYAP8 
188 Cyanothece sp. (strain PCC 8801) B7JZR8_CYAP8 
189 Cyanothece sp. (strain PCC 8801) B7K1R3_CYAP8 
190 Cyanothece sp. (strain PCC 8801) B7K2J6_CYAP8 
191 Cyanothece sp. (strain PCC 8801) B7K3U9_CYAP8 
192 Cyanothece sp. (strain PCC 8801) B7K4M2_CYAP8 
193 Cyanothece sp. (strain PCC 8801) B7K5H1_CYAP8 
194 Dechloromonas aromatica (strain RCB) Q47A02_DECAR 
195 Dechloromonas aromatica (strain RCB) Q47BW0_DECAR 
196 Dechloromonas aromatica (strain RCB) Q47DY5_DECAR 
197 Desulfatibacillum alkenivorans (strain AK-01) B8F9F4_DESAA 
198 Desulfatibacillum alkenivorans (strain AK-01) B8FEW8_DESAA 
199 Desulfitobacterium hafniense (strain Y51) Q24NL9_DESHY 
200 Desulfitobacterium hafniense (strain Y51) Q24TJ9_DESHY 
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201 Desulfobacterium autotrophicum (strain ATCC 43914 / DSM 3382 / HRM2) C0QC05_DESAH 
202 Desulfococcus oleovorans (strain DSM 6200 / Hxd3) A8ZZH8_DESOH 
203 Desulfococcus oleovorans (strain DSM 6200 / Hxd3) A9A029_DESOH 
204 Desulfonatronospira thiodismutans ASO3-1 C0GPH8_9DELT 
205 Desulfuromonas acetoxidans DSM 684 Q1JX43_DESAC 
206 Diaphorobacter sp. (strain TPSY) B9MGR6_DIAST 
207 Dorea formicigenerans ATCC 27755 B0G6J3_9FIRM 
208 Dorea longicatena DSM 13814 A6BKR7_9FIRM 
209 Erythrobacter litoralis (strain HTCC2594) Q2NDU5_ERYLH 
210 Erythrobacter sp. NAP1 A3WA93_9SPHN 
211 Erythrobacter sp. NAP1 A3WB86_9SPHN 
212 Erythrobacter sp. NAP1 A3WHL2_9SPHN 
213 Erythrobacter sp. SD-21 A5P909_9SPHN 
214 Erythrobacter sp. SD-21 A5PAK2_9SPHN 
215 Escherichia coli O6:K15:H31 (strain 536 / UPEC) Q0TGL3_ECOL5 
216 Escherichia coli O6 Q8FGH9_ECOL6 
217 Escherichia coli O7:K1 (strain IAI39 / ExPEC) B7NL44_ECO7I 
218 Escherichia sp. 3_2_53FAA C1HM08_9ESCH 
219 Eubacterium eligens (strain ATCC 27750 / VPI C15-48) C4Z355_9FIRM 
220 Eubacterium hallii DSM 3353 C0ESW3_9FIRM 
221 Eubacterium siraeum DSM 15702 B0MKZ3_9FIRM 
222 Eubacterium siraeum DSM 15702 B0MMI9_9FIRM 
223 Faecalibacterium prausnitzii M21/2 A8S996_9FIRM 
224 Finegoldia magna (strain ATCC 29328) B0S0S4_FINM2 
225 Flavobacteria bacterium BBFL7 Q26CI6_9BACT 
226 Frankia alni (strain ACN14a) Q0REB5_FRAAA 
227 Frankia alni (strain ACN14a) Q0REH0_FRAAA 
228 Frankia alni (strain ACN14a) Q0REH8_FRAAA 
229 Frankia alni (strain ACN14a) Q0RF07_FRAAA 
230 Frankia alni (strain ACN14a) Q0RFT3_FRAAA 
231 Frankia alni (strain ACN14a) Q0RFV3_FRAAA 
232 Frankia alni (strain ACN14a) Q0RGM6_FRAAA 
233 Frankia alni (strain ACN14a) Q0RI85_FRAAA 
234 Frankia alni (strain ACN14a) Q0RIN9_FRAAA 
235 Frankia alni (strain ACN14a) Q0RIR9_FRAAA 
236 Frankia alni (strain ACN14a) Q0RIT4_FRAAA 
237 Frankia alni (strain ACN14a) Q0RIX3_FRAAA 
238 Frankia alni (strain ACN14a) Q0RKI0_FRAAA 
239 Frankia alni (strain ACN14a) Q0RNC0_FRAAA 
240 Frankia alni (strain ACN14a) Q0RPP6_FRAAA 
241 Frankia alni (strain ACN14a) Q0RPX3_FRAAA 
242 Frankia alni (strain ACN14a) Q0RPX4_FRAAA 
243 Frankia alni (strain ACN14a) Q0RRH7_FRAAA 
244 Frankia alni (strain ACN14a) Q0RSJ2_FRAAA 
245 Frankia alni (strain ACN14a) Q0RSZ9_FRAAA 
246 Frankia alni (strain ACN14a) Q0RT62_FRAAA 
247 Frankia alni (strain ACN14a) Q0RTF6_FRAAA 
248 Frankia sp. (strain CcI3) Q2J5A8_FRASC 
249 Frankia sp. (strain CcI3) Q2J7D9_FRASC 
250 Frankia sp. (strain CcI3) Q2J7E9_FRASC 
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251 Frankia sp. (strain CcI3) Q2J8P0_FRASC 
252 Frankia sp. (strain CcI3) Q2JBL6_FRASC 
253 Frankia sp. (strain CcI3) Q2JCV5_FRASC 
254 Frankia sp. (strain CcI3) Q2JEN2_FRASC 
255 Frankia sp. (strain CcI3) Q2JGC9_FRASC 
256 Frankia sp. (strain EAN1pec) A8KXQ9_FRASN 
257 Frankia sp. (strain EAN1pec) A8KZ03_FRASN 
258 Frankia sp. (strain EAN1pec) A8L0X3_FRASN 
259 Frankia sp. (strain EAN1pec) A8L102_FRASN 
260 Frankia sp. (strain EAN1pec) A8L106_FRASN 
261 Frankia sp. (strain EAN1pec) A8L235_FRASN 
262 Frankia sp. (strain EAN1pec) A8L2D0_FRASN 
263 Frankia sp. (strain EAN1pec) A8L2Q4_FRASN 
264 Frankia sp. (strain EAN1pec) A8L472_FRASN 
265 Frankia sp. (strain EAN1pec) A8L7E0_FRASN 
266 Frankia sp. (strain EAN1pec) A8L863_FRASN 
267 Frankia sp. (strain EAN1pec) A8L8F6_FRASN 
268 Frankia sp. (strain EAN1pec) A8L8G1_FRASN 
269 Frankia sp. (strain EAN1pec) A8L8G2_FRASN 
270 Frankia sp. (strain EAN1pec) A8L8G9_FRASN 
271 Frankia sp. (strain EAN1pec) A8LA46_FRASN 
272 Frankia sp. (strain EAN1pec) A8LG62_FRASN 
273 Frankia sp. (strain EAN1pec) A8LG86_FRASN 
274 Frankia sp. (strain EAN1pec) A8LG93_FRASN 
275 Frankia sp. (strain EAN1pec) A8LGL3_FRASN 
276 Frankia sp. (strain EAN1pec) A8LGX9_FRASN 
277 Fusobacterium nucleatum subsp. nucleatum Q8RFH6_FUSNN 
278 Fusobacterium nucleatum subsp. polymorphum ATCC 10953 A5TW81_FUSNP 
279 Fusobacterium nucleatum subsp. vincentii ATCC 49256 Q7P7J3_FUSNV 
280 Fusobacterium sp. 4_1_13 C3WSB4_9FUSO 
281 Fusobacterium sp. 7_1 C3WUA1_9FUSO 
282 gamma proteobacterium HTCC5015 B5JTY8_9GAMM 
283 gamma proteobacterium HTCC5015 B5JV79_9GAMM 
284 gamma proteobacterium NOR5-3 B8KL00_9GAMM 
285 Gemmatimonas aurantiaca (strain T-27 / DSM 14586 / JCM 11422 / NBRC 100505) C1ADH7_GEMAT 
286 Geobacter lovleyi (strain ATCC BAA-1151 / DSM 17278 / SZ) B3E9D8_GEOLS 
287 Geobacter lovleyi (strain ATCC BAA-1151 / DSM 17278 / SZ) B3EB23_GEOLS 
288 Geobacter metallireducens (strain GS-15 / ATCC 53774 / DSM 7210) Q39WD7_GEOMG 
289 Geobacter metallireducens (strain GS-15 / ATCC 53774 / DSM 7210) Q39WE1_GEOMG 
290 Geobacter sp. (strain FRC-32) B9M1H6_GEOSF 
291 Geobacter sulfurreducens Q749Z9_GEOSL 
292 Geobacter uraniireducens (strain Rf4) A5G548_GEOUR 
293 Geobacter uraniireducens (strain Rf4) A5GF28_GEOUR 
294 Geodermatophilus obscurus DSM 43160 C0U2U1_9ACTO 
295 Geodermatophilus obscurus DSM 43160 C0U6E5_9ACTO 
296 Geodermatophilus obscurus DSM 43160 C0U6V3_9ACTO 
297 Geodermatophilus obscurus DSM 43160 C0U754_9ACTO 
298 Geodermatophilus obscurus DSM 43160 C0U991_9ACTO 
299 Geodermatophilus obscurus DSM 43160 C0U9P3_9ACTO 
300 Gloeobacter violaceus Q7NE51_GLOVI 
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301 Haemophilus parasuis serovar 5 (strain SH0165) B8F7Y2_HAEPS 
302 Haliangium ochraceum DSM 14365 C1URW1_9DELT 
303 Helicobacter pullorum MIT 98-5489 C5F1P7_9HELI 
304 Herminiimonas arsenicoxydans A4G5B3_HERAR 
305 Hydrogenivirga sp. 128-5-R1-1 A8UX53_9AQUI 
306 Hyphomonas neptunium (strain ATCC 15444) Q0C4A7_HYPNA 
307 Janthinobacterium sp. (strain Marseille) (Minibacterium massiliensis) A6T1M2_JANMA 
308 Kordia algicida OT-1 A9DMA4_9FLAO 
309 Leptothrix cholodnii (strain ATCC 51168 / LMG 8142 / SP-6) B1XZU8_LEPCP 
310 Leptothrix cholodnii (strain ATCC 51168 / LMG 8142 / SP-6) B1Y6N4_LEPCP 
311 Leuconostoc mesenteroides subsp. mesenteroides (strain ATCC 8293 / NCDO 523) Q03X98_LEUMM 
312 Limnobacter sp. MED105 A6GUE8_9BURK 
313 Limnobacter sp. MED105 A6GUW5_9BURK 
314 Magnetospirillum magneticum AMB-1 Q2W1R2_MAGMM 
315 Manganese-oxidizing bacterium (strain SI85-9A1) Q1YGV4_MOBAS 
316 Maricaulis maris (strain MCS10) Q0ALB9_MARMM 
317 marine gamma proteobacterium HTCC2080 A0Z485_9GAMM 
318 Marinobacter algicola DG893 A6F385_9ALTE 
319 Marinobacter aquaeolei (strain ATCC 700491 / DSM 11845 / VT8) A1U034_MARAV 
320 Marinomonas sp. MED121 A3Y9R2_9GAMM 
321 Mariprofundus ferrooxydans PV-1 Q0EWQ0_9PROT 
322 Mariprofundus ferrooxydans PV-1 Q0F0H5_9PROT 
323 Methanococcoides burtonii (strain DSM 6242) Q12US3_METBU 
324 Methanococcoides burtonii (strain DSM 6242) Q12YL2_METBU 
325 Methanosarcina barkeri (strain Fusaro / DSM 804) Q46EG7_METBF 
326 Methanosarcina barkeri (strain Fusaro / DSM 804) Q46F16_METBF 
327 Methylobacterium chloromethanicum (strain CM4 / NCIMB 13688) B7L2V6_METC4 
328 Methylobacterium chloromethanicum (strain CM4 / NCIMB 13688) B7L2W0_METC4 
329 Methylobacterium chloromethanicum (strain CM4 / NCIMB 13688) B7L2Y1_METC4 
330 Methylobacterium chloromethanicum (strain CM4 / NCIMB 13688) B7L3I7_METC4 
331 Methylobacterium extorquens (strain ATCC 14718 / DSM 1338 / AM1) C5B6R7_METEX 
332 Methylobacterium extorquens (strain PA1) A9W413_METEP 
333 Methylobacterium nodulans (strain ORS2060 / LMG 21967) B8IV87_METNO 
334 Methylobacterium nodulans (strain ORS2060 / LMG 21967) B8IXX4_METNO 
335 Methylobacterium populi (strain ATCC BAA-705 / NCIMB 13946 / BJ001) B1ZF35_METPB 
336 Methylococcus capsulatus Q602Q0_METCA 
337 Methylophaga thiooxidans C0N9D3_9GAMM 
338 Microcoleus chthonoplastes PCC 7420 B4VH43_9CYAN 
339 Microcoleus chthonoplastes PCC 7420 B4VH44_9CYAN 
340 Microcoleus chthonoplastes PCC 7420 B4VIZ2_9CYAN 
341 Microcoleus chthonoplastes PCC 7420 B4VJM6_9CYAN 
342 Microcoleus chthonoplastes PCC 7420 B4VL88_9CYAN 
343 Microcoleus chthonoplastes PCC 7420 B4VPI4_9CYAN 
344 Microcoleus chthonoplastes PCC 7420 B4VR58_9CYAN 
345 Microcoleus chthonoplastes PCC 7420 B4VS12_9CYAN 
346 Microcoleus chthonoplastes PCC 7420 B4VSH8_9CYAN 
347 Microcoleus chthonoplastes PCC 7420 B4VTX6_9CYAN 
348 Microcoleus chthonoplastes PCC 7420 B4VXA1_9CYAN 
349 Microcoleus chthonoplastes PCC 7420 B4VXV2_9CYAN 
350 Microcoleus chthonoplastes PCC 7420 B4VY01_9CYAN 
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351 Microcoleus chthonoplastes PCC 7420 B4W0R0_9CYAN 
352 Microcoleus chthonoplastes PCC 7420 B4W502_9CYAN 
353 Microcystis aeruginosa PCC 7806 A8YCI0_MICAE 
354 Microcystis aeruginosa PCC 7806 A8YJP3_MICAE 
355 Microcystis aeruginosa PCC 7806 A8YJP4_MICAE 
356 Microcystis aeruginosa PCC 7806 A8YKR2_MICAE 
357 Microcystis aeruginosa PCC 7806 A8YMR4_MICAE 
358 Microcystis aeruginosa (strain NIES-843) B0JFU8_MICAN 
359 Microcystis aeruginosa (strain NIES-843) B0JFU9_MICAN 
360 Microcystis aeruginosa (strain NIES-843) B0JHN4_MICAN 
361 Microcystis aeruginosa (strain NIES-843) B0JKB2_MICAN 
362 Microcystis aeruginosa (strain NIES-843) B0JNX3_MICAN 
363 Microcystis aeruginosa (strain NIES-843) B0JQF5_MICAN 
364 Micromonospora sp. ATCC 39149 C4RNC8_9ACTO 
365 Mycobacterium sp. (strain KMS) A1UCZ8_MYCSK 
366 Mycobacterium sp. (strain MCS) Q1BC00_MYCSS 
367 Nitrobacter winogradskyi (strain Nb-255 / ATCC 25391) Q3SW17_NITWN 
368 Nitrococcus mobilis Nb-231 A4BPP6_9GAMM 
369 Nitrosococcus oceani AFC27 B6C6I1_9GAMM 
370 Nitrosococcus oceani (strain ATCC 19707 / NCIMB 11848) Q3JF60_NITOC 
371 Nodularia spumigena CCY 9414 A0ZGX8_NODSP 
372 Nodularia spumigena CCY 9414 A0ZJM4_NODSP 
373 Nostoc punctiforme (strain ATCC 29133 / PCC 73102) B2IT78_NOSP7 
374 Nostoc punctiforme (strain ATCC 29133 / PCC 73102) B2IT96_NOSP7 
375 Nostoc punctiforme (strain ATCC 29133 / PCC 73102) B2IUT6_NOSP7 
376 Nostoc punctiforme (strain ATCC 29133 / PCC 73102) B2IVL0_NOSP7 
377 Nostoc punctiforme (strain ATCC 29133 / PCC 73102) B2IXB5_NOSP7 
378 Nostoc punctiforme (strain ATCC 29133 / PCC 73102) B2J0H4_NOSP7 
379 Nostoc punctiforme (strain ATCC 29133 / PCC 73102) B2J0I1_NOSP7 
380 Nostoc punctiforme (strain ATCC 29133 / PCC 73102) B2J919_NOSP7 
381 Nostoc punctiforme (strain ATCC 29133 / PCC 73102) B2J9B9_NOSP7 
382 Nostoc punctiforme (strain ATCC 29133 / PCC 73102) B2J9C0_NOSP7 
383 Oenococcus oeni ATCC BAA-1163 A0NHY7_OENOE 
384 Oenococcus oeni (strain BAA-331 / PSU-1) Q04DI5_OENOB 
385 Oligotropha carboxidovorans (strain ATCC 49405 / DSM 1227 / OM5) B6JHA2_OLICO 
386 Opitutus terrae (strain DSM 11246 / PB90-1) B1ZSG7_OPITP 
387 Oribacterium sinus F0268 C2KUX3_9FIRM 
388 Oribacterium sinus F0268 C2KYG0_9FIRM 
389 Parabacteroides johnsonii DSM 18315 B7BBI1_9PORP 
390 Paracoccus denitrificans (strain Pd 1222) A1AY86_PARDP 
391 Parvibaculum lavamentivorans (strain DS-1 / DSM 13023 / NCIMB 13966) A7HRR1_PARL1 
392 Pelobacter carbinolicus (strain DSM 2380 / Gra Bd 1) Q3A0F4_PELCD 
393 Pelobacter carbinolicus (strain DSM 2380 / Gra Bd 1) Q3A0F6_PELCD 
394 Pelodictyon phaeoclathratiforme (strain DSM 5477 / BU-1) B4SA08_PELPB 
395 Pelodictyon phaeoclathratiforme (strain DSM 5477 / BU-1) B4SBS9_PELPB 
396 Pelodictyon phaeoclathratiforme (strain DSM 5477 / BU-1) B4SBT3_PELPB 
397 Pelodictyon phaeoclathratiforme (strain DSM 5477 / BU-1) B4SC50_PELPB 
398 Pelodictyon phaeoclathratiforme (strain DSM 5477 / BU-1) B4SC53_PELPB 
399 Pelodictyon phaeoclathratiforme (strain DSM 5477 / BU-1) B4SEB5_PELPB 
400 Pelodictyon phaeoclathratiforme (strain DSM 5477 / BU-1) B4SFR7_PELPB 
  
272 
 
401 Pelodictyon phaeoclathratiforme (strain DSM 5477 / BU-1) B4SGS9_PELPB 
402 Pelodictyon phaeoclathratiforme (strain DSM 5477 / BU-1) B4SGT1_PELPB 
403 Pelodictyon phaeoclathratiforme (strain DSM 5477 / BU-1) B4SH53_PELPB 
404 Pelodictyon phaeoclathratiforme (strain DSM 5477 / BU-1) B4SHG6_PELPB 
405 Pirellula sp. Q7UEH8_RHOBA 
406 Pirellula sp. Q7UFB2_RHOBA 
407 Planctomyces limnophilus DSM 3776 C1ZL96_PLALI 
408 Planctomyces limnophilus DSM 3776 C1ZL97_PLALI 
409 Planctomyces limnophilus DSM 3776 C1ZM92_PLALI 
410 Planctomyces maris DSM 8797 A6CAG7_9PLAN 
411 Planctomyces maris DSM 8797 A6CGQ8_9PLAN 
412 Polaromonas sp. (strain JS666 / ATCC BAA-500) Q11ZR2_POLSJ 
413 Polaromonas sp. (strain JS666 / ATCC BAA-500) Q122B9_POLSJ 
414 Porphyromonas gingivalis Q7MTS7_PORGI 
415 Porphyromonas gingivalis Q7MX37_PORGI 
416 Porphyromonas gingivalis (strain ATCC 33277 / DSM 20709 / JCM 12257) B2RLS0_PORG3 
417 Prevotella copri DSM 18205 B9ALE6_9BACT 
418 Prosthecochloris aestuarii (strain DSM 271 / SK 413) B4S3R6_PROA2 
419 Prosthecochloris aestuarii (strain DSM 271 / SK 413) B4S588_PROA2 
420 Prosthecochloris aestuarii (strain DSM 271 / SK 413) B4S6D3_PROA2 
421 Prosthecochloris aestuarii (strain DSM 271 / SK 413) B4S6U5_PROA2 
422 Prosthecochloris aestuarii (strain DSM 271 / SK 413) B4S7V1_PROA2 
423 Prosthecochloris aestuarii (strain DSM 271 / SK 413) B4S8G9_PROA2 
424 Prosthecochloris aestuarii (strain DSM 271 / SK 413) B4S9P4_PROA2 
425 Proteus mirabilis ATCC 29906 C2LI69_PROMI 
426 Proteus penneri ATCC 35198 C0B384_9ENTR 
427 Pseudoalteromonas tunicata D2 A4C8V4_9GAMM 
428 Pseudomonas aeruginosa (strain PA7) A6V3V7_PSEA7 
429 Pseudomonas paucimobilis A2PZP2_PSEPA 
430 Pseudomonas putida (strain W619) B1JB70_PSEPW 
431 Pseudomonas syringae pv. syringae (strain B728a) Q500J4_PSEU2 
432 Pseudovibrio sp. JE062 B6R0S7_9RHOB 
433 Psychroflexus torquis ATCC 700755 Q1VPB0_9FLAO 
434 Pyrobaculum aerophilum Q8ZWK8_PYRAE 
435 Pyrobaculum arsenaticum (strain DSM 13514 / JCM 11321) A4WIW1_PYRAR 
436 Pyrobaculum islandicum (strain DSM 4184 / JCM 9189) A1RV78_PYRIL 
437 Reinekea blandensis MED297 A4BGA1_9GAMM 
438 Rhizobium loti Q8KGT6_RHILO 
439 Rhizobium sp. (strain NGR234) Y4LF_RHISN 
440 Rhodobacter sphaeroides (strain ATCC 17023 / 2.4.1 / NCIB 8253 / DSM 158) Q3IWD7_RHOS4 
441 Rhodobacter sphaeroides (strain ATCC 17025 / ATH 2.4.3) A4X0P4_RHOS5 
442 Rhodococcus sp. (strain RHA1) Q0RX19_RHOSR 
443 Rhodococcus sp. (strain RHA1) Q0RX26_RHOSR 
444 Rhodoferax ferrireducens (strain DSM 15236 / ATCC BAA-621 / T118) Q21Z38_RHOFD 
445 Rhodoferax ferrireducens (strain DSM 15236 / ATCC BAA-621 / T118) Q21ZJ5_RHOFD 
446 Rhodopseudomonas palustris Q6N9F4_RHOPA 
447 Rhodopseudomonas palustris (strain BisB5) Q132Y4_RHOPS 
448 Rhodopseudomonas palustris (strain HaA2) Q2IWS6_RHOP2 
449 Rhodopseudomonas palustris (strain TIE-1) B3Q7H7_RHOPT 
450 Robiginitalea biformata HTCC2501 A4CGS2_9FLAO 
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451 Roseovarius nubinhibens ISM A3SLC4_9RHOB 
452 Ruminococcus lactaris ATCC 29176 B5CS54_9FIRM 
453 Saccharophagus degradans (strain 2-40 / ATCC 43961 / DSM 17024) Q21DQ4_SACD2 
454 Saccharopolyspora erythraea (strain NRRL 23338) A4FF24_SACEN 
455 Salinispora arenicola (strain CNS-205) A8M4S0_SALAI 
456 Salinispora arenicola (strain CNS-205) A8M4S1_SALAI 
457 Salmonella agona (strain SL483) B5F4B2_SALA4 
458 Salmonella dublin (strain CT_02021853) B5FLV0_SALDC 
459 Salmonella enterica subsp. enterica serovar Schwarzengrund str. SL480 B5CAM1_SALET 
460 Salmonella enteritidis PT4 (strain P125109) B5QYT9_SALEP 
461 Salmonella gallinarum (strain 287/91 / NCTC 13346) B5RBH2_SALG2 
462 Salmonella schwarzengrund (strain CVM19633) B4TVM3_SALSV 
463 Shewanella baltica (strain OS223) B8EDL9_SHEB2 
464 Shewanella baltica (strain OS223) B8EDM1_SHEB2 
465 Shewanella denitrificans (strain OS217 / ATCC BAA-1090 / DSM 15013) Q12I73_SHEDO 
466 Shewanella denitrificans (strain OS217 / ATCC BAA-1090 / DSM 15013) Q12I75_SHEDO 
467 Shewanella pealeana (strain ATCC 700345 / ANG-SQ1) A8H493_SHEPA 
468 Shewanella putrefaciens 200 A2UVN5_SHEPU 
469 Shewanella woodyi (strain ATCC 51908 / MS32) B1KM00_SHEWM 
470 Shuttleworthia satelles DSM 14600 C4GE63_9FIRM 
471 Shuttleworthia satelles DSM 14600 C4GE64_9FIRM 
472 Slackia heliotrinireducens DSM 20476 C4CEV5_9ACTN 
473 Solibacter usitatus (strain Ellin6076) Q01R08_SOLUE 
474 Solibacter usitatus (strain Ellin6076) Q01U48_SOLUE 
475 Solibacter usitatus (strain Ellin6076) Q01WV2_SOLUE 
476 Solibacter usitatus (strain Ellin6076) Q028E9_SOLUE 
477 Sorangium cellulosum (strain So ce56) A9EU91_SORC5 
478 Sorangium cellulosum (strain So ce56) A9FJE9_SORC5 
479 Sorangium cellulosum (strain So ce56) A9G4K5_SORC5 
480 Sorangium cellulosum (strain So ce56) A9GJ82_SORC5 
481 Sorangium cellulosum (strain So ce56) A9GJ85_SORC5 
482 Sorangium cellulosum (strain So ce56) A9GM89_SORC5 
483 Sorangium cellulosum (strain So ce56) A9GSK2_SORC5 
484 Sorangium cellulosum (strain So ce56) A9GWR0_SORC5 
485 Sorangium cellulosum (strain So ce56) A9GWR7_SORC5 
486 Spirosoma linguale DSM 74 C4CUS0_9SPHI 
487 Spirosoma linguale DSM 74 C4D2A5_9SPHI 
488 Spirosoma linguale DSM 74 C4D3U9_9SPHI 
489 Staphylococcus aureus (strain MSSA476) Q6GD52_STAAS 
490 Staphylococcus hominis Q8VUX6_STAHO 
491 Stigmatella aurantiaca DW4/3-1 Q08W08_STIAU 
492 Stigmatella aurantiaca DW4/3-1 Q099H8_STIAU 
493 Streptococcus infantarius subsp. infantarius ATCC BAA-102 B1SE27_9STRE 
494 Streptococcus pneumoniae CDC0288-04 B2DVK7_STRPN 
495 Streptococcus pneumoniae CDC1873-00 B1S2R9_STRPN 
496 Streptococcus pneumoniae Q97NR7_STRPN 
497 Streptococcus pneumoniae serotype 2 (strain D39 / NCTC 7466) Q04IL6_STRP2 
498 Streptococcus pneumoniae (strain ATCC 700669 / Spain 23F-1) B8ZNV7_STRPJ 
499 Streptococcus pneumoniae (strain ATCC BAA-255 / R6) Q8DNF6_STRR6 
500 Streptococcus pneumoniae (strain JJA) C1CGN4_STRZJ 
  
274 
 
501 Streptococcus thermophilus Q70CB7_STRTR 
502 Streptomyces avermitilis Q82BJ2_STRAW 
503 Streptomyces avermitilis Q82CN6_STRAW 
504 Streptomyces clavuligerus ATCC 27064 B5GMC1_STRCL 
505 Streptomyces clavuligerus ATCC 27064 B5GMC2_STRCL 
506 Streptomyces clavuligerus ATCC 27064 B5GRK8_STRCL 
507 Streptomyces clavuligerus ATCC 27064 B5GY23_STRCL 
508 Streptomyces clavuligerus ATCC 27064 B5GY34_STRCL 
509 Streptomyces coelicolor O54182_STRCO 
510 Streptomyces coelicolor O86757_STRCO 
511 Streptomyces coelicolor O86768_STRCO 
512 Streptomyces coelicolor Q8CJY8_STRCO 
513 Streptomyces coelicolor Q93JD1_STRCO 
514 Streptomyces coelicolor Q9L0M8_STRCO 
515 Streptomyces coelicolor Q9L1H5_STRCO 
516 Streptomyces coelicolor Q9RL12_STRCO 
517 Streptomyces griseus subsp. griseus (strain JCM 4626 / NBRC 13350) B1VYB9_STRGG 
518 Streptomyces griseus subsp. griseus (strain JCM 4626 / NBRC 13350) B1VZZ4_STRGG 
519 Streptomyces griseus subsp. griseus (strain JCM 4626 / NBRC 13350) B1W249_STRGG 
520 Streptomyces pristinaespiralis ATCC 25486 B5H9R8_STRPR 
521 Streptomyces pristinaespiralis ATCC 25486 B5HBM5_STRPR 
522 Streptomyces sp. Mg1 B4VG65_9ACTO 
523 Streptosporangium roseum DSM 43021 C4E2W2_STRRS 
524 Streptosporangium roseum DSM 43021 C4E2W3_STRRS 
525 Streptosporangium roseum DSM 43021 C4E7Z6_STRRS 
526 Streptosporangium roseum DSM 43021 C4E912_STRRS 
527 Streptosporangium roseum DSM 43021 C4EGT7_STRRS 
528 Streptosporangium roseum DSM 43021 C4EH37_STRRS 
529 Sulfurovum sp. (strain NBC37-1) A6QC40_SULNB 
530 Sulfurovum sp. (strain NBC37-1) A6QC41_SULNB 
531 Sulfurovum sp. (strain NBC37-1) A6QC42_SULNB 
532 Sulfurovum sp. (strain NBC37-1) A6QC43_SULNB 
533 Sulfurovum sp. (strain NBC37-1) A6QC45_SULNB 
534 Sulfurovum sp. (strain NBC37-1) A6QC46_SULNB 
535 Synechococcus sp. PCC 7335 B4WMX4_9SYNE 
536 Synechococcus sp. PCC 7335 B4WW33_9SYNE 
537 Synechococcus sp. PCC 7335 B4WW34_9SYNE 
538 Synechococcus sp. PCC 7335 B4WW35_9SYNE 
539 Synechococcus sp. PCC 7335 B4WW38_9SYNE 
540 Synechococcus sp. (strain JA-2-3B'a(2-13)) Q2JHG5_SYNJB 
541 Synechococcus sp. (strain JA-3-3Ab) Q2JSZ1_SYNJA 
542 Synechococcus sp. WH 5701 A3YXY3_9SYNE 
543 Synechococcus sp. WH 5701 A3YYR2_9SYNE 
544 Synechococcus sp. WH 5701 A3YYT2_9SYNE 
545 Synechocystis sp. (strain PCC 6803) P74570_SYNY3 
546 Syntrophobacter fumaroxidans (strain DSM 10017 / MPOB) A0LH80_SYNFM 
547 Syntrophomonas wolfei subsp. wolfei (strain Goettingen) Q0AUP4_SYNWW 
548 Syntrophus aciditrophicus (strain SB) Q2LRS1_SYNAS 
549 Syntrophus aciditrophicus (strain SB) Q2LV14_SYNAS 
550 Thauera sp. MZ1T C4ZIE0_9RHOO 
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551 Thauera sp. MZ1T C4ZIJ8_9RHOO 
552 Thauera sp. MZ1T C4ZL12_9RHOO 
553 Thauera sp. MZ1T C4ZM27_9RHOO 
554 Thermobifida fusca (strain YX) Q47S01_THEFY 
555 Thermococcus gammatolerans (strain DSM 15229 / JCM 11827 / EJ3) C5A5G6_9EURY 
556 Thermomonospora curvata DSM 43183 C2AF71_THECU 
557 Thermosynechococcus elongatus (strain BP-1) Q8DIX1_THEEB 
558 Thermotoga neapolitana (strain ATCC 49049 / DSM 4359 / NS-E) B9K9U6_THENN 
559 Thiomicrospira crunogena (strain XCL-2) Q31IR1_THICR 
560 Trichodesmium erythraeum (strain IMS101) Q10WW3_TRIEI 
561 Verrucomicrobiae bacterium DG1235 B5JE28_9BACT 
562 Vibrio angustum S14 Q1ZMN4_9VIBR 
563 Vibrio cholerae 12129(1) C2C6Y0_VIBCH 
564 Vibrio cholerae 623-39 A6AEZ3_VIBCH 
565 Vibrio parahaemolyticus Q87NQ6_VIBPA 
566 Vibrio sp. MED222 A3Y2J7_9VIBR 
567 Vibrio vulnificus (strain YJ016) Q7MK82_VIBVY 
568 Xanthomonas axonopodis pv. citri (Citrus canker) Q8PHG0_XANAC 
569 Xanthomonas campestris pv. campestris (strain 8004) Q4V0F1_XANC8 
570 Xylanimonas cellulosilytica DSM 15894 C0VF34_9MICO 
571 Yersinia pestis biovar Antiqua str. B42003004 B0HCF2_YERPE 
572 Yersinia pestis biovar Antiqua str. E1979001 B0HXE7_YERPE 
573 Yersinia pestis biovar Antiqua str. UG05-0454 B0GIF8_YERPE 
574 Yersinia pestis biovar Mediaevalis str. K1973002 B0H7U8_YERPE 
575 Yersinia pestis biovar Orientalis str. F1991016 A9ZYS5_YERPE 
576 Yersinia pestis biovar Orientalis str. India 195 C4H5E6_YERPE 
577 Yersinia pestis biovar Orientalis str. IP275 A9ZFA1_YERPE 
578 Yersinia pestis biovar Orientalis str. MG05-1020 B0GS98_YERPE 
579 Yersinia pestis biovar Orientalis str. PEXU2 C4HNG7_YERPE 
580 Yersinia pestis bv. Antiqua (strain Antiqua) Q1C8J6_YERPA 
581 Yersinia pestis bv. Antiqua (strain Nepal516) Q1CHG0_YERPN 
582 Yersinia pestis Pestoides A C4HXL1_YERPE 
583 Yersinia pestis Q8CL16_YERPE 
584 Yersinia pestis (strain Pestoides F) A4TK27_YERPP 
585 Yersinia pseudotuberculosis Q6EVT5_YERPS 
586 Yersinia pseudotuberculosis serotype IB (strain PB1/+) B2K233_YERPB 
587 Yersinia pseudotuberculosis serotype O:1b (strain IP 31758) A7FIS4_YERP3 
588 Yersinia pseudotuberculosis serotype O:1b (strain IP 31758) A7FN30_YERP3 
589 Yersinia pseudotuberculosis serotype O:3 (strain YPIII) B1JGY8_YERPY 
590 Yersinia pseudotuberculosis serotype O:3 (strain YPIII) B1JN39_YERPY 
591 Zymomonas mobilis Q5NM47_ZYMMO 
 
Table 8.2 TIR domain containing bacterial proteins. Microbial proteins identified from 
Chapter 3 found to contain a TIR domain. Pathogenic strains are in red and commensal 
strains are in green text. Numbers 80 and 218 from this list were selected for study in Chapter 
3. 
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Abstract: 
L.monocytogenes is a gram positive bacterium which can cause septicaemia and meningitis. 
Toll-Like Receptors (TLRs) are central receptors of the innate immune system that drive 
inflammatory responses to invading microbes such as L.monocytogenes. Although intestinal 
epithelial cells (IECs) represent the initial point of entry utilised by L.monocytogenes for 
infection, the innate immune response to L.monocytogenes in these cells has been poorly 
characterised to-date. The aim of this study was to determine which TLRs are involved in 
mediating the immune response to L.monocytogenes in IECs. We performed an RNAi screen 
of TLRs 1-10 in the HT-29 IEC cell line and observed the most significant reduction in 
chemokine output following silencing of TLR10. This effect was also observed in the 
macrophage cell line, THP-1. The chemokines CCL20, CCL1 and IL-8 were reduced 
following knockdown of TLR10. Silencing of TLR10 resulted in increased viability of 
L.monocytogenes in both HT-29 and THP-1 cells. TLR10 was found to be predominantly 
expressed intracellularly in epithelia and activation required viable L.monocytogenes. NF-B 
activation was seen to require TLR2 in addition to TLR10. Together these data indicate novel 
roles for TLR10 in sensing of pathogenic infection in both the epithelium and macrophages 
and have identified L.monocytogenes as a source of ligand for the orphan receptor TLR10. 
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Introduction 
Listeria monocytogenes is a foodborne Gram-positive bacterium that can cause 
diseases such as septicaemia and meningitis particularly in immune-compromised individuals 
(1). Following ingestion, L.monocytogenes crosses the intestinal barrier by first invading 
intestinal epithelial cells. From here, infection of macrophages proceeds via phagocytosis 
followed by escape from the phagosome into the cytosol through the action of the pore-
forming toxin Listeriolysin O (LLO) (2, 3). The infecting organisms reach their first target 
organs; the liver and the spleen via the lymphoid system and the blood, where they are 
internalized by splenic and hepatic macrophages. Here, they actively multiply until the 
infection is controlled by a cell-mediated immune response.  
 Effective immune responses to L.monocytogenes infection relies on coordinated 
innate and adaptive immune responses, with the first line of innate defence being mediated by 
detection of the invading bacterium by Pattern Recognition Receptors (PRRs). Several 
families of these receptors have been identified including the transmembrane Toll-Like 
Receptors (TLRs), the cytosolic NOD-Like Receptors (NLRs) and RIG-I like Receptors 
(RLRs) and in more recent years C-type Lectin Receptors (CLRs) (4). The activation of 
innate immunity by PRRs in response to L.monocytogenes infection is still not fully 
understood. L.monocytogenes has been shown to be recognised by TLR2 (5, 6), NOD1 (7, 8) 
and NOD2 (9) resulting in NF-B activation and pro-inflammatory gene expression. The role 
of TLR5 in detection of L.monocytogenes remains unclear as although flagellin from 
L.monocytogenes activates TLR5, bacterial mutants deficient in flagellin display an unaltered 
virulence (10, 11). More recent studies have identified several inflammasome components 
responsible for recognition of the bacterium such as NLRC4 and AIM2. Recognition of 
L.monocytogenes through these receptors results in activation of caspase-1 and cleavage of 
IL1- (12). L.monocytogenes infection has also been shown to induce a type I interferon 
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response, potentially mediated by TLR2 and the adaptor protein TRIF in peritoneal 
macrophages (13). Most recently the IFN- response has been shown to be triggered by 
nucleic acids released from L.monocytogenes acting through the intracellular sensor RIG-I 
(14). Previous in vitro mouse studies have predominantly used intraperitoneal in vivo 
infection models where type I IFN responses were shown to be detrimental to bacterial 
clearance. Recently, however, using an in vivo mouse model of oral L.monocytogenes 
infection Kernbauer et al. proved that this is only the case when infection occurs through a 
route other than intra-gastric, highlighting the importance of study required in epithelial 
mediated innate immunity (15). 
Epithelial cells line the enteric mucosal surface providing barrier function against 
microbial invasion. Similar to immune cells, intestinal epithelial cells express many of these 
receptors of the innate immune system and are the first site of bacterial recognition in the 
intestine. Characterisation of the innate immune responses to L.monocytogenes infection has 
been studied in several cells types including endothelial cells, PBMCs, and macrophages 
(16). However, no extensive screen has been performed of innate mechanisms of detection of 
L.monocytogenes in the intestinal epithelia and little focussed attention has been paid to the 
role of specific PRRs in detecting L.monocytogenes infection at this barrier interface. To date 
only NOD2 has been directly shown to play a role in detecting L.monocytogenes in the 
intestinal epithelium (9). In this study, we examined the role of TLRs 1-10 in recognition of 
L.monocytogenes infection in epithelial cells. In doing so, we have uncovered a novel role for 
TLR10 in mediating the inflammatory response to infection by L.monocytogenes in IECs and 
also macrophages. As ligand specificity for TLR10 has to date remained elusive, this is the 
first report to show an essential role for TLR10 in mediating the inflammatory response to 
infection by an invasive pathogen.  
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Materials and Methods 
Cell culture  
HCT-116, HCA-7 and HEK 293T cells were maintained in DMEM (Thermo Scientific, 
Leics, UK), HT-29 in McCoys 5A (Thermo Scientific) and THP-1 cells  in RPMI (Thermo 
Scientific), supplemented with 10% FCS (Thermo Scientific)  and 10 g/ml of penicillin and 
streptomycin (Sigma-Aldrich, Dorset, UK) and cultured in a humidified incubator at 37ºC 
with 5% CO2. THP-1s were differentiated into macrophages by overnight stimulation with 5 
ng/ml PMA (Sigma). The ligands Pam3Cys (50μg/ml); PGN (10μg/ml); LTA (10μg/ml); 
FSL-1 (5μg/ml); LPS (10ng/ml); Poly(I:C) (20μg/ml); TNFα (10ng/ml) (All Invitrogen, 
Paisley, UK) were used for cells stimulation assays as were bacteria (below). Each of the 
ligands were obtained from Invitrogen. 
Bacterial cell culture, infections and survivability assays  
The L.monocytogenes strain EGD (serotype 1/2a) was a kind gift from Prof. C. Hill, (UCC, 
Cork, Ireland). Bacteria were grown to the logarithmic growth phase in brain heart infusion 
(BHI) broth (Sigma) at 37˚C shaking at 200 rpm. Bacteria were subsequently washed with 
PBS by two steps of centrifugation (4000 x g for 5 min) and diluted in PBS for infection at 
multiplicity of infection (MOI) of 50:1. The cells were washed at 2h post-infection with 
antibiotic free cell culture medium and supplemented with cell culture medium containing 
Gentamicin (Invitrogen) (50g/ml). Cells were then incubated for the times indicated in the 
results section. For bacterial survival assays, the cells were washed at 8 hours post-infection 
and treated with 0.2% Triton X-100 PBS. The lysates were then subjected to serial dilution 
and spotted on a BHI agar plate. Colony forming units (C.F.U.)/lysate of internalised bacteria 
was then determined. The Salmonella typhimurium strain SJW1103 (wild type) was a kind 
gift from Prof. P. O‘Toole (UCC, Cork, Ireland). Bacteria were grown to the logarithmic 
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growth phase in LB broth (Sigma) at 37˚C shaking at 200 rpm. Bacteria were subsequently 
washed with PBS by two steps of centrifugation (4000 x g for 5 min) and diluted in PBS for 
infection at multiplicity of infection (MOI) of 10:1. 
siRNA transfection 
All siRNA transfections were performed with SMARTpool siRNAs (Thermo). Sequences are 
contained in Supplemental Table 1A. For the TLR siRNA screen, cells were seeded at 
1x10
4
/well in a 96 well plate the day before transfection. DharmaFECT 4 (Thermo Scientific) 
was then used to transfect the cells with siRNA (50nM) according to the manufacturer‘s 
instructions 48 hours prior to infection. THP-1 siRNA transfections were performed using the 
Amaxa (Lonza, Basel, Switzerland) system according to the manufacturer‘s protocol. Cells 
were cultured for a further 48 hours prior to infection. The ―control siRNA‖ used in all 
experiments indicates the non-targeting scrambled siRNA. All analyses on siRNA treatment 
are of independent triplicate biological replicates. Technical replicates were included in each 
plate screen to address any intra assay variation. 
Gene expression analysis using qRT-PCR 
Total RNA was isolated using the RNeasy Kit (Qiagen, West Sussex, UK). cDNA synthesis 
was performed using Transcriptor RT (Roche, West Sussex, UK) according to 
manufacturers‘ instructions. 1g of total RNA was incubated with 50 pmoles of random 
hexamers at 25ºC for 5 min, 42 ºC for 50 min and 4ºC for 5 min. Individual PCR primer pairs 
and probes were designed using the Roche Universal ProbeLibrary Assay Design Centre 
(https://www.roche-applied-science.com/sis/rtpcr/upl/adc.jsp). Primer sequences and probe 
combinations are provided in Supplemental Table 1B. PCR reactions were performed using 
Sensi Mix II (Bio Line, London, UK), 900 nM of each primer and 250 nM of probe mix in 
the LightCycler480 System (Roche). Thermal cycling conditions were as recommended by 
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the manufacturer (Roche). β-actin was used as a housekeeping gene, the 2-ΔΔCt method (17) 
was used to calculate relative changes in gene expression. Relative expression in each figure 
refers to induction levels of the gene of interest relative to a housekeeper control, beta actin, 
and then compared to an untreated control calibrator sample. 
Flow Cytometry  
Antibodies against TLR1, TLR2 and TLR6 (IMG-5012, IMG-6720A, IMG-304A) were from 
Imgenex (San Diego, CA, USA) and the TLR10 antibody was from Santa Cruz 
Biotechnology (TLR10 H-165). As secondary antibodies, we used Alexa Fluor-488 goat anti-
mouse IgG (Invitrogen, Paisley, UK) and PE-conjugated goat anti-rabbit IgG H+L 
(Imgenex). The respective isotype controls for each antibody were also from Imgenex. On the 
day of analysis, 1x10
6 
cells were harvested using 0.2% EDTA PBS and washed twice in 
running buffer (PBS 0.5% BSA, 1% FBS 0.1% Sodium Azide). For intracellular staining, 
cells were fixed in BD Cytofix Cytoperm (Becton Dickinson, New Jersey, USA) for 30 
minutes on ice. For extracellular staining, cells were not fixed. Each primary antibody was 
used at 0.5 g/ml for 30 minutes on ice. Each wash step for intracellular staining was 
performed using BD Perm/Wash buffer (Becton Dickinson) while the running buffer was 
used for extracellular staining washes. The secondary antibodies were used at a 1:1000 
dilution for 20 minutes in the dark on ice and cells were analysed using the Accuri C6 flow 
cytometer (Becton Dickinson). The gating method employed was designed to include the live 
cell population only. Population gates were set using negative controls and IgG isotype 
controls. The results were expressed as the percentage or median fluorescence intensity 
(MFI) of the total live cell population after subtracting the MFI of control cells stained with 
the appropriate isotype control antibodies.  
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Western blot analysis  
Cell were lysed in RIPA lysis buffer (50mM Tris-HCL pH 8.0, 50mM, 150mM NaCl, 0.1% 
SDS, 0.5% Sodium deoxycholate, 1% Triton X-100, 1mM phenylmethylsulfonyl and 10% 
Protease Inhibitor Cocktail (Sigma). The following antibodies were used: anti-TLR10 (H-
165) (sc-30198, Santa Cruz, Heidelberg, Germany) and β-actin antibody (Sigma). Proteins 
were detected using the Fujifilm LAS-3000 Imager (R&D Sytems, Abingdon, UK). 
ELISA analysis of supernatants for cytokine production  
CCL-20 levels were quantified using the anti-CCL20 kit (Meso Scale Discovery (MSD), 
Maryland, USA) according to the manufacturer's instructions. Concentrations were 
determined using the MSD Sector Imager 2400. IL-8 levels were quantified using the Ready-
Set-Go!® Human IL-8 ELISA kit (eBiosciences, San Diego, USA) according to the 
manufacturer‘s instructions.  
Luciferase Assays   
HEK 293 cells were seeded at 2.5 x 10
4
/well in a 96 well plate 24h prior to transfection. Cells 
were transfected using Turbofect (Fermentas) according to the manufacturer‘s protocol using 
50ng of ISRE luciferase plasmid and 5ng of Thymidine kinase Renilla luciferase along with 
varing amounts of either TLR1, TLR2, TLR6 or TLR10 (gift from Prof. L. O‘Neill, Dublin, 
Ireland). 24 hours post transfection cells were infected with L.monocytogenes as described 
above for 8 hours. Extracts were prepared by lysing the cells for 15 minutes in 50μL Passive 
Lysis Buffer (Promega, Madison, Wisconsin, USA) and measured for Firefly luciferase and 
Renilla luciferase activity. Firefly luminescence readings were corrected for Renilla activity 
and expressed as fold stimulation over unstimulated empty vector (EV) control. 
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NF-κB Activity   
SEAP reporter HEK-Blue-MD2-CD-14 cells (Invivogen, Toulouse, France) were used 
according to the manufacturer‘s instructions. Briefly, cells were maintained in selective 
antibiotics and seeded at 2x10
4
 cells/well on a 96 well plate the day before transfection. Cells 
were then transfected and infected with L.monocytogenes as described above. Supernatants 
were collected 8 hours later and activity measured using QUANTI-Blue
TM
.  
Statistics  
Results were statistically evaluated using Student‘s t test. Values of P < 0.001 are indicated 
by three asterisks (***), P < 0.01 two asterisks (**), Values of P < 0.05 one asterisk (*). 
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Results 
Role of different TLRs in L.monocytogenes induced gene expression  
We initially investigated the involvement of all human TLRs in the response of HT-29 IECs 
to L.monocytogenes infection by use of a siRNA screening approach (Supplemental Fig. 1). 
Inflammatory readouts selected were Interleukin 8 (IL-8) and Early Growth Response 
protein-1 (EGR-1) as these demonstrate consistently robust expression patterns in response to 
infection. EGR-1 mRNA was induced 6 fold (p≤0.001) by L.monocytogenes infection. 
Knockdown of TLRs 1-10 did not affect EGR-1 induction by L.monocytogenes indicating 
that activation of EGR-1 expression is via a TLR independent mechanism (Figure 1A). IL-8 
mRNA expression was increased 4.5 fold following L.monocytogenes infection and this 
effect was significantly abrogated following silencing of TLRs 1 and 10 (Figure 1B). 
Knockdown of TLR2 resulted in reduced IL-8 expression following infection; however this 
did not reach statistical significance. Of the three genes where any effect was observed 
following siRNA-mediated knockdown (TLRs 1, 2 and 10), TLR10 silencing had the most 
significant effect on reduction of IL-8 expression. In addition silencing of the TLRs 1, 2 and 
10 were found to be specific and have no off-target effects on the other members of the 
closely related TLR1, 2, 6 or 10 gene expression  by qRT-PCR (Figure 1 C-F) and by flow 
cytometry (Supplemental Fig. 2). 
Role of TLR10 in mediating chemokine production in response to L.monocytogenes infection. 
This novel identification of TLR10 as a potential sensor of L.monocytogenes infection in an 
IEC cell line was intriguing given the fact that TLR10 expression is more commonly 
associated with immune cell subtypes (18). We confirmed both expression and effective 
silencing by siRNA of TLR10 in the HT-29 cell line by qRT-PCR (Figure 2A) and Western 
blotting (Figure 2B) . In order to fully characterise which cytokines and chemokines were 
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induced by L.monocytogenes in a TLR10 dependent manner we initially examined mRNA 
expression of an extensive number of TLR induced genes (EGR-1, IL-1, IL-2, IL-6, IL-8, 
IL-9, IL-12, IL-18, IL-23, caspase-1, CCL-1, CCL-2, CCL-5, CCL20, CXCL1, CXCL10) in 
HT-29 cells following infection. Of these genes only caspase-1, IL-1, IL-8, IL-18, IL-23, 
CCL-1, CCL20 and EGR-1 demonstrated detectable levels of expression by HT-29 cells and 
of these only EGR-1, CCL-1, CCL20 and IL-8 were significantly induced following infection 
(Supplemental Figure 3B). As results from the original screen implicated possible roles for 
TLRs 1 and 2 as well as TLR10 in the L.monocytogenes induced immune response, we 
performed single knockdown with siRNA against TLR1, TLR2 and TLR10 and measured 
CCL-20 and IL-8 mRNA expression. TLR10 silencing resulted in the most significant 
decreases in CCL-20 and IL-8 mRNA levels in response to L.monocytogenes infection 
(Figure 2 C and D respectively). TLR 2 silencing reduced IL-8 while TLR1 silencing reduced 
CCL20 expression. Since CCL-20 was the most strongly induced chemokine gene in 
response to L.monocytogenes, protein production was measured over a longer period of time 
and a consistent reduction in CCL20 was observed following knockdown of TLR10 by 
siRNA at all time points (Figure 2E). Given that L.monocytogenes is an invasive bacterium 
we hypothesised that TLR10 might be detecting the pathogen intracellularly. In Figure 2F, 
intracellular versus extracellular staining for TLR10 by flow cytometric analysis revealed 
much greater expression levels of intracellular TLR10 than extracellular. Furthermore, Heat-
Killed L.monocytogenes (HKLM) failed to induce CCL-20 or IL-8 to levels comparable to 
the induction seen when invasive live bacteria were administered to HT-29 cells (Figures 2G 
and H). This implies that bacterial invasion must be responsible for such high levels of CCL-
20 and IL-8 induction. Together with the data from Figure 2F, it implies that this induction 
could be mediated by intracellular TLR10.  
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To ensure that the effect seen was not restricted to one cell line (HT-29) an additional IEC 
line, HCA-7, was assessed. TLR10 silencing was confirmed by qRT-PCR in HCA-7 cells 
(Figure 3A). mRNA expression of TLR10 in HCA7 was observed to be much higher than in 
HT-29 cells. Silencing of TLR10 resulted in reduced CCL-20 and IL-8 mRNA expression in 
the HCA-7 cell line (Figure 3B and C) as seen in HT-29 cells. CCL-1 induction was, 
however, not significantly affected unlike TLR10 silenced HT-29s in response to 
L.monocytogenes infection (Supplemental Figure 3 C and D).  A consistent reduction in 
CCL-20 protein production was observed following knockdown of TLR10 by siRNA in 
HCT-116 cells at all time points (Figure 3D).  
As both L.monocytogenes infection and TLR10 have been predominantly studied in immune 
cell subtypes we next chose to examine PMA differentiated THP-1 macrophage-like cells in 
order to see if this was an IEC specific effect. A consistent reduction in CCL-20 protein 
production was observed following knockdown of TLR10 by siRNA after 48 hrs (Figure 3E). 
Confirmation of ~52% TLR10 silencing in THP-1s was confirmed by flow cytometry (Figure 
3F and G).  
TLR10 effects L.monocytogenes survival in IECs and macrophages 
Altering expression of the PRRs NALP3 and Aim2 has been previously shown to influence 
the ability of L.monocytogenes to survive and replicate within cells (12). We wished to 
identify whether altering expression of TLR10 would have a similar effect. Survival of 
L.monocytogenes was analysed by calculating the intracellular bacterial burden in both HT-
29 and THP-1 following TLR10 silencing over an 8 hour period. Increased survival of the 
bacteria is seen in both cell lines indicating a critical role for the receptor in antagonizing 
bacterial intracellular viability (Figure 4A and B respectively). 
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TLR10 requires TLR2 to mediate optimal NF-B activation in response to L.monocytogenes. 
Recognition of L.monocytogenes by different PRRs has been shown to lead to NF-B-
dependent pro-inflammatory gene expression, inflammasome activation and caspase-1 
cleavage and IFN-β responses (19). As both NF-B and IFN-β are major downstream 
signalling outputs of TLRs we investigated activation of these in response to overexpression 
of TLR constructs with or without stimulation by L.monocytogenes. We overexpressed a 
TLR10 construct in either an NF-B reporter cell line or in conjunction with an ISRE 
(Interferon Stimulated Response Element) - luciferase reporter construct. As TLR10 has been 
shown to dimerise with TLR2 (20), we overexpressed a variety of combinations of TLRs 
1/2/10 in conjunction with the reporter constructs. In Figure 5A it can be seen that 
overexpression of TLRs 1 or 10 alone did not activate NF-B significantly above control 
level. Stimulation of the overexpressed constructs with L.monocytogenes, however, results in 
a twofold level of activation above control with TLR2 and significantly higher NF-κB 
activation following co-transfection of TLR2 and TLR10 (5 fold above control), which was 
comparable to co-transfection of TLR1 and 2. This data indicates that TLR10 alone is not 
able to respond to L.monocytogenes but that together with TLR2. Endogenous TLR10 levels 
may explain the response to Listeria when TLR2 is transfected alone (see Supplemental Fig 
3A). ISRE activation was also measured by luciferase assay in response to L.monocytogenes 
following overexpression of combinations of TLR constructs. Unlike NF-B, no increase in 
the ability of any of the TLR combinations to drive an ISRE-luciferase construct was seen 
following L.monocytogenes stimulation (Figure 5B).  
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TLR10 is not involved in recognition of other known TLR2 ligands 
Since TLR10 is most closely related to TLR1 (20), we wished to compare TLR1 versus 
TLR10 mediated response to some known TLR2 ligands. Using THP-1 derived macrophages, 
IL-8 production was measured in response to a range of TLR2 ligands, including 2 strains of 
intracellular bacteria, following siRNA treatment against TLR1 or TLR10 (Figure 6). While a 
reduction in IL-8 production was seen following both TLR1 and TLR10 siRNA treatment in 
response to Salmonella infection, it was not as significant as the reduction seen during 
L.monocytogenes infection in TLR10 siRNA treated cells. Besides the significant reduction 
of IL-8 production seen in response to Pam3Cys following TLR1 siRNA treatment, no 
further statistically significant changes in IL-8 secretion was observed in response to the 
other TLR2 ligands or the positive control, LPS.  
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Discussion 
TLRs have been clearly established as the major sensors of the innate immune system. 
Currently a total of 10 human TLRs (1-10) and 12 mouse TLRs (1-9, 11-13) have been 
identified. Each TLR recognises a limited repertoire of broadly conserved molecules of 
microbial origin with ligand specificity having been elucidated for many of the TLRs thus far 
(4). Importantly, despite being identified over ten years ago as a member of this family, 
TLR10 has remained the only orphan TLR, having no known ligand (18). The absence of 
TLR10 in mice has, to date, precluded the identification of synthetic or natural ligands for 
this receptor. This study is the first identification of an essential role for TLR10 in mediating 
the inflammatory response to a specific microorganism, L.monocytogenes, in both intestinal 
epithelial cells and macrophages. 
The initial aim of this study was to identify which TLRs play a key role in detection 
of L.monocytogenes in the intestinal epithelia, as most prior work has focused predominantly 
on systemic infections and in doing so we have identified TLR10 as a key mediator of the 
innate immune response to infection in intestinal epithelial cells. Many human microbial 
infections are acquired via an oral transmission route and as such the first opportunity the 
immune system has to encounter and counter the infection occurs in the gastrointestinal tract. 
Despite this, very few studies have addressed which PRRs are directly involved in detecting 
L.monocytogenes at this interface. Whilst TLR2 (5) and MyD88 (21) have been shown to 
detect L.monocytogenes infection in other cell types only NOD2 has been directly shown to 
mediate the inflammatory response to L.monocytogenes in the intestine (9). Our screen 
investigating the role of TLRs in L.monocytogenes infection has yielded several interesting 
observations. TLR2 alone does not seem to play as critical a role in response to infection in 
epithelia as has been observed in immune cell types as shown by the slight but not significant 
reduction in chemokine expression following knockdown of TLR2. Knockdown of TLR1 
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seems to have a more significant effect on IL-8 production than knockdown of TLR2 and 
finally knockdown of TLR10 has the greatest effect on the ability of these cells to mount an 
immune response to L.monocytogenes. 
 
Here we have reported TLR10 to play a functional role in intestinal epithelial cells. In 
humans, TLR10 expression has been reported to be somewhat restricted. It was initially 
characterised to be primarily expressed on immune cell subtypes with a predominance found 
in spleen, lymph nodes, thymus and tonsils (18). It is worth noting that in this study by 
Chuang et al, expression of TLR10 in colon tissue was not investigated. Within immune cell 
populations the highest levels of TLR10 expression have been reported on T regulatory cells 
(22), B lymphoctes (23), and plasmacytoid DCs (24) with expression also reported on THP-1 
monocytes (25). The initial siRNA screen performed here which identified this novel role for 
TLR10 was performed in HT-29 intestinal epithelial cells, not in an immune cell type. 
Expression of TLR10 mRNA has previously been reported in the human SW480 intestinal 
epithelial cell line (26). In previous studies we have detected TLR10 mRNA in human colon 
biopsy samples, which comprise approximately 90% intestinal epithelial cells (27). As we 
have shown expression of TLR10 in two intestinal epithelial cell lines, HT-29 and HCA-7, by 
both mRNA and protein our data indicate a previously unappreciated role for TLR10 in non-
immune cell types in the gut. Moreover we have confirmed our findings in the macrophage 
cell line THP-1 indicating that the role of TLR10 in the detection and immune response to 
L.monocytogenes is not limited to intestinal epithelial cells.  
We have investigated signalling from TLR10 in response to L.monocytogenes and 
have shown that TLR10 alone is not sufficient to mediate L.monocytogenes induced NF-B 
activation but that it requires TLR2 to be present. We have also shown that co-expressing 
TLR2 and TLR10 drives NF-B activation significantly more than TLR2 alone. However a 
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caveat to this observation is that endogenous TLR10 levels may be present at low levels in 
HEK cells. Many studies involving TLR2 have shown that it can combine with either TLR1 
or TLR6 and that this interaction is essential for effective ligand binding by TLR2 and also 
for discrimination of triacyl and diacyl lipopeptides from bacteria (4). Phylogenetic analysis 
has shown that TLR10 is most closely related to TLR1 and TLR6 (18). The level of sequence 
homology between these three suggests the idea of a common 1/6/10 ancestor which evolved 
into a TLR1/6 precursor and TLR10 (28). Two prior studies have investigated the potential 
role of TLR10 as a TLR2 co-receptor and signalling via TLR10. Overexpressed TLR10 has 
been shown to co-immunoprecipitate with TLRs 1 and 2 (29) and also to translocate, co-
localise and physically interact with TLR2 in the phagosome (20). Both these studies also 
show interaction of TLR10 with the adaptor MyD88. Interestingly, the reports differ in their 
analysis of signalling from TLR10. Hasan et al used overexpression of a CD4-TLR10 
construct to show that it could activate an NF-B luciferase reporter and that this was 
blocked by a dominant negative form of MyD88, whilst Guan et al found no activation with 
the same construct. Our data indicate that, in response to L.monocytogenes, TLR10 is a 
functional receptor and can induce NF-B but that it requires TLR2 to do so. Interestingly, 
when we examined L.monocytogenes induced IL-8 induction following knockdown of TLRs 
1, 2 and 10 we saw the greatest effect with TLR10 knockdown possibly indicating that 
TLR10 is the dominant signalling partner in the 2/10 dimer in response to L.monocytogenes. 
Further studies are required to help identify the signalling components involved in this 
activation. 
Although we have not yet fully investigated the role of TLR10 in detection of other 
pathogens, it seems unlikely that it will be limited to L.monocytogenes detection. In a screen 
of TLR2 ligands to compare TLR1 against TLR10 induced IL-8 production; we have shown 
that TLR10 is also involved in detection of the intracellular pathogen Salmonella 
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typhimurium. Indeed the intracellular role of TLR10 detection, in epithelia, appears to be 
crucial as HKLM did not result in TLR10 activation and subsequent cytokine expression. 
Further work is required to identify other pathogens detected by TLR10.  
We have also shown that depletion of TLR10 increases Listeria survival in both HT-
29 epithelial and THP-1 macrophage cells. Previous studies have linked TLR10 to ROS 
activation in THP-1 cells (30), and together with our own data, this suggests that TLR10 may 
play a role in ROS mediated clearance of Listeria. How it acts to reduce bacterial 
survivability in intestinal epithelial cells such as HT-29s is unclear although reduced 
expression of antimicrobial factors such as CCL-20 in the absence of TLR10 signalling may 
be a key factor. Indeed observation by Yang et al. (31) and Starner et al. (32) have 
demonstrated the antimicrobial effect of chemokines and cytokines, however, specific 
mutagenesis studies of both TLR10 and bacterial strains may also further elaborate this 
question. 
The role of TLRs in defence against many pathogenic infections in the intestine 
remains unclear. Whilst the primary role of TLRs in the intestine is the same as in other 
tissues -defence against infection- other homeostatic functions have been described. TLR2, 
for example, is found to be expressed on both apical and basolateral surfaces of intestinal 
epithelial cells, and activation of TLR2 from the apical surface has been reported to result in 
cell homeostasis not inflammation (33). Similarly MyD88 has been shown to have a 
homeostatic role in the epithelium as mice lacking MyD88, are hyper-responsive to DSS-
induced colitis (34). Conversely however, another recent study has shown an essential role 
for MyD88 in inducing the bactericidal lectin RegIII in response to L.monocytogenes 
infection in epithelial cells (35). Indeed a recent study has found that the circadian rhythm of 
intestinal epithelial cells governs the signalling of TLR mediated homeostasis (36). Our data 
showing TLR10 as the dominant TLR involved in mediating the immune response to 
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L.monocytogenes in the intestine open up intriguing possibilities concerning the balance of 
pro-inflammatory versus homeostatic TLR responses to infection in epithelial cells. It is 
possible that a TLR2/10 dimer may be pro-inflammatory in epithelial responses whilst TLR2 
on its own or in combination with 1 and 6 may mediate a more homeostatic effect. 
 
Taken together, our results show that L.monocytogenes infected intestinal epithelial 
cells produce chemokines in a TLR10 dependant manner. Whilst mucosal and systemic 
immunity to pathogenic infection can be very distinct, our finding of a role for TLR10 in the 
inflammatory response in macrophages as well as IECs indicates a general role for TLR10 in 
response to L.monocytogenes infection. Although the precise ligand remains to be identified, 
this report shows the first definitive role for TLR10 in pathogen detection. 
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Figure legends 
FIGURE 1. Inflammatory response of HT-29 epithelial cells to L.monocytogenes 
following silencing of TLR 1-10 expression and siRNA specicity validation. Cells were 
treated with siRNA to TLRs as indicated, cultured overnight, and infected with L. 
monocytogenes (MOI 50:1) for 3 hours. Gene expression of (A) EGR1 or (B) IL-8 was 
determined by qRT-PCR. THP-1 cells were treated with control (scrambled) siRNA and 
TLR1 siRNA, TLR2 siRNA, or TLR10 siRNA as indicated with 5ng/ml PMA for 48 hours. 
qRT-PCR was used to monitor expression levels of TLR1, TLR2, TLR6 or TLR10 as 
indicated (C-F). * P<0.05, ** P<0.01 and *** P<0.001, Values are shown as Mean ± SEM, 
n=3.  
FIGURE 2. TLR10 silencing effects L.monocytogenes induced chemokines gene 
expression. HT-29 cells were treated with TLR10 siRNA and silencing was confirmed by 
qRT-PCR (A) and Western Blot (B) which contains the lysates from HT-29 which were 
transfected as follows; Untreated (lane A), TLR10 expressing plasmid (0.5 g) (lane B), 
TLR10 expressing plasmid (1 g) (lane C), TLR10 expressing plasmid (2 g) (lane D), 
TLR10 siRNA ( lane E) and Control siRNA (Lane F). Upper panel; TLR10 antibody, lower 
panel Beta-actin antibody. The effects of siRNA for TLR1 and TLR2 on CCL-20 and IL-8 
induction were determined following infection with L.monocytogenes (C and D). Secretion of 
CCL20 was determined by ELISA 8, 24 and 48 hours following infection in cells transfected 
with control or TLR10 siRNA (E). Extracellular versus intracellular expression of TLR10 in 
HT-29 cells was measured by flow cytometry (F) TLR10 siRNA treated cells were infected 
with Heat Killed L.monocytogenes (HKLM) or live L.monocytogenes, (MOI 50:1) as 
described previously, and the expression of the chemokines IL-8 and CCL20 were measured 
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by qRT-PCR (G and H respectively). * P<0.05, ** P<0.01 and *** P<0.001, Values are 
shown as Mean ± SEM, n=3 
FIGURE 3. L.monocytogenes induced chemokine production is effected by TLR10 
silencing in the epithelia and macrophage-like cell lines. HCA-7 cells were transfected 
with control or TLR10 siRNA and infected with L.monocytogenes, (MOI 50:1). qRT-PCR 
was used to measure TLR10 (A), CCL20 (B) and IL-8 expression (C). CCL20 secretion, 8, 
24 and 48 hours following infection in HCT-116 cells, was determined by ELISA (D). PMA 
differentiated THP1 cells, macrophage-like, were transfected with control of TLR10 siRNA 
and the cells were then infected with Listeria for 8, 24 and 48 hrs and CCL20 secretion 
determined (E). TLR10 expression was also analysed by flow cytometry following 
transfection with control siRNA (F) or TLR10 siRNA (G) in THP-1 macrophage-like cells. * 
P<0.05, ** P<0.01 and *** P<0.001, Values are shown as Mean ± SEM, n=3. 
FIGURE 4. TLR10 silencing increases intracellular L.monocytogenes survival in HT-29 
epithelial cells. HT-29 and THP1 macrophage like cells were transfected with control or 
TLR10 siRNA and then infected with L.monocytogenes,(MOI 50:1),  for 8 hours before 
intracellular bacterial survival was then determined by plate counting (A and B). * P<0.05, 
Values are shown as Mean ± SEM, n=3. 
FIGURE 5. TLR10 requires TLR2 for NF-κB activation in response to L.monocytogenes 
and is not required for ISRE activation. (A), The NF-κB SEAP reporter HEK293 cell line 
was transfected with the plasmid combinations indicated, and were then infected with or 
without L.monocytogenes for 8 hours. The cell free supernatants were then collected and used 
to quantify NF-κB activation by colorimetric QUANTI-blue™ determination (B). HEK293 
cells were transfected with an ISRE-luciferase reporter, plasmid combinations indicated, and 
were then infected with or without L.monocytogenes for 8 hours. Cell extracts were then 
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lysed and luciferase activity and corresponding luminescence was determined for ISRE 
activity ** P<0.01, Values are shown as Mean ± SEM, n=3. 
Figure 6. Effects of TLR1 versus TLR10 siRNA treatment on IL-8 production in THP-
1-macrophages following 24 hour stimulation with TLR2 ligands. THP-1 cells were 
treated with non-targeting control, TLR1, or TLR10 siRNA with 5ng/ml PMA for 48 hours. 
The cells were then subject to stimulation with the ligands indicated. Bacterial infections 
were performed as described in the methods section. 24 hours after stimulation, supernatants 
were analysed by ELISA for IL-8 production.  
 
298 
 
 
FIGURE 1. Inflammatory response of HT-29 epithelial cells to L.monocytogenes 
following silencing of TLR 1-10 expression and siRNA specicity validation.  
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FIGURE 2. TLR10 silencing effects L.monocytogenes induced chemokines gene 
expression.  
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FIGURE 3. L.monocytogenes induced chemokine production is effected by TLR10 
silencing in the epithelia and macrophage-like cell lines.  
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FIGURE 4. TLR10 silencing increases intracellular L.monocytogenes survival in HT-29 
epithelial cells.  
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FIGURE 5. TLR10 requires TLR2 for NF-κB activation in response to L.monocytogenes 
and is not required for ISRE activation.  
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Figure 6. Effects of TLR1 versus TLR10 siRNA treatment on IL-8 production in THP-
1-macrophages following 24 hour stimulation with TLR2 ligands.  
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SUPPLEMENTAL FIGURE 1. EGR-1 induction in HT-29 epithelial cells in response to 
L.monocytogenes following silencing of PRR expression. Cells were treated with siRNA to 
PRRs as indicated for TLRs, NLRs or CLRs. Following siRNA transfection, cells were then 
infected with L. monocytogenes (MOI 50:1) for 3 hours and gene expression of EGR1 (A) or 
IL-8 (B) was determined by qRT-PCR. * P<0.05, ** P<0.01 and *** P<0.001, Values are 
shown as Mean ± SEM, n=3. 
SUPPLEMENTAL FIGURE 2. Specificity of silencing of siRNA used against TLR1 
TLR2 and TLR10. THP-1 cells were treated with control (scrambled) siRNA and TLR1 
siRNA (A), TLR2 siRNA (B) or TLR10 siRNA (C) with 5ng/ml PMA for 48 hours. Flow 
cytometry was used as described in the methods to monitor expression levels of TLR1, TLR2 
and TLR10. Gating was performed against the isotype control and all control siRNA samples 
were measured against the corresponding TLR siRNA at the time of analysis to avoid intra-
assay variation in staining efficiency. Representative scatter plots of flow data are shown with 
relative knockdown (KD) of target TLR.  
SUPPLEMENTAL FIGURE 3. Western Blot of TLR10 expression levels in HEK and 
immune response to L.monocytogenes in IEC. Lysates of HEK cells were prepared for 
Western blotting analysis 48 hours after transfection as described in the methods section. 
TLR10 detection was confirmed using transfected TLR10 as a positive control. β-actin 
expression was also examined to ensure equal levels of protein were loaded on the gel (A). 
HT-29 cells were infected with L.monocytogenes, (MOI 50:1), for 3 hours. qRT-PCR was 
used to measure induction of the cytokine and chemokines indicated (B). Cells were treated 
with control siRNA or TLR10 siRNA as indicated and infected with L. monocytogenes (MOI 
50:1) for 3 hours. Gene expression of CCL-1was determined by qRT-PCR in HT-29 (C) or 
HCA-7 cells (D). * P<0.05, ** P<0.01 and *** P<0.001, Values are shown as Mean ± SEM, 
n=3. 
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SUPPLEMENTAL FIGURE 1. EGR-1 induction in HT-29 epithelial cells in response to 
L.monocytogenes following silencing of PRR expression.  
306 
 
 
SUPPLEMENTAL FIGURE 2. Specificity of silencing of siRNA used against TLR1 
TLR2 and TLR10.  
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SUPPLEMENTAL FIGURE 3. Western Blot of TLR10 expression levels in HEK and 
immune response to L.monocytogenes in IEC.  
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